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i	 Glossary	of	abbreviations	
95%	CI	 	 95%	confidence	interval	
AE	 Adverse	event	(in	main	text);	adverse	events	associated	with	anti-bacterials	
exhibiting	T>MIC	kill	characteristics	(forest	plots)	
AEa	 Adverse	events	associated	with	anti-bacterials	exhibiting	AUC/MIC	kill	
characteristics	(forest	plots)	
AEc	 Adverse	events	associated	with	anti-bacterials	exhibiting	Cmax/MIC	kill	
characteristics	(forest	plots)	
AfC	 	 Agenda	for	change	
APACHE		 Acute	Physiology	and	Chronic	Health	Score	
AUC	 	 Area	under	the	curve	
AUC0-24:MIC	 Area	under	the	curve	to	minimum	inhibitory	concentration	ratio	(used	in	some	
reproduced	tables)	
AUC/MIC	 Area	under	the	curve	to	minimum	inhibitory	concentration	ratio	(used	throughout	
the	text	of	the	thesis)	
B	 	 Bolus	intravenous	injection	usually	over	5	mins	or	less	
BOS	 	 Bristol	on-line	surveys	
CCU	 	 Critical	care	unit	
CCN	 	 Critical	Care	Network	
CI	 	 Continuous	infusion	
CINAHL	 	 Cumulative	Index	to	Nursing	and	Allied	Health	Literature	
CL	 	 (Drug)	Clearance	
Cmax/MIC	 Peak	serum	antibiotic	concentration	above	minimum	inhibitory	concentration	for	
the	microorganism		
CONSORT	 Consolidated	Standards	of	Reporting	Trials	
Df	(or	df)	 Degrees	of	freedom	
EII	 Extended	intermittent	infusion,	typically	given	over	3	to	4	hours	but	not	
continuously	
EU	 	 European	Union	
FDA	 	 Food	and	Drug	Administration	
FICM	 	 Faculty	of	Intensive	Care	Medicine	
HDU	 	 High	Dependency	Unit	
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I2	 Used	for	quantifying	heterogeneity	in	a	meta-analysis,	I2	describes	the	percentage	
of	variability	in	point	estimates	that	is	due	to	heterogeneity	rather	than	sampling	
error	
ICNARC	 	 Intensive	Care	National	Audit	and	Research	Centre	
ICU	 	 Intensive	Care	Unit	
MA	 	 Meta-analysis	
MH	 	 Mantel-Haenszel	test	
MIC	 	 Minimum	inhibitory	concentration	
n	 	 Number	(e.g.	of	participants)	
N/A	 	 Not	applicable	
NHS	 	 National	Health	Service	
NICE	 	 National	Institute	for	Clinical	Excellence	
OR	 	 Odds	ratio	
PAE	 	 Postantibiotic	effect	
PD	(pd)	 	 Pharmacodynamics	
PK	(pk)	 	 Pharmacokinetics	
PRISMA	 	 Preferred	Reporting	Items	for	Systematic	Review	and	Meta-Analysis	
PRISMA-P	 Preferred	Reporting	Items	for	Systematic	Review	and	Meta-Analysis	Protocols	
PROSPERO	 International	Prospective	Register	of	Systematic	Reviews	
QUOROM	 Quality	of	Reporting	of	Meta-analyses	
RCT	 	 Randomised	controlled	trial	
RR	 	 Risk	ratio	
S/B	 	 Short	infusion	or	bolus	injection	
S/SPC	 	 Short	infusion	as	described	in	the	summary	of	product	characteristics		
SAE	 	 Serious	adverse	event	
SAPS	 	 Simple	Acute	Physiology	Score		
SICSAG	 	 Scottish	Intensive	Care	Society	Audit	Group	
SOFA	 	 Sequential	Organ	Failure	Assessment	
SPC	 	 Summary	of	product	characteristics	
SPSS	 	 Statistical	package	for	the	social	sciences	
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T>MIC	 	 Time	that	antibacterial	levels	are	above	the	minimum	inhibitory	concentration	
TDM	 	 Therapeutic	drug	monitoring	
UK	 	 United	Kingdom	
UKCPA	 	 United	Kingdom	Clinical	Pharmacy	Association	
UKCPA	CCG	 United	Kingdom	Clinical	Pharmacy	Association	Critical	Care	Group	
UREC	 	 University	Research	Ethics	Committee		
USA	 	 United	States	of	America	
Vd	 	 Volume	of	distribution	
WAE	 	 Withdrawal	due	to	adverse	event	
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iii	 Abstract	
Introduction	 Physiological	 changes	 affecting	 critically	 ill	 septic	 patients	 may	 impact	 on	 the	
effectiveness	of	licensed	methods	of	antibiotic	administration.	It	has	been	postulated	that	extending	
the	infusion	time	over	which	time-dependent	action	antibiotics	are	administered,	giving	for	example	a	
4-hour	 infusion	 rather	 than	 an	 injection	 over	 5	 minutes,	 this	 may	 increase	 efficacy	 whilst	 not	
compromising	 safety	 in	 critically	 ill	 septic	 patients.	 However,	 no	 single	 study	 or	 meta-analysis	 of	
similar	 studies	 has	 yet	 shown	 any	 significant	 benefit	 in	 patient	 orientated	 outcomes.	 Even	 so	
anecdotal	 evidence	 suggests	 that	 this	 practice	 is	 becoming	 established	 in	 the	 critical	 care	
environment	but	the	extent	of	this	in	the	United	Kingdom	(UK)	has	never	been	assessed.		Method	A	
questionnaire	was	 developed	 to	 identify	 current	 intravenous	 antibiotic	 administration	 practice	 and	
the	 factors	 influencing	 choice	 in	 UK	 critical	 care	 units	 (CCUs).	 This	 was	 circulated	 to	 critical	 care	
pharmacists	via	the	United	Kingdom	Clinical	Pharmacy	Association	message	board.	Along	side	this	a	
systematic	review	and	meta-analysis	were	conducted	to	up	date	the	evidence	base.	Results	17	of	the	
22	 antibiotics	 surveyed	 have	 a	 single	 method	 of	 administration	 used	 on	 more	 than	 50%	 of	 the	
responding	 UK	 CCUs.	 Piperacillin/tazobactam	 and	 meropenem	 are	 used	 on	 22.2%	 and	 20.3%	
respectively	 of	 responding	 CCUs	 as	 extended	 intermittent	 infusions	 (EIIs)	 and	 vancomycin	 by	
continuous	 infusion	 (CI)	 on	 49.2%.	 Respondents	 most	 commonly	 sited	 both	 favourable	
pharmacokinetic/pharmacodynamics	 and	 an	 improvement	 in	 patient	 outcomes	 as	 reasons	 for	
adopting	extended	infusions.	 In	addition,	continuous	infusions	of	vancomycin	are	seen	to	be	a	safer	
and	 a	 more	 predictable	 method	 of	 administration	 than	 intermittent	 infusions.	 Where	 extended	
infusions	were	in	use,	this	practise	was	associated	with	a	high	level	of	pharmacist	input	into	the	multi	
professional	 team	 such	 as	 seven-day	 ward	 cover.	 The	 systematic	 review	 identified	 40	 randomised	
controlled	 trials	 comparing	 extended	 infusions	 to	 the	 licensed	 administration	 practice	 of	 the	 same	
antibiotic	covering	 in	 total	16	different	antibiotics.	Statistically	significant	differences	 in	clinical	cure	
and	 microbiological/bacteriological	 cure	 were	 found	 in	 favour	 of	 extended	 infusion	 methods.	 A	
statistically	 significant	 difference	 in	mortality	was	 observed	when	 time-dependent	 antibiotics	were	
analysed	 separately.	 No	 difference	 in	 adverse	 events	 was	 identified	 between	 the	 administration	
methods.	Conclusion	 Current	UK	 critical	 care	 practice	 of	 intravenous	 antibiotic	 administration	 is	 in	
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line	with	 the	evidence	base.	This	meta-analysis	 shows	that	extended	 infusions	are	both	safe	and	at	
least	as	effective	as	standard	licensed	administration	methods.	
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ix	 Preface	
I	am	a	specialist	critical	care	and	burns	pharmacist	and	have	been	practising	in	this	role	for	the	last	15	
years.	 I	 qualified	 as	 a	 pharmacist	 in	 1998	 from	 the	 University	 of	 Manchester	 and	 completed	 my	
hospital	pre-registration	training	the	following	year	at	St	Helens	and	Knowsley	Teaching	Hospitals	NHS	
Trust.	 I	 have	 since	 completed	 a	 number	 of	 postgraduate	 courses	 including	 the	 clinical	 pharmacist	
diploma	and	 supplementary	 prescribing	qualification,	 both	 at	 Liverpool	 John	Moores	University,	 an	
independent	 prescribing	 conversion	 qualification	 at	 Keele	 University	 and	 critical	 care	 course	 at	
Portsmouth	University.	 In	 2012	 I	 embarked	 part-time	 on	 a	 research	 qualification	 at	 Liverpool	 John	
Moores	University	whilst	 continuing	 to	work	 in	my	 specialist	 clinical	pharmacist	 role.	 For	 the	 last	7	
years	I	have	chaired	the	United	Kingdom	Clinical	Pharmacy	Associations	Critical	Care	Group.	
I	was	inspired	to	investigate	the	subject	of	extended	infusions	of	antibiotics	for	a	number	of	reasons.	
Antibiotics	are	one	of	the	only	truly	curative	interventions	available	for	the	management	of	patients	
with	 septic	 shock	 and	 currently	 not	 enough	 new	 antibiotics	 are	 coming	 on	 to	 the	 market	 and	
resistance	 to	 existing	 agents	 is	 increasingly	 becoming	 a	 problem.	 Approximately	 a	 decade	 ago	 I	
attended	 a	 presentation	 on	 extended	 antibiotic	 infusions	 at	 an	 international	 conference,	 I	 was	
immediately	drawn	to	the	idea	finding	the	logic	appealing	however	the	more	I	subsequently	read	on	
the	subject	the	more	 I	realised	that	the	evidence	of	clear	patient	benefit	wasn’t	there.	At	the	same	
time	I	was	aware	anecdotally	via	on	line	pharmacy	and	critical	care	forums	that	extended	infusions	of	
some	antibiotics	was	become	usual	practise	on	some	critical	care	units.	At	the	outset	of	my	MPhil	a	
number	of	large	studies	were	on	going	but	it	was	as	yet	unclear	how	these	studies	would	affect	the	
evidence	base.	
The	 factors	described	above	have	 in	 turn	 led	on	 to	shaping	 the	elements	of	 the	MPhil,	 I	wanted	 to	
know	what	usual	 intravenous	antibiotic	administration	practices	are	on	United	Kingdom	critical	care	
units	and	 then	 if	 the	published	up-to-date	evidence	supported	extended	 infusions.	These	questions	
are	important	to	answer	as	margins	can	be	very	fine	in	the	critically	ill	patient	and	it	is	important	to	
understand	if	current	practices	are	benefiting	patients.		
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I	haven’t	satisfied	myself	with	simply	working	in	my	own	silo	and	so	since	starting	this	MPhil	in	2012	I	
have	 collaborated	 with	 some	 of	 the	 major	 names	 working	 in	 this	 field	 both	 in	 the	 UK	 and	
internationally.	 I	 have	 co-authored	 an	 international	 survey	 of	 antibiotic	 administration	 and	
therapeutic	drug	monitoring	practice	conducted	on	behalf	of	the	European	Society	of	Intensive	Care	
Medicine	 (Tabah	 et	 al.,	 2015)	 and	 published	 a	 review	 of	 antibiotic	
pharmacokinetics/pharmacodynamics	in	the	critically	ill	patient	(Shah	et	al.,	2015).	I	have	also	actively	
involved	myself	in	the	on	going	research,	acting	as	UK	chief	investigator	and	legal	representative	for	
an	international	prospective	observational	study	investigating	gentamicin	(as	yet	unpublished	AMINO	
III	study).	Most	excitingly	I	am	on	the	UK	Trial	Management	Team,	and	also	Principal	Investigator	at	St	
Helens	 and	Knowsley	 Teaching	Hospital	NHS	Trust,	 for	 the	 “Beta-lactam	 infusion	 group	 (BLING)	 III”	
study.	This	study	will	be	by	far	the	largest	in	this	area	hoping	to	enrol	7000	critically	ill	septic	patients	
across	100	intensive	care	units	worldwide.	Based	on	all	of	this	activity	I	am	seen	within	critical	care	as	
a	 national	 expert	 on	 antibiotic	 pharmacokinetics/pharmacodynamics	 and	 stability	 and	 am	 regularly	
contacted	by	colleagues	across	the	UK	for	advice.	
The	 thesis	 that	 follows	 starts	 by	 providing	 an	 overview	 and	 background	 to	 the	 rationale	 for	 using	
extended	infusions	of	antibiotics	in	the	treatment	of	critically	ill	septic	patients.	This	is	followed	by	the	
overall	aim	and	objectives	of	this	MPhil	and	then	an	overview	of	the	methodology	used	to	answer	the	
aim.	 The	 next	 2	 chapters	 address	 in	 detail	 the	 two	 phases	 of	 the	 MPhil	 which	 were	 conducted	
simultaneously,	 a	 survey	 of	 UK	 critical	 care	 intravenous	 antibiotic	 administration	 practice	 and	 a	
systematic	review/meta-analysis	of	the	published	randomised	controlled	trials.	Finally	the	discussion	
draws	the	two	phases	together	followed	by	my	conclusions.								
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1	 Introduction	
1.1	 Intensive	care,	critical	care	and	the	critically	ill	patient	
Intensive	 care	medicine	 initially	 developed	 largely	 as	 a	 response	 to	 developments	 in	medicine	 and	
surgery	(Departmant	of	Health,	1999).	The	most	striking	example	of	this	was	the	response	to	the	1952	
poliomyelitis	epidemic	 in	Denmark	 (Lassen,	1953).	A	shortage	of	“iron	 lungs”	 in	hospitals	 led	to	the	
adoption	of	life	support	techniques	normally	used	only	in	operating	theatres,	with	the	most	critically	
ill	patients	being	concentrated	in	designated	areas	of	the	hospital.	These	areas	had	greater	levels	of	
nursing/medical	 intervention	 and	 observation	 than	was	 standard	 (Flaattens	 et	 al.,	 2010).	 Intensive	
care	 as	 a	 service	 developed	 steadily	 over	 the	 ensuing	 decades:	 the	 1960s	 saw	 the	 nationwide	
implementation	and	development	of	intensive	care	units	(ICUs)	across	the	United	Kingdom	(UK),	and	
through	the	1970s	and	1980s	medical	and	nursing	staff	started	to	professionalise	with	the	formation	
of	societies,	 journals,	training	and	associated	qualifications	(Reynolds	and	Tansey,	2011).	By	the	end	
of	the	20th	century	scoring	systems	specific	to	ICU,	such	as	the	Acute	Physiology	and	Chronic	Health	
Score	 (APACHE)	 (Bouch	and	Thompson,	2008),	had	been	developed	to	assess	severity	of	 illness	and	
associated	mortality.	 This	 time	 also	 saw	disciplines	 such	 as	 pharmacy	 and	physiotherapy	 becoming	
more	 directly	 involved	 in	 patient	 care	 and	 high	 dependency	 units	 (HDUs,	 areas	 of	 lower	 nurse	 to	
patient	ratios	than	ICU)	had	opened	(Reynolds	and	Tansey,	2011).	
	
In	 1999,	 the	 UK	 Department	 of	 Health	 launched	 a	 review	 of	 adult	 critical	 care	 services	 with	 the	
purpose	 of	 developing	 a	 framework	 for	 the	 future	 organisation	 and	 delivery	 of	 critical	 care	
(Departmant	 of	 Health,	 1999).	 The	 report	 suggested	 a	 patient-	 rather	 than	 specialty-oriented	 view	
and	coined	the	new	term	Comprehensive	Critical	Care.	As	a	result,	some	ICUs,	run	follow	up	clinics	to	
review	patients	post-hospital	discharge	(Griffiths	and	Jones,	2007).	Currently,	critical	care	is	a	mixture	
of	 a	 dedicated	 area	 of	 the	 hospital	 run	 by	 a	 multidisciplinary	 team	 which	 has	 all	 the	 therapeutic	
equipment	required	at	 their	disposal,	and	an	open	minded,	whole	patient	approach	to	care	before,	
during	 and	 after	 the	 patient’s	 critical	 care	 stay.	Many	 hospitals	 now	have	 critical	 care	 units	 (CCUs,	
combined	 ICU/HDUs)	with	 teams	of	out-reach	nurses	assessing	deteriorating	patients	on	 the	wards	
(Faculty	of	Intensive	Care	Medicine	and	Intensive	Care	Society,	2016).	
	
	 21	
1.2	 Sepsis	
	
Definition:	 The	 systemic	 response	 to	 infection	 has	 long	 been	 termed	 “sepsis”	 (Ayres,	 1985)	 but	
towards	the	end	of	the	last	century	is	was	becoming	clear	that	as	this	encompassed	the	whole	range	
of	 presentations	 from	 simple	 pyrexia	 through	 to	 circulatory	 collapse	 it	 was	 not	 adequate	 to	 help	
identify	those	patients	that	needed	immediate	attention.	The	lack	of	a	more	detailed	definition	also	
affected	the	clinicians’	ability	to	interpret	the	literature;	although	many	studies	investigated	“sepsis”	
what	they	meant	by	the	term	could	vary	greatly.		
	
In	1991	a	consensus	conference	was	held	with	the	goal	of	“agreeing	on	a	set	of	definitions	that	could	
be	applied	to	patients	with	sepsis	and	its	sequelae”	(Bone	et	al.,	1992).	Broad	definitions	of	systemic	
inflammatory	 response	 syndrome	 (SIRS),	 sepsis	 (SIRS	 with	 presumed	 or	 proven	 infection),	 severe	
sepsis	(sepsis	with	end	organ	dysfunction)	and	septic	shock	(severe	sepsis	with	hypotension	despite	
adequate	fluid	resuscitation	with	the	presence	of	perfusion	abnormalities)	were	agreed	upon.	In	2001	
a	large	body	of	experts	convened	to	revisit	the	definitions	published	in	1992,	believing	the	advent	of	
new	tests	 for	biomarkers	such	as	procalcitonin	or	 interleukin	6	would	 lead	to	change	but	the	group	
expanded	 on	 the	 signs	 and	 symptoms	 and	 left	 the	 definitions	 themselves	 untouched	 (Levy	 et	 al.,	
2003).	 2016	 however	 saw	 a	 major	 change	 with	 the	 advent	 of	 the	 Third	 International	 Consensus	
Definitions	 for	 Sepsis	 and	 Septic	 Shock	 (Sepsis-3)	 (Singer	 et	 al.,	 2016).	 There	 were	 two	 main	
outcomes,	 firstly	 “SIRS”	 was	 deemed	 to	 lack	 sensitivity	 and	 specificity	 and	 was	 replaced	 with	 the	
Sequential	 [Sepsis-related]	Organ	Failure	Assessment	(SOFA)	score	and	secondly	the	new	consensus	
task	force	thought	that	there	were	too	many	terms	currently	in	use	and	as	“severe	sepsis”	was	seen	
as	redundant	it	was	dropped.			
	
The	changes	described	above	mean	that	care	needs	to	be	taken	when	interpreting	statistics	quoted	in	
the	published	 literature	over	 time	but	 regardless	of	 the	definition	used	 it	 is	clear	 to	see	 that	sepsis	
kills.		
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Prevalence:	1	 in	20	deaths	 in	England	 in	2010	was	associated	with	sepsis	 (McPherson	et	al.,	2013).	
The	 now	 defunct	 patient	 group	 term	 “severe	 sepsis”	 accounted	 for	 approximately	 25%	 of	 all	
admissions	 to	 ICU	 in	England,	Wales	and	Northern	 Ireland	between	1996	and	2004	 (Harrison	et	al.,	
2006)	and	at	that	time	it	was	the	 leading	cause	of	non-cardiac	mortality	 in	 ICU	(Angus	et	al.,	2001).	
More	recently,	under	the	newest	definitions,	sepsis	and	septic	shock	amongst	ICU	patients	have	been	
shown	to	have	a	hospital	mortality	of	35.1%	and	55.5%	respectively	(Shankar-Hari	et	al.,	2017).	
	
In	2007	 the	Extended	Prevalence	of	 infection	 in	 Intensive	Care	 (EPIC	 II)	 study	 (Vincent	et	al.,	 2009)	
investigated	the	source	of	sepsis	on	ICU	and	identified	the	most	common	causative	microorganisms.	
This	1-day	point	prevalence	study	captured	data	on	13,796	patients	in	1,265	ICUs	across	75	countries.	
The	 lung	was	 the	most	 common	site	of	 infection	 (63.5%),	with	 the	abdomen	accounting	 for	19.6%,	
blood	15.1%	and	urinary	 tract	 at	 14.3%	 (patients	may	have	more	 than	one	 source,	hence	a	 total	 >	
100%).	46.8%	of	patients	had	Gram-positive	infections	(of	which	greater	that	2/3	were	Staphylococcus	
spp.),	 62.2%	had	Gram-negative	 infections	 and	 17%	were	 fungi.	 This	 remains	 the	 largest	 and	most	
comprehensive	prospective	study	providing	in	depth	details	of	the	nature	of	 infection	on	the	ICU	to	
date.		
	
Treatment:	 But	 sepsis	 needn’t	mean	 death.	When	 initiated	within	 an	 hour	 of	 diagnosis,	 antibiotic	
therapy	 along	with	 appropriate	 fluid	 and	 vasopressor	 support	 has	 been	 shown	 to	 reduce	mortality	
(Kumar	 et	 al.,	 2006;	 Rhodes	 et	 al.,	 2017).	 Once	 a	 diagnosis	 has	 been	 made,	 sepsis	 is	 treated	
empirically	with	broad-spectrum	antibiotics	that	reflect	the	target	site	and	cover	suspected	organisms	
(Rhodes	et	al.,	2017).	If	the	causative	microorganism	is	later	identified,	then	the	antibiotic	therapy	can	
be	tailored	to	target	that	specific	microorganism.	Over	time	a	combination	of	complacency,	a	lack	of	
interest	from	the	pharmaceutical	industry	and	indiscriminate	usage	in	both	humans	and	animals	but	
particularly	 in	 livestock	 to	 promote	 growth	 have	 put	 the	 “magic	 bullet”	 at	 real	 risk	 of	 becoming	 a	
blank.	
	
Very	few	new	classes	of	antibiotics	have	appeared	on	the	market	in	the	last	five	decades	(see	table	1)	
and	 although	 some	 have	 novel	 actions	 only	 one	 of	 these,	 Linezolid	 (an	 oxazolidinone),	 has	 a	
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completely	 new	mechanism	of	 action.	 There	 has	 also	 been	 a	 steady	 decline	 over	 time	 in	 the	 total	
number	of	 individual	antibiotics	being	approved	for	human	use.	 In	the	five	year	period	1983	-	1987	
the	US	Food	and	Drug	Administration	(FDA)	approved	16	new	antibiotics	 in	comparison	to	10	in	the	
period	 1993-97	 and	 only	 2	 between	 2008-12	 (Boucher	 et	 al.,	 2013).	 In	 the	 face	 of	 a	 potential	
humanitarian	crisis	associated	with	very	common	micro-organisms	becoming	resistant	to	all	existing	
antibiotics,	 independent	 researchers	and	pharmaceutical	 companies	are	being	 incentivised	 to	 focus	
their	 effort	 on	 bringing	 new	 antibiotics	 to	 the	market	 (Hampton,	 2015).	 This	may	 slowly	 be	 taking	
effect,	 in	 2015,	 2016	 and	 2017	 the	 FDA	 approved	 1,	 2	 and	 3	 new	 antibiotics	 in	 each	 of	 the	 years	
respectively	(Andrei	et	al.,	2018).		
 
 
Figure	1.1:	New	classes	of	antibiotic	arriving	on	the	market	(adapted	from	(Song,	2012))	
 
The	 lack	 of	 new	 antibiotics	 coupled	 with	 ever-increasing	 resistance	 to	 existing	 agents	 (Spellberg,	
2014)	 is	making	 the	management	of	 infection	more	difficult,	which	 is	 especially	 problematic	 in	 the	
critically	 ill	 patient.	 Antibiotics	 are	 the	 only	 truly	 curative	 intervention	 that	 exists	 for	 the	 septic	
patient,	 all	 other	 therapies	 such	 as	 vasopressors,	 intravenous	 fluids	 and	mechanical	 ventilation	 are	
merely	supportive,	buying	time	for	the	antibiotics	to	have	their	affect	(Rhodes	et	al.,	2017).		
	
One	possibility	for	 increasing	the	chances	of	antibiotic	therapy	being	successful	 is	to	give	antibiotics	
that	would	 normally	 be	 administered	 as	 a	 bolus	 injection	 or	 a	 short	 infusion	 (over	 30	minutes)	 as	
extended	 intermittent	 infusions	 (e.g.	 over	 three	 or	 four	 hours)	 or	 continuously	 (Shah	 et	 al.,	 2015).	
There	may	be	a	number	of	advantages	to	using	one	of	the	extended	administration	methods,	which	
are	 discussed	 in	 the	 next	 section,	 but	 any	 change	 in	 patient	 oriented	 outcomes	 (e.g.	 survival,	
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decreased	 hospital	 stay,	 etc.)	 have	 not	 been	 previously	 shown	 and	 this	 requires	 attention.	 The	
suitability	 of	 antibiotics	 to	 be	 given	 by	 extended	 administration	 methods	 is	 determined	 by	 their	
pharmacokinetic	and	pharmacodynamic	properties.	
	
1.3	 Factors	 affecting	 antibiotic	 therapy	 in	 critically	 ill	 patients	 –	 Pharmacokinetics	 and	
pharmacodynamics	
Pharmacokinetics	 is	 the	 effect	 the	 body	 has	 on	 a	 drug	 and	 is	 generally	 split	 into	 four	 phases:	
absorption,	distribution,	metabolism	and	elimination.	Below	is	a	brief	summary	of	each	process	and	
an	explanation	of	any	affect	environment	(critical	care)	or	disease	(e.g.	septic	shock)	has	on	it.	
Absorption:	 this	 generally	 refers	 to	 absorption	 from	 the	 gastrointestinal	 tract.	 In	 the	 critical	 care	
setting	 absorption	 often	 plays	 a	 minor	 role,	 as	 many	 antibiotics,	 are	 given	 intravenously.	 The	
assumption	being	that	the	patient	has	“absorbed”	100%	of	the	administered	dose.	
Distribution:	this	phase	describes	where	a	drug	goes	in	the	different	parts	of	the	body	and	how	long	it	
takes	 the	 drug	 to	 get	 there	 and	 equilibrate	 between	 the	 various	 tissues	 and	 organs	 of	 the	 body.	
Volume	of	distribution	(Vd)	can	be	greatly	increased	in	the	critically	ill	patient	(Gonçalves-Pereira	and	
Póvoa,	 2011)	 mainly	 due	 to	 the	 vasodilation	 associated	 with	 shock	 whereby	 fluid	 and	 protein	
(albumin)	leak	out	of	the	circulating	blood	volume	into	the	tissues	carrying	both	water	soluble	drugs	
and	 highly	 protein	 bound	 drugs	 with	 them.	 The	 increased	 volume	 of	 distribution	 in	 critically	 ill	
patients	may	impact	on	the	standard	dosing	regimens	leading	to	sub-therapeutic	blood	levels	of	drug.	
This	may	have	little	consequence	for	drugs	that	are	titrated	to	effect	(for	example,	noradrenaline	to	a	
target	 blood	 pressure)	 but	 for	 antibiotics	 where	 it	 is	 not	 possible	 to	 titrate	 to	 effect	 this	 may	
negatively	affect	efficacy.	
Metabolism:	 this	 is	the	process	of	enzymic	degradation	of	the	drug	to	products	or	metabolites	that	
are	eventually	cleared	from	the	body.	Metabolites	can	be	active	(that	 is,	have	an	action	 like	that	of	
the	parent	drug)	or	 inactive	 (be	 inert	and	have	no	 further	action	on	 the	body).	Drug	metabolism	 is	
generally	carried	out	in	the	liver	but	can	also	take	place	in	other	organs	for	example	the	kidneys	or	in	
the	tissues/blood.	Metabolism	can	be	affected	if	hepatic	blood	flow	is	compromised	or	if	the	liver	is	
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impaired	 (for	 example,	 ischemia	 secondary	 to	 hypo-perfusion).	 If	 renal	 dysfunction	 is	 also	 present	
then	 the	potential	 for	 accumulation	of	 active	 renally	 excreted	metabolites	must	 also	be	 taken	 into	
account	when	assessing	the	dosing	of	a	hepatically	metabolised	drug.	
Elimination:	this	final	phase	general	takes	place	via	the	kidneys	(though	some	can	occur	via	the	faecal	
route).	 Critically	 ill	 patients	 often	 have	 an	 increased	 cardiac	 output	 due	 to	 fluid	 loading	 and	 the	
administration	of	drugs	 that	 increase	 the	 force	and/or	 rate	of	 cardiac	 contraction	and	 this	 leads	 to	
increased	 kidney	 perfusion,	 an	 increased	 creatinine	 clearance	 and	 a	 subsequent	 increase	 in	
drug/antibiotic	 clearance.	 This	 phenomenon,	which	 has	 been	 termed	 “augmented	 renal	 clearance”	
(Carrie	 et	 al.,	 2017),	 increases	 the	 clearance	 rates	 of	 drugs	 and	 antibiotics	 effectively	 reducing	
antibiotic	 levels	and	therefore	efficacy.	Conversely,	some	critically	 ill	patients	may	have	pre-existing	
chronic	kidney	disease,	develop	a	sepsis/perfusion	related	kidney	 injury	 (for	example,	acute	tubular	
necrosis)	or	have	a	combination	of	the	two	(an	acute	on	chronic	kidney	injury).	This	is	a	very	different	
issue	as	the	resulting	affect	is	reduced	renal	perfusion	(titled	“end	organ	dysfunction”	in	figure	2	over	
leaf)	 and	 therefore	 reduced	 clearance	 of	 renally	 cleared	 drugs/antibiotics	 leading	 to	 supra-
therapeutic	 levels.	 If	 the	 kidneys	 stop	 working	 altogether	 then	 their	 function	 can	 be	 replicated	
artificially	 using	 a	method	 known	 generically	 as	 renal	 replacement	 therapy.	 This	 involves	 pumping	
blood	from	the	body,	past	a	semi-permeable	membrane	and	back	into	the	body,	the	membrane	acts	
in	 a	 similar	way	 to	 the	 kidney	 and	molecules	 ordinarily	 cleared	 renally	will	 either	 travel	 across	 the	
membrane	 down	 a	 concentration	 gradient,	 referred	 to	 as	 dialysis,	 or	 down	 a	 pressure	 gradient,	
referred	to	as	filtration.	Renal	replacement	therapy	can	potentially	have	any	of	a	number	of	effects	on	
the	 pharmacokinetics	 of	 a	 drug	 including	 increasing	 the	 Vd,	 influencing	 the	 clearance	 and	 in	 some	
cases	 drugs	may	 even	bind	 to	 the	plastic	 tubing,	 known	as	 an	 extracorporeal	 circuit	 (see	 figure	 2),	
used	throughout	the	therapy.		
The	flow-chart	over	 leaf	(figure	2)	summaries	the	pathophysiological	affects	that	sepsis	can	have	on	
the	body,	how	they	affect	pharmacokinetics	and	the	pharmacodynamic	outcomes.	
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Figure	 1.2.	 Pathophysiological	 changes	 that	 occur	 during	 sepsis	 and	 their	 effects	 on	 pharmacokinetics.	 Vd:	 volume	 of	
distribution;	CL:	clearance;	MIC:	minimum	inhibitory	concentration.	(Shah	et	al.,	2015)	
 
Pharmacodynamics	is	the	action	the	drug	has	on	the	body	(or	micro-organism).	This	includes	desired	
and	 adverse	 effects.	 Pharmacodynamic	 studies	 (known	 as	 pd-studies)	 have	 categorised	 antibiotics	
into	two	main	groups;	concentration-dependent	and	time-dependent	action	(Ambrose	et	al.,	2007).	
The	 effectiveness	 of	 the	 concentration-dependent	 antibiotics	 is	 determined	 by	 the	 peak	 serum	
antibiotic	concentration	above	minimum	inhibitory	concentration	(MIC)	for	the	microorganism,	often	
abbreviated	to	Cmax/MIC.	These	antibiotics	often	also	exhibit	a	significant	post-antibiotic	effect	(PAE)	
meaning	that	even	after	the	plasma	level	has	dropped	below	the	MIC	there	will	be	a	period	of	time	
before	 the	micro-organism	 recovers	 and	 starts	 to	 proliferate	 again	 (Craig,	 1998).	 Large	 infrequent	
(e.g.	daily)	doses	of	these	antibiotics	provides	best	efficacy.	Aminoglycosides,	such	as	gentamicin,	fit	
into	 this	 group.	 Time-dependent	 action	 antibiotics,	 the	 second	 group,	 have	 been	 shown	 to	 have	
greatest	efficacy	when	the	serum	antibiotic	concentration	is	maintained	above	the	MIC	for	prolonged	
periods	of	the	dosing	interval	(described	as	time	greater	than	the	MIC	or	T>MIC).	It	follows	therefore	
that	 a	 method	 of	 delivery	 that	 maintains	 the	 concentration	 consistently	 above	 the	 MIC	 (more	
frequent	 dosing	 or	 extended/continuous	 infusions)	 should	 achieve	 effective	 treatment	 more	
predictably	than	bolus	intermittent	dosing.	One	study	(Mouton	and	den	Hollander,	1994)	has	shown	
that	bacterial	killing	is	maximised	when	a	certain	concentration	of	antibiotic	above	the	MIC	has	been	
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reached.	Extended	 infusion	administration	over	3	or	4	hours	may	help	attain	 these	 targets	and	has	
been	shown	to	achieve	higher	trough	(i.e.	between	dose)	concentrations	(Roberts	and	Lipman,	2006).	
Penicillins,	carbapenems	and	cephalosporins	(together	known	as	β-lactams)	fit	into	this	group.			
	
Although	all	antibiotics	are	described	as	having	either	time-	or	concentration-dependent	action	not	all	
of	them	can	have	their	action	neatly	described	by	the	two	parameters	described	previously,	Cmax/MIC	
or	 T>MIC.	A	 final	 parameter	 exists,	 the	 ratio	 of	 the	 area	under	 the	 concentration	 time-curve	 at	 24	
hours	 (AUC)	 to	 the	 MIC	 (abbreviated	 to	 AUC0-24:MIC	 or	 AUC/MIC),	 where	 neither	 the	 peak	
concentration	nor	 the	time	spent	above	the	MIC	alone	matter	but	 the	 total	concentration	over	 the	
MIC	 over	 24	 hours	 predicts	 efficacy	 (Moise	 et	 al.,	 2000;	 Abdul-Aziz	 et	 al.,	 2015).	 Somewhat	
confusingly	 antibiotics	 described	 as	 both	 time-dependent,	 such	 as	 vancomycin	 and	 linezolid,	 and	
concentration-dependent,	 such	 as	 fluroquinolones,	 are	 best	 described	 by	 this	 parameter.	 Figure	 3	
below	shows	a	graphical	representation	of	these	parameters	over	a	single	dosing	interval.	
	
 
 
Figure	1.3.	PK/PD	parameters	of	antibiotics	on	a	concentration	vs	time	curve.	AUC,	area	under	the	concentration–time	curve;	
Cmax,	maximum	drug	concentration;	MIC,	minimum	inhibitory	concentration;	T>MIC,	duration	of	time	that	drug	concentration	
remains	above	MIC.	Adapted	from	Roberts	and	Lipman	2009	(Roberts	and	Lipman,	2009)	
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1.4	 Extended	dose	administration	
The	concept	of	giving	extended	or	continuous	infusions	has	been	regularly	investigated	since	at	least	
the	1970s	(Feld	et	al.,	1977;	Bodey	et	al.,	1979;	Wright	et	al.,	1979)	and	for	many	different	antibiotics	
in	various	different	patient	groups	but	interest	from	the	critical	care	community	as	a	whole	has	arisen	
relatively	 recently	 (Roberts	 et	 al.,	 2009c).	 Using	 this	 approach	 is	 rational	 for	 antibiotics	with	 time-
dependent	action,	in	particular	for	those	antibiotics	in	which	T>MIC	is	the	parameter	best	correlating	
with	 efficacy	 (Shah	 et	 al.,	 2015).	 Researchers	 have	 taken	 two	 methodological	 approaches	 to	
investigating	the	effects	of	extended	administration	method,	either	focusing	on	the	pk/pd	interaction	
between	 the	 antibiotics	 and	 the	 human	 subjects	 (both	 healthy	 and	 infected)	 or	 by	 investigating	
efficacy	and	safety	in	clinical	practice.	
There	 are	 three	 potential	 alternative	 administration-time	 methods	 of	 antibiotic	 dosing	 that	 may	
increase	the	length	of	time	spent	at	target	serum	antibiotic	levels	above	the	MIC.	
	
1.4.1	Frequent	small	doses:	This	is	not	an	extended	administration	method,	as	it	would	involve	bolus	
injection	 or	 short	 infusions,	 but	worth	 considering	 nonetheless	 as	 it	 would	 potentially	 achieve	 the	
desired	outcome	of	maintaining	the	antibiotic	level	in	the	serum	above	the	MIC	for	prolonged	periods	
of	 time.	 In	 theory,	 giving	 a	 small	 dose	 of	 antibiotic	 more	 frequently	 may	 avoid	 unnecessary	 high	
concentration	peaks	and	keep	between-dose	troughs	above	the	MIC.	However,	in	practice	there	are	
many	reasons	why	this	would	not	be	practical	or	effective.	Firstly,	without	a	loading	dose	being	given,	
the	small	single	doses	may	never	achieve	a	concentration	high	enough	above	the	MIC	for	the	drug	to	
be	effective.	This	might	not	 just	 lead	 to	 treatment	 failure	but	also	promote	antibiotic	 resistance	by	
maintaining	 levels	 in	 the	 “mutant	 selection	window”,	 an	 antibiotic	 concentration	 at	 the	 target	 site	
that	is	above	the	MIC	so	will	kill	sensitive	organisms	but	at	a	concentration	that	is	too	low	to	kill	the	
less	 susceptible	organisms	effectively	promoting	 their	 growth	 (Abdul-Aziz	 et	 al.,	 2015).	 Even	with	a	
loading	 dose	 there	 are	major	 drawbacks	 predominately	 relating	 to	 cost	 effectiveness,	 for	 example	
excess	waste	 due	 to	 vial	 size,	 nursing	 time	 required	 to	 prepare,	 double-check	 and	 administer	 each	
dose	and	the	infection	risks	associated	with	frequent	manipulations	of	intravenous	access	devices	all	
make	this	approach	undesirable.		
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1.4.2	 Continuous	 infusions:	 Antibiotics	 may	 be	 administered	 as	 a	 continuous	 infusion	 over	 the	
duration	 of	 treatment.	 The	 administration	 of	 vancomycin	 by	 this	 method	 is	 both	 logical	 and	 well	
described	 (James	 et	 al.,	 1996;	Wysocki	 et	 al.,	 2001)	 as	 is	 the	 pharmacokinetics	 in	 different	 patient	
groups	 (Rybak	 et	 al.,	 1990;	 Grace,	 2012)	 but	 there	 are	 no	 prospective	 studies	 showing	 patient-
orientated	 benefits	 (Roberts	 et	 al.,	 2008b;	 Gonçalves-Pereira	 and	 Póvoa,	 2011)	 and	 the	 use	 of	
continuous	 infusion	 is	 still	 generally	 not	 well	 studied	 in	 the	 critically	 ill	 population	 with	 just	 one	
randomised	controlled	trial	 investigating	 its	efficacy	(Wysocki	et	al.,	2001).	More	recently	β-lactams	
(the	broad	group	including	penicillins,	carbapenems	and	cephalosporins),	for	which	T>MIC	exclusively	
correlates	with	efficacy,	have	become	the	main	focus	of	researchers’	attention	(Dulhunty	et	al.,	2015;	
Abdul-Aziz	et	al.,	2016;	Roberts	et	al.,	2016;	Zhao	et	al.,	2017).	Continuous	 infusions	however	have	
their	disadvantages:	 these	 include	vascular	access,	unknown	stability	when	mixed	with	other	drugs,	
and	restricted	patient	mobility.	
		
1.4.3	Extended	intermittent	infusions:	Three-	or	four-hour	infusions	of	antibiotics	may	have	the	same	
potential	benefits	as	continuous	infusions	and	overcome	some/all	of	the	disadvantages.	A	number	of	
studies	have	been	conducted	over	the	last	decade	in	this	area	(Lü	et	al.,	2013;	Bao	et	al.,	2017;	Fan	et	
al.,	 2017;	 Yang	 et	 al.,	 2017;	 Ram	 et	 al.,	 2018)	 but	 as	 of	 yet	 no	 single	 study	 has	 been	 adequately	
powered	to	show	any	mortality	benefit.		
	
A	recent	meta-analysis	of	individual	patient	data	from	RCTs	using	continuous	infusions	has	called	for	a	
large,	definitive	study	to	be	conducted	(Roberts	et	al.,	2016)	and	there	 is	yet	to	be	a	published	RCT	
conducted	in	the	UK	critical	care	population.		
	
Although	the	concept	of	extended	administration	methods	has	been	around	for	a	long	time	a	number	
of	large	studies	(Dulhunty	et	al.,	2015;	Abdul-Aziz	et	al.,	2016;	Fan	et	al.,	2017)	have	been	published	
since	the	last	major	systematic	review	of	the	literature	(Shiu	et	al.,	2013)	and	antibiotic	administration	
practices	 in	 UK	 CCUs	 have	 never	 been	 investigated.	 It	 is	 important	 to	 understand	 the	 current	 UK	
position	 in	 relation	 to	 the	 evidence	 base	 to	 ensure	 that	 patients	 are	 receiving	 optimal	 care.	 The	
following	studies	address	this	and	form	the	thesis.		
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1.5	 MPhil	aim	and	objectives	
1.5.1	 Aim	
To	 investigate	 whether	 UK	 critical	 care	 practice	 of	 antibiotic	 administration	 is	 supported	 by	 the	
current	evidence	base	to	maximise	clinical	efficacy	and	safety.	
	
1.5.2	 Objectives	
i. To	ascertain	current	usual	 local	methods	of	 intravenous	antibiotic	administration	across	UK	
critical	care	units	to	define	if	a	common	practice	exists	
ii. To	 ascertain	 the	 factors	 influencing	 the	 adoption	 of	 extended	 or	 continuous	 infusions	 of	
antibiotics.	
iii. To	 conduct	 an	 up-to-date	 evaluation	 of	 the	 evidence	 base	 for	 extended	 infusions	 of	
antibiotics	in	adult	patients	with	sepsis		
iv. To	ascertain	if	the	literature	supports	the	adoption	of	any	particular	practices	in	UK	CCUs	
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2	 Study	design	and	methodology	
2.1	 Methodological	considerations	
In	order	to	meet	the	overall	aim	of	this	study,	 two	main	questions	needed	addressing.	Firstly,	what	
antibiotic	administration	practices	are	common	on	UK	critical	care	units	(CCUs)	and	to	ascertain	the	
factors	 influencing	the	adoption	of	novel	or	extended	methods	of	 infusions	of	antibiotics.	Secondly,	
does	 the	published	 literature	support	 the	use	of	extended	 infusions	of	antibiotics	 in	 the	critically	 ill	
patient	 population?	 This	 thesis	 will	 bring	 these	 elements	 together	 and	 reflect	 in	 the	 discussion	
whether	UK	CCU	practice	is	supported	by	the	published,	peer-reviewed	evidence	base.	
2.1.1	 Phase	1:	Assessing	intravenous	antibiotic	administration	practice		
There	are	numerous	approaches	 that	could	be	 taken	 to	collecting	data	on	current	practice	but	 two	
key	elements	of	 the	study	needed	 to	be	 taken	 into	consideration	when	making	 this	choice,	namely	
the	 geographical	 population	 to	be	 sampled	 and	who	 is	 going	 to	be	providing	 the	data.	Once	 these	
factors	 had	 been	 decided	 upon	 a	 decision	 was	 made	 about	 the	 most	 suitable	 method	 of	 data	
collection	and	an	appropriate	approach	to	statistical	analysis	of	these	data.		
	
2.1.1.1	 Choice	of	geographical	population	
The	most	influential	guidance	on	the	management	of	sepsis	is	the	surviving	sepsis	campaign,	now	in	
its	third	update	(Rhodes	et	al.,	2017),	which	is	international	in	both	its	authorship	and	assessment	of	
the	evidence	base	and	 so	 a	potential	 approach	would	be	 to	 investigate	practice	on	a	wider,	 global	
level.	An	 international	or	Europe-wide	study	of	practice	would	have	had	wide	 reaching	 interest	but	
would	not	have	provided	any	meaningful	results	beyond	simply	stating	what	practices	exist.	Globally	
there	 are	 many	 differences	 in	 healthcare	 systems	 leading	 to	 different	 definitions	 of	 critical	 care,	
antibiotic	availability	and	antibiotic	resistance	patterns	between	different	countries.	Another	factor	to	
consider	is	the	logistics	of	gathering	data	across	such	a	huge	area	and	the	fact	that	a	response	rate	as	
such	would	have	been	impossible	to	calculate.	Data	would	have	been	further	biases	by	the	response	
being	largely	restricted	to	English	speaking	participants.		
Conversely,	a	much	smaller	geographical	population	could	have	been	 investigated,	 for	example	 the	
focus	could	have	been	on	Merseyside	or	the	North	West	of	England.	These	data	would	have	been	of	
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interest	to	local	policy	makers	and	a	high	response	rate	would	have	been	likely	as	following	up	non-
responders	would	have	been	relatively	simple	due	to	the	small	sample	size.	But	as	a	UK	wide	survey	
would	 still	 have	been	missing	 from	 the	published	 literature,	 the	 impact	 of	 such	 a	 small	 study	on	 a	
wider	audience,	UK	or	international,	would	have	been	limited.		
	
Choosing	to	study	the	UK	as	a	whole	rather	than	just	one	country	e.g.	England	was	influenced	by	the	
structure	of	UK	healthcare	as	the	National	Health	Service	(NHS)	covers	all	four	countries	in	the	UK	so	
therefore	systems,	structure	and	governance	are	largely	the	same	throughout	so	there	is	a	common	
language	describing	what	critical	care	is,	how	it	functions	and	the	grades	of	doctors,	pharmacists,	etc.	
The	 common	 microorganisms,	 resistance	 patterns	 and	 antibiotic	 availability	 are	 also	 relatively	
uniform	across	the	UK.	The	number	of	critical	care	units	across	the	UK	is	known	and	so	an	accurate	
response	rate	could	be	calculated	and	although	response	was	likely	to	be	lower	and	the	practicalities	
of	 chasing	 individual	 CCUs	more	 challenging	 than	 focusing	 on	 a	 smaller	 region	 the	 benefits	 of	 the	
quality	of	data	outweigh	the	negatives	of	a	smaller	proportional	response.	
	
2.1.1.2	 Choice	of	target	respondents	
Critical	 care	 pharmacists	 were	 chosen	 as	 the	 target	 recipients	 of	 the	 questionnaire	 based	 on	 a	
number	of	factors.	Specialist	pharmacists	in	general	have	day-to-day	involvement	in	patient	care	and	
as	 part	 of	 their	 role	 will	 be	 involved	 in	 the	 development	 and	 implementation	 of	 local	 guidance	
pertaining	to	drug	administration.	A	fundamental	part	of	the	pharmacists	role	is	to	check	the	accuracy	
of	 prescriptions	 in	 line	with	 licensed	 or	 local	 practice	 and	 advise	 staff	 of	 all	 grades	 and	 disciplines	
involved	in	direct	patient	care	on	how	to	prescribe,	prepare	and	administer	medicines	safely.	Because	
of	 these	 factors	 pharmacists	 will	 be	 aware	 of	 what	 actually	 happens	 as	 usual	 practice	 in	 their	
specialist	area,	in	this	instance	critical	care	and	are	therefore	the	ideal	respondents.	A	final	aspect	is	
the	fact	that	the	United	Kingdom	Clinical	Pharmacy	Association	(UKCPA)	critical	care	message	board	
provides	 a	 simple	 way	 of	 contacting	 the	 target	 population;	 not	 all	 critical	 care	 pharmacists	 are	
members	but	 at	 the	 time	approximately	500	pharmacists	were	 registered	 to	 receive	messages	 and	
there	are	only	approximately	240	CCUs	in	the	UK.	
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2.1.1.3	 Choice	of	data	collection	method	
Following	the	decision	on	geographical	population	and	group	of	target	participants,	a	method	of	data	
collection	was	required.	The	core	element	was	engaging	with	the	pharmacists	who	are	involved	in	the	
process	 under	 investigation,	 in	 this	 instance	 intravenous	 antibiotic	 administration.	 This	 interaction	
can	 range	 from	 face-to-face	 meetings	 with	 small	 groups	 of	 participants	 through	 to	 sending	
questionnaires	 out	 to	 very	 large	 numbers	 of	 participants	 and	 hoping	 the	 majority	 of	 them	 will	
respond.		
Focus	groups	are	the	most	personal	option	and	involve	gathering	small	groups	of	participants	with	a	
moderator	 guiding	 the	 discussion.	 These	 groups	 lend	 themselves	 to	 open	 discussion	 where	 the	
investigator	 may	 not	 need	 or	 want	 clear-cut	 binary	 yes/no	 answers	 and	 exploring	 and	 clarifying	
perspectives	is	actively	encouraged	(Tong	et	al.,	2007).	They	are	however	a	very	time	consuming	and,	
if	 the	participants	are	 spread	over	a	 large	geographical	 area,	a	potentially	expensive	way	 to	gather	
data	if	that	form	of	discussion	is	not	required.	In	healthcare,	focus	groups	are	usually	used	in	studies	
that	collect	predominantly	qualitative	data	to	contribute	new	perspectives	(Tong	et	al.,	2007).		
A	more	structured	approach	can	be	taken	in	the	form	of	a	list	of	questions	or	questionnaire.	This	can	
be	delivered	in	a	number	of	ways	ranging	from	one	to	one	interviews	with	the	participants	through	to	
sending	the	questions	out	to	a	target	group	of	potential	participants.	Questionnaires	are	widely	used	
in	 epidemiological	 studies	 as	 a	 practical	 and	 structured	method	 of	 data	 collection	 (Edwards	 et	 al.,	
2010).	A	questionnaire	consists	of	a	 list	of	questions	 in	either	an	“open”	 (free	text)	or	“closed”	 (set	
options)	style	and	are	designed	to	answer	the	over	all	question	being	posed.	The	investigator	tailors	
the	questionnaire	 to	suit	his	or	her	own	needs;	using	predominantly	closed	type	questions	restricts	
the	 respondents	 options	 and	 ability	 to	 express	 themselves	 but	 therefore	 reduces	 variability	 of	
response	making	 the	 results	much	more	amenable	 to	 statistical	 analysis	 (Boynton	and	Greenhalgh,	
2004).		
Face-to-face	 or	 telephone	 interviews	 of	 individual	 participants	 would	 likely	 be	 the	 most	
comprehensive	way	to	collect	the	data;	achieving	a	high	response	rate	and	ensuring	the	participant	
understood	and	answered	each	of	the	questions	(Bowling,	2005).	For	this	study	the	advantage	of	an	
interview	style	over	focus	groups	would	be	that	the	questions	could	be	closed	and	focused,	as	the	aim	
was	to	 investigate	what	practice	was	 in	a	particular	critical	care	unit	and	what	had	directly	affected	
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that	 participants	 choice	 of	 practice.	 This	 method	 also	 has	 major	 drawbacks	 which	 include	 the	
potential	for	the	researcher	to	create	bias	in	the	responses	and	the	fact	that	this	approach	could	be	
prohibitively	 time	 consuming,	 expensive	 and	 simply	 not	 practical	 for	 a	 survey	 of	 practice	 covering	
potentially	 hundreds	of	 participants	over	 a	 large	 geographical	 area	 (Boynton,	 2004;	 Edwards	et	 al.,	
2010).	
Rather	than	the	investigator	contacting	participants	individually	a	more	practical	solution	would	be	to	
present	the	questions	in	the	form	of	a	questionnaire	to	all	potential	participants	electronically	or	via	
post.	The	postal	method	has	shown	repeatedly	over	time	to	deliver	better	response	rates	than	online	
questionnaires	(Mavis	and	Brocato,	1998;	Grava-Gubins	and	Scott,	2008;	Hohwü	et	al.,	2013)	however	
it	was	unsuitable	for	this	study.	As	described	above	critical	care	pharmacists	were	chosen	to	be	the	
sole	 target	 participants	 for	 this	 study	 but	 as	 a	 list	 of	 critical	 care	 pharmacists	 for	 UK	 CCUs	 is	 not	
available	the	only	means	of	contacting	potential	participants	was	either	a	generic	letter	sent	to	“the	
pharmacist”	on	each	UK	CCU	or	to	post	the	link	to	the	questionnaire	on	the	United	Kingdom	Clinical	
Pharmacy	Association	Critical	Care	Group	message	board,	 the	 later	option	was	 chosen	 for	practical	
reasons.		
A	systematic	review	and	meta-analysis	performed	for	the	Cochrane	collaboration	 in	2009	examined	
factors	 influencing	 the	 response	 rate	 to	 both	 postal	 and	 electronic	 questionnaires	 (Edwards	 et	 al.,	
2010).	 Of	 the	 513	 eligible	 trials	 examined	 32	 investigated	 electronic	 questionnaires	 reporting	 27	
different	 interventions.	 The	 positive	 outcomes	 associated	 with	 statements	 about	 response	 rate	 to	
date,	use	of	a	white	background	and	offering	to	report	results	back	to	respondents	were	all	taken	into	
account	 in	 the	 design	 of	 this	 questionnaire	 and	 supporting	 information	 sent	 to	 the	 potential	
participants.		
2.1.1.4	Choice	of	statistical	methods	
Where	possible	 the	questionnaire	used	closed	questions	 restricting	 the	 respondent	 to	a	number	of	
options	and	no	free	text.	In	the	first	instance	all	data,	demographic	and	outcome,	was	analysed	using	
simple	 frequency	analysis.	 The	data	was	assessed	 for	 trends	and	potential	 confounding	 factors	and	
reported	descriptively	or	as	simple	percentages.		
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In	general,	data	can	be	split	in	to	three	main	types	–	interval	scale	(continuous	measurement),	ordinal	
scale	(categorical	data	with	a	logical	order	e.g.	highest	to	lowest)	and	nominal	scale	(categorical	data	
with	no	assumption	of	order	e.g.	yes/no	or	male/female)	(Rowe,	2007).	The	vast	majority	of	the	data	
collected	through	the	questionnaire	was	nominal	in	nature.	To	further	analyse	certain	aspects	of	the	
data,	whether	one	answer	provided	influences	the	answers	to	another	question,	a	chi-test	was	used.	
The	Chi-square	test	is	intended	to	test	how	likely	it	is	that	an	observed	distribution	is	due	to	chance.	
Also	 known	 as	 a	 “goodness	 of	 fit	 test”,	 it	 measures	 how	 well	 the	 observed	 distribution	 of	 two	
categorical	variables	fits	with	the	distribution	that	is	expected	if	the	variables	are	independent	and	as	
such	was	deemed	the	most	suitable	test	to	identify	any	relationships	between	different	demographics	
and	the	usual	intravenous	method	of	administration	of	each	antibiotic.		
2.1.1.5	 Summary	of	final	approach	to	assessing	practice	
The	decision	was	made	to	focus	the	investigation	on	administration	practice	in	UK	critical	care	units	
and	collect	the	data	via	survey	of	the	critical	care	pharmacists,	with	each	element	contributing	to	the	
choice	of	the	others.	
The	 full	 questionnaire	 is	 available	 in	 appendix	 2.	 Details	 of	 the	 literature	 review	 that	 guided	 the	
development	of	the	questionnaire,	design,	the	platform	used	and	piloting	of	the	questionnaire	are	in	
Chapter	3.	
2.1.2	 Phase	2:	Assessing	the	evidence	base	
2.1.2.1	 Choice	of	method	of	data	collection	
‘Usual’	practice,	whether	at	an	individual	CCU	level	or	a	UK	level,	will	follow	guidelines	and	protocols.	
These	documents	will	be	built	using	the	evidence	base	available	at	the	time	of	development,	which	
can	 potentially	 range	 from	 expert	 opinion	 or	 best	 practice	 through	 to	 one	 or	 more	 large	 well-
conducted	 randomised	 controlled	 trials	 (RCTs).	 Many	 common	 conditions	 such	 as	 myocardial	
infarction	or	diabetes	management	will	 have	 large	 influential	 RCTs	 that	will	 guide	 therapy	and	one	
would	expect	management	 to	be	 consistent	between	hospitals.	 In	 the	 critical	 care	 setting	however	
the	pool	of	patients	available	to	be	enrolled	in	studies	is	relatively	small,	there	is	a	high	mortality	rate	
and	the	patients	presenting	are	often	clinically	heterogeneous.	A	study	enrolling	critically	ill	patients	
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with	sepsis	 is	 likely	 to	have	a	very	variable	cohort	of	patients	with	different	 infection	sites/sources,	
causative	organisms,	pre-existing	co-morbidities	(e.g.	chronic	obstructive	pulmonary	disease,	diabetes	
mellitus,	 etc.)	 and	 new	 clinical	 conditions	 (acute	 kidney	 injury,	 atrial	 fibrillation,	 etc.).	 All	 of	 these	
confounders	potentially	hide	any	important	results.	Considering	these	factors,	studies	in	the	critically	
ill	 patient	 tend	 to	 target	 the	 enrolment	 of	 relatively	 small	 numbers	 and	 so	 the	 choice	 of	 primary	
outcomes	tends	to	reflect	this	with	studies	frequently	now	focusing	on	length	of	stay	on	critical	care	
and	morbidity	 rather	 than	mortality.	 	 Even	 the	biggest	 critical	 care	 studies	 rarely	 show	outstanding	
differences	between	therapies.	Searching	for	and	finding	all	publications	addressing	a	specific	clinical	
question	 then	analysing	 the	pooled	 results	 can	potentially	 identify	benefits	of	 therapies	 that	would	
otherwise	be	missed;	 the	 first	part	of	 this	process	 is	known	as	a	systematic	 review	of	 the	 literature	
and	the	second	part	is	a	meta-analysis.	
The	 key	 to	 both	 processes	 is	 rigor	 and	 therefore	 thoroughness	 and	 openness	make	 this	means	 of	
generating	evidence	very	powerful.	For	example,	one	main	element	of	the	systematic	review	process	
is	 to	 assess	 for	 bias	 within	 each	 study	 and	 potential	 publishing	 bias,	 and	 these	 assessments	 are	
completed	to	a	set	 format	and	published	 in	the	final	article	for	the	clinician	to	pore	over	and	reach	
their	own	conclusions.	For	a	number	of	decades	this	process	has	been	seen	as	generating	the	highest	
grade	of	evidence	allowing	data	to	be	pooled	from	multiple	similar	studies	so	that	conclusions	can	be	
drawn	that	the	original	studies	were	not	designed	or	powered	to	assess	(Canadian	Task	Force	on	the	
Periodic	Health	Examination,	1979;	Burns	et	al.,	2011;	Howick	et	al.,	2011).		
However	the	success	of	the	systematic	review	and	meta-analysis	is	not	a	given	and	over	a	number	of	
years	many	elements	have	been	developed	to	minimise	the	risk	of	poorly	thought	out	reviews.	The	
process	of	increasing	the	consistency	in	quality	of	systematic	reviews	and	meta-analyses	started	with	
the	Quality	of	Reporting	of	Meta-Analysis	 (QUOROM)	statement	(Moher	et	al.,	1999),	this	was	then	
expanded	 to	 include	 the	 systematic	 review	process	 –	 the	Preferred	Reporting	 Items	 for	 Systematic	
Reviews	 and	 Meta-Analysis	 (PRISMA)	 statement	 (Moher	 et	 al.,	 2009)	 and	 finally	 the	 PRISMA-P	
statement	focussing	specifically	on	the	initial	protocol	writing	(Moher	et	al.,	2015).	The	later	of	thse	
strongly	 recommends	 that	 the	preparation	and	 registration	of	 systematic	 review	and	meta-analysis	
protocols	occur	to	reduce	publication	bias	of	systematic	reviews	and	to	reduce	the	risk	of	duplication	
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of	 effort.	 An	 example	 of	 such	 a	 register	 is	 the	 International	 Prospective	 Register	 of	 On-going	
Systematic	Reviews	called	PROSPERO	http://www.crd.york.ac.uk/prospero		
For	 the	 systematic	 review	 process	 to	 realise	 its	 full	 potential	 the	 data	 being	 pooled	 needs	 to	 be	
available	 in	the	articles	being	analyses	and	this	 is	another	area	where	over	the	years	attempts	have	
been	made	to	standardise	the	information	presented	in	the	published	articles.	In	1996	the	CONSORT	
(Consolidated	Standards	of	Reporting	Trials)	statement	(Begg	et	al.,	1996)	was	published	in	an	effort	
to	encourage	researchers	to	include	in	their	articles	“complete,	clear	and	transparent	information	on	
its	methodology	 and	 findings”	 to	 allow	 the	 reader	 to	 accurately	 assess	 the	 impact	 of	 the	 study	 on	
their	practice.	The	CONSORT	statement	is	now	on	its	third	revision	(Schulz	et	al.,	2010).	
The	process	of	systematically	reviewing	the	literature	provides	a	structured	means	of	identifying	and	
capturing	the	evidence	base,	meta-analysis	then	appraises	the	articles	as	a	whole	and	if	the	process	is	
conducted	 properly	 it	 provides	 the	 highest	 grade	 of	 evidence	 and	 thus	 is	 the	 logical	 choice	 for	
addressing	this	phase	of	work.	
A	protocol	was	developed	in	line	with	the	PRISMA-P	statement	(Moher	et	al.,	2015)	and	based	around	
the	 PICOS	 (population,	 intervention,	 control,	 outcomes,	 study	 design)	 method	 of	 formulating	 a	
question.	This	protocol	was	registered	on	the	PROSPERO	database	(PROSPERO	ID	CRD42017067213)	
at	 the	 outset	 of	 the	 study.	 The	 systematic	 review	 included	 only	 randomised	 controlled	 trials	 (RCT)	
(blinded	or	open	label)	comparing	two	different	administration	method	of	the	same	antibiotic	in	adult	
patients	with	 presumed	 or	 proven	 sepsis.	 The	 choice	 to	 focus	 on	 RCTs	was	made	 as	 these	 studies	
represent	the	highest	level	and	quality	of	individual	pieces	of	evidence.		
It	was	also	decided	from	the	outset	to	apply	no	geographical,	publication	date	or	language	restrictions	
on	the	search	as	it	was	felt	that	although	the	focus	of	the	over	all	study	is	on	UK	practice	this	would	
be	based	on	the	global	evidence	base.		
The	 major	 limitation	 of	 the	 process	 of	 systematic	 review	 is	 that	 one	 could	 argue	 that	 the	 overall	
quality	 of	 the	data	 it	 produces	 is	 only	 as	 good	 as	 the	weakest	 study	 included,	 but	 if	 the	processes	
described	above	are	followed	then	the	reader	can	for	themselves	judge	what	if	any	weaknesses	exist	
for	themselves	and	draw	their	own	conclusion.	
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2.1.2.2	 Choice	of	method	of	statistical	analysis	
The	 Preferred	 Reporting	 Items	 for	 Systematic	 Reviews	 and	Meta-Analyses:	 The	 PRISMA	 Statement	
(Moher	 et	 al.,	 2009)	 clearly	 sets	 out	 high	 level	 details	 of	 what	 the	 international	 group	 of	 expert	
authors	 consider	 to	be	 the	minimum	standards	 for	all	 aspects	of	 the	 statistical	 analysis	of	 the	data	
extracted	 from	a	 systematic	 review	of	 the	 literature.	A	partner	article	 (Liberati	et	al.,	 2009)	 further	
expands	on	and	explains	the	statements.	Items	12	–	16	in	the	suggested	checklist	relate	directly	to	the	
statistical	analysis	and	are	reproduced	below,	as	1-5,	with	an	explanation	as	to	how	these	elements	
are	approached	in	this	study.	
1. Risk	 of	 bias	 in	 individual	 studies	 –	 “Describe	 methods	 used	 for	 assessing	 risk	 of	 bias	 of	
individual	studies	(including	specification	of	whether	this	was	done	at	the	study	or	outcome	
level),	and	how	this	information	is	to	be	used	in	any	data	synthesis”	(Moher	et	al.,	2009).	The	
Cochrane	 risk	of	bias	 tool	 (Higgins	et	al.,	2011)	was	adopted	 for	 this	 study,	 it	 consists	of	5	
items	 for	 which	 there	 is	 evidence	 for	 their	 biasing	 influence	 on	 the	 estimates	 of	 an	
intervention’s	effectiveness	in	RCTs	(sequence	generation,	allocation	concealment,	blinding,	
incomplete	 outcome	 data,	 and	 selective	 outcome	 reporting)	 and	 a	 catch-all	 item	 called	
‘‘other	sources	of	bias’’	which	included	funding	sources,	declarations	of	interest,	use	of	open	
label	antibiotics	and	any	mismatch	between	treatment	and	control	groups.	All	aspects	were	
assessed	for	each	individual	paper	and	reported	as	absolute	numbers	of	each	risk	(high,	low	
or	 unclear)	 within	 each	 item	 and	 presented	 pictographically	 in	 table	 4.1	 “Methodological	
quality	summary”	in	the	results	section	of	chapter	4.	
2. Summary	measures	–	“State	 the	principal	 summary	measures	 (e.g.,	 risk	 ratio,	difference	 in	
means)”	 (Moher	 et	 al.,	 2009).	 All	 outcomes	 in	 this	 study	 were	 dichotomous	 and	 the	
treatment	effect	was	measured	using	the	risk	ratio	(RR)	with	its	associated	95%	confidence	
interval	 (95%	CI)	 and	using	a	 random-effects	model.	A	 random-effects	model	was	deemed	
most	appropriate	due	to	the	 large	amount	of	perceived	clinical	heterogeneity	between	the	
studies	and	to	balance	the	weighting	applied	to	the	studies	so	as	not	to	reduce	the	effect	of	
the	 many	 smaller	 studies.	 The	 Cochrane	 handbook	 (http://handbook-5-1.cochrane.org;	
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section	9.2.2.1)	suggests	that	interpretation	of	odds	is	more	complicated	than	risk	hence	the	
choice	of	RR	in	this	meta-analysis.		3. Synthesis	 of	 results	 –	 “Describe	 the	 methods	 of	 handling	 data	 and	 combining	 results	 of	
studies,	 if	done,	 including	measures	of	consistency	(e.g.,	 I2)	for	each	meta-analysis”	(Moher	
et	al.,	2009).	The	I2	statistic	has	been	used	as	the	main	measure	of	statistical	heterogeneity.	
Overall	heterogeneity	should	be	assessed	in	the	wider	context	of	the	studies	included	but	as	
a	general	rule	 I2	greater	than	50%	was	considered	as	 important	heterogeneity,	an	 I2	of	 less	
than	30%	was	considered	lower	risk	(Higgins	and	Thompson,	2002;	Higgins	et	al.,	2003).	
4. Risk	 of	 bias	 across	 studies	 –	 “Specify	 any	 assessment	 of	 risk	 of	 bias	 that	 may	 affect	 the	
cumulative	evidence	(e.g.,	publication	bias,….)”	(Moher	et	al.,	2009).	Evidence	of	publication	
bias	was	assessed	both	visually	using	funnel	plots	(Egger	et	al.,	1997)	and	statistically.	Duval	
and	 Tweedie’s	 Trim	 and	 Fill	 (Duval	 and	 Tweedie,	 2000)	 method	 was	 used	 to	 impute	 the	
number	 of	 studies	 that	 might	 exist	 but	 that	 were	 missing	 from	 the	 literature	 search	 and	
estimate	what	effect	these	studies	might	have	had	on	the	outcome.	Both	the	observed	and	
imputed	studies	were	viewed	visually	 in	funnel	plots.	Asymmetry	and/or	a	 large	number	of	
imputed	studies	and	their	effect	was	noted	and	attempts	made	to	ascertain	the	reasons.	
5. Additional	analysis	–	“Describe	methods	of	additional	analyses	(e.g.,	sensitivity	or	subgroup	
analyses,	 meta-regression),	 if	 done,	 indicating	 which	 were	 pre-specified”	 (Moher	 et	 al.,	
2009).	The	only	subgroup	defined	for	separate	analysis	a	priori	was	individual	antibiotics	that	
featured	in	5	or	more	articles.	In	view	of	the	results	of	the	questionnaire	reported	in	chapter	
3,	 antibiotics	 with	 significant	 UK-wide	 usage	 as	 extended	 infusions	 were	 also	 analysed	
individually.	 Subgroups	were	 analysed	 using	 the	 same	 statistical	methods	 as	 described	 for	
the	 main	 results.	 Specifics	 of	 the	 sensitivity	 analysis	 were	 not	 defined	 a	 priori	 but	 were	
performed	on	primary	outcomes	and	any	outcomes	 yielding	a	 significant	 result.	 Sensitivity	
analysis	was	 conducted	 to	assess	 the	 impact	of	decisions	made	 in	 the	design	phase	of	 the	
meta-analysis	on	 the	 significance	of	 the	 results.	 For	 example,	 replacing	RR	with	odds	 ratio	
(OR)	and	in	another	instance	using	a	fixed-effects	model	rather	than	random-effects	as	part	
of	the	overall	analysis	to	investigate	what	effect,	if	any,	the	choice	of	statistical	test	had	had.	
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2.2	Summary	of	overall	methodological	approach	
To	 summarise,	 the	 final	 approach	 taken	 to	 address	 the	 aim	 of	 the	 study	 was	 as	 follows.	 A	
questionnaire	 was	 circulated	 to	 UK	 critical	 care	 pharmacists	 electronically	 via	 the	 UKCPA	 CCG	
message	 board	 to	 assess	 current	methods	 of	 intravenous	 antibiotic	 administration	 practice	 on	 UK	
critical	care	units.	Along	side	this,	a	systematic	review	and	meta-analysis	of	published	RCTs	comparing	
methods	 of	 intravenous	 antibiotic	 administration	was	 conducted	 to	 assess	 the	 evidence	 base.	 The	
findings	of	the	review	were	used	to	examine	UK	practice	and	assess	its	appropriateness.			
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3	 Phase	1:	An	investigation	to	define	the	current	practices	of	intravenous	
antibiotic	administration	in	septic	patients	in	United	Kingdom	Critical	Care	
Units	(UK	CCUs)	
	
3.1	 Introduction	
	
Choice	of	 antibiotic	 in	 the	hospital	 setting	 is	 largely	 guided	by	 local	policy	 and	antibiotic	 guidelines	
that	 have	 been	 developed	 with	 common	 organisms/infection	 sites	 and	 resistance/susceptibility	
patterns	 in	 mind.	 Antibiotic	 policies	 will	 generally	 state	 the	 antibiotic	 to	 be	 prescribed,	 its	 dose,	
frequency	and	route	of	administration	but	it	rarely	states	a	method	of	administration	e.g.	how	quickly	
a	bolus	should	be	given	or	the	time	over	which	an	infusion	should	run.	
	
At	 the	 time	 of	 conception	 of	 this	 study	 there	was	 nothing	 in	 the	 published	 literature	 investigating	
current	 practice.	 Conducted	 at	 a	 similar	 time	 to	 this	 questionnaire	 and	 published	 in	 2015	 was	 an	
international	survey	led	by	Alexis	Tabah	(Tabah	et	al.,	2015),	it	investigated	what	current	practices	of	
antimicrobial	dosing	and	monitoring	exist	in	Intensive	Care	Units	(ICU)	around	the	world.	402	health	
care	 professionals	 from	 53	 countries	 responded.	 Respondents	 were	 predominantly	 specialist	 ICU	
medical	staff	(78%)	with	12%	being	pharmacists.	The	survey	was	based	around	a	clinical	scenario	with	
a	questionnaire	devised	to	gather	information	on	the	dosing,	administration	and	monitoring	practices	
for	5	antibacterial	agents/groups	commonly	used	 in	critically	 ill	patients,	namely	glycopeptides	 (e.g.	
vancomycin),	piperacillin/tazobactam,	carbopenems,	aminoglycosides	and	colistin.	The	study	showed	
very	 diverse	 practices	 in	 the	 dosing	 and	 monitoring	 of	 the	 antibiotics	 studied	 and	 suggested	 that	
further	research	to	develop	best	practice	guidelines	is	required.	
	
Guidance	is	important	and	is	often	issued	nationally	to	standardise	practice	in	line	with	gold	
standards.	This	is	particularly	important	in	common	conditions	that	are	often	managed	in	non-
specialist	environments.	For	instance	a	ruptured	aortic	aneurism	would	be	managed	in	a	specialist	
cardiothoracic	centre	but	a	myocardial	infarction	would	be	dealt	with	in	any	hospital	and	there	is	an	
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expectation	that	care	would	be	the	same	wherever	the	patient	presented.	Infection	and	more	
specifically	sepsis	are	major	causes	of	mortality	globally	with	lower	respiratory	tract	infection	ranked	
2nd	in	2010	behind	ischaemic	heart	disease	(Lozano	et	al.,	2012).	In	the	general	intensive	care	setting	
infection	and	related	sepsis	is	the	leading	cause	of	death	with	a	mortality	rate	of	up	to	60%	(Vincent	
et	al.,	2009).	In	the	modern	era	of	evidenced	based	medicine	many	causes	of	significant	
morbidity/mortality	have	nationally	recommended	therapies	that	are	consistently	applied	unless	the	
patient	has	a	contra-indication.	For	example	NICE	have	issued	many	guidelines	on	the	prevention	and	
management	of	cardiac	disease	even	down	to	documents	for	specific	therapies	such	as	lipid	
modification	(NICE,	2014).	Regardless	of	where	one	presents	in	the	UK	with	a	cardiovascular	event	
they	should	receive	atorvastatin	80mg	once	daily	unless	contraindicated	and	if	they	don’t	this	would	
be	very	hard	to	justify.	Although	guidance	exists	around	certain	aspects	of	antibacterial	therapy	such	
as	timing	(i.e.	how	soon	after	a	patient	presents	with	sepsis	antibiotics	need	to	be	administered)	and	
which	classes	of	antibacterial	should	be	used	(Dellinger	et	al.,	2013)	there	is	very	little	to	guide	
clinicians	around	methods	of	intravenous	antibacterial	administration.	In	light	of	the	plethora	of	
favourable	pk/pd	evidence	for	extended	infusions	of	certain	antibiotic	classes	some	clinicians	may	be	
adopting	these	methods	first	line	whilst	as	yet	they	are	off-label	and	there	is	no	compelling	evidence	
of	mortality/morbidity	benefit.	Guidance	in	this	area	may	aid	the	clinician	to	make	a	balanced	
decision	on	whether	they	adopt	this	practice	or	not.	
	
A	survey	of	UK	practice	would	provide	 insight	 into	current	approaches	and	any	deviations	 from	the	
methods	of	administration	detailed	in	the	marketing	authorisation.	It	would	also	allow	us	to	examine	
whether	 any	of	 the	novel	methods,	 such	 as	 EIIs	 and	CIs,	 are	 commonplace	or	 usual	 practice.	 CCUs	
would	be	able	to	gauge	their	practice	relative	to	a	UK-wide	database	of	practice	and	this	in	turn	may	
lead	some	outliers	to	modify	practice	accordingly	to	standardise	care.	
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3.2	 Aim	and	objectives	
	
3.2.1	 Aim	
To	ascertain	current	usual	local	methods	of	intravenous	antibiotic	administration	across	UK	critical	
care	units	to	determine	if	a	common	practice	exists	and	the	factors	influencing	the	adoption	of	
extended	or	continuous	infusions	of	antibiotics.	
3.2.2	 Objectives		
i. To	collect	demographic	data	about	the	responding	pharmacist/critical	care	unit		
ii. To	identify	how	antibiotic	prescribing	is	managed	in	the	critical	care	setting		
iii. To	 identify	 if	 any	 antibiotics	 in	 a	 given	 class	 are	used	 in	 preference	 to	others	 of	 the	 same	
class	nationally	e.g.	carbopenems	
iv. To	identify	whether	any	usual	practice	exists	
v. To	identify	whether	extended	or	continuous	infusion	administration	is	used	in	preference	to	
licensed	administration	practices	in	any	critical	care	units	
vi. To	examine	the	driving	forces	e.g.	grade	of	pharmacist	for	adoption	of	uncommon	practices	
in	outlying	units		
vii. To	 examine	 what	 patient	 orientated	 factors	 influence	 choice	 of	 method	 of	 intravenous	
administration	e.g.	renal	function	
	
3.3	 Methods	
	
3.3.1	 Literature	Search	
	
A	title	and	abstract	search	was	conducted	through	Medline,	Embase	and	CINAHL	electronically	from	
launch	 (1950,	 1980	 and	 1982	 respectively)	 to	 31st	 May	 2013.	 Searches	 were	 restricted	 to	 human	
studies	 but	 performed	without	 any	 other	 limits	 such	 as	 language	 or	 age	 of	 subject.	 Searches	 used	
combinations	of	the	following	terms	matched	in	each	database	thesaurus:	critical	care,	intensive	care,	
antibiotic,	 anti-bacterial	 and	health	 care	 survey	 (see	 appendix	 6	 for	 full	 search	 strategy).	 Titles	 and	
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abstracts	were	 retrieved	 and	 reviewed.	 Duplicates	were	 removed	 and	 articles	were	 filtered	 at	 this	
stage	to	exclude	those	without	an	English	abstract,	whose	subject	was	the	paediatric	population,	and	
any	 that	 did	 not	 contain	 information	 about	 antibiotic	 administration.	 Articles	 including	 patients	
managed	outside	of	the	critical	care	environment	were	included	as	access	to	critical	care	as	defined	in	
the	UK	may	not	be	the	same	worldwide.	Where	necessary	full	articles	were	retrieved	and	reviewed	
for	the	remaining	articles.		
	
3.3.2	 Questionnaire	development	and	design	
	
3.3.2.1	 Participants		
	
The	 participant	 group	 for	 this	 study	was	 critical	 care	 pharmacists	who	 are	members	 of	 the	United	
Kingdom	Clinical	Pharmacy	Association	Critical	Care	Group	(UKCPA	CCG).	Only	pharmacists	currently	
working	in	UK	CCUs	with	an	up	to	date	knowledge	of	their	CCU	antibiotic	administration	practice	were	
invited	to	participate.		
	
Critical	care	pharmacists	practicing	outside	of	the	UK	were	excluded	as	their	practice	may	differ	due	
to	differences	in	licensing,	drug	availability,	causative	organisms	and	resistance	patterns.	No	Non-UK	
critical	 care	 pharmacists	 (i.e.	 Non-UK	 members	 of	 the	 UKCPA	 CCG)	 responded,	 only	 pharmacists	
registered	with	the	UKCPA	CCG	message	board	received	the	invite	to	participate	and	they	were	asked	
to	provide	details	of	the	hospital	trust	in	which	they	worked.	Other	exclusion	criteria	were	not	being	a	
critical	care	pharmacist	and/or	not	being	a	member	of	the	UKCPA	CCG.	Non-critical	care	pharmacists	
were	 asked	 to	 exit	 the	 questionnaire	 at	 the	 first	 question.	 Critical	 care	 pharmacists	 that	 are	 not	
members	of	the	UKCPA	CCG	were	excluded	by	the	fact	that	they	did	not	receive	the	email	alerts	with	
the	hyperlink	attached.	
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3.2.2.2	 Questionnaire	design		
	
The	questionnaire	was	designed	using	a	web-based	provider,	Bristol	Online	Surveys,	and	is	attached	
in	full	as	appendix	2.			
	
Choice	 of	 the	 topics	 and	 questions	 for	 inclusion/exclusion	 in	 the	 questionnaire	 was	 guided	 by	
personal	experience	of	the	subject	matter	and	by	taking	into	account	published	literature	to	identify	
common	 themes	 and	 relevant	 antibiotics	 (Craig,	 1998;	 Roberts	 et	 al.,	 2011a;	 Drusano	 and	 Lodise,	
2012;	Carlier	et	al.,	2013;	Dulhunty	et	al.,	2013a).		
	
The	questionnaire	begins	with	conformation	 that	 the	 respondent	 is	a	 currently	practicing	UK-based	
critical	care	pharmacist.	 If	they	weren’t	they	were	asked	to	stop	at	this	point.	The	remainder	of	the	
questionnaire	comprises	questions	that	capture	the	following:	
1. Pertinent	demographic	information.			
2. The	usual/common	method	of	intravenous	administration	of	each	antibiotic		
3. Alternative	methods	being	used	to	administer	intravenous	antibiotics		
4. The	driving	forces	for	selection	of	certain	intravenous	administration	practices	
The	questions	in	full	are	available	in	appendix	2.	
	
Where	possible	the	questionnaire	used	closed	questions	and	radio	buttons	restricting	the	respondent	
to	 set	 answers.	 The	 perceived	 benefit	 of	 this	 style	 of	 question	 was	 that	 it	 would	 categorise	 the	
information	received.	Where	this	approach	wasn’t	possible	a	semi-closed	style	was	used	with	drop-
down	options	with	an	option	for	free-type	responses.	Open	questions	were	limited	to	instances	were	
there	 were	 too	 many	 options	 to	 practically	 list	 e.g.	 Hospital	 Trust,	 the	 answer	 couldn’t	 easily	 be	
predicted	or	a	description	of	practice	was	required.	
	
An	area	where	there	was	potential	for	confusion	and	which	could	affect	the	reliability	of	the	result	
was	in	the	choice	of	administration	method,	e.g.	an	infusion	over	1	or	2	hours	would	usually	be	
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described	as	a	short	infusion	but	respondents	may	also	describe	this	as	an	extended	intermittent	
infusion.	To	manage	this	risk	five	methods	of	administration	were	described	with	a	help	option	for	
participant	to	hover	over	for	further	description	of	the	method	in	question.	Four	main	methods	of	
administration	were	described.	It	was	also	necessary	to	describe	a	fifth	that	is	a	combination	of	2.	
These	methods	and	their	explanations	are	reproduced	in	table	3.1	below.	
	
Table	3.1	An	explanation	of	the	different	methods	of	administration,	and	the	abbreviation	used	in	the	
text	
Method	of	administration	(abbreviation	used	in	
the	text)	
Description	
Bolus	(B)	 Bolus	injection	i.e.	over	5	minutes	or	less,	also	
called	a	“slow	push”	in	clinical	practice.		
Short	infusion	(S/SPC)	 Short	infusion	as	per	the	SPC.	
Short	infusion/Bolus	(S/B)	 Short	 infusion	 as	 per	 the	 Summary	 of	 Product	
Characteristics	 (SPC)	 or	 Bolus	 injection	
dependent	on	dose.	For	some	antibiotics	the	SPC	
suggests	 different	 methods	 of	 administration	
dependent	 upon	 the	 size	 of	 the	 dose	 being	
administered.	 For	example,	 Flucloxacillin	1g	as	a	
bolus	or	short	infusion	but	2g	as	a	short	infusion	
only.	
Extended	intermittent	infusion	(EII)	 The	 drug	 is	 infused	 over	 a	 period	 that	 is	 longer	
than	that	suggested	in	the	SPC,	usually	over	3	or	
4	hours	but	not	continuously	
Continuous	infusion	(CI)	 The	drug	is	 infused	continuously,	usually	at	a	set	
rate,	for	the	duration	of	the	treatment	course	
	
3.3.2.3	 Ethics	and	consent	
	
Ethical	approval	 for	 the	study	was	obtained	 from	Liverpool	 John	Moores	University	Research	Ethics	
Committee	(UREC)	(13/SPS/044).		
	
Three	 questions	 were	 included	 that	 could	 potentially	 allow	 identification	 of	 the	 pharmacist	 who	
completed	the	questionnaire;	NHS	Trust,	grade	and	level	of	experience.	These	details	were	required	
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to	 allow	 identification	 and	 removal	 of	 duplicate	 responses	 from	 the	 same	 Trust	 but	 no	 details	
identifying	Trusts	will	be	published,	as	the	aim	of	the	study	is	to	look	at	UK	trends	not	individual	Trust	
practice.	
	
By	completing	the	questionnaire	it	was	assumed	that	the	participant	was	consenting	to	be	involved	in	
the	 study,	 as	 informed	 in	 the	 participant	 information	 (see	 appendix	 2)	 at	 the	 start	 of	 the	
questionnaire.		
	
3.3.2.4	 Piloting	
	
Following	 UREC	 approval,	 the	 questionnaire	 underwent	 a	 pilot	 phase	 on	 four	 purposively	 sampled	
critical	care	pharmacists	in	other	UK	NHS	Trusts	to	assess	validity	and	reliability	and	to	test	practical	
issues	such	as	ease	of	use,	unforeseen	question	ambiguity,	etc.	The	questionnaire	was	then	further	
piloted	 on	 a	 small	 group	 of	 intended	 recipients	 to	 test	 reliability	 of	 response.	 Comments	 received	
were	considered	but	no	changes	to	the	questionnaire	were	deemed	necessary.		
	
3.3.2.5	 Recruitment		
	
Participants	were	invited	to	complete	the	questionnaire	via	the	UKCPA	CCG	message	board.	After	the	
first	posting	there	were	two	follow-up	messages	with	the	link	as	reminders	at	2	weeks	and	6	weeks	
after	 the	 initial	 posting	 (see	 appendix	 3	 for	 the	 participant	 information	 sheet	 and	 appendix	 4	 for	
copies	 of	 the	messages	 posted).	 There	 are	 approximately	 240	 CCUs	 in	 the	 UK	 and,	 at	 the	 time	 of	
posting	 the	 link,	 600	 pharmacists	 registered	 with	 the	 CCG	 message	 board.	 As	 there	 were	 more	
pharmacists	registered	with	the	message	board	than	there	are	CCUs	in	the	UK	(and	it	is	the	practice	
on	the	CCUs	that	the	research	is	focused	on)	there	was	a	risk	of	duplicate	responses	(from	the	same	
hospital	by	different	pharmacists).	The	approach	to	duplicates	was	standardised	 for	 the	study;	 they	
were	 screened	 by	 CCU	 and	 the	 response	 from	 the	 most	 experienced	 pharmacist	 selected.	 This	
method	 was	 selected	 on	 the	 basis	 that	 they	 would	 potentially	 be	more	 knowledgeable	 about	 the	
practices	than	more	junior	pharmacists.	Agenda	for	Change	band	(AfC)	(Jones	et	al.,	2005)	was	used	
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as	 the	marker	of	 experience	 (8b-9	being	 the	most	experienced	and	6	being	 the	 least),	 if	 there	was	
more	than	one	pharmacist	on	the	same	band	the	years	experience	was	taken	into	account	next.	A	list	
of	 all	 Critical	 Care	 Units	 was	 obtained	 from	 the	 Intensive	 Care	 National	 Audit	 &	 Research	 Centre	
(ICNARC,	England,	Wales	and	Northern	Ireland)	and	the	Scottish	Intensive	Care	Societies	Audit	Group	
(SICSAG,	Scotland)	and	all	units	 listed	with	a	pharmacist	who	 is	a	member	of	 the	UKCPA	CCG	were	
invited	to	participate.	This	information	also	enabled	an	accurate	response	rate	to	be	calculated	during	
final	data	analysis.	
	
3.3.2.6	 Data	analysis		
	
Before	the	questionnaire	was	 launched,	a	plan	of	statistical	analysis	was	developed	and	 included	 in	
the	 university	 ethics	 application.	 Data	 were	 exported	 from	 Bristol	 Online	 Surveys®	 into	 Excel®	
(Microsoft®	Excel®	of	Mac®	2011,	version	14.6.2)	and	SPSS®	(IBM	SPSS	statistics	version	21)	as	comma	
separated	values	(.csv).	Demographic	data	(questions	2-10)	were	presented	using	Excel	as	distribution	
frequencies	and	percentages	as	were	data	comparing	antibiotics,	the	method	of	administration,	the	
stated	 factors	 influencing	 practice	 and	 the	 rate	 of	 TDM	 (questions	 12-17).	 Usual	 practice	 was	
identified	as	existing	when	an	antibiotic	was	administered	by	the	same	method	on	greater	than	50%	
of	 responding	 CCUs.	 SPSS®	was	 used	 to	 perform	 a	 Chi	 squared	 test	 to	 assess	 differences	 between	
groups,	specifically	antibiotic	administration	practice	and	certain	demographics	(questions	2-5	and	7-
10).	A	two-sided	P-value	<0.05	was	considered	statistically	significant.	
	
3.4	 Results	
	
3.4.1	 Literature	search	
	
A	 structured	 search	 of	 the	 literature	 found	 no	 articles	 reporting	 surveys	 of	 antibacterial	
administration	 practices	 in	 the	 adult	 critical	 care	 setting	 in	 UK	 or	 elsewhere	 in	 the	 world.	 For	 full	
search	strategy	see	appendix	1.		
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3.4.2	 Questionnaire	pilot	
	
The	questionnaire	was	piloted	on	a	total	of	6	UK	critical	care	pharmacists.	They	fed	back	verbally	or	
via	email.	Only	one	suggested	change	was	made,	that	a	respondent	should	fill	out	one	form	per	Trust	
rather	than	per	unit	but	this	was	rejected	on	the	basis	that	it	would	affect	the	ability	to	analyse	data	
on	different	 units	 in	 the	 same	Trust	 if	 practice	on	 the	units	was	different.	 The	pilot	 data	were	not	
included	in	the	study	as	the	pharmacists	were	unable	to	use	the	live	online	survey,	once	launched	the	
survey	could	not	then	be	altered	in	any	way.	
	
3.4.3	 Response	rate	
	
At	 the	 time	 of	 the	 questionnaire	 there	were	 244	 CCUs	 in	 the	UK.	 The	 questionnaire	 asked	 for	 the	
pharmacist	responding	to	do	so	for	all	the	CCUs	that	they	worked	on,	some	may	cover	multiple	CCUs	
within	the	same	Trust.	 In	total,	54	pharmacists	responded	on	behalf	of	64	CCUs,	a	response	rate	of	
26.2%.		
	
3.4.4	 Pharmacist	Demographics	
	
90.6%	 (58/64)	 of	 responding	 CCUs	 were	 from	 England,	 one	 CCU	 was	 in	 Northern	 Ireland	 and	 the	
remaining	 5	 in	 Scotland	 (Table	 3.2).	 At	 least	 one	 unit	 responded	 from	 the	majority	 of	 Critical	 Care	
Networks	(CCNs)/regions	in	the	UK	as	defined	by	ICNARC/SICSAG	(23/29,	Chart	3.1).	The	specialty	of	
93.7%	 (60/64)	 of	 the	 CCUs	 was	 described	 as	 General/Mixed	 (as	 apposed	 to	 specifically	 Medical,	
Surgical	or	Neurosciences	for	example)	by	the	responding	pharmacist	(Table	3.2).		
Of	the	54	pharmacists	92.6%	(50/54)	were	“senior”	pharmacists,	AfC	banding	8a	or	greater	(Table	3.3)	
and	44.4%	(24/54)	have	greater	than	10	years	experience	in	Critical	Care	(Table	3.3).	The	pharmacist	
attended	the	ward	to	review	patients	only	on	weekdays	on	84.3%	of	units	(54/64),	everyday	on	14.1%	
(9/64)	and	rarely	on	1.6%	(1/64)	(Table	3.3).	On	75%	(48/64)	of	units	the	pharmacist	regularly	attends	
the	 consultant-led	 ward	 round	 (Table	 3.3).	 81.3%	 (52/64)	 of	 units	 had	 a	 ward	 round	 with	 the	
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microbiologist	 at	 least	 on	 weekdays,	 the	 remaining	 units	 (18.7%,	 12/64)	 had	 weekly	 ward	 rounds	
(Table	3.3).		
	
3.4.5	 Administration	practices	
The	 usual	method	 of	 administration	 of	 22	 antibacterials	was	 ascertained	 on	 each	 CCU	 (Table	 3.4).	
Frequency	analysis	shows	that	17	of	the	22	antibiotics	have	a	single	method	of	administration	used	on	
more	than	50%	of	the	responding	CCUs	(Table	3.5).		
Four	 antibiotics	 are	 administered	 on	 at	 least	 20%	 of	 CCUs	 by	 EII	 or	 CI:	 Piperacillin/tazobactam,	
doripenem,	meropenem	and	 vancomycin.	Doripenem	 is	 only	 used	 on	 3	 of	 the	 responding	 CCUs	 so	
was	not	included	in	further	analysis.	Piperacillin/tazobactam	and	meropenem	are	used	on	22.2%	and	
20.3%	respectively	of	responding	CCUs	as	EIIs	and	vancomycin	by	CI	on	49.2%	(Table	3.4).	Different	
factors	 significantly	 affected	 the	 adoption	 of	 EII/CI	 for	 each	 drug.	 Higher	 pharmacist	 AfC	 banding	
(p=0.028),	 greater	 pharmacist	 cover	 (p<0.001)	 but	 not	 pharmacist	 attendance	 on	 the	 ward	 round	
(p=0.82)	and	greater	microbiologist	input	(p=0.031)	all	significantly	influenced	the	adoption	of	EIIs	as	
the	usual	method	of	administration	of	piperacillin/tazobactam	in	preference	to	the	method	stated	in	
the	 SPC.	 Practice	 also	 varied	 significantly	 between	 CCNs/Regions	 (Table	 3.6)	 with	 some	 regions	
adopting	 predominantly	 EII	 usage	 and	 others	 using	 either	 bolus	 or	 short	 infusion.	 The	 only	 factor	
significantly	 driving	 EII	 administration	 of	 meropenem	 was	 greater	 pharmacist	 cover	 (p<0.001,	 see	
Table	3.7).	Adoption	of	a	policy	of	vancomycin	administration	by	CI	was	significantly	affected	by	the	
presence	of	the	pharmacist	on	the	consultant-led	ward	round	(p=0.03,	see	Table	3.8).	7.8%	(5/64)	of	
CCUs	 altered	 the	 method	 of	 administration	 in	 patients	 on	 renal	 replacement	 therapy	 (Table	 3.9).	
15.6%	 (10/64)	of	CCUs	altered	 the	method	of	 administration	 for	other	patient	 factors	 (Table	3.10).	
The	 most	 commonly	 stated	 rationale	 for	 using	 EII/CI	 was	 “Evidence	 Based	 –	
pharmacokinetic/pharmacodynamics	 properties”	 with	 48.4%	 (31/64)	 of	 CCUs,	 cost	 was	 the	 least	
popular	 with	 only	 3.7%	 (2/64)	 (Table	 3.11).	 9.4%	 (6/64)	 thought	 that	 the	 total	 daily	 dose	 of	 drug	
differed	when	using	EII/CI,	in	all	cases	the	drug	in	question	was	vancomycin,	on	2	CCUs	they	thought	
they	would	use	a	 lower	over	all	dose	but	on	4	 they	thought	 they	would	use	a	bigger	dose.	No	CCU	
used	EII	with	the	specific	aim	of	reducing	the	total	daily	dose	of	antibacterial	required.	 	Therapeutic	
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drug	 monitoring	 (TDM)	 is	 done	 on	 100%	 of	 responding	 CCUs	 but	 only	 on	 the	 antibacterials	 that	
traditionally	require	it	i.e.	aminoglycosides	(e.g.	gentamicin)	and	glycopeptides	(e.g.	vancomycin).	
	
	 52	
	
	
	
Table	3.2:	Characteristics	of	participating	critical	care	units	(CCUs).	Frequencies	(%)		
	
Variable	 	 No.	of	CCUs	(n=64)	
Country	 	 	 	
	 England	 58	 (90.6)	
	 Wales	 0	 (0)	
	 Scotland	 5	 (7.8)	
	 Northern	Ireland	 1	 (1.6)	
Geographical	location	
(according	to	Critical	
Care	Network	
	 	 	
See	Chart	1	 	 	
	 	 	
	 	 	 	
Type	of	CCU	 	 	 	
	 Medical	 0	 (0)	
	 Surgical	 1	 (1.6)	
	 General/mixed	 60	 (93.7)	
	 Cardiothoracic	 1	 (1.6)	
	 Neurosciences	 0	 (0)	
	 Other*	 2	 (3.1)	
	 Not	known	 	 	
Size	of	CCU	 	 	 	
	 <10	beds	 14	 (21.9)	
	 10-20	beds	 31	 (48.4)	
	 >20	beds	 12	 (18.8)	
	 Not	known	 7	 (10.9)	
*Burns/trauma	x	1,	complex	respiratory	x1	
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Table	3.3:	Characteristics	of	pharmacist	and	microbiologist	input	on	the	CCU.	Frequencies	(%)	
 
Variable	 	 No.	of	CCUs	(n=64)	
Agenda	for	Change	band	 	 	 	
	 6	 0	 (0)	
	 7	 6	 (9.4)	
	 8a	 31	 (48.4)	
	 8b-9	 27	 (42.2)	
Number	of	years	working	in	critical	care	 	 	 	
	 <1	 2	 (3.1)	
	 1-5	 11	 (17.2)	
	 6-10	 19	 (29.7)	
	 >10	 32	 (50.0)	
Does	the	CCU	have	pharmacist	cover	 	 	 	
	 Never	 0	 (0)	
	 Rarely/ad	hoc	 1	 (1.6)	
	 Weekdays	 52	 (81.3)	
	 Weekdays	and	Saturdays	 0	 (0)	
	 Everyday	 11	 (17.2)	
Does	the	pharmacist	generally	attend	the	
consultant-led	ward	round	
	 	 	
Yes	 47	 (73.4)	
No	 17	 (26.6)	
Does	the	medical	microbiologist	do	regular	
ward	rounds	on	the	CCU	
	 	 	
No	 0	 (0)	
Weekly	 13	 (20.3)	
Weekdays	 41	 (64.1)	
Everyday	 10	 (15.6)	
Not	sure	 0	 (0)	
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Table	3.4:	Comparison	of	antibiotic	with	its	usual	method	of	administration	on	each	CCU.	Frequency	
(%	of	total	CCUs	using	the	antibiotic)	
	
Antibiotic	
Usual	method	of	administration*	
B	 S/B	 S/SPC	 EII	 CI	 N/A	 Number	
of	CCUs	
Benzylpenicillin	 30		 (48.4)	 6	 (9.7)	 22	 (35.5)	 	 	 4		 (6.4)	 2	 62	
Flucloxacillin	 30	 (46.9)	 8	 (12.5)	 22	 (34.4)	 	 	 4	 (6.2)	 	 64	
Amoxicillin	 38	 (65.5)	 8	 (13.8)	 12	 (20.7)	 	 	 	 	 6	 58	
Ampicillin	 1	 (50)	 	 	 1	 (50)	 	 	 	 	 62	 2	
Co-amoxiclav	 40	 (67.8)	 	 	 13	 (22)	 6	 (10.2)	 	 	 5	 59	
Piperacillin/	
Tazobactam	
17	 (27)	 	 	 32	 (50.8)	 14	 (22.2)	 	 	 1	 63	
Ticarcillin/	
Clavulanic	acid	
	 	 	 	 10	 (100)	 	 	 	 	 54	 10	
Cefotaxime	 20	 (60.6)	 2	 (6.1)	 11	 (33.3)	 	 	 	 	 31	 33	
Ceftazidime	 20	 (40.8)	 1	 (2)	 20	 (40.8)	 8	 (16.4)	 	 	 15	 49	
Ceftriaxone	 22	 (36.7)	 1	 (1.7)	 33	 (55)	 4	 (6.6)	 	 	 4	 60	
Cefuroxime	 24	 (61.5)	 	 	 11	 (28.2)	 4		 (10.3)	 	 	 25	 39	
Doripenem	 	 	 	 	 2	 (66.7)	 1	 (33.3)	 	 	 61	 3	
Ertapenem	 5	 (13.2)	 	 	 33	 (86.8)	 	 	 	 	 26	 38	
Imipenem/	
Cilastatin	
	 	 	 	 5	 (100)	 	 	 	 	 59	 5	
Meropenem	 29	 (45.3)	 4	 (6.3)	 18	 (28.1)	 13	 (20.3)	 	 	 	 64	
Tigecycline	 	 	 	 	 38	 (100)	 	 	 	 	 26	 38	
Clarithromycin	 	 	 	 	 63	 (98.4)	 1	 (1.6)	 	 	 	 64	
Clindamycin	 	 	 	 	 62	 (96.8)	 2	 (3.2)	 	 	 	 64	
Vancomycin	 	 	 	 	 32	 (50.8)	 	 	 31	 (49.2)	 1	 63	
Teicoplanin	 34	 (57.6)	 	 	 25	 (42.4)	 	 	 	 	 5	 59	
Linezolid	 	 	 	 	 60	 (96.7)	 2	 (1.7)	 	 	 2	 62	
Ciprofloxacin	 	 	 	 	 64	 (100)	 	 	 	 	 	 64	
	
*Key	to	heading	abbreviations	
B	=	Bolus	injection	i.e.	over	5	minutes	or	less,	also	called	a	“slow	push”	in	clinical	practice.	
S/B	=	Short	infusion	as	per	the	Summary	of	Product	Characteristics	(SPC)	or	Bolus	injection	
dependent	on	dose.	For	some	antibiotics	the	SPC	suggests	different	methods	of	
administration	dependent	up	the	size	of	the	dose	being	administered.	For	example,	
Flucloxacillin	1g	as	a	bolus	or	short	infusion	but	2g	as	a	short	infusion	only.	
S/SPC	=	Short	infusion	as	per	the	SPC.	
EII	=	Extended	intermittent	infusion	i.e.	the	drug	is	infused	over	a	period	that	is	longer	than	
that	suggested	in	the	SPC	
CI	=	Continuous	infusion	i.e.	the	drug	is	infused	continuously	for	the	duration	of	the	
treatment	course	
N/A	=	not	used	on	a	given	CCU	
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Table	3.5:	Antibiotic,	its	usual	method	of	administration	and	the	percentage	of	CCU	administering	
this	way	
	
Antibiotic	 Method	of	
Administration*	
Frequency/CCUs	using	(%)	
Amoxicillin	 B	 38/58	 (65.5)	
Co-amoxiclav	 B	 40/59	 (67.8)	
Piperacillin/Tazobactam	 S/SPC	 32/63	 (50.8)	
Ticarcillin/Clavulanic	acid	 S/SPC	 10/10	 (100)	
Cefotaxime	 B	 20/33	 (60.6)	
Ceftriaxone	 S/SPC	 33/60	 (55)	
Cefuroxime	 B	 24/39	 (61.5)	
Doripenem	 S/SPC	 2/3	 (66.7)	
Ertapenem	 S/SPC	 33/38	 (86.8)	
Imipenem/Cilastatin	 S/SPC	 5/5	 (100)	
Tigecycline	 S/SPC	 38/38	 (100)	
Clarithromycin	 S/SPC	 63/64	 (98.4)	
Clindamycin	 S/SPC	 62/64	 (96.8)	
Vancomycin	 S/SPC	 32/63	 (50.8)	
Teicoplanin	 B	 34/59	 (57.6)	
Linezolid	 S/SPC	 60/62	 (96.7)	
Ciprofloxacin	 S/SPC	 64/64	 (100)	
		
*Key	to	heading	abbreviations	
B	=	Bolus	injection	i.e.	over	5	minutes	or	less,	also	called	a	“slow	push”	in	clinical	practice.	
S/SPC	=	Short	infusion	(e.g.	over	20	minutes)	as	per	Summary	of	Product	Characteristics	
(SPC).			
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Table	3.6:	Factors	affecting	method	of	administration	of	piperacillin/tazobactam	
	
Variable	 Method	of	administration*	 	
	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Country	 	 	 	 	 	 	 	
	 England	 16	 	 27	 14	 	 1	 0.129	
	 Scotland	 	 	 5	 	 	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 1	 	 	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 For	details	see	table	7a	 0.017	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 5	 	 6	 3	 	 	 0.177	
10	–	20		 6	 	 17	 8	 	 	 	
>20		 5	 	 3	 3	 	 1	 	
Not	known	 1	 	 6	 	 	 	 	
AfC	band	 	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.028	
	 7	 	 	 6	 	 	 	 	
	 8a	 12	 	 13	 5	 	 1	 	
	 >8b	 5	 	 13	 9	 	 	 	
How	long	have	you	been	working	in	Critical	Care	(years)	
	 	 	 	
	 <1	 	 	 2	 	 	 	 0.604	
	 1-5	 5	 	 5	 1	 	 	 	
	 6-10	 5	 	 10	 4	 	 	 	
	 >10	 7	 	 15	 9	 	 1	 	
Does	the	CCU	have	pharmacist	cover	
	 	 	 	 	 	
	 Never	 	 	 	 	 	 	 <0.001	
Rarely/ad	hoc	 1	 	 	 	 	 	 	
	 Weekdays	 15	 	 31	 5	 	 1	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	
	 Everyday	 1	 	 1	 9	 	 	 	
Does	the	pharmacist	generally	attend	the	ward	round	
	 	 	 	
	 Yes	 12	 	 23	 11	 	 1	 0.820	
	 No	 5	 	 9	 3	 	 	 	
Does	the	CCU	have	regular	ward	rounds	with	the	microbiologist	
	 	 	 	
7	days	a	week	 2	 	 3	 4	 	 1	 0.031	
Monday	to	Friday	 9	 	 22	 10	 	 	 	
Weekly	 6	 	 7	 	 	 	 	
	 No	 	 	 	 	 	 	 	
	 Not	sure	 	 	 	 	 	 	 	
§Chi-squared	test	
*Key	to	heading	abbreviations	
B	=	Bolus	injection	i.e.	over	5	minutes	or	less,	also	called	a	“slow	push”	in	clinical	practice.	
S/B	=	Short	infusion	as	per	the	Summary	of	Product	Characteristics	(SPC)	or	Bolus	injection	
dependent	on	dose.		
S/SPC	=	Short	infusion	as	per	the	SPC.	
EII	=	Extended	intermittent	infusion	i.e.	the	drug	is	infused	over	a	period	that	is	longer	than	
that	suggested	in	the	SPC	
CI	=	Continuous	infusion	i.e.	the	drug	is	infused	continuously	for	the	duration	of	the	
treatment	course	
N/A	=	not	used	on	a	given	CCU	
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Table	3.7:	factors	affecting	method	of	administration	of	meropenem	
	
Variable	 Method	of	administration*	 	
	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Which	country	 	 	 	 	 	 	 	
	 England	 25	 4	 16	 13	 	 	 0.556	
	 Scotland	 3	 	 2	 	 	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 1	 	 	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 	 For	details	see	table	7a	 	 	 0.089	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 6	 	 5	 3	 	 	 0.424	
10	–	20	 14	 1	 8	 8	 	 	 	
>20	 6	 2	 2	 2	 	 	 	
Not	known	 3	 1	 3	 	 	 	 	
AfC	band	 	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.056	
	 7	 2	 	 4	 	 	 	 	
	 8a	 18	 1	 8	 4	 	 	 	
	 >8b	 9	 3	 6	 9	 	 	 	
How	long	have	you	been	working	in	Critical	Care	(years)	
	 	 	 	 	
	 <1	 	 	 2	 	 	 	 0.521	
	 1-5	 5	 1	 4	 1	 	 	 	
	 6-10	 10	 1	 5	 3	 	 	 	
	 >10	 14	 2	 7	 9	 	 	 	
Does	the	CCU	have	pharmacist	cover	
	 	 	 	 	 	
	 Never	 	 	 	 	 	 	 <0.001	
Rarely/ad	hoc	 	 	 1	 	 	 	 	
	 Weekdays	 28	 4	 16	 4	 	 	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	
	 Everyday	 1	 	 1	 9	 	 	 	
Does	the	pharmacist	generally	attend	the	ward	round	
	 	 	 	
	 Yes	 23	 1	 13	 10	 	 	 0.194	
	 No	 6	 3	 5	 3	 	 	 	
Does	the	CCU	have	regular	ward	rounds	with	the	microbiologist	
	 	 	 	
7	days	a	week	 5	 	 1	 4	 	 	 0.087	
Monday	to	Friday	 16	 3	 13	 9	 	 	 	
Weekly	 8	 1	 4	 	 	 	 	
	 No	 	 	 	 	 	 	 	
	 Not	sure	 	 	 	 	 	 	 	
§Chi-squared	test	
*Key	to	heading	abbreviations	
B	=	Bolus	injection	i.e.	over	5	minutes	or	less,	also	called	a	“slow	push”	in	clinical	practice.	
S/B	=	Short	infusion	as	per	the	Summary	of	Product	Characteristics	(SPC)	or	Bolus	injection	
dependent	on	dose.		
S/SPC	=	Short	infusion	as	per	the	SPC.	
EII	=	Extended	intermittent	infusion	i.e.	the	drug	is	infused	over	a	period	that	is	longer	than	
that	suggested	in	the	SPC	
CI	=	Continuous	infusion	i.e.	the	drug	is	infused	continuously	for	the	duration	of	the	
treatment	course	
N/A	=	not	used	on	a	given	CCU	
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Table	3.8:	Factors	affecting	method	of	administration	of	vancomycin	
	
Variable	 Method	of	administration*	 	
	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Which	country	 	 	 	 	 	 	 	
	 England	 	 	 30	 	 27	 1	 0.455	
	 Scotland	 	 	 1	 	 4	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 	 	 1	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 	 For	details	see	table	7a	 	 	 0.154	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 	 	 10	 	 4	 	 0.580	
10	–	20	 	 	 14	 	 16	 1	 	
>20	 	 	 5	 	 7	 	 	
Not	known	 	 	 3	 	 4	 	 	
AfC	band?	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.142	
	 7	 	 	 3	 	 3	 	 	
	 8a	 	 	 20	 	 11	 	 	
	 >8b	 	 	 9	 	 17	 1	 	
How	long	have	you	been	working	in	Critical	Care	(years)	 	 		 	 	
	 <1	 	 	 1	 	 1	 	 0.291	
	 1-5	 	 	 7	 	 4	 	 	
	 6-10	 	 	 12	 	 6	 1	 	
	 >10	 	 	 12	 	 20	 	 	
Does	the	CCU	have	pharmacist	cover	 	
	 	 	 	 	
	 Never	 	 	 	 	 	 	 0.109	
Rarely/ad	hoc	 	 	 1	 	 	 	 	
	 Weekdays	 	 	 29	 	 22	 1	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	
	 Everyday	 	 	 2	 	 9	 	 	
Does	the	pharmacist	generally	attend	the	ward	round	 	
	
	 	
	 Yes	 	 	 19	 	 27	 1	 0.030	
	 No	 	 	 13	 	 4	 	 	
Does	the	CCU	have	regular	ward	rounds	with	the	microbiologist	 	
	
	 	
7	days	a	week	 	 	 3	 	 7	 	 0.342	
Monday	to	Friday	 	 	 20	 	 20	 1	 	
Weekly	 	 	 9	 	 4	 	 	
	 No	 	 	 	 	 	 	 	
	 Not	sure	 	 	 	 	 	 	 	
§Chi-squared	test	
*Key	to	heading	abbreviations	
B	=	Bolus	injection	i.e.	over	5	minutes	or	less,	also	called	a	“slow	push”	in	clinical	practice.	
S/B	=	Short	infusion	as	per	the	Summary	of	Product	Characteristics	(SPC)	or	Bolus	injection	
dependent	on	dose.		
S/SPC	=	Short	infusion	as	per	the	SPC.	
EII	=	Extended	intermittent	infusion	i.e.	the	drug	is	infused	over	a	period	that	is	longer	than	
that	suggested	in	the	SPC	
CI	=	Continuous	infusion	i.e.	the	drug	is	infused	continuously	for	the	duration	of	the	
treatment	course	
N/A	=	not	used	on	a	given	CCU	
	 60	
	
*Ease	of	administration	and/or	monitoring	
	
	
	
	
	
	
	
	
	
	
	
Table	3.9:	Administration	practices	in	patients	receiving	renal	replacement	therapy	where	different	
from	usual	practice	
	
Change	in	practice	 Frequency	
Reduce	volume	 2	
CI	of	Piperacillin/Tazobactam	as	9g	over	24hrs	 1	
Piperacillin/Tazobactam	as	short	infusion	rather	than	bolus	 1	
Vancomycin	as	per	SPC	rather	than	CI	 1	
	
	
Table	3.10:	Other	factors	influencing	deviation	from	usual	administration	practices	in	CCU	patients	
	
Factor	 Frequency	
Reduce	volume	if	fluid	restricted	 2	
Divide	dose	of	vancomycin	if	endocarditis	 1	
EII/CI	if	pt	“septic	shock”	 4	
EII/CI	in	major	burns	 1	
EII	for	Pseudamonas	spp	 2	
	
	
	
Table	3.11:	Reasons	for	choosing	EIIs	or	CIs	over	conventional	administration	strategies		
	
Factor	 Frequency	
Cost	 2	
Reduced	toxicity	 13	
Evidence	based	–	improved	outcomes	 26	
Evidence	based	–	pk/pd	properties	 31	
Never	used	 22	
Other*	 9	
*Other		
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3.5	 Discussion	
3.5.1	 Overview	
This	is	the	first	UK-wide	survey	of	critical	care	units	conducted	to	examine	methods	of	intravenous	
antibiotic	administration,	establish	what	usual	practice	exists	and	the	extent	of	novel	methods	of	
administration.	It	was	found	that	usual	administration	practice	existed	for	the	majority	of	intravenous	
antibiotics	surveyed	and	in	all	instances	this	usual	practice	followed	the	licensed	method	stated	in	the	
SPC.	Three	antibiotics	are	frequently	administered	by	EII	or	CI;	meropenem	and	
piperacillin/tazobactam	by	EII	and	vancomycin	by	CI.	The	significant	demographic	and	patient-
orientated	driving	forces	varied.	The	most	commonly	stated	rationale	for	adoption	of	EII	or	CI	was	the	
PK/PD	profile	of	the	drug	but	TDM	was	only	routinely	done	for	glycopeptides	and	aminoglycosides.	
	
3.5.2	 Questionnaire	design		
	
For	a	questionnaire	to	be	successful	in	collecting	accurate	information	every	effort	must	be	made	to	
make	 sure	 the	 results	 yielded	 are	 both	 valid	 and	 reliable.	 Validity	 refers	 to	 the	 accuracy	 of	 the	
measurement	i.e.	does	the	questionnaire	ask	the	right	questions	to	meet	the	aims	of	the	study.	Are	
any	 key	 subjects	missed/excluded.	Can	 the	 results	be	generalised	 to	 the	wider	UK	CCU	population.	
Reliability	refers	to	the	consistency	of	the	measurement	i.e.	the	degree	to	which	the	questions	used	
elicit	 the	 same	 type	 response.	 Reliability	 and	 validity	 were	 both	 addressed	 extensively	 at	 the	
questionnaire	design	and	development	phase.	
	
3.5.3	 Response	rate	
	
26.2%	 of	 UK	 CCUs	 responded	 to	 this	 questionnaire.	 What	 constitutes	 a	 “good”	 or	 “adequate”	
response	rate	is	much	debated	and	there	does	not	appear	to	be	a	clear	answer.	The	annual	Faculty	of	
Intensive	Care	Medicine	(FICM)	survey	of	the	critical	care	consultant	workforce	over	a	4	year	period	
between	 2010	 and	 2014	 has	 had	 a	 response	 rate	 varying	 between	 40	 and	 50%	 (The	 Faculty	 of	
Intensive	Care	Medicine,	2015).	Response	rates	in	general	to	questionnaires	circulated	by	the	UKCPA	
are	generally	between	10	and	20%	 (Carter,	2015).	 This	 rate	 is	however	 lower	 than	other	published	
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surveys	 involving	 specifically	 critical	 care	 pharmacist	 members	 of	 the	 UKCPA	 (Yassin	 et	 al.,	 2014;	
Bourne,	2015),	both	of	which	had	response	rates	of	approximately	60%.	These	surveys	 investigated	
UK	 practice	 via	 the	 UKCPA	 CCG	 message	 board	 but	 had	 active	 follow	 up	 of	 non-responders	 by	
telephone	 call	 and	 direct	 email.	 Another	 study	 (Tabah	 et	 al.,	 2015),	 an	 international	 survey	 of	
antibiotic	administration	practices	on	CCUs	carried	out	at	a	similar	time	to	this	study,	did	not	measure	
response	rate	but	documented	responses	from	328	hospitals	in	53	different	countries.		
	
Several	factors	may	have	influenced	the	response	rate.	The	general	level	of	interest	in	the	subject	at	
the	 time	 the	 questionnaire	 was	 posted	 and	 the	 time	 required	 to	 complete	 the	 questionnaire,	 the	
participant	 information	 sheet	 gave	a	 guide	 time	of	15	minutes,	may	have	adversely	 influenced	 this	
overall	response	rate.	Another	potential	problem	associated	with	all	questionnaires	conducted	in	this	
manner	 is	 the	 risk	of	 convenience	 sampling	 and	 its	 associated	bias.	 Convenience	 sampling	 involves	
selecting	 subjects	 because	 of	 their	 convenient	 accessibility	 and	 risks	missing	 those	 that	 don’t	 have	
access	 to	 the	 questionnaire,	 in	 this	 case	 critical	 care	 pharmacists	 that	 were	 not	 members	 of	 the	
UKCPA	CCG.	Hopefully	this	will	have	had	little	biasing	effects	on	the	overall	results,	as	there	are	many	
more	 pharmacists	 registered	 with	 the	 message	 board	 than	 there	 are	 CCUs	 in	 the	 UK.	 There	 is	
currently	no	way	of	determining	if	the	pharmacist	on	any	given	CCU	is	also	a	member	of	the	UKCPA	
CCG	but	 a	 recent	workforce	 survey	 showed	 that	 only	 2%	of	 CCUs	where	without	pharmacist	 cover	
(Borthwick	 et	 al.,	 2018).	 A	 final	 potential	 limitation	 is	 that	 there	was	 no	way	 of	 checking	 that	 the	
pharmacist	completing	the	questionnaire	was	who	they	said	they	were	or	worked	in	that	Trust.	
	
3.5.4	 Demographics	
	
Most	(90.6%)	of	the	responses	were	from	pharmacists	practicing	in	England	and	English	CCUs	account	
for	 80.3%	 (196/244)	 of	 the	 UK	 total	 as	 listed	 by	 ICNARC	 and	 SICSAG.	 This	 geographical	 split	 is	
consistent	 with	 that	 reported	 in	 the	 previously	 mentioned	 UK	 studies	 with	 higher	 total	 response	
rates,	 in	 a	 survey	 of	 pharmacist	 independent	 prescribers	 86%	 of	 respondents	 were	 from	 England	
(Bourne,	2015).	5	of	the	24	Scottish	CCUs	responded	(20%)	but	only	1	CCU	in	Northern	Ireland	out	of	
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a	possible	9	and	none	of	the	15	Welsh	CCUs	responded.	This	bias	towards	English	CCUs	may	be	due	to	
the	 demographics	 of	 the	 membership	 of	 the	 UKCPA	 CCG,	 i.e.	 it	 may	 be	 that	 the	 members	 are	
predominantly	 based	 in	 England.	 Alternatively,	 as	 previously	 discussed,	 it	 may	 reflect	 the	 level	 of	
interest	 in	 the	subject	matter;	 it	may	be	that	critical	care	pharmacists	working	 in	England	are	more	
interested	in	antibiotic	administration	or	pk/pd	aspects	of	drug	administration.	The	pattern	of	regions	
responding	(see	chart	3.1)	may	give	us	more	insight	into	the	reason	for	the	bias.	England	and	Wales	
have	been	divided	into	Critical	Care	Networks	(CCNs,	organization	networks	that	oversee	the	delivery	
of	 critical	 care	 services	 across	 a	 geographical	 area),	 review	 the	 geography	 of	 the	 responses	 and	
although	most	 regions/CCNs	 are	 represented	 in	 the	 responses	 some	 areas	 have	 a	 higher	 response	
rate	than	others,	namely	my	own	CCN	and	those	neighbouring	 in	the	North	West	of	England.	Again	
this	may	reflect	the	level	of	interest	locally	in	the	subject	rather	than	people	responding	because	they	
know	 the	 investigator.	 Another	 possible	 reason	 for	 variation	 is	 that	 some	CCUs	may	not	 have	CCU	
pharmacists	 and	 this	may	 be	 not	 just	 an	 individual	 hospital	 problem	 but	 also	 a	 regional/CCN	 one.	
Although	a	recent	workforce	survey	showed	that	only	2%	of	UK	CCUs	are	currently	without	a	critical	
care	 pharmacist,	 many	 pharmacists	 do	 not	 class	 themselves	 as	 specialists	 and	 may	 not	 have	 felt	
confident	responding.		
	
93.7%	 of	 respondents	 described	 their	 CCU	 as	 a	 general/mixed	 unit;	 this	 is	 consistent	 with	 other	
published	surveys	of	CCUs,	for	example	91.7%	in	Yassin	et	al	(Yassin	et	al.,	2014),	and	implies	that	the	
CCU	 admits	 both	 medical	 and	 surgical	 emergency	 and	 elective	 patients.	 Different	 administration	
practices	between	specialties	e.g.	medicine	and	surgery,	was	not	investigated	further	because	of	the	
lack	of	specialist	units	responding.	Approaching	half	(48.4%)	of	CCUs	were	stated	to	have	between	10	
and	20	beds	with	the	remainder	being	evenly	split	either	side	of	this	i.e.	<10	and	>20.		
	
3.5.5	 The	pharmacist	
	
There	was	only	one	duplicate	 response	 recorded	and	one	pharmacist	had	both	a	higher	 grade	and	
more	years	critical	care	experience	so	the	junior	respondent	was	excluded	from	the	data	analysis.		
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90.6%	of	responding	pharmacists	were	AfC	band	8a	or	above,	and	again	this	is	in	keeping	with	other	
studies	 involving	 critical	 care	pharmacists,	 e.g.	 Yassin	et	al	 reported	>85%	 (Yassin	et	al.,	 2014),	 and	
seems	 to	 show,	 along	 with	 previously	 mentioned	 points,	 that	 the	 respondents	 are	 a	 cohort	
representative	of	the	current	critical	care	pharmacist	workforce..		
	
50%	 of	 responding	 pharmacists	 had	 greater	 than	 10	 years	 experience	 working	 in	 critical	 care,	
approximately	 80%	 had	 more	 than	 5	 years	 and	 only	 3.1%	 had	 less	 than	 a	 years	 experience.	 Any	
underrepresentation	 of	 the	 less	 experienced	 pharmacists	 is	 likely	 to	 have	 happened	 where	 those	
pharmacists	were	part	of	a	team	with	more	experienced	leads	and	so	therefore	unlikely	to	have	any	
impact	on	the	overall	trends/patterns.			
		
The	 respondent	was	asked	 if	 the	CCU	had	 “pharmacist	 cover”:	 this	was	 intended	 to	mean	 that	 the	
pharmacist	visit	involved	reviewing	the	patients	and	their	medication	charts	but	as	it	was	not	defined	
as	this	it	is	not	possible	to	say	whether	this	was	the	case	in	all	instances.	It	is	unlikely	but	possible	that	
in	some	instances	the	pharmacist	fulfils	an	ordering	and	stock	management	role	rather	than	a	clinical	
role.	 Approximately	 4/5th	 (81.3%)	 of	 CCUs	 had	weekday	 pharmacist	 visits,	 1/5th	 (17.2%)	 had	 a	 visit	
everyday	and	1	CCU	had	only	an	ad-hoc	service.	No	responding	pharmacists	suggested	that	their	CCU	
had	 no	 cover	 although	 it	 is	 thought	 that	 about	 2%	 of	 UK	 CCUs	 still	 have	 no	 pharmacist	 input	
(Borthwick	 et	 al.,	 2018).	 It	 is	 proposed	 that	 the	 reason	 this	 later	 point	 is	 not	 reflected	 in	 the	
questionnaire	responses	is	two-fold.	Firstly	the	target	audience	was	pharmacists	who	were	members	
of	 the	UKCPA	CCG	who	would	tend	to	be	working	 in	critical	care	but	 this	 isn’t	necessarily	 true	 (e.g.	
some	 UKCPA	members	 sign	 up	 to	 all	 of	 the	 message	 boards).	 The	 second	 reason	 is	 that	 the	 first	
question	 asked	 if	 the	 respondent	was	 currently	working	 in	 critical	 care;	 if	 they	 answered	 “no”	 the	
questionnaire	stopped	at	that	point.	A	limitation	to	be	considered	when	analysing	practice	compared	
with	 frequency	 of	 pharmacist	 visit	 is	 that	 two	 hospital	 trusts	 accounted	 for	 8	 of	 the	 11	 CCUs	with	
everyday	visits	(both	Trusts	have	4	CCUs)	and	so	it	could	be	argued	that	the	practices	of	the	these	two	
Trusts	will	exaggerate	the	effect	of	differences	 in	these	data.	The	questionnaire	could	have	avoided	
this	by	asking	for	responses	by	hospital	trust	not	CCU	but	this	would	run	the	risk	of	missing	variances	
in	practice	between	different	units	with	different	specialties	e.g.	surgical,	cardiothoracic	etc	and	may	
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have	left	respondent	unable	to	complete	the	questionnaire	if	there	where	differences.	In	addition	to	
this,	different	pharmacists	with	different	practices/levels	of	input	may	cover	each	CCU	independently.	
	
Approximately	75%	of	 responding	pharmacists	 stated	 that	 they	 generally	 attend	 the	 consultant	 led	
ward	round.	Ward	round	attendance	 in	this	study	has	been	used	as	a	 further	marker	of	pharmacist	
involvement	in	the	“Critical	Care	Team”.	It	is	an	indication	that	the	pharmacist	who	attends	the	ward	
potentially	has	more	 input	and	a	deeper	professional	 relationship	with	 the	 team	than	a	pharmacist	
who	just	visits,	which	may	mean	a	quick	 look	at	the	medicine	charts	without	necessarily	having	any	
meaningful	input	into	the	decision	making	around	patient	care.	
	
To	 analyse	 whether	 the	 presence	 of	 a	 pharmacist	 on	 the	 CCU	 affected	 administration	 practices	 a	
survey	targeting	the	multi	disciplinary	team	as	a	whole	would	be	required.		
	
3.5.6	 Antibiotic	choice	
	
This	study	identifies	national	trends	towards	prescribing	specific	antibiotics	within	certain	classes.	Of	
the	 broad-spectrum	 penicillins,	 amoxicillin	 alone	 and	 in	 combination	 with	 clavulanic	 acid	 (co-
amoxiclav)	were	used	by	most	units	whereas	ampicillin	was	rarely	used.	Piperacillin/tazobactam	was	
the	clear	favourite	out	of	the	anti-pseudomonal	penicillins	and	meropenem	was	the	most	commonly	
prescribed	carbopenem.	The	reason	for	choice	of	an	antibacterial	within	a	given	class	was	not	asked	
as	it	was	beyond	the	aims	and	objectives	of	the	study	but	it	is	likely	to	be	influenced	by	many	factors	
such	efficacy,	resistance,	cost	and	side-effect	profile.	For	example,	locally	meropenem	is	the	favoured	
carbopenem	as	 it	has	a	broader	spectrum	of	activity	 than	ertapenem	and	 lower	risk	of	CNS	toxicity	
than	imipenem.	
	
These	observations	confirm	that	pursuing	the	study	of	meropenem	or	piperacillin/tazobactam	will	be	
relevant	to	clinical	practice.	
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3.5.7	 Existence	of	“usual”	practice	
	
To	 date,	 methods	 of	 administration	 which	 are	 being	 commonly	 used	 on	 UK	 CCUs	 have	 not	 been	
adequately	 evaluated.	 As	 previously	 discussed,	 a	 literature	 review	 at	 the	 time	 of	 inception	 of	 the	
study	 found	no	UK	or	 international	 studies	of	current	practice	 in	CCUs.	 In	 the	 intervening	 time	one	
international	 study	 has	 been	 published	 (Tabah	 et	 al.,	 2015).	 This	 study,	 an	 international	 survey	
published	in	2015	but	conducted	in	2013	at	a	similar	time	to	my	own	survey,	investigated	practices	of	
antimicrobial	dosing	and	monitoring	in	existence	in	Intensive	Care	Units	(ICU)	around	the	world	with	
respondents	 being	 predominantly	 from	 3	 regions	 (UK,	 Australia/New	 Zealand	 and	 USA/Canada).	
Where	overlap	with	my	questionnaire	exists	results	are	similar.	
	
The	method	by	which	an	intravenous	antibiotic	is	administered	forms	part	of	the	product	license	and	
is	 therefore	stated	 in	the	Summary	of	Product	Characteristics	 (SPC).	 In	 line	with	this,	where	a	given	
antibiotic	 was	 used,	 90.1%	 of	 all	 administration	 across	 the	 22	 antibiotics	 investigated	 and	 64	
responding	CCUs	was	in	line	with	the	SPC.	Of	these	22	antibiotics,	17	(Table	4)	had	an	identified	usual	
method	of	administration	as	defined	by	more	than	50%	of	responding	units	usually	administering	the	
drug	by	the	same	method	-	no	definition	of	a	standard	value	for	usual	practice	could	be	found	in	the	
literature.	In	all	 instances	this	usual	practice	reflected	a	licensed	method	of	administration	as	stated	
in	 the	 SPC.	 For	 the	 remaining	 5	 antibiotics	 practice	was	 largely	 split	 across	 2	 licensed	methods	 of	
administration	leading	to	neither	one	coming	out	as	a	clear	favourite.	For	example	the	SPC	for		
benzylpenicillin	 states	 that	 it	 can	be	administered	either	as	a	bolus	 injection	or	as	a	 short	 infusion.	
40.8%	of	respondents	usually	gave	as	a	bolus,	35.5%	as	a	short	 infusion	and	9.7%	a	combination	of	
both	 dependent	 on	 the	 dose	 being	 administered.	 This	 factor	 can	 also	 be	 seen	 even	 where	 usual	
practice	was	 seen.	 Amoxicillin	 is	 licensed	 as	 either	 a	 bolus	 or	 a	 short	 infusion	 but	 in	 this	 instance	
rather	than	a	close	split,	approximately	two	thirds	of	respondents	gave	as	a	bolus.	Three	antibiotics	
have	very	low	usage	amongst	the	responding	units.	Only	5	CCUs	use	imipenem/cilastatin	but	they	all	
administer	by	short	 infusion.	3	units	use	doripenem	(2	giving	via	short	 infusion	and	one	by	EII)	and	
only	 2	 units	 use	 ampicillin	 (1	 by	 each	 of	 bolus	 and	 short	 infusion).	Usual	 practice	 for	 these	 later	 2	
antibiotics	is	therefore	hard	to	define.	
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In	general,	where	only	one	method	of	administration	was	stated	in	the	SPC	nearly	all	CCUs	adopted	
that	one	practice.	Ciprofloxacin,	 linezolid,	 tigecycline,	 tiracillin/clavulanic	acid	and	clarithromycin	all	
have	very	specific	methods	of	administration	stipulated	and	little	or	no	evidence	in	the	literature	to	
suggest	or	support	deviation	 from	the	 license	so	unsurprisingly	all	have	standard	practice	reflecting	
this	 (100%,	 96.7%,	 100%,	 100%	 and	 98.4%	 of	 respondents	 for	 a	 sole	 method	 for	 each	 antibiotic	
respectively,	see	tables	3.4	and	3.5).	
	
	
3.5.8	 Are	 extended	 intermittent	 (EII)	 or	 continuous	 infusions	 (CI)	 of	 any	 antibiotics	 used	 in	
preference	to	licensed	administration	practices	in	any	critical	care	units?	
	
	
There	are	logical	reasons	for	extending	the	length	of	time	over	which	certain	antibiotics	are	infused	in	
the	 light	 of	 pk/pd	 studies	 but	 with	 no	 proven	 improvement	 in	 morbidity/mortality	 outcomes	 the	
question	remains	why	one	would	deviate	from	the	product	licence.	
Of	the	22	antibiotics	investigated	in	the	questionnaire,	13	were	given	on	at	least	one	CCU	by	either	EII	
or	CI	(table	3.4).	
Most	of	this	deviation	(10/13	antibiotics)	was	restricted	to	a	small	number	of	CCUs	(4	or	less)	for	each	
antibiotic	and	 limited	to	only	5	hospital	 trusts.	Some	of	these	responses	may	have	been	erroneous,	
one	CCU	suggested	they	used	EIIs	of	Clarithromycin	(the	only	CCU	to	do	so),	clindamycin	and	linezolid	
for	which	evidence	is	lacking	in	the	literature,	but	do	not	use	EIIs	for	any	of	the	antibiotics	for	which	
there	is	at	least	pk/pd	related	evidence,	such	as	meropenem	and	piperacillin/tazobactam.		
One	Trust	with	4	CCUs	accounted	for	66.6%	(4	out	of	6	CCUs)	of	co-amoxiclav	EII	practice	and	all	EII	
practice	of	ceftriaxone	and	ceftazidime.	Another	Trust	with	4	CCUs	accounted	for	all	of	the	CI	practice	
of	 benzylpenicillin	 and	 flucloxacillin.	 These	 two	 Trusts	 combined	 accounted	 for	 all	 EII	 practice	 of	
ceftazidime	(see	table	3.4).	Counting	CCUs	separately	 rather	 than	analysing	the	results	by	Trust	has	
led	to	an	inflated	appearance	in	some	of	the	values,	for	example	16%	(8/49)	of	CCUs	give	ceftazidime	
as	 an	 EII	 but	 this	 equates	 to	 only	 5%	 of	 Trusts	 (2/37).	 CCUs	 were	 counted	 separately	 to	 identify	
differences	between	specialties	e.g	medical	units	versus	surgical	or	cardiothoracic,	as	well	as	between	
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Trusts,	 through	 93.7%	 (60/64)	 of	 responding	 units	 described	 themselves	 as	 “General/mixed”	 so	
deeper	analysis	by	specialty	is	not	practical	or	worthwhile.	
Three	antibiotics	stand	out	where	>20%	of	CCUs	administer	these	by	EII	or	CI	as	the	standard	method	
of	administration.	Piperacillin/tazobactam	and	meropenem	are	both	commonly	given	by	EII,	on	22.2%	
and	20.3%	of	CCUs	respectively	and	vancomycin	is	given	by	CI	on	49.2%	of	units.	
	
3.5.9	 Where	 EIIs/CIs	 are	 usual	 practice	 what	 at	 are	 the	 driving	 forces	 for	 adoption	 of	 these	
practices	and	do	any	patient	orientated	factors	influence	choice	of	practice?	
	
3.5.9.1	 Vancomycin	
	
Vancomycin	pk/pd	remains	only	partially	understood	(Vandecasteele	et	al.,	2012);	in	vitro,	like	the	β-
lactam	 antibiotics,	 it	 exhibits	 slow	 time	 dependent	 kill	 (Löwdin	 et	 al.,	 1998)	 however	 it	 has	 a	
moderately	 long	 post-antibiotic	 effect,	 unlike	 β-lactams	 and	more	 like	 an	 aminoglycoside,	meaning	
the	time	spent	above	the	MIC	becomes	less	relevant	(Moise-Broder	et	al.,	2004).	More	recently	it	has	
been	suggested	 that	 the	most	 important	parameter	 is	actually	MIC/AUC	 (Holmes	et	al.,	 2013).	This	
uncertainty	 didn’t	 stop	 investigators	 as	 early	 as	 the	 1980s	 looking	 into	 the	 efficacy	 of	 continuous	
infusions	 (Barois	 et	 al.,	 1986;	 Brinquin	 et	 al.,	 1993);	 these	 early	 studies,	 although	 small,	 showed	
consistent	achievement	of	target	 levels,	clinical	cure	and,	 in	one	study,	no	increase	in	renal	toxicity.	
Possibly	the	best	and	most	referenced	study	conducted	to	date	was	published	in	2001.	Marc	Wysocki	
conducted	 the	 first	prospective	multicentre	 randomised	 study	which	 compared	efficacy,	 safety	 and	
cost	effectiveness	of	CIs	compared	with	standard	therapy	(Wysocki	et	al.,	2001).	This	was	a	relatively	
large	study	with	approximately	60	patients	in	each	arm	and	even	though	it	showed	a	shorter	time	to	
target	concentrations	in	the	CI	arm	it	failed	to	demonstrate	any	microbiological	or	clinical	superiority	
of	 CIs.	 Toxicity	 was	 similar	 in	 both	 groups	 and	 CIs	 were	 23%	 cheaper	 for	 a	 10	 day	 course	 than	
standard	dosing.	The	controversy	continues	with	a	recent	study	showing	that	nephrotoxicity	increases	
as	trough	levels	increase	in	patients	receiving	standard	dosing,	5%	incidence	when	initial	trough	<10	
mg/L	compared	with	33%	if	trough	>20	mg/L	(Lodise	et	al.,	2009).	It	is	not	discussed	in	the	paper	but	
this	 effect	may	be	due	 to	higher	peak	 concentrations	 associated	with	high	 troughs	 rather	 than	 the	
trough	itself	but	it	is	none	the	less	of	concern	as	published	CI	protocols	target	levels	of	15	–	25mg/L		
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In	 light	 of	 the	 lack	 of	 definitive	 evidence	 to	 support	 the	 use	 of	 CIs	 over	 licensed	 methods	 of	
administration	it	is	possibly	surprising	to	see	that	approximately	half	of	responding	CCUs	(49.2%)	have	
adopted	CIs	as	their	standard	practice.	Of	all	the	factors	investigated,	only	pharmacist	attendance	on	
the	 ward	 round	 seemed	 to	 significantly	 influence	 the	 choice	 of	 method	 of	 administration	 of	
vancomycin	 (see	 table	 3.8,	 p=0.03).	 Simply	 attending	 the	 ward	 to	 review	 patient	 charts	 had	 no	
influence	on	choice	(p=0.109).	This	potentially	implies	that	the	level	of	involvement	of	the	pharmacist	
in	 the	 wider	 team	may	 influence	 administration	 choice	 but	 other	 factors	 such	 as	 grade	 and	 years	
experience	 that	may	 similarly	 but	more	 weakly	 correlate	 to	 input	 did	 not	 show	 this	 (p=0.142	 and	
0.291	respectively).	With	vancomycin	the	significance	is	possibly	more	clear-cut	than	in	the	cases	of	
piperacillin/tazobactam	 and	meropenem.	 It	 involved	 comparing	 the	 usage	 of	 just	 two	methods	 of	
administration	rather	than	three	or	four	i.e.	short	infusion	to	that	of	CIs	and	so	is	likely	to	be	a	truly	
significant	factor.	With	the	exception	of	microbiologist	input	and	CCN/region,	these	data	suggest	that	
where	EIIs/CIs	are	used	as	usual	practice	 the	pharmacist	 is	experienced	and	an	 integral	member	of	
the	 CCU	 team.	 In	 only	 a	 small	 group	 of	 instances	 did	 a	 patient	 orientated	 factor	 affect	 choice	 of	
administration	 practice.	 One	 respondent	 switched	 from	 CI	 to	 standard	 therapy	 if	 the	 patient	 was	
receiving	renal	replacement	therapy	and	another	similarly	switched	in	patients	with	endocarditis.	This	
may	be	through	fear	of	treatment	failure	or	in	the	case	of	endocarditis	to	conform	with	national	and	
international	guidance	which	generally	advise	to	dose	at	30mg/kg/day	in	2	divided	doses	(Habib	et	al.,	
2015).	Therapeutic	drug	monitoring	 (TDM)	was	used	to	guide	 therapy	 in	all	CCUs	using	vancomycin	
regardless	 of	 method	 of	 administration.	 In	 the	 UK	 TDM	 is	 standard	 practice	 with	 intravenous	
vancomycin	therapy	historically	to	avoid	toxicity	but	latterly	to	ensure	therapeutic	levels	so	this	is	not	
surprising	(Llopis-Salvia	and	Jiménez-Torres,	2006).	CIs	potentially	make	TDM	easier	(discussed	below)	
and	this	 is	potentially	another	driving	force	for	CI	selection	with	vancomycin,	although	this	question	
was	not	specifically	asked	in	the	survey.	
3.5.9.2	 Piperacillin/tazobactam	and	meropenem	
	
Both	 piperacillin	 and	 meropenem	 fit	 into	 a	 wider	 class	 of	 antibiotics	 referred	 to	 β-lactams	 that	
includes	 all	 penicillins,	 cephalosporins	 and	 carbopenems.	 Both	 the	 pharmacokinetics	 and	
pharmacodynamics	have	been	well	described	for	the	β-lactams	as	a	whole	(Craig,	1998;	Lodise	et	al.,	
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2006)	 and	 when	 piperacillin/tazobactam	 and	 meropenem	 (Nicolau,	 2008)	 have	 been	 investigated	
they	 have	 fitted	 with	 previous	 finding	 for	 the	 class	 as	 a	 whole.	 The	 β-lactams	 all	 exhibit	 a	 slow	
continuous	 kill	 that	 is	 related	 almost	 entirely	 to	 the	 time	 spent	 above	 the	 minimum	 inhibitor	
concentration	 (T>MIC).	 Once	 concentrations	 of	 drug	 fall	 below	 the	 MIC	 bacteria	 start	 to	 multiply	
almost	immediately.	
		
Both	antibiotics	are	generally	administered	every	eight	hours	and	have	half-lives	of	approximately	1	
hour	in	patients	with	normal	renal	function.		These	factors	combined	show	that	for	a	period	in	each	
dosing	interval	not	only	will	drug	level	be	below	the	MIC	for	approximately	3	hours	there	may	be	no	
detectable	drug	level	at	all.	This	is	not	only	going	to	lead	to	treatment	failure	but	also	potentially	to	
increased	resistance	to	these	agents	(Roberts	et	al.,	2008a).	Both	bigger	and/or	more	frequent	doses	
or	 the	 use	 of	 EIIs/CIs	 have	 been	 suggested	 as	 ways	 of	 improving	 clinical	 outcome	 and	 reducing	
resistance	(Felton	et	al.,	2013;	Abdul-Aziz	et	al.,	2015).	
	
The	popularity	 of	 these	 two	agents	 in	 particular	 has	 lead	 to	 their	methods	of	 administration	being	
much	studied.	They	are	both	currently	licensed	to	be	administered	as	short	infusions	with	a	suggested	
duration	of	30	minutes.	Meropenem	 is	also	 licensed	 to	be	administered	as	a	bolus	 injection	over	5	
minutes.	Advice	to	bolus	piperacillin/tazobactam	was	removed	from	the	UK	SPC	in	2011	to	bring	it	in	
line	with	the	rest	of	the	EU	where	it	is	only	licensed	to	be	given	by	short	infusion,	the	reason	stated	
was	 harmonisation	 (european	 medicines	 agency,	 2011).	 There	 are	 now	 many	 papers	 and	 review	
articles	suggesting	the	pk/pd	benefits	of	CIs	and	EIIs	of	these	two	agents	(Roberts	et	al.,	2008b;	Abdul-
Aziz	 et	 al.,	 2012)	 and	 more	 recently	 studies	 suggesting	 there	 may	 be	 improved	 clinical	 and	
bacteriological	efficacy	(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016).	
	
22.2%	and	20.3%	of	responding	CCUs	give	piperacillin/tazobactam	and	meropenem	respectively	as	an	
EII,	 and	none	of	 the	 respondents	 currently	 use	 continuous	 infusions	of	 either	drug.	 This	 pattern	of	
usage	 reflects	 the	 literature;	 whilst	 there	 are	 plenty	 of	 papers	 touting	 the	 potential	 benefits	 of	
extended	infusion	periods,	until	recently	(post	the	questionnaire),	these	all	report	use	of	3-	or	4-hour	
EIIs	 rather	 than	CIs.	CIs	have	 the	disadvantage	of	 tying	up	an	 intravenous	 line	24	hours	a	day	 for	a	
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single	 drug	 and	 also	 restrict	 the	 movement	 of	 patients	 if	 they	 are	 otherwise	 mobile.	 With	 the	
exception	of	the	beta-lactam	study	group	(BLING)	in	Australia,	most	antibiotic	studies	are	of	EIIs	with	
the	exception	of	vancomycin	where	a	CI	has	the	advantage	of	making	TDM	easier	–	the	sample	can	be	
taken	at	anytime	in	a	24	hour	period	rather	than	having	to	wait	for	a	trough	(i.e.	the	lowest	level	in	
the	dosing	period)	immediately	before	a	dose.	In	my	practice	where	CIs	of	vancomycin	are	used,	each	
patient	has	a	TDM	level	with	the	routine	6	am	blood	test	so	necessary	adjustments	can	be	made	on	
the	ward	round	after	9	am.	Not	all	infections	are	necessarily	in	the	blood	though	and	so	a	postulated	
advantage	of	β-lactam	CIs	is	that	tissue	levels	are	consistently	maintained.	The	lower	uptake	of	CCUs	
using	EIIs	of	piperacillin/tazobactam	and	meropenem	than	CIs	of	vancomycin	may	well	be	due	to	the	
fact	that	the	practice	has	appeared	much	more	recently	in	the	literature	and/or	because	of	the	added	
benefit	with	regards	to	vancomycin	TDM.	
	
Of	the	factors	investigated,	one	showed	a	significant	correlation	with	the	choice	of	EIIs	over	licensed	
practice	and	this	was	the	frequency	of	pharmacists	reviewing	the	patients	on	the	CCU	(p	<0.001,	see	
tables	 3.6	 and	 3.7).	 With	 both	 piperacillin/tazobactam	 and	 meropenem	 on	 CCUs	 where	 the	
pharmacist	 reviewed	patients	on	weekdays	only	 they	were	more	 likely	 to	use	either	bolus	or	 short	
infusions	(92%	and	90%	respectively)	whereas	on	the	CCUs	with	a	daily	visit	EIIs	were	more	common	
(both	 82%).	 Although	 this	 result	 was	 highly	 significant	 and	 11	 of	 the	 62	 responding	 CCUs	 have	 a	
pharmacist	visit	every	day	this	actually	only	accounts	for	4	of	the	52	responding	Trusts	(2	Trusts	with	
everyday	visits	had	4	 responding	CCUs	each).	 There	were	other	 factors	 seeming	 to	affect	 choice	of	
administration	method	for	both	piperacillin/tazobactam	and	meropenem.	The	higher	the	pharmacist	
AfC	 banding	 (piperacillin/tazobactam	 p=0.028,	 meropenem	 p=0.056)	 and	 more	 frequent	 the	
microbiology	input	(piperacillin/tazobactam	p=0.031,	meropenem	p=0.087)	the	more	likely	they	were	
to	use	EIIs.	The	former,	combined	with	level	of	pharmacy	cover,	may	imply	that	the	larger	and	better	
staffed	CCUs	are	more	likely	to	adopt	unusual	practice	but	against	this	 is	the	fact	that	there	was	no	
correlation	 with	 size	 of	 CCU	 or	 pharmacist	 ward	 round	 attendance.	 A	 factor	 that	 may	 have	
contributed	to	these	important	variations	in	practice	with	piperacillin/tazobactam	and	meropenem	is	
the	fact	that,	at	launch,	both	drugs	had	two	licensed	methods	of	administration	either	as	a	bolus	or	as	
a	short	infusion.	CCUs	may	have	picked	which	method	suited	their	needs	best	at	that	time	and	then	
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just	 stuck	 with	 it.	 It	 may	 therefore	 have	 made	 more	 sense	 to	 combine	 the	 2	 originally	 licensed	
methods	and	compare	them	to	EIIs,	in	doing	this	the	significance	may	well	have	then	disappeared.	
3.5.10	 Where	EIIs/CIs	are	not	usual	practice	what	factors,	if	any,	influence	deviation	to	use	these	
methods?		
	
Where	EIIs	or	CIs	where	not	the	usual	method	of	administration,	some	respondents	stated	that	under	
certain	 circumstances	 they	would	use	 them	 (see	 tables	 3.9	 and	3.10).	 The	 reasons	 stated	 could	be	
split	into	two	categories.	The	first	would	be	classed	as	patients	with	conditions	that	are	perceived	to	
have	significantly	altered	the	pk/pd	parameters	such	as	septic	shock	and	major	burn	 injury.	Both	of	
these	 conditions	 cause	 an	 increase	 in	 volume	 of	 distribution	 and	 an	 increase	 in	 renal	 clearance	 of	
water	 soluble,	 low	 protein	 bound	 drugs	 such	 as	 the	 β-lactams	 being	 discussed	 (Shah	 et	 al.,	 2015).	
Multiple	 studies	 have	 shown	 drug	 levels	 to	 be	 altered	 in	 these	 patient	 groups	 (Weinbren,	 1999;	
Roberts	 et	 al.,	 2011a;	 Udy	 et	 al.,	 2015)	 and	 some	 have	 shown	 that	 EIIs	 or	 CIs	 lead	 to	 a	 more	
favourable	pk/pd	profile	(De	Waele	et	al.,	2014).	It	is	therefore	logical	that	prescribers	may	target	the	
patients	who	 are	 likely	 to	 gain	 the	most	 from	 these	 practices.	 The	 second	 category	 is	 in	 targeting	
organisms	that	have	the	highest	MICs	and	therefore	require	high	concentrations	of	antimicrobial	at	
the	target	site;	2	CCUs	used	EIIs	of	piperacillin/tazobactam	and	meropenem	solely	for	the	treatment	
of	 Pseudomonas	 spp.	 which	 have	 a	 high	 MIC	 and	 are	 noted	 for	 high	 treatment	 failure	 rates	 and	
development	of	resistance	(McCarthy,	2015).	Many	studies	investigating	EIIs	of	β-lactams	exploit	their	
ability	 to	maintain	 levels	4	 times	greater	 than	 the	MIC	of	Pseudomonas	spp.	as	 the	 target	 (Mouton	
and	den	Hollander,	1994;	Lodise	et	al.,	2007b).		
	
3.5.11	 Factors	influencing	choice	of	administration	method	
	
Participants	were	asked	to	state	their	reasons	for	choosing	EIIs/CIs	over	conventional	administration	
strategies,	and	could	select	as	many	options	as	applied	to	them	and	also	suggest	reasons	not	listed.	
31	 out	 of	 62	 respondents	 stated	 that	 the	 driving	 force	 was	 the	 published	 evidence	 on	 the	 pk/pd	
benefits	 of	 EIIs	 and	 CIs,	 with	 26	 stating	 that	 they	 considered	 the	 evidence	 showed	 improved	
outcomes	 -	 however,	 currently	 it	 is	 difficult	 to	 fully	 agree	 with	 this	 and	 perhaps	 indicates	 some	
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pharmacists	 may	 have	 only	 a	 superficial	 grasp	 of	 the	 evidence.	 13	 respondents	 reported	 reduced	
toxicity,	 specifically	 of	 vancomycin,	 as	 a	 driving	 force.	 Here	 the	 general	 opinion	 was	 that	 CIs	 of	
vancomycin	 are	 more	 convenient	 –	 easier	 for	 the	 nursing	 staff	 to	 manage,	 easier	 to	 adjust,	 with	
timings	 of	 TDM	 less	 important,	 simpler	 interpretation	 and	 therefore	 under/over	 dosing	 easier	 to	
avoid.	Interestingly	only	2	respondents	stated	cost	saving	as	a	driving	force.	Cost	improvement	plans	
and	means	of	efficiencies	in	drug	budgets	are	at	the	forefront	of	most	pharmacists’	decision	making	
at	some	point	during	every	working	day	and	given	that	there	are	many	papers,	particularly	from	the	
USA,	 reporting	 lower	 total	daily	doses	being	required	were	EIIs/CIs	are	used	 it	 is	perhaps	surprising	
more	respondents	didn’t	mention	this	as	a	consideration.	One	study	explored	using	a	loading	dose	of	
4.5g	piperacillin/tazobactam	followed	by	a	CI	of	9g	per	day	rather	than	the	licensed	dose	of	4.5g	three	
or	 four	 times	 daily;	 this	 study	 (Grant	 et	 al.,	 2002)	 showed	 similar	 clinical	 efficacy	 but	 a	 treatment	
course	cost	of	$399.38	for	CIs	vs	$523.49	for	licensed	practices	(p=0.028).	
	
3.5.12	 The	role	of	therapeutic	drug	monitoring	
	
TDM	 is	universally	 carried	out	 for	aminoglycosides	 (such	as	gentamicin)	 and	glycopeptides	 (such	as	
vancomycin).	 This	 is	 no	 surprise	 as	 in	 the	UK	 as	 TDM	 is	 a	 part	 of	 standard	 care	when	 using	 these	
antibiotics	 due	 to	 their	 nephrotoxic	 and	 ototoxic	 nature	 and	 narrow	 therapeutic	 drug	 index	 (the	
window	of	serum	level	where	the	drug	is	effective	but	not	toxic)	and	more	recently	with	vancomycin	
to	make	sure	the	serum	level	 is	consistently	above	the	MIC.	A	recent	international	survey	(Tabah	et	
al.,	 2015)	asked	a	 similar	question	but	 found	 that	many	centres	outside	 the	UK	don’t	do	any	TDM,	
20%	of	respondents	did	no	gentamicin	 levels	and	a	further	19%	only	did	 levels	 if	 the	patient	was	 in	
renal	failure.	Where	there	does	seem	to	be	some	disconnect	within	UK	practice	though	is	in	the	fact	
that	 although	 75%	 of	 those	 using	 EIIs/CIs	 profess	 to	 be	 doing	 so	 for	 pk/pd	 reasons	 no	 one	 is	
measuring	serum	levels	of	the	other	commonly	use	drug,	piperacillin/tazobactam	or	meropenem.	This	
doesn’t	 give	 the	 whole	 picture	 though	many	 of	 the	 respondents	 will	 only	 have	 been	 doing	 CIs	 of	
vancomycin	and	no	EIIs	and	will	be	doing	TDM	to	guide	their	dosing.	Another	factor	to	consider	is	that	
although	CCUs	aren’t	doing	levels,	that	doesn’t	mean	they	wouldn’t	do	them	if	they	had	the	ability	to.	
Most	TDM	was	developed	for	drugs	with	narrow	therapeutic	indexes	to	avoid	toxicity	were	as	the	aim	
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with	 antibiotics	 such	 as	 piperacillin/tazobactam	 and	meropenem	would	 be	 to	 check	 the	 patient	 is	
therapeutic.	Currently	very	few	institutions	have	the	ability	to	do	levels	for	these	drugs	and	even	less	
are	able	to	take	samples	from	NHS	patients.	Where	this	facility	is	available	it	invariably	takes	to	long	
for	the	results	to	come	back	for	them	to	be	useful	clinically.		I	do	however	envisage	this	changing	in	
the	 future	 as	preserving	 the	 existing	 antibiotics	we	have	available	 to	use	becomes	more	 and	more	
important,	 TDM	 of	 common	 antibiotics	 will	 not	 only	 allow	 the	 clinician	 to	 tailor	 the	 dose	 to	 the	
patient	and	microorganism	but	to	also	potentially	avoid	the	development	of	antimicrobial	resistance.	
	
3.6	 Conclusion	
	
In	 conclusion,	 common	 intravenous	 administration	 practices	 exist	 for	 most	 antibiotics	 used	 in	 UK	
CCUs.	 CCUs	 tended	 to	 follow	 licensed	 methods	 of	 administration	 and	 where	 there	 was	 no	 usual	
practice	 this	 was	 because	 there	 was	 a	 split	 in	 responses	 across	 multiple	 licensed	 methods	 of	
administration.	
The	 most	 common	 deviation	 from	 usual	 (mainly	 licensed)	 practice	 was	 the	 adoption	 of	 either	
extended	 intermittent	or	continuous	 infusion.	Piperacillin/tazobactam,	meropenem	and	vancomycin	
are	commonly	prescribed	on	UK	CCUs	and	their	pk/pd	profiles	lend	themselves	to	extended	methods	
of	infusion.	Respondents	sited	these	properties	and	a	perceived	improvement	in	patient	outcomes	as	
reasons	for	adopting	extended	infusions.	In	addition,	due	to	its	narrow	therapeutic	index	and	high	risk	
of	serious	toxicity,	continuous	 infusions	of	vancomycin	are	seen	to	be	a	safer	and	more	predictable	
method	 of	 administration	 than	 intermittent	 infusions.	 Where	 extended	 infusions	 were	 in	 use	 this	
practice	was	associated	with	a	high	level	of	pharmacist	input	into	the	multi	professional	team	such	as	
seven-day	 ward	 cover.	 Although	 these	 unlicensed	 methods	 are	 widespread	 there	 is	 still	 limited	
evidence	 showing	 any	 patient	 benefit,	 such	 as	 reduced	 length	 of	 CCU	 stay,	 and	 none	 showing	
improved	mortality.	This,	 combined	with	a	 lack	of	access	 to	 therapeutic	drug	monitoring	 for	all	but	
one	or	two	antibiotics,	makes	it	hard	to	justify	using	these	unlicensed	methods	as	common	practice	in	
all	CCU	patients.	
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4	 Phase	2:	A	systematic	review	and	meta-analysis	comparing	the	efficacy	and	
safety	 of	 extended	 versus	 intermittent	 infusions	 of	 antibiotics	 in	 adult	
patients	with	sepsis		
4.1	 Introduction	
Previous	 systematic	 reviews	 have	 approached	 this	 subject	 in	 two	 ways,	 by	 either	 focusing	 on	 the	
pk/pd	interaction	between	the	antibiotics	and	the	human	subjects	(both	health	and/or	infected)	or	by	
investigating	efficacy	and	safety	 in	clinical	practice	focusing	on	critically	 ill	patients	with	a	proven	or	
suspected	infection.	
4.1.1	 Published	reviews		
4.1.1.1	 Pharmacokinetics	and	pharmacodynamics	(pk/pd)	studies	
Many	 studies	 focus	 on	 modelling	 the	 pharmacokinetics	 and	 pharmacodynamics	 of	 individual	
antibiotics	in	animal	and	human	models	using	biological	samples	and	simulations	such	as	Monte	Carlo	
modelling.	Monte	Carlo	simulations	use	computer	software	to	virtually	expand	the	sample	size	of	a	
study	and	in	doing	so	provide	predictions	of	the	likely	outcomes	of	a	range	of	therapeutic	responses	
(Roberts	et	al.,	2011b).	This	approach	 is	useful	 to	maximise	knowledge	of	drug	pharmacokinetics	 in	
areas	such	as	critical	care	and	paediatrics	where	there	is	an	absence	of	large	scale	studies	(Bradley	et	
al.,	2010;	Roberts	et	al.,	2011b).		
In	2005,	Kasiakou	and	colleagues	conducted	a	systematic	review	focussing	specifically	on	randomised	
controlled	 trials	 in	 humans	 exploring	 the	 pharmacokinetic	 and	 pharmacodynamics	 parameters	
associated	with	continuous	and	intermittent	infusions	of	time-dependent	kill	antibiotics	(Kasiakou	et	
al.,	2005a).	As	might	be	expected,	where	reported,	the	maximum	serum	concentration	(Cmax)	in	the	
intermittent	 infusion	 groups	 was	 higher	 than	 the	 steady	 state	 concentration	 in	 the	 continuous	
infusion	 group.	 As	 previously	 discussed,	 for	 time	 dependent	 kill	 antibiotics	 Cmax	 is	 less	 important	
than	the	total	time	spent	above	the	MIC	for	that	antibacterial/micro-organism	combination	(T>MIC).	
Six	trials	 looked	at	infected	patients	and	reported	T>MIC.	No	difference	was	reported	in	3	trials	and	
T>MIC	was	higher	for	patients	receiving	continuous	infusions	in	the	remaining	3	of	which	two	looked	
at	critically	ill	patients	(Benko	et	al.,	1996;	Hanes	et	al.,	2000).		
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4.1.1.2		 Trials	in	patients	with	presumed	or	proven	infections	
Since	2005	a	number	of	systematic	reviews	and	meta-analyses	of	trials	in	patients	with	presumed	or	
proven	 infections	 have	 been	 published.	 These	 reviews	 have	 approached	 this	 broad	 subject	 in	 a	
number	of	ways.	Firstly	they	have	either	investigated	all	antibiotics	(Kasiakou	et	al.,	2005b;	Chant	et	
al.,	2013;	Shiu	et	al.,	2013),	specifically	focused	on	β-lactams	(Roberts	et	al.,	2009c,	2016;	Tamma	et	
al.,	2011;	Falagas	et	al.,	2013;	Lal	et	al.,	2016)	or	some	of	the	most	recent	reviews	have	even	focused	
on	 individual	 agents	 such	 as	 meropenem	 (Yu	 et	 al.,	 2018).	 Many	 of	 these	 reviews	 selected	
randomised	controlled	trials	only	but	a	number	have	also	included	cohort	studies	(Chant	et	al.,	2013;	
Falagas	et	al.,	2013;	Lal	et	al.,	2016).	Reviewers	have	tended	to	focus	on	studies	investigating	septic	
patients	 as	 a	whole,	 but	 some	 have	 chosen	 specific	 patient	 groups	 such	 as	 those	with	 nosocomial	
pneumonia	(Lal	et	al.,	2016).	A	2016	review	(Roberts	et	al.,	2016)	had	very	specific	 inclusion	criteria	
analysing	 only	 available	 individual	 patient	 data	 from	 randomised	 controlled	 trials,	 leading	 to	 the	
inclusion	of	only	3	papers	all	published	in	the	preceding	5	years	and	all	by	the	same	authors	as	of	the	
review.		
Another	difference	is	in	the	approach	to	the	presentation	of	the	data	with	a	split	between	reviewers	
favouring	to	report	clinical	success	(Roberts	et	al.,	2008b;	Tamma	et	al.,	2011;	Shiu	et	al.,	2013)	and	
clinical	 failure	(Kasiakou	et	al.,	2005b;	Chant	et	al.,	2013).	However,	“mortality”	 is	fairly	consistently	
reported	across	reviews.	
On	 the	whole,	many	 of	 these	 reviews	 have	 found	 improved	 clinical	 cure	 or	 reduced	 clinical	 failure	
rates,	 sometimes	 statistically	 significant,	 but	 by	 and	 large	 have	 not	 shown	 any	 improvement	 in	
mortality	associated	with	this.		
The	most	comprehensive	review	currently	available	 (Shiu	et	al.,	2013)	 is	still	widely	quoted	but	this	
predates	some	of	the	most	important	and	robust	studies	now	published	in	this	area	(Dulhunty	et	al.,	
2015;	Abdul-Aziz	et	al.,	2016)	and	so	a	new	review	 is	urgently	needed.	Other	 reviews	have	been	of	
varying	quality	and	have	generally	extended	beyond	RCTs	or	been	very	specific	to	individual	classes	of	
antibiotic	e.g.	β-lactams,	or	groups	of	patients	e.g.	those	on	critical	care.	Another	factor	to	consider	is	
that	 many	 papers	 in	 earlier	 reviews	 are	 3	 or	 4	 decades	 old,	 have	 small	 patient	 numbers	 and	 use	
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antibiotics	that	are	rarely,	if	ever,	used	today.	Whilst	these	studies	are	still	of	value	in	a	meta-analysis,	
the	 last	decade	has	seen	a	number	of	much	 larger	and	perhaps	more	relevant	studies.	Most	of	 the	
more	 recent	 publications	 follow	 the	 internationally	 accepted	 guidance	 on	 the	 preparation	 and	
publication	 of	 systematic	 reviews	 and	 meta-analyses	 (Moher	 et	 al.,	 2015)	 and	 therefore	 there	 is	
clarity	around	the	quality	of	the	studies	included	and	it	is	easier	to	assess	where	any	bias	may	lie.	
4.2	 Aim	and	objectives	
4.2.1	 Aim	
The	 aim	of	 this	 phase	was	 to	 conduct	 an	 up-to-date	 evaluation	of	 the	 evidence	base	 for	 extended	
infusions	of	antibiotics	in	adult	patients	with	sepsis.	
4.2.2	 Objectives	
i. Perform	a	systematic	review	of	relevant	published	randomised	controlled	trials	(RCTs)		
ii. Perform	 a	 meta-analysis	 of	 suitable	 RCTs	 to	 compare	 the	 clinical	 efficacy	 and	 safety	 of	
extended	and	intermittent	intravenous	administration	of	antibiotics	in	adult	patients	with	a	
severe	acute	bacterial	(presumed	or	proven)	infection.	
iii. Perform	sub-group	analysis	of	individual	antibiotics	
iv. Perform	sensitivity	analysis	on	primary	and	significant	outcomes	
4.3	 Method	
4.3.1		 Study	selection	
4.3.1.1	 Types	of	studies	
Open	 label	 or	 blinded	 parallel	 group	 randomised	 controlled	 trials	 (RCTs)	 comparing	 extended	 and	
intermittent	intravenous	administration	of	the	same	antibiotic	were	selected	for	review.	Studies	were	
excluded	 from	 the	 systematic	 review	 based	 on	 the	 following	 conditions:	 studies	 not	 involving	
humans,	all	studies	in	humans	under	the	age	of	18,	RCTs	involving	cross-over	of	participants,	and	non-
RCTs	(e.g.	retrospective	studies,	commentaries,	meeting	abstracts,	editorials,	review	articles	and	book	
chapters).	
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4.3.1.2	 Types	of	participants	
Male	or	non-pregnant	females	aged	18	years	or	over	with	a	presumed	or	proven	bacterial	 infection	
requiring	intravenous	antibiotics.	
4.3.1.3	 Types	of	interventions	
Extended	 intravenous	 administration	 includes	 extended	 (for	 example	 over	 3	 or	 4	 hours)	 and	
continuous	 infusions.	 Standard	 intravenous	 administration	 includes	 licensed	 intermittent	 infusions	
and	boluses.	
4.3.1.4	 Outcome	measures	and	definitions	
The	following	outcomes	were	defined	a	priori:	
Primary	outcomes	
i. Clinical	 cure	 (any	 pre-defined	 criteria	 specific	 to	 the	 infection	 being	 studied	 that	
addresses	signs	and	symptoms	of	infection)		
ii. Number	of	patients	who	experienced	at	least	one	serious	adverse	event	(SAE)	(defined	
as	resulting	in	death,	is	 life	threatening,	involved	or	prolonged	hospitalisation,	involved	
persistent	 or	 significant	 disability	 or	 incapacity,	 is	 another	 condition	 that	 investigators	
judge	to	represent	significant	harm/hazard)	
Secondary	outcomes	
i. Mortality	 (any	 time	 frame,	where	multiple	 time	points	were	 reported	 the	 longest	was	
selected	for	data	analysis)	
ii. Infection	recurrence	(same	organism)	within	14	days	of	resolution	of	primary	infection	
iii. Microbiological	cure	(any	pre-defined	criteria	that	assessed	microbiological	outcomes)	
iv. Secondary/super	 infection	 (a	 new	 infection	 with	 different	 organisms	 from	 those	
observed	in	the	primary	infection)	
v. Number	of	patients	withdrawing	as	a	result	of	an	adverse	event	(WAE)	
vi. Number	of	patients	with	at	least	one	adverse	event	(AE)	
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4.3.2 Protocol	development	
The	protocol	for	this	systematic	review	was	developed	in	line	with	the	PRISMA-P	guidelines	(Moher	et	
al.,	 2015)	 and	 registered	 on	 the	 PROSPERO	 website	 (www.crd.york.ac.uk/PROSPERO/).	 These	 two	
processes	 dovetail	 together	 to	 support	 the	 development	 of	 reproducible	 and	 robust	 systematic	
reviews	and	meta-analyses.		
Many	published	studies	recorded	a	measure	of	positive	clinical	response,	for	example	a	combination	
of	 clinical	 cure	 and	 clinical	 improvement.	 This	was	 reported	 either	 alone	 or	with	 clinical	 cure.	 This	
outcome	measure	was	added	during	data	extraction.	In	some	instances	authors	reported	a	composite	
of	 cure	and	 improvement	as	 “clinical	 cure”	 for	 the	purpose	of	 the	meta-analysis	 this	was	 recorded	
and	analysed	as	“clinical	 response”	 in	 line	with	 the	definition	of	 this	 in	other	articles.	Some	articles	
reported	“clinical	 failure”	 i.e.	a	 lack	of	cure	or	 improvement,	where	the	data	was	unambiguous	and	
the	 patients	 who	 had	 responded	 positively	 could	 be	 accurately	 assessed,	 then	 these	 data	 were	
included	as	“clinical	response”.	The	raw	data	as	extracted	from	each	study	are	presented	in	appendix	
9.	
4.3.3	 Search	strategy		
The	following	databases	were	utilised:		
• Cochrane	Central	Register	of	Controlled	Trials	(The	Cochrane	Library),	accessed	June	2016		
• Medline	(ProQuest),	1946	to	Week	1	June	2016		
• Embase	(Ovid),	1974	to	Week	1	June	2016	
The	searches	were	built	around	three	core	elements	(for	full	search	strategy	see	appendix	6)	
i. The	 drug,	 combining	 broad	 terms	 such	 as	 “antibiotic”	 through	 to	 narrower	 terms	 such	 as	
individual	drug	names	e.g.	“meropenem”	
ii. The	severity	of	illness,	incorporating	terms	for	critical	illness	and	sepsis	
iii. Method	of	administration	including	pharmacokinetics	
The	terms	were	searched	in	each	database	as	they	were	and	also	matched	to	the	thesaurus.	Where	
appropriate	the	terms	were	exploded	and/or	asterisked	to	find	all	possibilities	with	the	same	root	(for	
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example	 antibiotic*)	 and/or	 hyphenated	 (for	 example	 anti-bacterial).	 Initial	 searches	 were	 not	
restricted	by	any	limits,	for	example,	to	participant	age,	date	or	language.	
The	searches	were	further	refined	by	applying	the	search	strategy	suggested	in	“The	Cochrane	Highly	
Sensitive	 Search	 Strategies	 for	 identifying	 randomised	 trials”	 (Higgins	 and	 Green,	 2011a).	 This	 was	
developed	to	 identify	 randomised	 trials	 in	Medline	but	has	also	been	adapted	 for	use	with	Embase	
(Higgins	 and	 Green,	 2011b).	 The	 Cochrane	 handbook	 offers	 two	 versions:	 a	 sensitivity-maximising	
version	 and	 a	 sensitivity-	 and	 precision-maximising	 version;	 the	 sensitivity-maximising	 version	 was	
used	in	these	searches.	
Following	 this,	 restrictions	were	 applied	 to	 remove	 animal	 studies	 and	 focus	 the	 results	 on	human	
adults.	References	from	relevant	papers	were	also	be	reviewed,	as	was	the	investigator’s	own	library.	
Expert	 opinion	 was	 sought	 to	 identify	 other	 papers	 including	 those	 in	 press	 or	 RCTs	 likely	 to	 be	
published	in	the	very	near	future.	
In	April	2018	the	search	was	updated	by	re-running	the	database	searches	as	described	above.	Some	
terms	 and	 abbreviations	 within	 Athens	 had	 changed	 since	 the	 original	 search	 so	 this	 search	 was	
modified	to	take	this	into	account.	A	final	step	was	added	to	restrict	the	results	at	this	stage	to	2015	
to	 present	 day.	 Again	 references	 and	 the	 investigators	 own	 library	 were	 examined	 for	 relevant	
articles.		Details	of	the	complete	searches	including	numbers	of	titles	retrieved	at	each	stage	can	be	
found	in	appendix	6.	
4.3.4	 Data	collection	and	analysis	
4.3.4.1	 Study	selection	
Titles,	 and	where	 necessary	 the	 abstracts,	 of	 the	 search	 results	were	 screened	 by	 the	 investigator	
(GB).	A	second	independent	researcher	(ML)	reviewed	a	20%	sample	of	the	search	results	in	the	spirit	
of	good	practice	to	enhance	the	robustness	and	the	investigator’s	confidence	in	the	outcome	of	the	
screening	process.	GB	generated	this	20%	sample	by	listing	the	results	alphabetically	in	their	entirety	
and	 selecting	 every	 5th	 title/abstract	 for	 review	by	ML.	 Any	 discrepancies	 between	 reviewers	were	
resolved	 by	 re-review	 of	 those	 studies	 until	 agreement	 was	 reached.	 Studies	 not	 meeting	 the	
inclusion	criteria	as	defined	a	priori	were	excluded.	Studies	meeting	the	inclusion	criteria	were	further	
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examined,	 full	 texts	were	 retrieved	 and	where	 possible	 English	 translations	 obtained.	GB	 reviewed	
these	studies	and	the	reason	for	rejection	at	this	point	was	recorded.	If	data	from	a	study	had	been	
published	 on	 more	 than	 one	 occasion	 then	 care	 was	 taken	 to	 ensure	 that	 outcomes	 were	 only	
included	once	and	that	all	publications	were	referenced	for	the	study.		
4.3.4.2	 Data	extraction	
Data	 extraction	was	 performed	 by	 GB	 using	 two	 pre-formed	 Excel	 datasheets	 (Microsoft	 Excel	 for	
Mac	2011,	version	14.7.2);	one	form	for	bias	assessments	and	one	for	outcome	data	(see	appendices	
8	and	9).	If	only	an	English	abstract	was	available	then	as	much	information	as	possible	was	included	
from	the	information	available.	Where	clarification	of	results	or	further	information	was	required	the	
corresponding	author	was	emailed.	The	following	data	were	extracted:	
1. For	Bias	assessments	
a. Method	(e.g.	prospective,	blinded,	etc)	
b. Participants	(e.g.	number,	gender,	age,	inclusion/exclusion	criteria)	
c. Interventions	(e.g.	antibiotic,	dose	and	method	of	administration)	
d. Outcomes	(overview	of	the	relevant	outcomes)	
e. Areas	of	bias	(selection,	performance,	detection,	attrition,	reporting	and	other	bias	
as	described	by	Higgins	et	al	(Higgins	et	al.,	2011))	
2. For	meta-analysis	
a. Antibiotic(s)	studied	
b. Intervention	(continuous	or	extended	infusion)	
c. Details	of	outcome	measures	
d. Sample	tested	(intention	to	treat,	per	protocol,	etc.)	
e. Events	for	each	outcome	
4.3.4.3	 Assessment	of	risk	of	bias	in	included	studies	
The	quality	of	the	randomised	controlled	trials	included	in	the	systematic	review	was	assessed	using	
the	 following	 criteria	 as	 laid	 out	 in	 “The	 Cochrane	 Collaboration’s	 tool	 for	 assessing	 risk	 of	 bias	 in	
randomised	trials”	(Higgins	et	al.,	2011)	
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• Selection	bias	(random	sequence	generation)	
• Selection	bias	(allocation	concealment)	
• Performance	bias	(blinding	of	participants	and	personnel)	
• Detection	bias	(blinding	of	outcome	assessment)	
• Attrition	bias	(incomplete	outcome	data)	
• Reporting	bias	(selective	reporting)	
• Other	bias	(anything	else,	ideally	pre-specified)		
Definitions	of	low,	high	and	unclear	risk	for	each	of	the	domains	were	set	out	prior	to	the	start	of	data	
collection	and	are	available	in	appendix	7.	The	detailed	results	for	each	paper	are	shown	in	appendix	
8.	
4.3.4.4	 Measure	of	treatment	effect	
All	outcomes	were	dichotomous	and	the	treatment	effect	was	measured	using	the	risk	ratio	(RR)	with	
its	associated	95%	confidence	interval	(95%	CI)	and	using	a	random-effects	model.	The	justification	of	
the	choice	of	these	measures	is	described	in	detail	in	chapter	2	“2.1.2.2	Choice	of	method	of	statistical	
analysis”.	
4.3.4.5	 Unit	of	analysis	
The	unit	of	analysis	used	was	 the	patient	participant	and	data	 from	each	 randomized	patient	were	
included	 in	 the	 analysis.	Where	 results	were	presented	as	 a	 total	 number	of	 events	but	 it	was	not	
clear	how	many	individual	patients	had	been	affected	then	the	results	were	excluded	from	the	final	
analysis.	For	example,	if	adverse	events	were	tallied	by	the	type	of	event	and	therefore	an	individual	
patient	may	have	had	more	than	one	type	of	event,	or	had	the	same	event	more	than	once,	then	the	
total	number	of	patients	affected	in	the	study	was	unknown	and	these	data	were	excluded.	
4.3.4.6	 Missing/ambiguous	data	
Efforts	were	made	to	contact	authors	for	clarification	if	any	data	in	published	studies	were	considered	
to	 be	 missing	 or	 the	 published	 data	 were	 ambiguous,	 for	 example	 if	 data	 in	 the	 text	 and	 tables	
appeared	not	to	correspond.	
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4.3.4.7	 Assessment	of	heterogeneity	
The	 I2	 statistic	 has	 been	 used	 as	 the	 main	 measure	 of	 heterogeneity.	 Heterogeneity	 should	 be	
assessed	 in	 the	wider	context	of	 the	studies	 included	but	as	a	general	 rule	 I2	greater	 than	50%	was	
considered	as	important	heterogeneity,	an	I2	of	less	than	30%	was	considered	lower	risk	(Higgins	and	
Thompson,	2002;	Higgins	et	al.,	2003).	
A	random-effects	model	was	used	to	assess	if	there	was	a	statistically	significant	difference	between	
the	intervention	and	control	groups	in	the	studies.	This	model	was	chosen	due	to	the	large	number	of	
small	studies	and	inter-study	differences	in	class	of	antibiotic	and	type	of	infection	being	treated.		
4.3.4.8	 Assessment	of	reporting	bias	
Evidence	 of	 publication	 bias	was	 assessed	 both	 visually	 using	 funnel	 plots	 (Egger	 et	 al.,	 1997)	 and	
statistically	using	Duval	and	Tweedie’s	Trim	and	Fill	(Duval	and	Tweedie,	2000)	method	as	described	in	
chapter	2	“2.1.2.2	Choice	of	method	of	statistical	analysis”.	
4.3.4.9	 Data	synthesis	
Data	 from	 the	 retrieved	 studies	 were	 exported	 from	 Excel	 into	 Comprehensive	 Meta	 Analysis	
(Comprehensive	Meta	Analysis,	version	3.3.070,	November	20,	2014),	which	was	used	to	perform	all	
data	synthesis	and	analysis,	including	funnel	plots	and	high-resolution	forest	plots.		
4.3.4.10	Subgroup	analysis	
The	only	subgroup	defined	for	separate	analysis	a	priori	was	individual	antibiotics	that	featured	in	5	or	
more	studies.	In	view	of	the	results	of	the	questionnaire	conducted	for	chapter	3	of	this	programme	
of	 work,	 antibiotics	 with	 significant	 UK-wide	 usage	 as	 extended	 infusions	 were	 also	 analysed	
individually.	In	articles	that	reported	investigating	antibiotics	by	general	class,	e.g.	β-lactams,	and	data	
for	 individual	 antibiotics	 were	 not	 published,	 then	 attempts	 were	made	 to	 contact	 the	 authors	 to	
provide	a	breakdown	of	the	published	data	by	antibiotic	if	that	information	was	available.	
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4.3.4.11	Sensitivity	analysis	
Specifics	 of	 the	 sensitivity	 analysis	 were	 not	 defined	 a	 priori	 but	 were	 performed	 on	 primary	
outcomes	and	any	outcomes	yielding	a	significant	result.	Sensitivity	analysis	was	conducted	to	assess	
the	 impact	 of	 arbitrary	 decisions	 made	 in	 the	 design	 phase	 of	 the	 systematic	 review	 on	 the	
significance	of	the	results.		
4.4	 Results	
4.4.1	 Literature	search	
The	 initial	 database	 search	 conducted	 in	 June	 2016	 identified	 6190	 articles	 with	 an	 additional	 2	
articles	 being	 identified	 from	 other	 sources.	 After	 removal	 of	 duplicates	 4255	 articles	 remained.	
Titles,	 and	 where	 appropriate	 abstracts,	 of	 these	 articles	 were	 screened	 and	 4196	 articles	 were	
excluded	 for	 not	meeting	 the	 pre-defined	 inclusion	 criteria.	 59	 potentially	 eligible	 full	 text	 articles	
were	reviewed	and	24	excluded	for	not	meeting	the	pre-defined	inclusion	criteria	(see	figure	4.1)	and	
the	remaining	35	articles	were	included	in	the	systematic	review.	Of	the	35	articles	included,	2	were	
only	available	as	English	abstracts	(one	full	 text	article	 in	Japanese	and	one	in	Chinese)	(Okimoto	et	
al.,	2009;	Lü	et	al.,	2013)	but	sufficient	 information	was	available	within	the	abstract	to	deem	them	
suitable	for	 inclusion	in	the	review.	Two	articles	 included	patients	from	the	same	study	(McNabb	et	
al.,	2001;	Nicolau	et	al.,	2001)	but	both	presented	different	outcomes,	one	clinical	success	(Nicolau	et	
al.,	2001)	and	the	other	adverse	events	(McNabb	et	al.,	2001),	therefore	both	studies	were	included	
in	the	systematic	review.		
In	April	2018	the	database	search	was	rerun	and	an	additional	649	articles	 identified	with	1	 further	
article	 coming	 from	 other	 sources.	 After	 removal	 of	 duplicates	 439	 articles	 remained	 and	 after	
screening	 of	 titles	 and	 abstracts	 7	 articles	 potentially	 met	 the	 pre-defined	 inclusion	 criteria	 and	
required	full	text	review.	Two	articles	were	excluded	and	the	remaining	5	included	in	the	systematic	
review	(see	figure	4.1).	
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Figure	4.1:	PRISMA	Flow	diagram	showing	selection	process	study	selection	process	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
6190	articles	
identified	from	
database	searching	
(June	2016)	
	
649	articles	identified	
from	database	
searching	(April	2018)	
2	articles	identified	
from	additional	sources	
(June	2016)	
	
1	article	identified	from	
additional	sources	(April	
2018)	
4255	articles	after	
duplicates	removed	
(June	2016)	
	
439	articles	after	
duplicates	removed	
(April	2018)	
	
4196	excluded	
(June	2016)	
	
431	excluded	
(April	2018)	
4255	articles	screened	
(June	2016)	
	
439	articles	screened	
(April	2018)	
59	Full	text	articles	
assessed	for	eligibility	
(June	2016)	
		
8	full	text	articles	
assessed	for	eligibility	
(April	2018)	
24	Full	text	articles	excluded	(June	2016)	
	
1	=	conference	abstract	
	
2	=	duplicate	
	
1	=	case	report	
	
1	=	preliminary	data	of	an	included	published	study	
	
1	=	part	not	randomised	
	
1	=	crossover	
	
2	=	not	RCT	
	
1	=	uncontrolled	
	
4	=	retrospective	
	
1	=	not	clear	if	randomised	
	
1	=	dosing	simulation	
	
6	=	pk	outcome	data	only	
	
1	=	48	hours	then	all	received	same	therapy	
	
1	=	study	protocol	
	
1	=	unable	to	obtain	translation	
	
	
3	full	text	articles	excluded	(April	2018)	
	
2	=	not	RCT	
	
1	=	unable	to	obtain	translation	
	
	
35	articles	included	for	
meta-analysis	(June	
2016)	
	
5	articles	included	for	
meta-analysis	(April	
2018)	
	
Total	=	40	articles	
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4.4.1.1	Included	studies	
Forty	 articles	 were	 included	 in	 the	 meta-analysis,	 34	 investigating	 continuous	 infusions	 and	 6	
extended	 infusions.	 The	 studies	 ranged	 in	 size	 from	 10	 to	 422	 patients,	 with	 a	 mean	 size	 of	 85	
patients	 (median	 50)	 and	 10	 articles	 reported	 on	 studies	 containing	 at	 least	 100	 patients.	 The	
systematic	 review	 contained	 a	 combined	 total	 of	 more	 than	 3300	 patients.	 All	 included	 articles	
investigated	adults	over	the	age	of	18	exclusively	with	the	exception	of	two	(Feld	et	al.,	1977;	Wright	
et	al.,	1979).	The	age	range	across	the	studies	was	11	to	102	years	old.	One	article	(Feld	et	al.,	1977)	
stated	 no	 age	 range	within	 their	 inclusion/exclusion	 criteria	 but	 included	 patients	 of	 15	 and	 over,	
however	as	the	median	age	was	43	to	46	years	old,	the	study	was	included	as	it	was	deemed	that	the	
number	of	patients	under	18	would	have	been	small.	One	article	(Wright	et	al.,	1979)	again	did	not	
specify	 within	 the	 inclusion/exclusion	 criteria	 that	 patients	 must	 be	 over	 18	 years	 old	 but	 the	
documented	age	ranges	in	both	the	pneumonia	and	shock	lung	groups	are	11-69	(mean	44)	and	11-55	
(mean	33)	years	old	respectively.	The	article	by	Bao	et	al	stated	in	their	inclusion	criteria	an	upper	age	
limit	 of	 70	 years	 old	 but	 had	 a	median	 age	 in	 both	 groups	 of	 71	 and	 a	maximum	age	of	 82	 in	 the	
extended	infusion	group	and	80	in	the	intermittent	infusion	group	(Bao	et	al.,	2017).	Two	articles	did	
not	comment	on	the	age	range	of	the	patients	included	(Lagast	et	al.,	1983;	Lipman	et	al.,	1999).	
Males	accounted	for	between	42%	and	89%	of	the	patients	in	the	included	articles;	in	only	3	articles	
were	 there	more	 females	 than	male	 participants.	 Two	 articles	 did	 not	 state	 the	male/female	 split	
(Wright	et	al.,	1979;	Lipman	et	al.,	1999).	
Antibiotics	 studied	 included	piperacillin	 (+/-	 tazobactam)	 (number	of	 articles	 =	 14),	 ceftazidime	 (9),	
meropenem	 (7),	 cefepime	 (2),	 temocillin	 (2),	 ticarcillin-clavulanate	 (2),	 tobramycin	 (2),	 vancomycin	
(2),	 cefamandole	 (1),	 cefoperazone	 (1),	 cefotaxime	 (1),	 ceftriaxone	 (1),	 gentamicin	 (1),	 imipenem-
cilastatin	 (1),	 linezolid	 (1),	sisomicin	 (1).	A	number	of	studies	 investigated	more	than	one	antibiotic,	
these	 were	 multi-centre	 studies	 and	 allowed	 for	 the	 choice	 of	 β-lactam	 antibiotic	 to	 reflect	 local	
practice.	
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In	 24	 articles	 the	 use	 of	 non-study	 antibiotics	 was	 not	 documented	 nor	 was	 it	 clear	 whether	
concomitant	 use	 of	 non-study	 antibiotics	 was	 allowed.	 Two	 studies	 stated	 the	 use	 of	 non-study	
antibiotics	in	the	exclusion	criteria	(Lubasch	et	al.,	2003;	Lau	et	al.,	2006).	The	remaining	14	articles	all	
allowed	 the	 use	 of	 additional	 open	 label	 antibiotics	 during	 the	 study	 but	 with	 varying	 levels	 of	
restrictions.	Bao	et	al	 (Bao	et	al.,	2017)	allowed	their	use	but	counted	their	use	as	a	sign	of	clinical	
failure	when	assessing	clinical	outcome.	Fan	et	al.	 (Fan	et	al.,	2017)	excluded	concomitant	β-lactam	
use	 but	 allowed	 all	 other	 antibiotics.	Most	 articles	 stated	 they	were	 allowed	 but	 did	 not	 allude	 to	
which	 antibiotics	 had	 been	 used	 and	 in	 how	 many	 patients.	 Two	 studies	 listed	 the	 antibiotics	
prescribed	and	assessed	for	statistically	significant	differences	between	treatment	and	control	groups	
(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016).	
Seven	articles	 included	 in	 the	systematic	 review	contributed	no	data	 to	 the	meta-analysis.	Three	of	
these	 articles	 did	 not	 present	 any	 outcomes	 relevant	 to	 the	 meta-analysis	 (Lipman	 et	 al.,	 1999;	
Pedeboscq	 et	 al.,	 2001;	 Yang	 et	 al.,	 2017).	 One	 article	 reported	 adverse	 events	 but	 only	 for	 the	
treatment	group	and	no	other	relevant	outcomes	(Nicolau	et	al.,	1999b).	For	two	articles	only	English	
abstracts	were	available	and	it	was	not	possible	to	align	the	outcomes	described	within	these	with	the	
outcomes	predetermined	for	the	meta-analysis	(Okimoto	et	al.,	2009;	Lü	et	al.,	2013)	(see	appendix	9	
for	 raw	outcome	data).	Finally,	Bodey	and	colleagues	 reported	outcomes	as	events	 rather	 than	per	
patient	(Bodey	et	al.,	1979).		
Reported	clinical	cure	and	response	rates	varied	within	one	article	and	as	the	true	values	could	not	be	
ascertained	these	outcomes	from	the	study	were	excluded	from	the	meta-analysis	(Cotrina-Luque	et	
al.,	2016)	
As	described	earlier,	two	articles	included	patients	from	the	same	study	(McNabb	et	al.,	2001;	Nicolau	
et	al.,	2001)	but	both	presented	different	outcomes,	one	clinical	success	(Nicolau	et	al.,	2001)	and	the	
other	 adverse	 events	 (McNabb	et	 al.,	 2001),	 the	 relevant	 data	was	 extracted	 for	 the	meta-analysis	
with	care	taken	to	avoid	any	duplication	of	patients.		
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4.4.1.2	 Excluded	studies	
Twenty-seven	of	the	67	articles	identified	for	full	text	review	were	excluded	for	the	following	reasons:	
not	 RCT	 (8),	 pk	 outcome	 data	 only	 (6),	 duplicate	 (3),	 conference	 abstract	 (1),	 case	 report	 (1),	
preliminary	 data	 of	 an	 included	 published	 study	 (1),	 part	 not	 randomised	 (1),	 crossover	 (1),	
uncontrolled	(1),	not	clear	 if	 randomised	(1),	dosing	simulation	(1),	48	hours	then	all	 received	same	
therapy	(1),	study	protocol	(1).	
4.4.2	 Assessment	of	risk	of	bias	in	the	included	studies	
On	 the	 whole	 the	 articles	 generally	 showed	 a	 high	 or	 unclear	 risk	 of	 bias.	 This	 was	 particularly	
apparent	with	performance	bias,	as	only	three	studies	out	of	 the	40	assessed	were	double	blinded.	
Attrition	and	reporting	bias	faired	much	better	 in	general	with	62%	and	45%	of	articles	respectively	
being	 assessed	 as	 low	 risk.	No	 article	was	 low	 risk	 for	 all	methodological	 quality	markers	 assessed	
although	one	study	was	judged	to	be	at	low	risk	for	all	fields	except	for	an	unclear	risk	in	“other	bias”	
due	to	pharmaceutical	industry	sponsorship	(Dulhunty	et	al.,	2015).	For	an	overview	of	the	risk	of	bias	
assessments	 see	 table	 4.1	 “Methodological	 quality	 summary”.	 For	 full	 details	 of	 the	 assessment	 of	
each	article	see	appendix	8	–	“Risk	of	bias”	tables.	
	
	
	
	
	
	
	
	
	
	
	
	 89	
	
	
	
Table	4.1:	Methodological	quality	summary	–	review	author’s	judgement	of	the	risk	of	bias	associated	
with	each	methodological	quality	item	for	that	of	each	of	the	included	studies	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	R
an
do
m
	se
qu
en
ce
	g
en
er
at
io
n	
	(s
el
ec
tio
n	
bi
as
)	
	A
llo
ca
tio
n	
co
nc
ea
lm
en
t	
	(s
el
ec
tio
n	
bi
as
)	
	B
lin
di
ng
	o
f	p
ar
tic
ip
an
ts
	a
nd
	
re
se
ar
ch
er
s	(
pe
rf
or
m
an
ce
	b
ia
s)
	
	B
lin
di
ng
	o
f	o
ut
co
m
e	
as
se
ss
m
en
t		
	(p
er
fo
rm
an
ce
	b
ia
s)
	
	In
co
m
pl
et
e	
ou
tc
om
e	
da
ta
		
	(a
tt
rit
io
n	
bi
as
)	
	S
el
ec
tiv
e	
re
po
rt
in
g	
	(r
ep
or
tin
g	
bi
as
)	
	O
th
er
	b
ia
s	
Abdul-Aziz	2016	 +	 +	 -	 -	 +	 +	 +	
Adembri	2008	 ?	 ?	 -	 -	 +	 +	 ?	
Angus	2000	 ?	 ?	 ?	 ?	 -	 -	 -	
Bao	2017	 ?	 ?	 -	 -	 ?	 +	 +	
Bodey	1979	 +	 ?	 ?	 ?	 -	 -	 ?	
Buck	2005	 ?	 ?	 -	 -	 +	 ?	 ?	
Chytra	2012	 ?	 +	 -	 -	 +	 +	 +	
Contrina-Luque	2015	 +	 ?	 ?	 ?	 ?	 ?	 ?	
De	Jongh	2007	 ?	 ?	 -	 -	 -	 ?	 ?	
Dulhunty	2013	 +	 ?	 +	 +	 +	 +	 ?	
Dulhunty	2015	 +	 +	 +	 +	 +	 +	 ?	
Fan	2017	 +	 -	 -	 -	 +	 ?	 ?	
Feld	1977	 ?	 ?	 ?	 ?	 -	 +	 ?	
Feld	1984	 ?	 ?	 ?	 ?	 +	 ?	 ?	
Georges	2005	 ?	 ?	 -	 -	 ?	 -	 ?	
Hanes	2000	 ?	 ?	 ?	 ?	 ?	 -	 ?	
Lagast	1983	 ?	 ?	 ?	 ?	 +	 -	 ?	
Laterre	2015	 ?	 ?	 ?	 ?	 ?	 -	 ?	
Lau	2006	 ?	 ?	 -	 -	 -	 -	 -	
Lipman	1999	 +	 ?	 ?	 ?	 ?	 ?	 -	
Lu	2013	 ?	 ?	 -	 -	 +	 ?	 ?	
Lubasch	2003	 ?	 ?	 -	 -	 +	 +	 ?	
McNabb	2001	 ?	 ?	 -	 -	 -	 +	 ?	
Nicolau	1999a	 ?	 ?	 ?	 ?	 +	 -	 ?	
Nicolau	1999b	 ?	 ?	 -	 -	 -	 -	 ?	
Nicolau	2001	 ?	 ?	 -	 -	 -	 +	 ?	
Okimoto	2009	 ?	 ?	 -	 -	 ?	 ?	 ?	
Rafati	2006	 ?	 ?	 ?	 ?	 +	 +	 ?	
Ram	2018	 +	 +	 -	 +	 +	 +	 ?	
Roberts	2007	 +	 +	 -	 +	 +	 +	 -	
Roberts	2009a	 ?	 +	 ?	 ?	 +	 ?	 ?	
Roberts	2009b	 ?	 +	 -	 -	 +	 +	 -	
Roberts	2010	 ?	 +	 -	 -	 +	 ?	 -	
Sakka	2007	 ?	 ?	 -	 -	 +	 ?	 ?	
Schmelzer	2013	 +	 ?	 -	 -	 ?	 ?	 -	
Van	Zanten	2006	 ?	 ?	 -	 -	 -	 ?	 ?	
Wright	1979	 ?	 ?	 -	 -	 ?	 ?	 ?	
Wysocki	2001	 +	 +	 -	 ?	 -	 -	 -	
Yang	2017	 ?	 ?	 -	 ?	 +	 +	 +	
Zhao	2017	 ?	 +	 -	 ?	 +	 +	 ?	
Key	–	risk	of	bias	
+	 Low	
?	 Unclear	
-	 High	
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4.4.2.1	 Selection	bias	-	Random	sequence	generation	
Eleven	 articles	 (Bodey	 et	 al.,	 1979;	 Lipman	 et	 al.,	 1999;	Wysocki	 et	 al.,	 2001;	 Roberts	 et	 al.,	 2007;	
Dulhunty	 et	 al.,	 2013a,	 2015;	 Schmelzer	 et	 al.,	 2013;	 Abdul-Aziz	 et	 al.,	 2016;	 Cotrina-Luque	 et	 al.,	
2016;	 Fan	 et	 al.,	 2017;	 Ram	 et	 al.,	 2018)	 adequately	 described	 the	 generation	 of	 randomisation	
sequences	to	be	deemed	at	low	risk	of	bias.	The	remaining	29	articles	were	judged	to	have	an	unclear	
risk	of	bias	as	although	they	all	stated	that	the	patients	were	randomised	they	did	not	describe	the	
method	 of	 random	 sequence	 generation	 or	 the	 information	 was	 not	 available	 in	 the	 English	
translations	of	the	abstracts	(Okimoto	et	al.,	2009;	Lü	et	al.,	2013).	
4.4.2.2	 Selection	bias	-	Allocation	concealment	
Ten	 articles	 (Wysocki	 et	 al.,	 2001;	 Roberts	 et	 al.,	 2007,	 2009a,	 2009b,	 2010;	 Chytra	 et	 al.,	 2012;	
Dulhunty	 et	 al.,	 2015;	 Abdul-Aziz	 et	 al.,	 2016;	 Zhao	 et	 al.,	 2017;	 Ram	 et	 al.,	 2018)	 stated	 that	
randomisation	occurred	using	 sealed	opaque	envelopes	and	so	were	deemed	 to	be	 low	 risk.	 Seven	
articles	(Bodey	et	al.,	1979;	Feld	et	al.,	1984;	Buck	et	al.,	2005;	Sakka	et	al.,	2007;	Adembri	et	al.,	2008;	
Dulhunty	et	al.,	2013a;	Bao	et	al.,	2017)	stated	that	randomisation	occurred	using	sealed	envelopes	
but	 opacity	 was	 not	 stated	 so	 were	 deemed	 to	 be	 of	 unclear	 risk.	 One	 article	 (Fan	 et	 al.,	 2017)	
randomised	patients	by	hospital	number	 therefore	 the	enrolling	physician	would	be	able	 to	predict	
which	treatment	arm	the	patient	would	enter	so	was	deemed	to	be	high	risk.	Allocation	concealment	
was	 unclear	 in	 one	 article	 (Cotrina-Luque	 et	 al.,	 2016)	were	 it	 was	 not	 stated	whether	 un-blinded	
pharmacy	staff	involved	in	supply	of	the	randomised	therapy	were	involved	in	the	clinical	care	of	the	
patients	 so	 was	 deemed	 to	 be	 of	 unclear	 risk.	 The	 remaining	 21	 articles	 were	 judged	 to	 have	 an	
unclear	 risk	of	bias	as	 the	method	of	allocation	concealment	was	not	 stated,	 in	 two	cases	only	 the	
abstract	was	available	in	English	(Okimoto	et	al.,	2009;	Lü	et	al.,	2013).	
4.4.2.3	 Performance	bias	-	Blinding	of	participant	and	researchers	
Nineteen	articles	(Georges	et	al.,	1999;	Nicolau	et	al.,	2001;	Wysocki	et	al.,	2001;	McNabb	et	al.,	2001;	
Lubasch	et	al.,	2003;	Buck	et	al.,	2005;	Lau	et	al.,	2006;	Roberts	et	al.,	2007,	2009b,	2010;	van	Zanten	
et	 al.,	 2007;	Adembri	 et	 al.,	 2008;	De	 Jongh	et	 al.,	 2008;	Okimoto	et	 al.,	 2009;	 Chytra	 et	 al.,	 2012;	
Abdul-Aziz	et	al.,	 2016;	Yang	et	al.,	 2017;	 Fan	et	al.,	 2017;	Ram	et	al.,	 2018)	described	 studies	 that	
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were	open	label/un-blinded	at	the	point	of	administration	so	deemed	to	be	at	high	risk	of	bias.	Two	
articles	(Dulhunty	et	al.,	2013a,	2015)	describe	studies	that	were	double	blinded	and	so	deemed	to	be	
at	low	risk	of	bias.	One	article	(Nicolau	et	al.,	1999b)	described	the	study	as	single	blinded	but	did	not	
state	which	part	of	the	process	was	blinded	so	was	deemed	to	be	at	unclear	risk	of	bias.	One	article	
(Lü	et	al.,	2013)	was	only	available	as	an	English	abstract	and	did	not	describe	the	blinding	process	so	
was	 deemed	 to	 be	 at	 unclear	 risk	 of	 bias.	 The	 remaining	 seventeen	 articles	 did	 not	 comment	 on	
blinded	as	so	were	deemed	to	be	at	unclear	risk	of	bias.		
4.4.2.4	 Detection	bias	-	Blinding	of	outcome	assessment	
Fifteen	articles	(Georges	et	al.,	1999;	Nicolau	et	al.,	2001;	McNabb	et	al.,	2001;	Lubasch	et	al.,	2003;	
Buck	et	al.,	2005;	Lau	et	al.,	2006;	van	Zanten	et	al.,	2007;	Adembri	et	al.,	2008;	De	Jongh	et	al.,	2008;	
Okimoto	et	al.,	2009;	Roberts	et	al.,	2009b,	2010;	Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016;	Fan	et	
al.,	2017)	described	studies	that	were	open	label/un-blinded	at	the	point	of	outcome	assessment	so	
deemed	to	be	at	high	risk	of	bias.	 	Two	articles	 (Dulhunty	et	al.,	2013a,	2015)	were	double	blinded	
and	so	assessed	as	being	at	a	 low	risk	of	bias.	Three	more	articles	were	single	blinded;	 two	articles	
(Roberts	et	al.,	2007;	Ram	et	al.,	2018)	were	un-blinded	at	the	point	of	administration	to	the	patient	
but	 the	 investigators	 assessing	 outcomes	were	 blinded	 so	 these	were	 deemed	 to	 be	 at	 low	 risk	 of	
bias,	one	article	(Nicolau	et	al.,	1999b)	described	the	study	as	single	blinded	but	did	not	state	which	
part	of	the	process	was	blinded	so	was	deemed	to	be	at	unclear	risk	of	bias.	One	article	(Wysocki	et	
al.,	2001)	appeared	to	be	blinded	at	the	point	of	outcome	assessment	but	did	not	explicitly	state	this	
so	was	 deemed	 to	 be	 at	 unclear	 risk	 of	 bias.	One	 article	 (Lü	 et	 al.,	 2013)	was	 only	 available	 as	 an	
English	abstract	and	did	not	describe	the	blinding	process	so	was	deemed	to	be	at	unclear	risk	of	bias.	
The	remaining	eighteen	articles	did	not	comment	on	blinding	so	were	deemed	to	be	at	unclear	risk	of	
bias.	
4.4.2.5	 Attrition	bias	-	Incomplete	outcome	data	
All	enrolled	patients	were	accounted	for	in	the	results	of	twenty-one	articles	(Lagast	et	al.,	1983;	Feld	
et	al.,	1984;	Nicolau	et	al.,	1999a;	Lubasch	et	al.,	2003;	Buck	et	al.,	2005;	Rafati	et	al.,	2006;	Roberts	et	
al.,	2007,	2009a,	2009b,	2010;	Sakka	et	al.,	2007;	Adembri	et	al.,	2008;	Chytra	et	al.,	2012;	Dulhunty	et	
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al.,	 2013a,	 2015;	 Abdul-Aziz	 et	 al.,	 2016;	 Cotrina-Luque	 et	 al.,	 2016;	 Yang	 et	 al.,	 2017;	 Zhao	 et	 al.,	
2017;	Fan	et	al.,	2017;	Ram	et	al.,	2018)	and	twenty	of	these	studies	were	deemed	to	be	at	low	risk	of	
bias,	one	(Cotrina-Luque	et	al.,	2016)	was	deemed	to	be	at	unclear	risk	of	bias	as	although	 it	was	a	
multi-centre	study	the	majority	of	patients	came	from	a	single	centre	and	the	study	fell	very	short	of	
the	target	number	of	patients.	One	article	 (Lü	et	al.,	2013)	only	available	as	an	English	abstract	was	
deemed	to	be	at	low	risk	of	bias	as	all	patients	randomised	were	accounted	for.	One	article	(Okimoto	
et	al.,	2009)	also	only	available	as	an	English	abstract	did	not	comment	on	patient	numbers	so	was	
deemed	to	be	at	unclear	risk	of	bias.	One	article	(Lipman	et	al.,	1999)	did	not	discuss	the	number	of	
patients	 screened	or	enrolled	 in	 the	 study	and	 so	was	deemed	 to	have	an	unclear	 risk	of	bias.	The	
remaining	 sixteen	 articles	 had	 one	 or	more	 issues	 relating	 to	 data	 completeness	 such	 as	 excluded	
patients,	patients	 lost	 to	 follow	up,	additional	outcomes	 included	not	 stated	a	priori.	 These	articles	
were	deemed	to	be	at	unclear	or	high	risk	of	bias.	
4.4.2.6	 Reporting	bias	-	Selective	reporting	
Fifteen	 articles	 (Feld	 et	 al.,	 1977;	McNabb	 et	 al.,	 2001;	 Nicolau	 et	 al.,	 2001;	 Lubasch	 et	 al.,	 2003;	
Roberts	et	al.,	2007,	2009b;	Adembri	et	al.,	2008;	Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	
Abdul-Aziz	et	al.,	2016;	Yang	et	al.,	2017;	Zhao	et	al.,	2017;	Bao	et	al.,	2017;	Ram	et	al.,	2018)	reported	
on	all	pre-specified	outcomes	so	were	deemed	to	be	at	a	low	risk	of	bias.	One	article	(Cotrina-Luque	
et	 al.,	 2016)	 reported	 on	 all	 pre-stated	 outcomes	 but	 states	 in	 the	 article	 the	 outcomes	 changed	
during	 the	 study	 due	 to	 low	enrolment	 and	was	 deemed	 to	 be	 at	 an	 unclear	 risk	 of	 bias.	 Thirteen	
articles	(Wright	et	al.,	1979;	Georges	et	al.,	1999;	Nicolau	et	al.,	1999b;	Angus	et	al.,	2000;	Hanes	et	
al.,	2000;	Rafati	et	al.,	2006;	Sakka	et	al.,	2007;	van	Zanten	et	al.,	2007;	De	Jongh	et	al.,	2008;	Roberts	
et	al.,	2009a,	2010;	Laterre	et	al.,	2015;	Fan	et	al.,	2017)	reported	on	one	or	more	outcome	not	stated	
a	priori	 and	were	deemed	 to	be	at	unclear	or	high	 risk	of	bias.	One	article	 (Schmelzer	et	al.,	2013)	
collected	 data	 on	 clinical	 outcome	 but	 did	 not	 report	 the	 results	 in	 the	 article	 so	 was	 deemed	 at	
unclear	 risk	 of	 bias.	 Selective	 reporting	 was	 un-evaluable	 and	 therefore	 deemed	 unclear	 in	 two	
articles	 (Okimoto	 et	 al.,	 2009;	 Lü	 et	 al.,	 2013)	 which	were	 only	 available	 as	 English	 abstracts.	 The	
remaining	eight	articles	did	not	report	results	for	all	individual	patients,	they	reported	“events”	or	did	
not	state	absolute	numbers	and	were	deemed	to	be	at	unclear	or	high	risk	of	bias.	
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4.4.2.7	 Other	bias		
No	other	potential	sources	of	bias	were	identified	in	four	articles	(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	
2016;	Bao	et	al.,	2017;	Yang	et	al.,	2017)	and	these	were	deemed	at	low	risk	of	bias.	Other	potential	
sources	 of	 bias	were	 unclear	 in	 two	 articles	 (Okimoto	 et	 al.,	 2009;	 Lü	 et	 al.,	 2013)	 as	 only	 English	
abstracts	 were	 available	 and	 so	 these	 studies	 were	 deemed	 to	 have	 unclear	 risk	 of	 bias.	 The	
remaining	thirty-four	articles	contained	one	or	more	of	the	following	potential	sources	of	other	bias;	
conflicts	 of	 interest	 not	 stated	 or	 potentially	 influential;	 industry	 funding	 or	 supply	 of	 antibiotics;	
unclear	 or	 unstated	 use	 of	 open	 label	 antibiotics;	 demographics	 of	 treatment	 groups	 not	 evenly	
matched;	antibiotic	dosing	not	evenly	matched	between	treatment	groups;	severely	underpowered,	
these	articles	were	deemed	to	be	at	unclear	or	high	risk	of	bias.	
4.4.3	 Outcomes	
No	single	study	reported	on	all	of	the	meta-analyses	pre-stated	outcomes.	The	table	below	describes	
the	number	of	articles	reporting	each	outcome.	
Table	 4.2:	 Number	 of	 articles	 reporting	 meta-analysis	 primary	 and	 secondary	 outcomes	
	
	
Outcome	 Number	of	articles	(out	of	a	possible	40)	
Clinical	cure	 11	
Clinical	response	 12	
Serious	adverse	event	(SAE)	 2	
All-cause	mortality	 23	
Infection	recurrence	within	14	days	of	resolution	
of	primary	infection	 3	
Microbiological/bacteriological	cure	 5	
Secondary/super-infection	 9	
Withdrawal	secondary	to	adverse	event	(WAE)	 4	
Adverse	event	(AE)	 14		
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4.4.3.1	 Primary	and	secondary	outcomes		
Primary	outcomes	
Clinical	cure:	Eleven	articles	reported	clinical	cure	(Nicolau	et	al.,	2001;	Georges	et	al.,	2005;	Roberts	
et	al.,	2009a,	2007;	Adembri	et	al.,	2008;	De	Jongh	et	al.,	2008;	Chytra	et	al.,	2012;	Dulhunty	et	al.,	
2013a,	2015;	Laterre	et	al.,	2015;	Abdul-Aziz	et	al.,	2016).	Two	articles	(De	Jongh	et	al.,	2008;	Roberts	
et	al.,	2009a)	reported	clinical	cure	in	all	patients	assessed	therefore	a	risk	ratio	is	not	estimable	and	
these	 articles	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 All	 of	 these	 articles	 reported	 studies	
investigating	 time-dependent	 antibiotics.	 A	 statistically	 significant	 difference	 in	 clinical	 cure	 was	
observed	(n	=	1083,	risk	ratio	(RR)	1.231,	95%	CI	1.081	to	1.403,	P	=	0.002).	No	evidence	of	statistical	
heterogeneity	was	found	(degrees	of	freedom	(df)	=	8,	P	=	0.357,	I2	=	9.4%).		
	
Figure	4.1a:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	interval	(95%	CI)	of	clinical	cure	of	patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	antibiotics.	MH	=	Mantel-Haenszel	test.	
Analysis	 of	 the	 funnel	 plot	 showing	 observed	 (white)	 and	 imputed	 (black)	 articles	 suggests	 that	
publication	bias	exists	favouring	articles	showing	a	positive	effect	from	extended	infusions.		
Study name Outcome Events / Total MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Abdul-Aziz 2016Clinical cure 24 / 70 39 / 70 10.37 1.625 1.105 2.390
Adembri 2008 Clinical cure 6 / 8 6 / 8 5.07 1.000 0.568 1.761
Chytra 2012 Clinical cure 24 / 120 30 / 120 7.10 1.250 0.779 2.007
Dulhunty 2013 Clinical cure 15 / 30 23 / 30 9.33 1.533 1.019 2.307
Dulhunty 2015 Clinical cure 109 / 220 111 / 212 34.55 1.057 0.878 1.272
Georges 2005 Clinical cure 16 / 24 22 / 26 13.94 1.269 0.915 1.760
Laterre 2015 Clinical cure 11 / 14 13 / 14 15.32 1.182 0.867 1.611
Nicolau 2001 Clinical cure 6 / 18 7 / 17 2.22 1.235 0.520 2.936
Roberts 2007 Clinical cure 5 / 28 13 / 29 2.10 2.510 1.030 6.120
1.231 1.081 1.403
0.1 0.2 0.5 1 2 5 10
Favours  Intermittent Favours Extended
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Figure	4.1b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	clinical	cure	
Trim	and	Fill	(Duval	and	Tweedie,	2000)	identifies	4	potentially	missing	studies	and	renders	the	result	
no	longer	significant	(random	effects	model,	point	estimate	1.109,	95%	CI	0.952	to	1.293).	
Number	of	patients	who	experienced	at	least	one	serious	adverse	event	(SAE):	Two	articles	reported	
the	number	of	patients	who	had	experienced	at	least	one	SAE	(Dulhunty	et	al.,	2015;	Bao	et	al.,	2017).	
Both	 of	 these	 articles	 reported	 studies	 investigating	 time-dependent	 antibiotics.	 No	 statistically	
significant	difference	in	SAE	was	observed	(n	=	482,	RR	0.858,	95%	CI	0.515	to	1.431,	P	=	0.558).	No	
evidence	of	statistical	heterogeneity	was	found	(df	=	1,	P	=	0.468,	I2	=	0.0%)	
	
Figure	 4.2:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	95%	 confidence	 interval	 (95%	CI)	 of	 serious	 adverse	 events	
(SAE)	of	patients	receiving	“Extended”	(extended	intermittent	or	continuous	 infusions	(EI))	versus	“Intermittent”	(bolus	or	
short	infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
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Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Dulhunty 2015 SAE 25 / 220 19 / 212 81.61 0.789 0.448 1.389
Bao 2017 SAE 4 / 25 5 / 25 18.39 1.250 0.379 4.118
0.858 0.515 1.431
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The	number	of	articles	reporting	SAE	was	insufficient	to	assess	for	publication	bias.	
Secondary	outcomes	
Clinical	response:	Twelve	articles	reported	clinical	response	(Hanes	et	al.,	2000;	Wysocki	et	al.,	2001;	
Nicolau	et	al.,	2001;	Lubasch	et	al.,	2003;	Buck	et	al.,	2005;	Lau	et	al.,	2006;	Roberts	et	al.,	2007;	van	
Zanten	et	al.,	2007;	Chytra	et	al.,	2012;	Bao	et	al.,	2017;	Zhao	et	al.,	2017;	Ram	et	al.,	2018).	Eleven	of	
these	articles	 reported	 studies	 investigating	 time-dependent	antibiotics	and	one	article	 (Wysocki	et	
al.,	2001)	MIC:AUC	ratio.	No	statistically	significant	difference	in	clinical	response	was	observed	(n	=	
1132,	RR	1.027,	95%	CI	0.974	to	1.083,	P	=	0.319).	No	evidence	of	statistical	heterogeneity	was	found	
(df	=	11,	P	=	0.743,	I2	=	0.0%).	
	
Figure	 4.3a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	 clinical	 response	 of	
patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test.	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
publication	 bias	 exists	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	 extended	
infusions.	Trim	and	Fill	(Duval	and	Tweedie,	2000)	identifies	2	potentially	missing	studies	but	doesn’t	
alter	 the	 statistical	 significance	 of	 the	 result	 (random	 effects	model,	 point	 estimate	 1.007,	 95%	 CI	
0.958	to	1.058).	
Study name Outcome Events / Total MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Buck 2005 Clinical response 8 / 12 8 / 12 0.88 1.000 0.568 1.761
Chytra 2012 Clinical response 81 / 120 88 / 120 10.41 1.086 0.922 1.281
Hanes 2000 Clinical response 10 / 14 9 / 16 0.95 0.788 0.457 1.357
Lau 2006 Clinical response 104 / 130 96 / 128 16.19 0.938 0.822 1.070
Lubasch 2003 Clinical response 36 / 40 37 / 41 13.54 1.003 0.868 1.158
Nicolau 2001 Clinical response 15 / 18 16 / 17 4.96 1.129 0.890 1.433
Roberts 2007 Clinical response 23 / 28 25 / 29 5.52 1.049 0.837 1.315
van Zanten 2006 Clinical response 40 / 43 37 / 40 19.44 0.994 0.882 1.122
Wysocki 2001 Clinical response a 47 / 58 48 / 61 8.65 0.971 0.811 1.163
Bao 2017 Clinical response 20 / 25 22 / 25 4.74 1.100 0.862 1.403
Ram 2018 Clinical response 47 / 58 44 / 47 13.36 1.155 0.999 1.336
Zhao 2017 Clinical response 14 / 25 16 / 25 1.36 1.143 0.725 1.802
1.027 0.974 1.083
0.5 1 2
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Figure	4.3b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	clinical	response	
Analysis	 of	 the	 eleven	 articles	 reporting	 clinical	 response	 for	 time-dependent	 antibiotics	 only	 also	
showed	no	statistically	significant	difference	between	the	treatment	groups	(n	=	1013,	RR	1.033,	95%	
CI	0.977	to	1.092,	P	=	0.254).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	10,	P	=	0.702,	I2	
=	0.0%).	
Analysis	of	the	funnel	plot	with	imputed	studies	using	the	Trim	and	Fill	method	(Duval	and	Tweedie,	
2000)	identifies	3	potentially	missing	studies	but	doesn’t	alter	the	statistical	significance	of	the	result	
(random	effects	model,	point	estimate	1.015,	95%	CI	0.952	to	1.08364).	
All	cause	mortality:	Twenty	three	articles	reported	all-cause	mortality	(Feld	et	al.,	1977,	1984;	Wright	
et	al.,	1979;	Angus	et	al.,	2000;	Hanes	et	al.,	2000;	Wysocki	et	al.,	2001;	Georges	et	al.,	2005;	Rafati	et	
al.,	2006;	Roberts	et	al.,	2007,	2009a,	2010;	Sakka	et	al.,	2007;	van	Zanten	et	al.,	2007;	De	Jongh	et	al.,	
2008;	Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	Laterre	et	al.,	2015;	Abdul-Aziz	et	al.,	2016;	
Cotrina-Luque	et	al.,	2016;	Zhao	et	al.,	2017;	Fan	et	al.,	2017;	Ram	et	al.,	2018).	Two	articles	(De	Jongh	
et	al.,	2008;	Roberts	et	al.,	2010)	reported	no	deaths	in	all	patients	assessed	and	are	not	represented	
visually	 in	 the	 forest	plot.	Nineteen	of	 these	articles	 reported	 studies	 investigating	 time-dependent	
antibiotics,	3	(Feld	et	al.,	1977,	1984;	Wright	et	al.,	1979)	concentration	dependent	and	one	MIC:AUC	
ratio	(Wysocki	et	al.,	2001).	No	statistically	significant	difference	in	mortality	was	observed	(n	=	2165,	
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RR	0.868,	95%	CI	0.743	to	1.014,	P	=	0.075).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	
20,	P	=	0.82,	I2	=	0.0%).	
	
Figure	 4.4a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	mortality	 of	 patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	 the	 funnel	plot	 showing	both	observed	 (white)	and	 imputed	studies	 suggests	 that	 there	
are	no	missing	studies	and	that	no	publication	bias	exists.		
	
Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Abdul-Aziz 2016 Mortality 26 / 70 18 / 70 9.63 0.692 0.419 1.143
Angus 2000 Mortality 9 / 11 3 / 10 2.49 0.367 0.137 0.984
Chytra 2012 Mortality 28 / 120 21 / 120 9.45 0.750 0.452 1.244
Cotrina-Luque 2016 Mortality 1 / 38 0 / 40 0.24 0.317 0.013 7.552
Dulhunty 2013 Mortality 6 / 30 3 / 30 1.45 0.500 0.138 1.817
Dulhunty 2015 Mortality 62 / 220 56 / 212 25.49 0.937 0.689 1.276
Feld 1977 Mortality c 6 / 57 8 / 63 2.44 1.206 0.446 3.266
Feld 1984 Mortality c 5 / 16 2 / 10 1.17 0.640 0.152 2.693
Georges 2005 Mortality 3 / 24 3 / 26 1.07 0.923 0.206 4.141
Hanes 2000 Mortality 4 / 25 5 / 20 1.75 1.563 0.482 5.065
Laterre 2015 Mortality 5 / 14 2 / 14 1.13 0.400 0.093 1.727
Rafati 2006 Mortality 6 / 20 5 / 20 2.36 0.833 0.303 2.293
Roberts 2007 Mortality 0 / 28 3 / 29 0.28 6.767 0.365 125.325
Roberts 2009a Mortality 0 / 5 2 / 5 0.30 5.000 0.299 83.685
Sakka 2007 Mortality 2 / 10 1 / 10 0.48 0.500 0.054 4.672
van Zanten 2006 Mortality 1 / 46 4 / 47 0.52 3.915 0.455 33.719
Wright 1979 Mortality c 3 / 13 5 / 23 1.53 0.942 0.267 3.319
Wysocki 2001 Mortality a 19 / 58 21 / 61 9.46 1.051 0.634 1.743
Fan 2017 Mortality 59 / 185 52 / 182 24.93 0.896 0.656 1.223
Ram 2018 Mortality 2 / 58 1 / 47 0.43 0.617 0.058 6.597
Zhao 2017 Mortality 8 / 25 7 / 25 3.36 0.875 0.374 2.046
0.868 0.743 1.014
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Figure	4.4b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	mortality	
Nineteen	 articles	 compared	 time-dependent	 antibiotics	 (Angus	 et	 al.,	 2000;	 Hanes	 et	 al.,	 2000;	
Georges	 et	 al.,	 2005;	 Rafati	 et	 al.,	 2006;	 Roberts	 et	 al.,	 2007,	 2009a,	 2010;	 Sakka	 et	 al.,	 2007;	 van	
Zanten	et	al.,	2007;	De	Jongh	et	al.,	2008;	Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	Laterre	et	
al.,	2015;	Abdul-Aziz	et	al.,	2016;	Cotrina-Luque	et	al.,	2016;	Zhao	et	al.,	2017;	Fan	et	al.,	2017;	Ram	et	
al.,	2018).	Two	articles	(De	Jongh	et	al.,	2008;	Roberts	et	al.,	2010)	reported	no	deaths	in	all	patients	
assessed	 and	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 A	 statistically	 significant	 difference	 in	
mortality	 was	 observed	 (n	 =	 1861,	 RR	 0.844,	 95%	 CI	 0.713	 to	 0.999,	 p	 =	 0.049).	 No	 evidence	 of	
statistical	heterogeneity	was	found	(df	=	16,	P	=	0.676,	I2	=	0.0%).	
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Figure	 4.5a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	mortality	 of	 patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	time-dependent	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	 the	 funnel	plot	 showing	both	observed	 (white)	and	 imputed	studies	 suggests	 that	 there	
are	no	missing	studies	and	that	no	publication	bias	exists.		
	
Figure	4.5b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	mortality	(time-dependent	only)	
	
	
Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Abdul-Aziz 2016 Mortality 26 / 70 18 / 70 11.28 0.692 0.419 1.143
Angus 2000 Mortality 9 / 11 3 / 10 2.91 0.367 0.137 0.984
Chytra 2012 Mortality 28 / 120 21 / 120 11.07 0.750 0.452 1.244
Cotrina-Luque 2016 Mortality 1 / 38 0 / 40 0.28 0.317 0.013 7.552
Dulhunty 2013 Mortality 6 / 30 3 / 30 1.70 0.500 0.138 1.817
Dulhunty 2015 Mortality 62 / 220 56 / 212 29.85 0.937 0.689 1.276
Georges 2005 Mortality 3 / 24 3 / 26 1.26 0.923 0.206 4.141
Hanes 2000 Mortality 4 / 25 5 / 20 2.05 1.563 0.482 5.065
Laterre 2015 Mortality 5 / 14 2 / 14 1.32 0.400 0.093 1.727
Rafati 2006 Mortality 6 / 20 5 / 20 2.77 0.833 0.303 2.293
Roberts 2007 Mortality 0 / 28 3 / 29 0.33 6.767 0.365 125.325
Roberts 2009b Mortality 0 / 5 2 / 5 0.36 5.000 0.299 83.685
Sakka 2007 Mortality 2 / 10 1 / 10 0.57 0.500 0.054 4.672
van Zanten 2006 Mortality 1 / 46 4 / 47 0.61 3.915 0.455 33.719
Fan 2017 Mortality 59 / 185 52 / 182 29.20 0.896 0.656 1.223
Ram 2018 Mortality 2 / 58 1 / 47 0.51 0.617 0.058 6.597
Zhao 2017 Mortality 8 / 25 7 / 25 3.93 0.875 0.374 2.046
0.844 0.713 0.999
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Infection	 recurrence	within	14	days	of	 resolution	of	primary	 infection:	Three	articles	(Lagast	et	al.,	
1983;	Roberts	et	al.,	2007;	Lü	et	al.,	2013)	reported	on	recurrence	of	the	primary	infection	within	14	
days	of	stopping	the	antibiotic	therapy.	No	statistical	significant	difference	was	observed	(n	=	152,	RR	
1.024,	95%	CI	0.219	to	4.793,	p	=	0.976).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	2,	P	
=	0.670,	I2	=	0.0%).	
	
Figure	4.6a:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	 interval	 (95%	CI)	of	 infection	recurrence	of	
patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
some	 publication	 bias	 may	 exist	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	
extended	 infusions.	 Trim	and	 Fill	 (Duval	 and	Tweedie,	 2000)	 identifies	 2	potentially	missing	 studies	
which	 do	 not	 alter	 the	 statistical	 significance	 of	 the	 result	 (random	 effects	 model,	 point	 estimate	
0.500,	95%	CI	0.145	to	1.718).	
Study name Outcome Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Lu 2013 Recurrence 2 / 25 1 / 25 43.67 0.500 0.048 5.168
Roberts 2007 Recurrence 0 / 28 1 / 29 23.86 2.900 0.123 68.331
Lagast 1983 Recurrence 1 / 25 1 / 20 32.47 1.250 0.083 18.763
1.024 0.219 4.793
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Figure	4.6b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	infection	recurrence		
Microbiological/bacteriological	cure:	Five	articles	(Georges	et	al.,	2005;	Roberts	et	al.,	2007;	Adembri	
et	al.,	2008;	Chytra	et	al.,	2012;	Cotrina-Luque	et	al.,	2016)	reported	microbiological	or	bacteriological	
cure.		
	
Figure	 4.7a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	
microbiological/bacteriological	 cure	 of	 patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	
versus	“Intermittent”	(bolus	or	short	infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
All	 of	 these	 articles	 reported	 studies	 investigating	 time-dependent	 antibiotics.	 A	 statistically	
significant	difference	in	microbiological	cure	was	observed	(n	=	403,	RR	1.177,	95%	CI	1.054	to	1.313,	
p	=	0.004).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	4,	P	=	0.936,	I2	=	0.0%).	
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Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit p-Value
Adembri 2008 Microbiological cure 7 / 11 8 / 9 4.77 1.397 0.845 2.310 0.193
Chytra 2012 Microbiological cure80 / 102 87 / 96 83.20 1.155 1.024 1.303 0.019
Cotrina-Luque 2016Microbiological cure 3 / 38 3 / 40 0.51 0.950 0.204 4.420 0.948
Georges 2005 Bacteriological cure 13 / 24 18 / 26 6.00 1.278 0.816 2.001 0.284
Roberts 2007 Bacteriological cure 14 / 28 18 / 29 5.53 1.241 0.778 1.980 0.364
1.177 1.054 1.313 0.004
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Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
some	 publication	 bias	 may	 exist	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	
extended	infusions.	Trim	and	Fill	(Duval	and	Tweedie,	2000)	only	identifies	1	potentially	missing	study	
which	 doesn’t	 alter	 the	 statistical	 significance	 of	 the	 result	 (random	 effects	model,	 point	 estimate	
1.166,	95%	CI	1.048	to	1.299).	
	
Figure	4.7b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	microbiological/bacteriological	cure	
Secondary/super-infection:	Nine	articles	 (Feld	et	al.,	1984;	Hanes	et	al.,	2000;	McNabb	et	al.,	2001;	
Georges	et	al.,	2005;	Roberts	et	al.,	2007;	Chytra	et	al.,	2012;	Laterre	et	al.,	2015;	Cotrina-Luque	et	al.,	
2016;	 Zhao	 et	 al.,	 2017)	 reported	 secondary/super-infection	 with	 a	 presumed	 or	 proven	 different	
organism.	Eight	of	these	articles	reported	studies	investigating	time-dependent	antibiotics,	one	(Feld	
et	 al.,	 1984)	 investigated	 concentration-dependent.	 No	 statistically	 significant	 difference	 in	
secondary/super-infection	was	observed	 (n	=	596,	RR	1.120,	 95%	CI	 0.662	 to	1.896,	 P	 =	0.673).	No	
evidence	of	statistical	heterogeneity	was	found	(df	=	8,	P	=	0.548,	I2	=	0.0%).	
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Figure	4.8a:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	interval	(95%	CI)	of	super-infection	of	patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
some	 publication	 bias	 may	 exist	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	
extended	infusions.	Trim	and	Fill	(Duval	and	Tweedie,	2000)	only	identifies	1	potentially	missing	study	
which	doesn’t	alter	the	statistical	significance	of	the	result	(random	effects	model,	RR	1.044,	95%	CI	
0.622	to	1.753).	
	
Figure	4.8b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	super-infection	
	
Study name Outcome Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit p-Value
Chytra 2012 Superinfection 8 / 102 7 / 96 29.13 0.930 0.351 2.466 0.884
Cotrina-Luque 2016Superinfection 0 / 38 4 / 40 3.32 8.561 0.476 153.835 0.145
Feld 1984 Superinfection c 1 / 40 2 / 30 5.00 2.667 0.253 28.054 0.414
Georges 2005 Superinfection 4 / 24 3 / 26 14.34 0.692 0.172 2.780 0.604
Hanes 2000 Superinfection 3 / 14 7 / 16 21.08 2.042 0.649 6.426 0.222
Laterre 2015 Superinfection 0 / 14 1 / 14 2.85 3.000 0.133 67.910 0.490
McNabb 2001 Superinfection 3 / 18 3 / 17 13.06 1.059 0.247 4.544 0.939
Roberts 2007 Superinfection 2 / 28 1 / 29 5.05 0.483 0.046 5.030 0.543
Zhao 2017 Superinfection 4 / 25 1 / 25 6.17 0.250 0.030 2.083 0.200
1.120 0.662 1.896 0.673
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Number	of	patients	withdrawing	as	a	result	of	an	adverse	event	(WAE):	Four	articles	(Hanes	et	al.,	
2000;	Lau	et	al.,	2006;	Chytra	et	al.,	2012;	Bao	et	al.,	2017)	reported	WAE.	Two	articles	(Hanes	et	al.,	
2000;	Chytra	et	al.,	2012)	reported	no	WAEs	for	all	patients	assessed	and	are	not	represented	visually	
in	the	forest	plot.	All	of	 these	articles	reported	studies	 investigating	time-dependent	antibiotics.	No	
statistically	significant	difference	in	WAE	was	observed	(n	=	597,	RR	0.970,	95%	CI	0.243	to	3.877,	P	=	
0.966).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	1,	P	=	0.455,	I2	=	0.0%)	
	
Figure	4.9:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	interval	(95%	CI)	of	withdrawal	due	to	adverse	
events	of	patients	receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	
short	infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
The	number	of	articles	reporting	WAE	was	insufficient	to	assess	for	publication	bias.	
Number	of	patients	with	at	 least	one	AE:	Fourteen	articles	(Feld	et	al.,	1984;	Nicolau	et	al.,	1999b;	
Wysocki	et	al.,	2001;	McNabb	et	al.,	2001;	Lau	et	al.,	2006;	Sakka	et	al.,	2007;	van	Zanten	et	al.,	2007;	
Schmelzer	et	al.,	2013;	Dulhunty	et	al.,	2013a,	2015;	Laterre	et	al.,	2015;	Abdul-Aziz	et	al.,	2016;	Bao	
et	al.,	2017;	Fan	et	al.,	2017)	reported	AE.	Six	articles	 (Nicolau	et	al.,	1999b;	Sakka	et	al.,	2007;	van	
Zanten	et	al.,	2007;	Dulhunty	et	al.,	2013a;	Abdul-Aziz	et	al.,	2016;	Fan	et	al.,	2017)	reported	no	AE	in	
all	 patients	 assessed	 and	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 Eleven	 of	 these	 articles	
reported	 studies	 investigating	 time-dependent	 antibiotics,	 one	 (Feld	 et	 al.,	 1984)	 concentration-
dependent	and	two	(Wysocki	et	al.,	2001;	Schmelzer	et	al.,	2013)	MIC:AUC	ratio.	One	article	(Wysocki	
et	al.,	2001)	reported	nephrotoxicity	separately	from	other	adverse	events	and	therefore	no	absolute	
number	of	patients	suffering	from	an	AE	in	each	arm	could	be	identified,	this	article	was	not	included	
in	the	analysis.	No	statistically	significant	difference	in	AE	was	observed	(n	=	1625,	RR	1.015,	95%	CI	
Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Lau 2006 Withdrawal due to AE 1 / 132 2 / 130 33.66 2.031 0.186 22.123
Bao 2017 Withdrawal due to AE 3 / 25 2 / 25 66.34 0.667 0.122 3.653
0.970 0.243 3.877
0.01 0.1 1 10 100
Favours Extended Favours Intermittent
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0.791	to	1.302,	P	=	0.907).	No	significant	evidence	of	statistical	heterogeneity	was	found	(df	=	6,	P	=	
0.282,	I2	=	19.4%).	
	
Figure	4.10a:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	interval	(95%	CI)	of	adverse	events	(AE)	of	
patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	 of	 the	 funnel	 plot	 showing	 both	 observed	 (white)	 and	 imputed	 studies	 suggests	 that	 no	
publication	bias	exists		
	
Figure	4.10b:	Funnel	plot	comparison	showing	existing	(o)	and	imputed	()	studies:	adverse	events	
	
	
Study name Outcome Events / Total MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Dulhunty 2015 AE 28 / 220 20 / 212 16.42 0.741 0.431 1.274
Feld 1984 AE c 6 / 40 2 / 28 2.57 0.476 0.104 2.190
Laterre 2015 AE 0 / 14 1 / 14 0.63 3.000 0.133 67.910
Lau 2006 AE 18 / 132 22 / 130 15.00 1.241 0.699 2.203
McNabb 2001 AE 13 / 18 11 / 17 21.45 0.896 0.569 1.410
Schmelzer 2013 AE a 3 / 27 1 / 28 1.26 0.321 0.036 2.903
Bao 2017 AE 19 / 25 23 / 25 42.67 1.211 0.944 1.552
1.015 0.791 1.302
0.01 0.1 1 10 100
Favours Extended Favours Intermittent
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4.4.3.2	 Subgroup	analysis	
Piperacillin	(+/-	tazobactam)	
Thirteen	articles	(Pédeboscq	et	al.,	2001;	Buck	et	al.,	2005;	Lau	et	al.,	2006;	Roberts	et	al.,	2009b,	
2010,	Dulhunty	et	al.,	2013a,	2015;	Lü	et	al.,	2013;	Abdul-Aziz	et	al.,	2016;	Cotrina-Luque	et	al.,	2016;	
Bao	et	al.,	2017;	Fan	et	al.,	2017;	Ram	et	al.,	2018)	reported	on	piperacillin	used	in	combination	with	
tazobactam	and	one	article	(Rafati	et	al.,	2006)	piperacillin	alone.	The	following	outcomes	were	
reported	in	at	least	one	of	the	articles;	AE,	clinical	cure,	clinical	response,	mortality,	
microbiological/bacteriological	cure,	super-infection	and	WAE.	
Adverse	 events	 (AE):	 Five	 articles	 (Lau	 et	 al.,	 2006;	Dulhunty	 et	 al.,	 2013a,	 2015;	Abdul-Aziz	 et	 al.,	
2016;	 Fan	 et	 al.,	 2017)	 reported	 AE.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	more	
than	 one	 antibiotic	 and	 separate	 data	 for	 piperacillin/tazobactam	 was	 unavailable.	 Two	 articles	
(Abdul-Aziz	et	al.,	2016;	Fan	et	al.,	2017)	 reported	no	AE	 in	either	group.	No	statistically	 significant	
difference	was	observed	(n	=	716,	RR	1.241,	95%	CI	0.699	to	2.203,	p	=	0.461).	The	number	of	articles	
reporting	adverse	events	was	insufficient	to	assess	for	statistical	heterogeneity.	
Clinical	cure:	Five	articles	(Roberts	et	al.,	2009b;	Dulhunty	et	al.,	2013a,	2015;	Abdul-Aziz	et	al.,	2016;	
Cotrina-Luque	 et	 al.,	 2016)	 reported	 clinical	 cure.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	
investigated	 more	 than	 one	 antibiotic	 and	 although	 published	 data	 for	 piperacillin/tazobactam	 is	
unavailable	the	authors	were	able	to	provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	
One	 article	 (Cotrina-Luque	 et	 al.,	 2016)	 contained	 discrepancies	 within	 the	 published	 article	 and	
therefore	had	to	be	excluded.	One	article	(Roberts	et	al.,	2009b)	reported	clinical	cure	in	all	patients.	
A	statistically	significant	difference	in	clinical	cure	was	observed	(n	=	424,	RR	1.395,	95%	CI	1.035	to	
1.882,	p	=	0.029).	There	is	evidence	of	moderate	statistical	heterogeneity	between	the	studies	(df	=	2,	
P	=	0.230,	I2	=	31.9%).	
Clinical	 response:	Five	articles	(Buck	et	al.,	2005;	Lau	et	al.,	2006;	Cotrina-Luque	et	al.,	2016;	Bao	et	
al.,	 2017;	 Ram	 et	 al.,	 2018)	 reported	 clinical	 response.	 One	 article	 (Ram	 et	 al.,	 2018)	 investigated	
more	than	one	antibiotic	and	separate	data	for	piperacillin/tazobactam	was	unavailable.	One	article	
(Cotrina-Luque	et	al.,	2016)	contained	discrepancies	within	the	published	article	and	therefore	had	to	
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be	excluded.	No	statistically	significant	difference	was	observed	(n	=	332,	RR	=	0.973,	95%	CI	0.869	to	
1.090,	p	=	0.639).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	2,	P	=	0.521,	I2	=	0.0%).	
All-cause	mortality:	 Seven	articles	 (Rafati	 et	 al.,	 2006;	Roberts	 et	 al.,	 2010;	Dulhunty	et	 al.,	 2013a,	
2015;	Cotrina-Luque	et	al.,	2016;	Fan	et	al.,	2017;	Ram	et	al.,	2018)	reported	mortality.	Three	articles	
(Dulhunty	et	al.,	2013a,	2015;	Ram	et	al.,	2018)	 investigated	more	than	one	antibiotic	and	although	
published	data	for	piperacillin/tazobactam	is	unavailable	the	authors	of	two	articles	(Dulhunty	et	al.,	
2013a,	2015)	were	able	to	provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	One	article	
(Roberts	 et	 al.,	 2010)	 reported	no	deaths	 in	 either	 group.	No	 statistically	 significant	difference	was	
observed	 (n	 =	 824,	 RR	 0.904,	 95%	 CI	 0.716	 to	 1.141,	 p	 =	 0.396).	 No	 evidence	 of	 statistical	
heterogeneity	was	found	(df	=	4,	P	=	0.763,	I2	=	0.0%)	
Microbiological/bacteriological	 cure:	 One	 article	 (Cotrina-Luque	 et	 al.,	 2016)	 reported	
microbiological	cure	and	found	no	statistically	significant	difference	(n	=	78,	RR	0.950,	95%	CI	0.204	to	
4.420,	 p	 =	 0.948).	 The	 number	 of	 articles	 reporting	 microbiological/bacteriological	 cure	 was	
insufficient	to	assess	for	statistical	heterogeneity.	
Super-infection:	 One	 article	 (Cotrina-Luque	 et	 al.,	 2016)	 reported	 super-infection	 and	 found	 no	
statistically	significant	difference	(n	=	78,	RR	8.561,	95%	CI	0.476	to	153.835,	p	=	0.145).	The	number	
of	articles	reporting	super-infection	was	insufficient	to	assess	for	statistical	heterogeneity.	
Withdrawal	 due	 to	 adverse	 events	 (WAE):	 One	 article	 (Lau	 et	 al.,	 2006)	 reported	 WAE	 and	 no	
statistically	significant	difference	was	observed	(n	=	262,	RR	2.031,	95%	CI	0.186	to	22.123,	p	=	0.561).	
The	number	of	articles	reporting	WAE	was	insufficient	to	assess	for	statistical	heterogeneity.	
Meropenem	
Seven	articles	(Okimoto	et	al.,	2009;	Roberts	et	al.,	2009a;	Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	
2015;	Abdul-Aziz	et	al.,	2016;	Zhao	et	al.,	2017)	investigated	meropenem.	One	article	(Okimoto	et	al.,	
2009)	was	only	available	as	an	abstract	in	English	and	assessment	of	the	outcomes	was	not	possible	
so	it	was	excluded	from	further	analysis.	The	following	outcomes	were	reported	in	at	least	one	of	the	
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articles;	 AE,	 clinical	 cure,	 clinical	 response,	 mortality,	 microbiological/bacteriological	 cure,	 super-
infection	and	WAE.	
Adverse	events	(AE):	Four	articles	(Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	Abdul-Aziz	et	al.,	
2016)	 investigated	 AE.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	 more	 than	 one	
antibiotic	 and	 separate	 data	 for	meropenem	was	 unavailable.	 One	 article	 (Abdul-Aziz	 et	 al.,	 2016)	
reported	no	adverse	events	in	either	treatment	group.	No	statistically	significant	difference	in	AE	was	
observed	(n	=	380,	RR	0.833,	95%	CI	0.374	to	1.855,	p	=	0.655).	The	number	of	articles	reporting	AE	
was	insufficient	to	assess	for	statistical	heterogeneity.	
Clinical	 cure:	Four	articles	(Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	Abdul-Aziz	et	al.,	2016)	
reported	 clinical	 cure.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	 more	 than	 one	
antibiotic	 and	 although	 published	 data	 for	 meropenem	 is	 unavailable	 the	 authors	 were	 able	 to	
provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	No	statistically	significant	difference	in	
clinical	cure	was	observed	(n	=	428,	RR	1.214,	95%	CI	0.860	to	1.714,	p	=	0.271).	Significant	evidence	
of	statistical	heterogeneity	was	found	(df	=	3,	P	=	0.071,	I2	=	57.3%)	
Clinical	 response:	 Three	 articles	 (Dulhunty	 et	 al.,	 2013a;	 Abdul-Aziz	 et	 al.,	 2016;	 Zhao	 et	 al.,	 2017)	
reported	clinical	response.	One	article	(Dulhunty	et	al.,	2013a)	investigated	more	than	one	antibiotic	
and	 separate	 data	 for	meropenem	was	 unavailable.	 No	 statistically	 significant	 difference	 in	 clinical	
response	 was	 observed	 (n	 =	 290,	 RR	 1.093,	 95%	 CI	 0.936	 to	 1.276,	 p	 =	 0.261).	 No	 evidence	 of	
statistical	heterogeneity	was	found	(df	=	1,	P	=	0.837,	I2	=	0.0%)	
All-cause	mortality:	 Five	 articles	 (Roberts	 et	 al.,	 2009a;	Chytra	et	 al.,	 2012;	Dulhunty	et	 al.,	 2013a,	
2015;	Zhao	et	al.,	2017)	reported	mortality.	Two	articles	 (Dulhunty	et	al.,	2013a,	2015)	 investigated	
more	 than	 one	 antibiotic	 and	 although	 published	 data	 for	 meropenem	 is	 unavailable	 the	 authors	
were	able	to	provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	One	article	(Dulhunty	et	
al.,	2013a)	reported	no	deaths	in	either	group.	No	statistically	significant	difference	in	mortality	was	
observed	 (n	 =	 445,	 RR	 0.816,	 95%	 CI	 0.586	 to	 1.136,	 p	 =	 0.229).	 No	 evidence	 of	 statistical	
heterogeneity	was	found	(df	=	3,	P	=	0.630,	I2	=	0.0%).	
	 110	
Microbiological/bacteriological	 cure:	One	article	 (Chytra	et	al.,	2012)	reported	microbiological	cure	
and	no	statistically	significant	difference	between	treatment	groups	was	observed	(n	=	198,	RR	1.148,	
95%	CI	 0.936	 to	 1.408,	 p	 =	 0.184).	 The	 number	 of	 articles	 reporting	microbiological/bacteriological	
cure	was	insufficient	to	assess	for	statistical	heterogeneity.	
Super-infection:	Two	articles	(Chytra	et	al.,	2012;	Zhao	et	al.,	2017)	reported	super-infection	and	no	
significant	 statistical	 difference	 between	 treatment	 groups	was	 observed	 (n	 248,	 RR	 0.682,	 95%	 CI	
0.227	to	2.049,	p	=	0.495).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	1,	P	=	0.267,	I2	=	
18.9%)	
Withdrawal	 due	 to	 adverse	 events	 (WAE):	 One	 article	 (Chytra	 et	 al.,	 2012)	 reported	WAE	 but	 no	
events	were	observed	in	either	group.	
Vancomycin	
Two	articles	(Wysocki	et	al.,	2001;	Schmelzer	et	al.,	2013)	investigated	the	use	of	vancomycin.	The	
following	outcomes	were	reported	in	at	least	one	of	the	articles;	AE,	clinical	response,	all-cause	
mortality.	
Adverse	events	(AE):	Both	articles	reported	the	adverse	events,	specifically	the	incidence	of	
nephrotoxicity.	No	statistically	significant	difference	in	nephrotoxicity	was	observed	(n	=	174,	RR	
0.775,	95%	CI	0.372	to	1.612,	p	=	0.494).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	1,	P	
=	0.403,	I2	=	0.0%).		
Clinical	response:	One	article	(Wysocki	et	al.,	2001)	reported	clinical	response	(n	=	119,	RR	0.971,	95%	
CI	0.811	to	1.163,	p	=	0.750)	
All-cause	mortality:	One	article	(Wysocki	et	al.,	2001)	reported	mortality	(n	=	119,	RR	1.051,	95%	CI	
0.634	to		1.743,	p	=	0.847)	
Ceftazidime	
Nine	articles	(Lipman	et	al.,	1999;	Nicolau	et	al.,	1999a,	1999b,	2001;	Angus	et	al.,	2000;	Hanes	et	al.,	
2000;	McNabb	et	al.,	2001;	Lubasch	et	al.,	2003;	Ram	et	al.,	2018)	investigated	the	use	of	ceftazidime.	
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One	article	(Ram	et	al.,	2018)	was	primarily	a	study	of	piperacillin/tazobactam	and	only	6%	(7/105)	of	
patients	 received	 ceftazidime,	 a	 breakdown	 of	 results	 by	 antibiotic	 was	 unavailable	 at	 the	 time	 of	
thesis	 write	 up	 and	 so	 this	 study	 could	 not	 be	 further	 analysed.	 The	 following	 outcomes	 were	
reported	 in	 at	 least	 one	 of	 the	 articles;	 AE,	 clinical	 cure,	 clinical	 response,	 mortality,	
microbiological/bacteriological	cure	and	super-infection.	
Adverse	events	(AE):	Six	articles	(Lipman	et	al.,	1999;	Nicolau	et	al.,	1999a,	1999b,	2001;	McNabb	et	
al.,	2001;	Lubasch	et	al.,	2003)	reported	adverse	events.	Two	articles	(Lipman	et	al.,	1999;	Nicolau	et	
al.,	1999a)	reported	adverse	events	but	by	event	not	patient	and	were	therefore	not	assessable	and	
so	not	included.	Two	articles	(Nicolau	et	al.,	2001;	Lubasch	et	al.,	2003)	reported	AE	as	a	total	number	
rather	 than	 by	 treatment	 arm	 however	 the	 events	 from	Nicolau	 et	 al.	 2001	 are	 reported	 in	 full	 in	
McNabb	 et	 al.	 2001.	 One	 article	 (Nicolau	 et	 al.,	 1999b)	 reported	 no	 adverse	 events	 in	 either	
treatment	 arm.	No	 statistically	 significant	 difference	 in	AE	was	observed	 (n	 =	 59,	 RR	0.896,	 95%	CI	
0.569	to	1.410,	p	=	0.635).	The	number	of	articles	reporting	AE	was	insufficient	to	assess	for	statistical	
heterogeneity.	
Clinical	 cure:	One	 article	 (Nicolau	 et	 al.,	 2001)	 reported	 clinical	 cure	 and	 no	 statistically	 significant	
difference	 between	 treatment	 groups	was	 observed	 (n	 =	 35,	 RR	 1.235,	 95%	CI	 0.520	 to	 2.936,	 p	 =	
0.632).	 The	 number	 of	 articles	 reporting	 clinical	 cure	 was	 insufficient	 to	 assess	 for	 statistical	
heterogeneity.	
Clinical	 response:	 Three	 articles	 (Hanes	 et	 al.,	 2000;	 Nicolau	 et	 al.,	 2001;	 Lubasch	 et	 al.,	 2003)	
reported	clinical	response.	No	statistically	significant	difference	in	clinical	response	was	observed	(n	=	
146,	 RR	 1.021,	 95%	 CI	 	 0.906	 to	 1.152,	 p	 =	 0.729).	 No	 evidence	 of	 statistical	 heterogeneity	 was	
observed	(df	=	2,	P	=	0.407,	I2	=	0.0%).	
All-cause	mortality:	One	article	 (Angus	et	al.,	2000)	reported	mortality	and	a	statistically	significant	
difference	in	mortality	was	observed	(n	=	21,	RR	0.367,	95%	CI	0.137	to	0.984,	p	=	0.046).	The	number	
of	articles	reporting	clinical	cure	was	insufficient	to	assess	for	statistical	heterogeneity.	
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Microbiological/bacteriological	 cure:	One	 article	 stated	 “microbiological	 eradication”	 as	 a	 primary	
outcome	but	this	was	reported	as	“microbiological	response”	in	the	results	of	the	article	so	no	articles	
provided	results	analysable	for	this	outcome.	
Super-infection:	Three	articles	(Hanes	et	al.,	2000;	McNabb	et	al.,	2001;	Nicolau	et	al.,	2001)	reported	
super-infection.	One	 article	 (Nicolau	 et	 al.,	 2001)	was	 not	 analysed	 further	 as	 it	 did	 not	 report	 the	
actual	 number	 of	 events	 in	 each	 treatment	 arm,	 results	 from	 this	 study	 for	 super-infection	 were	
available	in	the	article	by	McNabb	et	al..	No	statistically	significant	difference	in	super-infection	rate	
was	 observed	 (n	 =	 65,	 RR	 1.588,	 95%	 CI	 0.645	 to	 3.910,	 p	 =	 0.314).	 No	 evidence	 of	 statistical	
heterogeneity	was	found	(df	=	1,	P	=	0.487,	I2	=	0.0%).	
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Table	4.3:	Summary	of	meta-analysis	results		
Outcome	 Group	 n	 MH	RR	
95%	CI	
P	
value	
Statistical	
heterogeneity	
Assessment	of		
publication	bias	
LL	 UL	 df	 I2	(%)	 Imputed	studies	
Point	
estimate	
95%	
CI	
Clinical	cure	 	 	 	 	 	 	 	 	 	 	
	
All	 1083	 1.231	 1.081	 1.403	 0.002	 8	 9.4	 4	 1.109	
0.952	
to	
1.293	
	 Time	
only	 1083	 1.231	 1.081	 1.403	 0.002	 8	 9.4	 4	 1.109	
0.952	
to	
1.293	
	 P/T	 424	 1.395	 1.035	 1.882	 0.029	 2	 31.9	 	 	 	
	 M	 428	 1.214	 0.860	 1.714	 0.271	 3	 57.3	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 35	 1.235	 0.520	 2.936	 0.632	 NA	 NA	 	 	 	
Clinical	response	 	 	 	 	 	 	 	 	 	 	
	
All	 1132	 1.027	 0.974	 1.083	 0.319	 11	 0.0	 2	 1.007	
0.958	
to	
1.058	
	 Time	
only	 1013	 1.033	 0.977	 1.092	 0.254	 10	 0.0	 3	 1.011	
0.960	
to	
1.064	
	 P/T	 332	 0.973	 0.869	 1.090	 0.639	 2	 0.0	 	 	 	
	 M	 290	 1.093	 0.936	 1.276	 0.261	 1	 0.0	 	 	 	
	 V	 119	 0.971	 0.811	 1.163	 0.750	 NA	 NA	 	 	 	
	 C	 146	 1.021	 0.906	 1.152	 0.729	 2	 0.0	 	 	 	
All	cause	mortality	 	 	 	 	 	 	 	 	 	 	
	
All	 2165	 0.868	 0.743	 1.014	 0.075	 20	 0.0	 0	 0.868	
0.743	
to	
1.014	
	 Time	
only	 1861	 0.844	 0.713	 0.999	 0.049	 16	 0.0	 0	 0.844	
0.743	
to	
0.999	
	 P/T	 824	 0.904	 0.716	 1.141	 0.396	 4	 0.0	 	 	 	
	 M	 445	 0.816	 0.586	 1.136	 0.229	 3	 0.0	 	 	 	
	 V	 119	 1.051	 0.634	 1.743	 0.847	 NA	 NA	 	 	 	
	 C	 21	 0.367	 0.137	 0.984	 0.046	 NA	 NA	 	 	 	
AE	 	 	 	 	 	 	 	 	 	 	 	
	
All	 1625	 1.015	 0.791	 1.302	 0.907	 6	 19.4	 0	 1.015	
0.791	
to	
1.302	
	 Time	
only	 1502	 1.068	 0.859	 1.329	 0.551	 4	 11.1	 0	 1.068	
0.859	
to	
1.329	
	 P/T	 716	 1.241	 0.699	 2.203	 0.461	 NA	 NA	 	 	 	
	 M	 380	 0.833	 0.374	 1.855	 0.655	 NA	 NA	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 59	 0.896	 0.569	 1.410	 0.635	 NA	 NA	 	 	 	
SAE	 	 	 	 	 	 	 	 	 	 	 	
	 All	 482	 0.858	 0.515	 1.431	 0.558	 1	 0.0	 NA	 NA	 NA	
	 Time	
only	 482	 0.858	 0.515	 1.431	 0.558	 1	 0.0	 NA	 NA	 NA	
	 P/T	 	 	 	 	 	 	 	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
WAE	 	 	 	 	 	 	 	 	 	 	 	
	 All	 597	 0.970	 0.243	 3.877	 0.966	 1	 0.0	 NA	 NA	 NA	
	 Time	
only	 597	 0.970	 0.243	 3.877	 0.966	 1	 0.0	 NA	 NA	 NA	
	 P/T	 262	 2.031	 0.186	 22.123	 0.561	 NA	 NA	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
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Key:	n	=	number	of	patients,	MH	RR	=	Mantel-Haenszel	risk	ratio,	95%	CI	=	95%	confidence	interval,	LL	=	lower	limit,	UL	=	upper	
limit,	df	=	degrees	of	freedom,	All	=	all	antibiotics,	Time	only	=	time-dependent	action	antibiotics	only,	P/T	=	piperacillin	(+/-	
tazobactam),	M	=	meropenem,	V	=	vancomycin,	C	=	ceftazidime,	grey	shaded	boxes	=	no	data,	NA	=	not	enough	data	to	run	
analysis	
	
	
	
	
	
	
Table	4.3:	Summary	of	meta-analysis	results	(cont.)	
Outcome	 Group	 n	 MH	RR	
95%	CI	
P	
value	
Statistical	
heterogeneity	
Assessment	of	
publication	bias	
LL	 UL	 df	 I2	(%)	 Imputed	studies	
Point	
estimate	
95%	
CI	
Infection	recurrence	 	 	 	 	 	 	 	 	 	
	 All	 152	 1.024	 0.219	 4.793	 0.976	 2	 0.0	 1	 0.500	
0.145	
to	
1.718	
	 Time	only	 152	 1.024	 0.219	 4.793	 0.976	 2	 0.0	 1	 0.500	
0.145	
to	
1.718	
	 P/T	 	 	 	 	 	 	 	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
Microbiological/bacteriological	cure	 	 	 	 	 	 	 	
	
All	 403	 1.177	 1.054	 1.313	 0.004	 4	 0.0	 1	 1.166	
1.048	
to	
1.299	
	 Time	only	
403	 1.177	 1.054	 1.313	 0.004	 4	 0.0	 1	 1.166	
1.048	
to	
1.299	
	 P/T	 78	 0.950	 0.204	 4.420	 0.948	 NA	 NA	 	 	 	
	 M	 198	 1.148	 0.936	 1.408	 0.184	 NA	 NA	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
Super-infection	 	 	 	 	 	 	 	 	 	 	
	 All	
596	 1.120	 0.662	 1.896	 0.673	 8	 0.0	 1	 1.044	
0.622	
to	
1.753	
	 Time	only	
526	 1.070	 0.623	 1.837	 0.806	 7	 0.0	 0	 1.070	
0.623	
to	
1.837	
	 P/T	 78	 8.561	 0.476	 153.835	 0.145	 NA	 NA	 	 	 	
	 M	 248	 0.682	 0.227	 2.049	 0.495	 1	 18.9	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 65	 1.588	 0.645	 3.910	 0.314	 1	 0.0	 	 	 	
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4.4.4	Sensitivity	analysis	for	primary	and	significant	outcomes		
4.4.4.1	 Effect	of	removing	individual	studies	on	outcomes	
The	 removal	 of	 individual	 studies	 had	 no	 effect	 on	 the	 statistical	 significance	 of	 the	 primary	
outcomes.	 Clinical	 cure	 still	 favours	 CI	 (RR	 range	 1.192	 –	 1.335	 with	 associated	 p-value	 range	 of	
<0.001	 to	0.012)	 and	 SAE	 shows	no	difference	between	administration	methods	 (RR	 range	0.789	–	
1.250	with	associated	p-value	range	of	0.411	to	0.714).		
Mortality	remains	not	statistically	significant	(RR	range	0.846	–	0.889	with	associated	p-value	range	of	
0.053	 to	 0.160).	 Analysis	 of	 mortality	 in	 articles	 investigating	 only	 time-dependent	 antibiotics	 had	
previously	 shown	 a	 difference	 between	 administration	 methods	 favouring	 CIs,	 re-analysis	 with	
individual	 studies	 removed	 renders	 a	 neutral	 result	 favouring	 neither	 method	 in	 11	 out	 of	 17	
instances	(RR	range	0.808	–	0.866	with	associated	p-value	range	of	0.036	to	0.114).	In	addition	to	the	
17	articles	analysed,	 two	articles	 (De	Jongh	et	al.,	2008;	Roberts	et	al.,	2010)	reported	no	deaths	 in	
either	 group.	 Only	 the	 removal	 of	 the	 study	 by	 Chytra	 et	 al	 affects	 the	 statistical	 significance	 of	
microbiological/bacteriological	cure	(RR	range	1.170	to	1.287	with	associated	p-value	range	of	0.004	
to	0.065)	
4.4.4.2		 Using	fixed	effect	rather	than	random	effect	
The	random	effects	model	will	potentially	 increase	the	role	that	smaller	studies	will	play	 in	a	meta-
analysis	when	compared	to	using	fixed	effects.	Using	fixed	effect	analysis	on	the	primary	outcomes	of	
clinical	cure	and	SAE	has	no	affect	on	the	statistical	significance.	Clinical	cure	remains	in	favour	of	CIs	
(RR	 1.236,	 95%	 CI	 1.088	 to	 1.403,	 p-value	 0.001)	 and	 SAE	 still	 shows	 no	 difference	 between	
administration	methods	(RR	0.853,	95%	CI	0.513	to	1.421,	p-value	0.542)	
Mortality	remains	neutral	(RR	0.879,	95%	CI	0.753	to	1.026,	p-value	0.102).	However,	using	the	fixed	
effects	 model	 on	 mortality	 associated	 with	 time-dependent	 antibiotics	 renders	 the	 previously	
statistically	 significant	 result	 neutral	 suggesting	no	difference	between	 administration	methods	 (RR	
0.858,	 95%	 CI	 0.726	 to	 1.013,	 P	 =	 0.071).	 Microbiological/bacteriological	 cure	 still	 favours	 CIs	 (RR	
1.188,	95%	CI	1.050	to	1.344,	p-value	0.006).	
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4.4.4.3		 Using	odds	ratio	rather	than	risk	ratio	
Using	odds	ratio	(OR)	as	the	measure	of	effect	on	the	primary	outcomes	of	clinical	cure	and	SAE	has	
no	affect	on	the	statistical	significance.	Clinical	cure	remains	in	favour	of	CIs	(OR	1.678,	95%	CI	1.209	
to	 2.329,	 p-value	 0.002)	 and	 SAE	 still	 shows	 no	 difference	 between	 administration	 methods	 (OR	
0.836,	95%	CI	0.469	to	1.488,	p-value	0.542)	
Mortality	remains	neutral	(OR	0.832,	95%	CI	0.672	to	1.030,	p-value	0.091).	However,	using	odd	ratio	
to	 analyse	mortality	 associated	with	 time-dependent	 antibiotics	 renders	 the	 previously	 statistically	
significant	 result	 neutral,	 favouring	 neither	 method	 of	 administration	 (OR	 0.802,	 95%	 CI	 0.637	 to	
1.010,	 P	 =	 0.061).	Microbiological/bacteriological	 cure	 still	 favours	 CIs	 (OR	 2.036,	 95%	 CI	 1.204	 to	
3.444,	p-value	0.008).	
4.4.4.4		 Analysing	only	articles	looking	at	continuous	infusions	
Analysis	 of	 articles	 just	 reporting	 studies	 investigating	 continuous	 infusions,	 i.e.	 excluding	 those	
looking	 at	 extended	 intermittent	 infusions,	 did	 not	 affect	 the	 statistical	 significance	 of	 the	 primary	
outcomes;	 clinical	 cure	 still	 favours	extended	 infusions	 (RR	1.231,	95%	CI	1.081	 to	1.403,	p-value	=	
0.002)	and	SAE	remained	neutral	(RR	0.789,	95%	CI	0.448	to	1.389,	p-value	=	0.411).		
Mortality	 remained	 neutral	 (RR	 0.861,	 95%	 CI	 0.719	 to	 1.031,	 p-value	 =	 0.103),	 the	 statistical	
significance	of	mortality	associated	with	 just	 time-dependent	antibiotics	however	was	affected;	 this	
result	no	 longer	favoured	either	administration	method	(RR	0.826,	95%	CI	0.675	to	1.009,	p-value	=	
0.062).	Microbiological	 cure	 remained	 in	 favour	 of	 CIs	 (RR	 1.178,	 95%	CI	 1.055	 to	 1.315,	 p-value	 =	
0.004).		
4.4.4.5		 Including	vancomycin	in	“time	only”	analysis	
Two	articles	investigated	vancomycin	(Wysocki	et	al.,	2001;	Schmelzer	et	al.,	2013)	and	one	Linezolid	
(Adembri	 et	 al.,	 2008),	 the	 remaining	 articles	 investigating	 time-dependent	 action	 antibiotics	 all	
investigated	β-lactams.	All	though	all	time-dependent	in	action	the	efficacy	of	β-lactams	and	linezolid	
relates	entirely	or	 in	part	to	T>MIC	were	as	the	efficacy	of	vancomycin	relates	solely	to	AUC:MIC.	 It	
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was	 decided	 a	 priori	 to	 exclude	 vancomycin	 from	 “time	 only”	 analysis	 as	 a	 major	 part	 of	 the	
justification	for	extended	infusions	is	to	increase	the	T>MIC.	
Neither	 vancomycin	 article	 reported	 the	 primary	 outcomes	 or	 microbiological/bacteriological	 cure	
therefore	the	results	for	these	outcomes	remain	unchanged.		Analysis	of	mortality	no	longer	favours	
extended	infusions	(RR	0.863,	95%	CI	0.736	to	1.012,	p-value	=	0.071).		
4.5		 Discussion	
4.5.1	Author’s	interpretation	
4.5.1.1	Summary	of	the	main	findings		
A	 statistical	 significant	 difference	 in	 both	 clinical	 cure	 and	microbiological/bacteriological	 cure	was	
observed	between	extended	and	 intermittent	 infusions	of	 antibiotics	 favouring	 extended	 infusions.	
No	 difference	 in	 all-cause	 mortality,	 clinical	 response,	 super-infection	 or	 infection	 recurrence	 was	
observed	 between	 administration	 methods.	 Nor	 was	 any	 difference	 in	 adverse	 events,	 serious	
adverse	events	or	withdrawal	due	to	adverse	events	found	between	administration	methods.	Analysis	
of	only	antibiotics	exhibiting	 time-dependent	action	observed	a	 statistically	 significant	difference	 in	
all-cause	 mortality,	 clinical	 cure	 and	 microbiological/bacteriological	 cure	 between	 extended	 and	
intermittent	 infusions	 favouring	 extended	 infusions.	 Analysis	 of	 all	 other	 primary	 and	 secondary	
outcomes	 found	 no	 difference	 between	 administration	methods.	 Sub-group	 analysis	 of	 all	 primary	
and	 secondary	 outcomes	 for	 individual	 antibiotics	 observed	 a	 statistically	 significant	 difference	
between	administration	methods	associated	with	piperacillin	 (+/-	 tazobactam)	and	clinical	 cure	and	
ceftazidime	and	all-cause	mortality	again	favouring	extended	infusions.	No	differences	were	found	for	
all	 other	 outcomes	 and	 the	 individual	 antibiotics	 investigated.	 Sensitivity	 analysis	 supported	 the	
positive	 findings	 associated	 with	 both	 clinical	 cure	 and	 microbiological/bacteriological	 cure	 and	
extended	infusions	as	the	difference	was	observed	in	both	random	and	fixed	effect	models	and	with	
both	odds	and	risk	ratio	analysis.	This	is	however	not	the	case	for	time-dependent	action	antibiotics	
and	all-cause	mortality,	the	difference	was	not	observed	in	both	random	and	fixed	effects	models	nor	
was	it	seen	when	using	odd	ratio	rather	than	risk	ratio.		
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4.5.1.2	Overview	of	the	nature	of	the	articles	included		
As	 shown	 by	 this	 systematic	 review,	 interest	 in	 the	 potential	 benefits	 of	 extended	 infusions	 of	
antibiotics	is	wide	reaching	and	the	subject	has	been	intensively	investigate	for	at	least	the	last	four	
decades.	Since	2003,	on	average,	2	RCTs	have	been	published	each	year	with	12	published	in	the	last	
5	 years.	 Many	 different	 benefits	 have	 been	 postulated	 predominately	 focusing	 on	 two	 general	
themes,	efficacy	and	safety.	Investigators	have	also	looked	into	other,	non-clinical,	outcomes	such	as	
length	of	 stay,	 reducing	 the	 total	 amount	of	 antibiotic	used	or	 cost	 savings.	Reducing	antimicrobial	
resistance	is	a	newer	emerging	theme.		
Forty	 articles	 were	 identified	 as	 suitable	 for	 inclusion	 in	 the	 systematic	 review	 and	 what	 was	
immediately	apparent	was	the	sheer	diversity	in	the	way	the	topic	has	been	approached.	Across	the	
40	articles,	16	different	antibiotics	have	been	investigated	as	extended	infusions.	This	is	usually	as	the	
only	study	drug	but	sometimes	with	a	second	antibiotic	given	to	both	groups	by	a	standard	method	to	
increase	 the	 spectrum	 of	 activity.	 A	 number	 of	 more	 recent	 studies	 investigated	 more	 than	 one	
antibiotic	 under	 the	umbrella	of	 “β-lactams”	 (Dulhunty	et	 al.,	 2013a,	 2015;	Abdul-Aziz	 et	 al.,	 2016)	
allowing	individual	sites	in	multi-centred	international	studies	to	use	antibiotics	in	line	with	their	local	
antimicrobial	guidelines.	Although	there	was	a	great	number	of	antibiotics	investigated	the	majority,	
thirty-three,	of	 the	articles	 focused	solely	on	β-lactams.	This	 is	both	 logical	and	evidenced	based	as	
not	 only	 do	 β-lactams	 exhibit	 time-dependent	 action	 but	 the	 main	 pk/pd	 parameter	 aligned	 with	
efficacy	 is	T>MIC	 (Ambrose	et	al.,	2007).	Of	 the	remaining	7	articles	4	 investigated	aminoglycosides	
(Feld	 et	 al.,	 1977,	 1984;	 Bodey	 et	 al.,	 1979;	 Wright	 et	 al.,	 1979).	 Although	 this	 would	 now	 seem	
illogical,	at	the	time	in	the	mid	to	late	1970s,	the	influence	of	the	pk/pd	relationship	on	the	efficacy	of	
antibiotics	was	poorly	appreciated.	Harry	Eagle	had	postulated	that	continuous	infusions	of	penicillins	
would	 be	 beneficial	 in	 the	 1950s	 (Eagle	 et	 al.,	 1953)	 but	 it	 wasn’t	 really	 until	 the	 1990s	 that	 the	
different	groups	of	antibiotics	and	their	pk/pd	parameters	was	being	fully	understood	(Craig,	1998).		
Aside	 from	 the	 antibiotic	 being	 investigated	 most	 studies	 either	 did	 not	 discuss	 or	 allowed	
concomitant	 prescribing	 of	 non-study	 antibiotics	 at	 the	 treating	 clinicians	 discretion.	 Where	
discussed,	some	articles	compared	additional	antibiotics	used	by	class	in	both	treatment	and	control	
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groups	to	assess	for	significant	differences	between	groups	but	many	did	not.	One	article	described	
the	 need	 to	 prescribe	 non-study	 antibiotics	 as	 clinical	 failure	 (Bao	 et	 al.,	 2017).	 	 Substantial	
differences	in	the	approach	to	concomitant	antibiotic	use	make	interpretation	of	the	overall	result	of	
the	 meta-analysis	 complex.	 In	 many	 cases	 a	 microorganism	 isn’t	 cultured	 and	 so	 it	 would	 be	
impossible	 to	 state	 categorically	 which	 antibiotic	 had	 been	 effective	 and	 therefore	 which	 infusion	
method	is	superior.	
Another	 source	 of	 variation	 throughout	 the	 articles	 is	 the	 patient	 group	 selected.	 Although	 the	
systematic	 review	 identified	 articles	 investigating	 patients	 with	 sepsis,	 this	 is	 a	 very	 generic	 term.	
Some	articles	reported	studies	investigating	sepsis	in	general	regardless	of	the	source	(Dulhunty	et	al.,	
2015)	others	focused	on	specific	end	organ	sites	e.g.	the	lungs	(van	Zanten	et	al.,	2007)	and	others	on	
specific	micro-organisms	e.g.	pseudomonas	 (Cotrina-Luque	et	al.,	2016).	The	patient	group	selected	
also	 varied,	 frequently	 it	 focused	on	 “critically	 ill”	 patients	 regardless	of	 premorbid	 state	but	 some	
articles	looked	at	specific	patient	groups,	for	example	with	malignancies	+/-	neutropenia	(Bodey	et	al.,	
1979),	 trauma	 (Hanes	 et	 al.,	 2000)	 or	 chronic	 co-morbidities	 such	 as	 pneumonia	 in	 the	 context	 of	
patients	with	chronic	obstructive	airways	disease	(van	Zanten	et	al.,	2007).	To	complicate	this	further,	
as	described	 in	 chapter	1,	 the	definition	of	 sepsis	has	evolved	over	 time.	What	 an	article	pre-1992	
describes	as	sepsis	will	potentially	include	a	very	different	cohort	of	patients	from	those	included	in	a	
study	developed	after	the	2016	sepsis-3	definition	(Singer	et	al.,	2016).		An	article	published	between	
1992	and	2016	may	well	describe	a	cohort	of	patients	as	having	“severe	sepsis”	(Bone	et	al.,	1992),	a	
sub-group	of	septic	patients	that	had	not	previously	been	defined,	but	that	have	now	been	removed	
from	the	most	recent	definition.		
The	affect	 that	 the	 factors	described	above	will	 have	on	 the	 results	of	 the	meta-analysis	 is	hard	 to	
precisely	quantify	and	can	only	 really	be	highlighted	 so	 the	 reader	 can	make	 their	own	 judgement.	
However,	 due	 to	 the	 volume	of	RCTs	 in	 the	 literature	 future	 systematic	 reviews	 could	afford	 to	be	
more	 specific	 with	 their	 inclusion	 criteria	 and	 focus	 the	 review	 to	 specific	 groups	 of	 antibiotics,	
definitions	of	sepsis	or	sources/causes	of	sepsis.	
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4.5.1.3		 Assessment	of	risk	of	bias	within	each	study	
It	is	no	surprise	that	no	single	study	was	completely	without	some	elements	of	bias.	It	isn’t	as	simple	
as	saying	that	many	studies	were	poor	quality	and/or	at	a	high	risk	of	bias	though.	Approximately	50%	
of	the	 individual	assessments	(136	out	of	280,	see	table	4.1)	were	 judged	to	be	at	unclear	risk.	This	
was	generally	because	the	information	just	wasn’t	available	from	the	published	article.	There	may	be	
no	excuse	for	articles	published	in	the	last	few	years,	but	the	concept	of	reporting	standard	items	in	a	
randomised	controlled	trial	is	relatively	new.	The	CONSORT	statement	in	the	mid	1990s	set	out	to	try	
to	formalise	how	RCTs	were	reported	and	is	now	on	its	third	incarnation	(Schulz	et	al.,	2010).	It	is	also	
true	to	say	that	the	idea	of	grouping	RCTs	together	to	look	for	effects	that	individual	studies	may	not	
have	 been	 powered	 for	 is	 also	 relatively	 new.	 Although	 the	 meta-analysis	 has	 been	 around	 in	
medicine	 since	 the	 early	 1900s	 (Pearson,	 1904),	 the	 idea	 of	 a	 systematic	 review	 of	 the	 literature	
which	is	then	analysed,	was	only	really	introduced	with	the	formation	of	the	Cochrane	collaboration	
in	the	early	1990s.	The	tool	for	assessing	the	risk	of	bias	in	randomised	trials	currently	used	was	only	
published	in	2011	(Higgins	et	al.,	2011).			
The	 most	 common	 potential	 sources	 of	 bias	 were	 associated	 with	 blinding.	 This	 was	 primarily	
“performance	bias”	associated	with	the	blinding	of	patients	and	researcher	involved	in	direct	patient	
care	but	also	to	a	lesser	extent	with	“detection	bias”	associated	with	those	assessing	the	outcome	of	
the	study.	The	studies	in	this	review	all	investigated	different	methods	of	intravenous	administration	
of	 the	 same	active	 agent	 rather	 than	 comparing	 an	 active	 agent	 to	 a	 placebo.	 To	 adequately	 blind	
these	studies	at	the	point	of	care	both	the	treatment	and	control	groups	would	require	a	placebo	i.e.	
an	active	extended	infusion	and	an	inactive	short	infusion/bolus	and	visa	versa.	Trying	to	provide	two	
placebos	would	generally	be	deemed	prohibitively	complicated	and	expensive.	Only	one	study	group	
in	the	articles	 included	in	the	systematic	review	adequately	described	“double-blinding”	their	study,	
i.e.	blind	both	at	 the	point	of	care	and	at	 the	point	of	assessment,	 to	be	 judged	at	 low	risk	of	both	
performance	 and	 detection	 bias.	 After	 publishing	 the	 study	 protocol	 (Dulhunty	 et	 al.,	 2013b)	 the	
group	then	went	on	to	do	a	small	scale	RCT	in	part	aimed	at	validating	the	blinding	process	(Dulhunty	
et	 al.,	 2013a)	 before	 finally	 stepping	 up	 to	 an	 adequately	 powered	 study	 (Dulhunty	 et	 al.,	 2015).	
“Single-blinding”,	 usually	 at	 the	 point	 of	 assessing	 the	 outcome	 to	 minimise	 detection	 bias,	 is	
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comparably	easy	as	this	assessment	can	be	done	away	from	the	clinical	environment	but	most	articles	
either	simply	stated	that	they	were	open-label/un-blinded	or	did	not	comment	on	that	aspect	of	the	
study.	Three	articles	described	their	studies	as	single-blinded	but	one	failed	to	state	which	part	of	the	
process	 was	 blinded/un-blinded.	 Although	 a	 lack	 of	 blinding	 is	 predictable	 this	 is	 none	 the	 less	
disappointing	and	it	can	be	seen	as	a	major	flaw	in	these	studies.	Clinicians	often	feel	strongly	about	
the	studies	they	are	involved	in	and	may	have	deeply	ingrained	opinions	as	to	which	therapy	option	
they	think	is	superior,	this	can	lead	to	patients	being	withheld	from	studies	for	fear	that	they	will	be	
enrolled	into	the	“inferior”	arm.	
Of	 the	 remaining	areas	of	potential	bias	assessed	“attrition	bias”,	 the	 loss	of	patients	 to	 follow	up,	
was	globally	managed	well	with	over	50%	of	articles	clearly	accounting	for	any	patients	that	were	not	
included	 in	 the	 final	 analysis	 and	 so	 deemed	 to	 be	 at	 low	 risk	 of	 bias.	 Many	 articles	 presented	
intention	to	treat	(ITT)	analysis,	where	all	enrolled	patients	regardless	of	whether	they	complete	the	
study	or	not,	were	 included	 in	the	assessments	of	the	result.	When	only	the	patients	that	complied	
fully	with	the	study	were	assessed	(referred	to	as	“per	protocol”	assessment)	frequently	the	missing	
patients	were	accounted	for.	
The	 catchall	 section	 entitled	 “other	 bias”	 is	 there	 to	 allow	 for	 the	 comparison	of	 biases	 associated	
with	the	specific	question	being	asked.	The	main	areas	of	 interest	for	this	review	were	concomitant	
non-study	antibiotic	use	and	pharmaceutical	industry	influence.	Only	4	articles	were	deemed	to	be	at	
low	risk	of	bias,	three	of	which	were	published	in	the	last	2	years,	with	the	majority	being	deemed	to	
be	at	unclear	risk.	As	discussed	previously	non-study	antibiotic	use	complicates	interpretation	of	the	
results	 of	 the	 meta-analysis.	 As	 for	 funding	 and	 declarations,	 it	 would	 be	 unfair	 to	 say	 that	 just	
because	 a	 study	 or	 one	 of	 its	 authors	 has	 an	 association	 with	 the	 pharmaceutical	 industry	 it	 is	
therefore	 inherently	 biased	 and	 therefore	 at	 high	 risk.	 Large	 studies	 cost	 vast	 sums	 of	money	 and	
would	 not	 be	 possible	 without	 external	 funding	 sources,	 be	 that	 national	 charitable/research	
organisations	 or	 the	private	 sector.	 Both	 these	 examples	will	 have	 their	 own	 reasons	 for	 providing	
funding	but	it	is	generally	unclear	what	level	of	influence	the	funding	organisation	has	had	in	the	over	
all	design	and	conduct	of	the	study.	
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4.5.1.4		 Review	of	outcomes	
Clinical	cure	and	clinical	response	
A	statistical	difference	in	clinical	cure	was	observed	favouring	extended	over	intermittent	infusions	of	
antibiotics.	 This	 difference	 was	 still	 present	 when	 only	 time-dependent	 action	 antibiotics	 were	
analysed	and	was	also	seen	in	subgroup	analysis	of	piperacillin/tazobactam	but	wasn’t	present	in	the	
other	individual	antibiotics	examined.	Sensitivity	analysis	carried	out	to	assess	the	influence	of	choice	
of	statistical	methods	appears	 to	support	 the	observed	difference;	 the	use	of	both	random	or	 fixed	
effects	models	and	odds	or	risk	ratio	favour	extended	infusions.		
This	appears	 to	be	the	 first	systematic	 review	to	separate	out	clinical	cure	from	clinical	 response	 (a	
combination	of	both	clinical	cure	and	clinical	 improvement).	Frequently	previous	systematic	reviews	
have	combined	papers	 reporting	cure	with	 those	 reporting	 response.	Other	 reviews	have	 looked	at	
clinical	failure	(usually	defined	as	the	opposite	of	clinical	response	i.e.	no	improvement,	worsening	or	
death).	 In	 keeping	 with	 previous	 reviews	 this	 meta-analysis	 has	 shown	 no	 difference	 in	 clinical	
response	rate.	
The	 different	 ways	 in	 which	 clinical	 success	 has	 been	 reported	 in	 the	 RCTs	 was	 not	 anticipated	 a	
priori.	The	decision	to	include	both	clinical	cure	and	clinical	response	as	separate	results	for	analysis	
has	unearthed	a	subtle	but	potentially	important	finding.		
There	 are	 a	 number	 of	 reasons	why	 these	 two	 outcomes	may	 differ.	 Firstly,	 “response”	 is	 a	much	
more	general	outcome	than	“cure”.	To	be	defined	as	responding	positively	to	a	treatment	regimen	a	
participant	 merely	 has	 to	 show	 some	 sign	 of	 improvement,	 be	 that	 biochemically,	 radiologically	
and/or	 clinically.	 This	 outcome	 is	 much	more	 open	 to	 researcher	 interpretation	 than	 “cure”	 were	
generally	all	signs	of	the	original	 infection	need	to	have	resolved.	This	 leads	on	to	the	second	point,	
even	a	 sub-optimal	 treatment	may	 lead	 to	a	positive	 clinical	 response	and	 therefore	 improvement.	
This	potentially	generates	background	noise;	 in	groups	of	 less	severely	unwell	patients,	 just	 looking	
for	 a	 positive	 response	 might	 not	 provide	 a	 rigorous	 enough	 test	 of	 the	 different	 administration	
methods	to	identify	significant	differences	in	efficacy.	
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Another	 important	 consideration	 is	 the	 RCTs	 themselves;	 eleven	 reported	 clinical	 cure	 and	 12	
reported	clinical	response	but	only	3	RCTs	reported	both	outcomes	(Nicolau	et	al.,	2001;	Roberts	et	
al.,	 2007;	 Chytra	 et	 al.,	 2012).	 Considering	 the	 limited	 overlap	 there	 may	 have	 been	 fundamental	
differences	between	the	2	sets	of	RCTs,	such	as	choice	of	antibiotic	or	patient	group,	that	account	for	
the	 differences	 seen	 between	 outcomes	 in	 the	 meta-analysis.	 All	 three	 articles	 reporting	 both	
outcomes	favoured	extended	infusions	when	assessing	for	either	clinical	cure	or	clinical	response,	one	
article	(Roberts	et	al.,	2007)	reported	a	statistically	significant	difference	in	cure	favouring	extended	
infusions.	This	 last	finding	reinforces	the	 idea	that	choice	of	clinical	response	in	studies	of	antibiotic	
administration	may	not	be	sensitive	enough	to	identify	a	clinically	relevant	difference	in	the	methods.		
Some	articles	reported	on	β-lactams	in	general.	In	practical	terms	this	would	have	allowed	for	greater	
recruitment,	as	each	participating	hospital	would	have	been	able	to	follow	its	own	antibiotics	policy	
based	 on	 local	 resistance	 patterns.	 One	 such	 article	 (Abdul-Aziz	 et	 al.,	 2016)	 also	 reports	 the	
breakdown	of	outcomes	by	 individual	antibiotic.	The	authors	of	two	further	articles	were	contacted	
and	were	 able	 to	 supply	 detailed	 breakdown.	 From	 these	 three	RCTs	 a	 large	 amount	 of	 data	 from	
some	of	the	biggest	and	more	methodologically	robust	studies	was	available	for	analysis	by	antibiotic.	
Sub	 group	 analysis	 of	 individual	 antibiotics	 with	 respect	 to	 clinical	 cure	 revealed	 some	 interesting	
results	to	be	considered.		Firstly,	although	piperacillin,	a	penicillin,	had	shown	a	statistically	significant	
difference	between	the	administration	methods	the	bigger	the	study	the	 less	of	a	 favourable	effect	
was	 found	 hence	 the	 unfavourable	 heterogeneity	 (I2	 =	 31.9%).	 The	 second	 observation	 was	 that	
clinical	cure	with	different	methods	of	meropenem	administration	was	not	statistically	significant;	this	
raises	 the	 question	 of	 whether	 all	 β-lactams	 are	 “equal”	 and	 if	 studies	 should	 be	 investigating	
individual	antibiotics	rather	than	broader	classes.	This	later	consideration	is	potentially	supported	by	
the	 literature.	 It	 has	 been	 suggested	 that	 the	 amount	 of	 time	 different	 antibiotics	 need	 to	 spend	
above	the	MIC	in	each	dosing	interval	varies	with	penicillins	(e.g.	piperacillin)	requiring	greater	time	
above	 the	MIC	 than	 carbapenems	 (e.g.	meropenem)	 (Drusano,	 2004).	 It	 is	 possible	 that	 a	 positive	
effect	 from	one	 class	 is	muted	 by	 an	 underwhelming	 effect	 by	 others.	 It	 is	 possible	 that	 a	 greater	
beneficial	effect	may	be	seen	with	longer	infusions	of	penicillins	compared	to	other	β-lactams.	
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Clinical	heterogeneity,	 the	differences	 in	design,	participants,	 interventions,	 etc	between	 studies,	 is	
low.	The	articles	predominantly	investigate	continuous	infusions	of	β-lactams	and	were	published	in	
the	last	decade.	The	risk	of	statistical	heterogeneity,	detectable	if	the	variation	between	the	results	of	
the	 studies	 is	 greater	 than	 that	 expected	 by	 chance,	 is	 low.	 Visual	 assessment	 of	 the	 funnel	 plot	
looking	for	publication	bias	reveals	asymmetry	with	a	lack	of	studies	on	the	left-hand	side.	Using	the	
trim	 and	 fill	 method	 (Duval	 and	 Tweedie,	 2000)	 to	 impute	 missing	 studies	 identifies	 4	 possible	
additional	 studies.	 Including	 these	 studies	 in	 the	over	all	 analysis	and	we	now	 find	no	difference	 in	
clinical	cure	between	the	administration	methods.	This	 later	point	reduces	the	certainty	with	which	
one	can	support	the	overall	finding.		
Adverse	events	(AE,	SAE	and	WAE)	
No	 differences	 in	 the	 incidence	 of	 all	 types	 of	 adverse	 events	 were	 found	 between	 the	 different	
administration	methods.	There	was	however	a	high	 incidence	of	clinical	heterogeneity	between	the	
articles.	The	rate	and	relevance	of	adverse	events	(AE),	serious	adverse	events	(SAE)	and	withdrawals	
due	to	adverse	events	(WAE)	were	hard	to	interpret	for	the	following	reasons,	
1. The	definition	of	an	AE	and	whether	it	was	serious	or	not	differed	greatly	between	articles.		
2. Only	one	article	(Bao	et	al.,	2017)	reported	all	3	outcomes,	i.e.	AE,	SAE	and	WAE.	
3. Some	articles	reported	all	adverse	events,	others	reported	only	the	events	that	they	thought	
were	related	to	the	study	drug	and	yet	another	small	group	reported	both.	
4. Some	articles	only	reported	one	type	of	adverse	event	e.g.	nephrotoxicity	(Schmelzer	et	al.,	
2013).		
5. Frequently	documented	as	events	rather	than	the	number	per	patient	for	example	a	study	of	
10	patients	may	have	5	AEs	but	all	in	one	patient.		
The	first	4	factors	listed	above	led	to	very	different	reporting	rates	and	hence	some	studies	showed	
no	AE	(Abdul-Aziz	et	al.,	2016;	Fan	et	al.,	2017)	and	some	suggesting	nearly	every	patient	suffers	an	
AE	(Bao	et	al.,	2017).	
As	 the	unit	of	measure	 for	 this	 review	was	 the	patient	and	many	adverse	events	were	 reported	as	
events	many	data	could	not	be	included	in	the	meta-analysis.	
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All	cause	mortality	
Analysis	 including	 all	 antibiotics	 found	 no	 difference	 in	 mortality	 between	 the	 two	 methods	 of	
administration	 but	 analysis	 of	 just	 time-dependent	 action	 antibiotics	 revealed	 a	 positive	 benefit	
associated	with	extended	infusions.	Of	the	antibiotics	analysed	individually	this	benefit	was	also	seen	
within	 the	 ceftazidime	 sub	 group,	 however	 this	 secondary	 result	 should	be	 viewed	with	 caution	 as	
only	one	ceftazidime	article	(Angus	et	al.,	2000)	reported	mortality	and	the	total	number	of	patients	
analysed	for	this	outcome	was	only	21.		
Twenty	 three	articles	 reported	mortality	 as	 an	outcome	but	 the	 relative	weighting	allocated	 to	 the	
papers	meant	 that	 slightly	 over	 50%	of	 the	 effect	 seen	 in	 the	meta-analysis	 of	 all	 antibiotics	 came	
from	just	2	articles	(Dulhunty	et	al.,	2015;	Fan	et	al.,	2017).	When	the	19	articles	investigating	time-
dependent	 action	 antibiotics	were	 analysed	 alone,	 4	 articles	 accounted	 for	 over	 80%	 of	 the	 effect	
with	the	papers	by	Dulhunty	et	al	and	Fan	et	al	accounting	for	approximately	30%	each	and	two	more	
articles	contributing	11%	each	(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016).	These	4	articles	all	report	
large,	 well-conducted	 RCTs	 published	 recently	 focusing	 predominantly	 on	 meropenem	 and	
piperacillin/tazobactam.	
Unfortunately	there	was	a	 lot	of	clinical	heterogeneity	between	the	articles.	Mortality	was	reported	
over	 different	 time	 frames,	 some	 relating	 to	 variable	 time	 frames	 such	 as	 “ICU	 mortality”	 and	
“hospital	 discharge”	and	others	picking	a	 specific	point	 in	 time,	 for	example	 “90	days”.	 In	 a	 similar	
way	to	 the	reporting	of	AE,	articles	also	varied	 in	whether	 they	reported	every	death	 i.e.	“all-cause	
mortality”	 or	 death	 that	was	 attributable	 to	 the	 infection	 and	 antibiotic	 failure.	 In	 both	 instances,	
analysis	of	all	antibiotics	and	time-dependent	only,	the	risk	of	statistical	heterogeneity	was	very	low	
(I2	=	0%).	There	was	no	evidence	of	publication	bias.		
Sensitivity	analysis	however	brings	in	to	question	the	robustness	of	the	positive	relationship	between	
extended	 infusions,	 time-dependent	action	antibiotics	and	mortality.	Both	the	use	of	a	 fixed	effects	
model	or	odds	ratio	finds	no	difference	between	infusion	methods.	
Secondary/super-infection	with	a	presumed	or	proven	different	organism	
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Secondary	 and	 super-infection	 were	 included	 as	 reported	 in	 the	 articles	 and	 their	 incidence	 was	
similar	between	 the	administration	methods.	Many	differences	existed	between	articles	 in	 the	way	
this	information	was	reported,	for	example	some	articles	included	all	patients	(Feld	et	al.,	1984)	whilst	
other	included	just	those	patients	from	whom	an	organism	had	been	isolated	(Chytra	et	al.,	2012).	In	
general	articles	just	reported	super-infection	regardless	of	the	nature	of	the	organism	i.e.	whether	it	
was	one	that	should	have	responded	to	the	antibiotic	being	investigated	or	an	organism	that	wouldn’t	
have	been	sensitive,	for	example	fungi;	only	one	article	sub-divided	the	two	outcomes	(Roberts	et	al.,	
2007).	Due	to	the	inconsistencies	it	is	hard	to	really	comment	on	the	relevance	of	this	as	an	outcome.	
It	 may	 add	 some	 detail	 to	 the	 more	 general	 outcome	 of	 clinical	 cure/response/failure	 but	 ideally	
future	studies	should	only	report	this	outcome	for	patients	with	a	proven	organism	whom	have	then	
regrown	 the	 same	 organism	 or	 another	 opportunistic	 organism	 such	 as	 yeast	 whilst	 on	 the	 study	
antibiotic	therapy.	
Infection	recurrence	within	14	days	of	resolution	of	primary	infection	
Only	3	articles	met	the	pre-define	criteria	for	inclusion	in	analysis	for	this	outcomes	and	no	difference	
was	found	between	methods	of	administration.	Again	there	is	a	similar	scenario	to	the	one	described	
above,	there	are	many	ways	articles	have	approached	this	ranging	from	reporting	all	new	infections	
post	 therapy	 regardless	 of	 whether	 or	 not	 an	 organism	 has	 been	 isolated	 at	 any	 point	 during	 the	
study	through	to	just	reporting	the	recurrence	of	the	originally	isolated	and	treated	organism.	These	
differences	 again	 make	 interpreting	 the	 combined	 results	 difficult	 and	 future	 systematic	 reviews	
could	afford	to	be	very	specific	a	priori	about	what	they	choose	to	include	in	the	meta-analysis.	
Bacteriological/microbiological	cure	
Many	 studies	didn’t	 report	 this	 outcome	and	where	 it	was	 reported	 the	numbers	of	 patients	were	
smaller	 than	the	total	enrolled	as	not	every	patient	had	a	verified,	culture	positive	 infection.	Again,	
the	 definition	 also	 varied	 from	 either	 proven	 eradication	 to	 overall	 eradication,	 the	 later	 including	
both	proven	and	presumed.	
Analysis	of	bacteriological/microbiological	cure	found	a	statistically	significant	difference	in	favour	of	
extended	 infusions	 when	 examining	 articles	 reporting	 results	 for	 both	 all	 antibiotics	 and	 time-
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dependent	 only	 antibiotics.	 However	 no	 difference	 between	methods	 of	 administration	was	 found	
when	antibiotics	where	examined	individual.	Interestingly	one	of	the	5	articles	accounted	for	83%	of	
the	 weighting	 (Chytra	 et	 al.,	 2012).	 This	 article	 looked	 solely	 at	 meropenem	 and	 reported	 a	
statistically	significant	result	 in	favour	of	continuous	infusions	(P	=	0.020)	for	overall	eradication	but	
no	difference	when	analysing	solely	proven	or	presumed	eradication	independently.	Encouragingly	it	
found	significantly	less	persistence	(i.e.	on	going	infection)	and	no	difference	in	resistance	in	the	point	
of	final	assessment.	
4.5.2		 Comparison	with	other	systematic	reviews	and	meta-analyses	
The	first	point	of	note	is	that	there	has	been	many	new	RCTs	published	over	the	last	five	years;	this	
systematic	 review	contains	eleven	more	articles	 than	 the	 last	 similarly	wide	 reaching	 review	of	 the	
literature	 conducted	 for	 the	 Cochrane	 Collaboration	 in	 2013	 (Shiu	 et	 al.,	 2013).	 This	 review	 also	
analyses	data	for	at	 least	an	additional	1700	patients	(approximately	1600	patients	in	the	review	by	
Shiu	et	al	 compared	 to	approximately	3300	 in	 this	 review).	Many	of	 these	additional	articles	are	of	
higher	quality,	 larger	patient	numbers	and	at	 lesser	risk	of	bias	than	the	earlier	articles.	These	facts	
combined	make	this	the	most	robust	review	to	date.		
Comparison	of	the	articles	 included	in	this	systematic	review	for	the	same	time	period	as	to	that	of	
the	 Cochrane	 review	 and	 the	 results	 are	 almost	 identical.	 This	 systematic	 review	 focused	 on	 only	
articles	 or	 abstracts	 published	 in	 English	 and	 the	 published	 peer	 reviewed	 data	 contained	 within	
them,	 Shiu	 et	 al	 obtained	 translations	 of	 non-English	 papers	 and	 invited	 authors	 to	 contributed	
unpublished	 data.	 For	 the	 purpose	 of	 this	 review	 authors	 were	 only	 contacted	 for	 clarification	 of	
anomalies	in	the	data	or	for	subdivision	of	the	data	for	individual	antibiotics	where	it	was	published	
by	group	e.g.	β-lactams.		
There	 are	 2	main	 differences	 however	 between	 this	 systematic	 review	 and	 those	 that	 have	 come	
before	 it.	 Firstly,	 the	 definitions	 of	 the	 outcomes	 of	 interest	 set	 out	 a	 priori	 for	 the	 reviews	 and	
secondly	differences	 in	approach	 to	data	extraction.	For	example,	 this	 review	has	examined	clinical	
cure	rather	than	response	or	failure	leading	to	a	slightly	different	insight	into	the	results.	This	review	
has	 interpreted	 and	 analysed	 adverse	 events	 differently	 to	 previous	 reviews.	 Secondly,	 previous	
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reviews	have	treated	glycopeptides,	specifically	vancomycin,	as	 time-dependent	whereas	as	already	
discussed	 in	 this	 review,	 vancomycin	 has	 been	 excluded	 from	 the	 “time-dependent”	 analysis.	
Sensitivity	 analysis	 highlighted	 that	 this	 decision	 had	 an	 impact	 on	 the	 results,	mortality	 no	 longer	
being	 positively	 influenced	 by	 extended	 infusions.	 The	 decision	 to	 exclude	 vancomycin	 from	 this	
analysis	is	however	logical	and	as	such	the	observed	benefit	remains	valid.	This	mortality	benefit	is	in	
keeping	with	the	recent	meta-analysis	of	individual	patient	data	from	RCTs	comparing	continuous	and	
intermittent	β-lactam	infusions	(Roberts	et	al.,	2016).	
4.5.3		 Impact	
This	 is	the	biggest	systematic	review	and	meta-analysis	to	date.	 It	 is	the	first	review	to	treat	clinical	
cure	 and	 clinical	 response	 as	 separate	 outcomes.	 In	 doing	 so	 it	 has	 highlighted	 a	 significant	 result	
when	 specifically	 looking	at	 articles	 that	 reported	 clinical	 cure	as	apposed	 to	assessing	 clinical	 cure	
and	 response	 under	 the	 same	 umbrella.	 In	 addition,	 this	 review	 has	 highlighted	 other	 previously	
unseen	improvements	in	bacteriological	cure	rates	and	mortality.	In	doing	so	it	has	shown	that	there	
truly	 is	 potential	 benefits	 from	 extended	 infusions.	 Sub	 group	 analysis	 of	 individual	 antibiotics	
however	 has	 highlighted	 the	 potential	 folly	 of	 the	 new	 trend	 to	 investigate	 β-lactams	 rather	 than	
individual	antibiotics	and	indicated	the	areas	that	future	studies	should	focus.	
4.5.4		 Limitations	and	assumptions	
Although	 statistical	 heterogeneity	was	 generally	 low	 or	 non-existent	 throughout	 this	meta-analysis	
clinical	and	methodological	heterogeneity	will	have	been	very	high.	Firstly,	these	articles	span	over	40	
years	 in	 which	 many	 aspects	 of	 clinical	 care	 have	 changed	 including	 effectiveness	 of	 other	 drug	
interventions,	accuracy	and	types	of	monitoring	equipment,	quality	of	nursing	interventions	and	even	
disease	definitions.	Secondly,	there	were	many	differences	throughout	the	articles	included	in	terms	
of	 definitions	 of	 the	 various	 outcomes	 and	 how	 outcome	 measures	 were	 applied.	 This	 makes	
generalising	 the	outcomes	very	difficult.	Many	outcomes	were	 reported	over	different	 time	 frames	
e.g.	mortality	reported	at	ICU	discharge,	hospital	discharge,	30	days,	90	days	or	without	a	stipulated	
time	frame.	An	example	of	how	this	may	affect	the	overall	outcome	can	be	seen	in	the	BLING	II	study	
(Dulhunty	 et	 al.,	 2015),	 hospital	mortality	was	 statistically	 significant	 but	was	 no	 longer	 significant	
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when	assessed	at	90	days.	Another	example,	 this	 time	of	data	unavailable	 for	 the	meta-analysis,	 is	
that	 many	 articles	 described	 adverse	 events	 by	 event	 rather	 than	 the	 number	 of	 patients	 that	
suffered	one	or	more	events	and	so	this	data	could	not	be	included	in	the	analysis.	A	final	problem,	
which	was	unforeseen,	was	the	issue	of	the	inconsistency	of	the	data	within	some	articles	where	data	
in	tables	did	not	correlate	with	the	same	data	in	the	text	of	the	article	and	this	data	therefore	needed	
to	be	exclude.		
4.6		 Conclusion	
This	large	systematic	review	identified	40	eligible	randomised	controlled	trials	investigating	extended	
infusions	 of	 antibiotics	 in	 adult	 patients	 with	 presumed	 or	 proven	 sepsis.	 Statistically	 significant	
differences	in	clinical	cure	and	microbiological/bacteriological	cure	were	found	in	favour	of	extended	
infusion	 methods.	 No	 difference	 in	 adverse	 events	 was	 identified	 between	 the	 administration	
methods.	 Although	 a	 difference	 in	 mortality	 was	 seen	 when	 time-dependent	 antibiotics	 were	
analysed	 separately	 this	 result	 may	 have	 been	 influenced	 by	 the	 choice	 of	 method	 of	 statistical	
analysis.	Sub	group	analysis	showed	statistically	significant	differences	in	benefits	between	antibiotics	
suggesting	that	 future	studies	should	 focus	on	 individual	antibiotics,	 for	example	piperacillin,	 rather	
than	classes	or	groups	such	as	β-lactams.	
 
	
	
	
	
	
	
	
5 Discussion	and	overall	conclusion		
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The	 overall	 aim	 of	 this	 thesis	 was	 to	 investigate	 the	 evidence	 base	 for	 current	 UK	 intravenous	
antibiotic	administration	practice.	A	questionnaire	was	circulated	to	critical	care	pharmacists	via	the	
United	Kingdom	Clinical	Pharmacy	Associations’	Critical	Care	Group	message	board	to	ascertain	what	
current	practice	existed	and	if	any	critical	care	units	(CCUs)	were	adopting	extended	infusion	methods	
of	administration	in	their	usual	practice.	At	the	same	time	a	systematic	review	was	performed	of	the	
randomised	controlled	trials	 (RCTs)	 in	the	published	 literature	and	with	knowledge	of	the	articles	 in	
the	 pipeline	 at	 the	 time	 it	 was	 decided	 to	 update	 the	 review	 in	 April	 2018.	 A	 meta-analysis	 was	
performed	 investigating	 the	evidence	base	 for	all	antibiotics	and	sub-group	analysis	 focused	on	 the	
antibiotics	 shown	 by	 the	 survey	 to	 be	 given	 commonly	 on	 UK	 CCUs	 by	 extended	 methods	 of	
administration.	
5.1	 Overview	
The	results	of	both	phases	of	 the	study	have	shown	a	wide-ranging	 interest	 in	 the	 literature	and	 in	
practice	 for	 extended	methods	 of	 administration.	 Aside	 from	 the	 RCTs	 described	 in	 the	 systematic	
review	there	is	a	large	number	of	observational	studies	in	patients	and	pk/pd	studies	in	both	animal	
models	and	humans	that	have	shown	a	scientific	basis	for,	and	a	potential	benefit	to	be	gained	from,	
extending	 the	 duration	 over	 which	 an	 antibiotic	 infusion	 is	 administered.	 The	 systematic	 review	
revealed	 that	 the	 focus	 of	 the	 literature	 is	 predominantly	 on	 β-lactam	 antibiotics	 and	 although	
extended	 infusions	of	antibiotics	 in	 this	class	are	popular,	vancomycin	 is	by	 far	 the	most	commonly	
administered	extended	infusion	in	practice	across	CCUs	in	the	UK.	This	is	despite	there	being	only	two	
RCTs	assessing	 its	 safety	and	only	one	 (Wysocki	et	al.,	2001)	 investigating	efficacy,	 compared	 to	14	
articles	reporting	studies	 investigating	piperacillin.	From	the	results	of	the	survey	 it	 is	clear	that	the	
reasons	for	adopting	extended	infusions	differed	between	vancomycin	and	β-lactams,	with	the	latter	
being	almost	exclusively	about	efficacy	whereas	the	former	is	about	a	combination	of	efficacy,	safety	
and	ease	of	administration.	Where	practice	and	the	literature	are	markedly	different	is	in	the	method	
of	extended	administration	utilised.	
5.2	 Continuous	(CI)	versus	extended	intermittent	(EII)	infusions	
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The	majority	of	the	published	RCTs,	34	out	of	the	40	articles,	 investigated	continuous	 infusions	(CI).	
Four	of	the	6	articles	focussing	on	extended	intermittent	infusions	(EII)	have	been	published	since	the	
beginning	 of	 2017.	 The	 survey	 of	 practice	 conducted	 at	 the	 end	of	 2013	 revealed	 that	 those	 CCUs	
using	 extended	methods	 of	 administration	 exclusively	 used	 EIIs	 for	 β-lactams	 and	 vancomycin	was	
given	only	by	CI.	These	findings	were	not	anticipated	during	the	study	design	phase	and	therefore	the	
questionnaire	 was	 not	 designed	 to	 collect	 data	 to	 investigate	 this	 aspect	 further.	 The	 following	
reasons	 can	be	postulated	 though	as	 to	why	EIIs	of	β-lactam	antibiotics	may	be	 the	administration	
method	of	choice	rather	than	CIs.	
Firstly,	there	may	be	many	more	articles	investigating	extended	administration	methods	that	are	not	
RCTs	and	so	therefore	not	included	in	the	meta-analysis.	One	such	article	that	stands	out	is	a	cohort	
study	comparing	30	minute	infusions	of	piperacillin/tazobactam	given	every	4	or	6	hours	with	4-hour	
infusions	given	every	8	hours	 to	treat	Pseudomonas	aeruginosa	 infection	 (Lodise	et	al.,	2007a).	The	
two	groups	comprised	194	patients	 in	total	and	the	authors	state	the	groups	were	evenly	matched.	
Even	 though	 a	 lower	 total	 daily	 dose	 of	 antibiotic	was	 used	 in	 the	 EII	 group	 this	 group	 had	 better	
target	 attainment,	 spending	 longer	 above	 the	MIC,	 and	 showed	a	 significantly	 lower	mortality	 rate	
than	the	intermittent	group	(12.2%	compared	to	31.6%;	P=0.04)	and	a	shorter	length	of	stay	(21	days	
compared	to	38	days;	P=0.02).	Pseudomonas	spp.	are	often	used	in	pk/pd	studies	of	β-lactams	as	they	
have	a	relatively	high	MIC,	are	relatively	common	in	the	ICU	patient	population	(Vincent	et	al.,	2009)	
and	have	a	high	associated	mortality	so	represent	a	“worst-case”	scenario.	
Secondly	are	the	practical	aspects	of	the	different	types	of	infusions.	A	CI	requires	the	patient	to	have	
intravenous	access	dedicated	to	the	administration	of	that	one	drug.	EIIs	have	periods	were	that	 IV	
access	port	 is	not	needed	so	can	be	utilised	 for	 the	administration	of	other	medicines.	 In	 the	most	
critically	ill	patients	this	intravenous	access	may	be	at	a	premium	and	many	other	medicines,	such	as	
sedatives,	analgesics,	insulin,	and	feeds	are	also	administered	by	CI	hence	the	option	of	EIIs	appearing	
favourable.	
Lastly	are	pharmaceutical	issues,	such	as	stability	of	the	antibiotic	in	a	diluent	at	room	temperature.	
This	 has	 not	 yet	 been	widely	 investigated	 but	 for	 example	 one	 study	 has	 shown	 that	meropenem	
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1g/100mL	of	diluent	is	only	stable	at	25oC	for	12	hours	and	then	degrades	(Berthoin	et	al.,	2010)	and	
that	 at	higher	 concentrations	and/or	 temperatures	 the	 rate	of	degradation	of	meropenem	 is	much	
higher.	For	this	reason	studies	investigating	meropenem	have	run	three	back-to-back	8-hour	infusions	
in	a	24	hour	period	to	provide	the	“continuous”	infusion	(Chytra	et	al.,	2012;	Dulhunty	et	al.,	2015).	
This	is	therefore	as	labour	intensive	for	nursing	staff	as	three	30-minute	or	4-hour	infusions	per	day	
and	 therefore	 confers	 no	 non-clinical	 benefits	 over	 the	 other	 administration	methods	 such	 as	 cost	
and	consumable	savings.	
5.3	 Piperacillin/tazobactam	and	meropenem	
The	β-lactams	make	an	obvious	choice	to	investigate	as	their	efficacy	depends	solely	on	the	amount	
of	 time	 they	 spend	above	 the	minimum	 inhibitory	 concentration	 (T>MIC).	 Since	 their	 release	on	 to	
the	world	market,	piperacillin	and	meropenem	have	formed	the	mainstay	of	empirical	treatment	for	
patients	with	 sepsis	or	 septic	 shock;	 they	are	both	broad	 spectrum	 including	 those	microorganisms	
not	sensitive	to	other	β-lactams	such	as	pseudomonas	aeruginosa,	and	face	comparably	low	levels	of	
resistance.	 Interest	in	maintaining	their	effectiveness	has	led	to	their	empirical	use	in	the	UK	largely	
being	restricted	to	the	critical	care	environment.	 International	sepsis	guidelines	encourage	their	use	
in	accordance	with	their	pk/pd	properties	(Rhodes	et	al.,	2017).		
Piperacillin,	 in	 all	 but	 one	 instance	 combined	 with	 tazobactam,	 was	 both	 the	 most	 commonly	
investigated	 antibiotic	 in	 the	 RCTs	 included	 in	 the	 systematic	 review.	 It	 is	 also	 the	 β-lactam	most	
commonly	administered	by	an	extended	infusion	method	on	UK	CCUs.	Meropenem,	although	third	in	
terms	 of	 the	 number	 of	 published	 RCTs,	was	 usually	 prescribed	 for	 extended	 infusion	 on	 a	 similar	
number	of	CCUs	as	piperacillin.	In	total,	across	all	of	the	patients	enrolled	in	the	RCTs,	approximately	
1400	received	piperacillin	and	more	than	500	received	meropenem.	Between	them	they	accounting	
for	nearly	2/3	of	 the	 total	number	of	patients	 investigated	 in	 the	studies.	These	two	antibiotics	are	
now	 commonly	 being	 investigated	 in	 the	 same	 studies	 under	 the	 umbrella	 term	 of	 β-lactams	
(Dulhunty	et	al.,	2015;	Abdul-Aziz	et	al.,	2016).		
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The	 large	number	of	studies,	 the	pk/pd	 logic	and	evidence	pointing	towards	their	potential	benefit,	
along	with	the	fact	that	they	are	first-line	empirical	therapies	for	septic	patients	on	UK	CCUs	means	
that	it	is	no	surprise	that	these	two	antibiotics	have	been	the	first	to	be	widely	adopted	as	EIIs.	
The	meta-analysis	showed	a	favourable	clinical	cure	rate	for	extended	methods	of	administration	of	
time-dependent	 action	 antibiotics,	 a	 reduction	 in	 mortality,	 and	 improved	
microbiological/bacteriological	 cure	 rates	 over	 standard	 methods,	 but	 no	 difference	 between	
administration	methods	for	any	of	the	adverse	events.	All	but	one	of	the	articles	included	in	the	time-
dependent	 analysis	 investigated	β-lactams,	 however	 individual	 analysis	 by	 antibiotic	 failed	 to	 show	
any	positive	difference	in	any	outcomes	for	meropenem,	and	only	a	superior	clinical	cure	rate	but	no	
mortality	benefit	for	piperacillin/tazobactam.			
Another	 point	 of	 note	 is	 that,	 as	 described	 above,	 the	 majority	 of	 articles	 reported	 studies	
investigating	 continuous	 infusions	 but	 all	 of	 the	 practice	 in	 UK	 CCUs	 for	 these	 two	 antibiotics	 is	
extended	intermittent	infusions.	
Although	the	evidence	base	points	towards	a	benefit	from	extended	infusions,	the	articles	included	in	
the	 systematic	 review	 show	 a	 large	 amount	 of	 clinical	 heterogeneity	 and	 analyses	 of	 individual	
antibiotics	for	the	most	part	do	not	show	any	statistically	significant	results.		Only	the	administration	
of	piperacillin/tazobactam	by	continuous	infusion	is	supported	by	the	available	published	literature.		
5.4	 Vancomycin	
The	benefit	of	CIs	of	vancomycin	may	initially	seem	to	be	less	obvious	than	that	of	β-lactams	but	this	
survey	showed	 that	 they	are	by	 in	 far	 the	most	popular	extended	 infusion	being	given	on	UK	CCUs	
and	the	only	antibiotic	given	by	CI.	50%	of	CCUs	give	vancomycin	by	extended	infusion	with	the	next	
most	popular	antibiotic,	piperacillin/tazobactam,	being	given	on	just	over	20%.		
As	 previously	 described	 vancomycin	 pk/pd	 still	 isn’t	 fully	 understood	 (Löwdin	 et	 al.,	 1998;	 Moise-
Broder	et	 al.,	 2004;	Vandecasteele	et	 al.,	 2012).	 It	 is	 now	widely	 accepted	 that	 although	 it	 exhibits	
elements	 of	 both	 time-	 and	 concentration-dependent	 action	 the	 pk/pd	 parameter	 that	 best	 aligns	
with	 efficacy	 is	 the	 total	 exposure	 over	 time	 (AUC:MIC	 ratio)	 (Holmes	 et	 al.,	 2013).	 Although	 this	
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systematic	 review	 only	 found	 two	 RCTs	 there	 have	 been	many	 other	 articles	 reviewing	 the	 use	 of	
vancomycin	 as	 a	 CI.	 Even	 though	 to	 date	 no	 benefit	 in	 efficacy	 has	 been	 shown,	 CIs	 appear	 to	 be	
simpler	to	administer,	cheaper	and	have	less	adverse	events	(Cataldo	et	al.,	2012;	Hao	et	al.,	2016).	
The	 responses	 to	 the	questionnaire	 confirm	 that	 these	 factors	have	been	 taken	 into	account	when	
adopting	this	practice.	
The	 benefits	 largely	 revolve	 around	 the	 ability	 to	 do	 therapeutic	 drug	monitoring	 (TDM)	 of	 serum	
vancomycin	 levels.	Unlike	 the	β-lactams,	which	 as	 a	 general	 rule,	 have	 a	 large	 therapeutic	window	
and	are	generally	deemed	to	be	safe,	vancomycin	has	a	narrow	therapeutic	window	and	overdose	or	
accumulation	 can	 lead	 to	 severe	 complications	 such	 as	 nephrotoxicity.	 Due	 to	 vancomycin’s	 side	
effect	 profile	 TDM	 has	 always	 been	 both	 advisable	 and	 readily	 available	 in	 all	 clinical	 situations	 in	
which	 vancomycin	 is	 used	 in	 the	 UK.	 As	 shown	 in	 the	 survey,	 TDM	 is	 used	 ubiquitously	 in	 the	
management	of	patients	on	vancomycin	throughout	UK	CCUs.		
CIs	allow	dosing	and	administration	to	be	simplified.	This	not	only	makes	the	job	of	the	nursing	staff	
easier,	 but	 also	 removes	 any	 elements	 of	 doubt	 in	 the	 pharmacist’s	mind	when	 trying	 to	 interpret	
TDM	levels,	which	are	otherwise	more	complex	with	standard	intermittent	dosing.		
Another	 important	 factor	 is	 safety.	A	study	 in	2009	showed	that	nephrotoxicity	 increases	as	 trough	
vancomycin	 levels	 increase	 in	 patients	 receiving	 standard	 dosing.	 A	 5%	 incidence	 was	 seen	 when	
initial	trough	was	<10	mg/L	compared	with	33%	if	the	trough	was	>20	mg/L	(Lodise	et	al.,	2009).	This	
is	worrying	as	 target	 levels	of	15-25mg/L	are	often	used	 in	CI	protocols	 (James	et	al.,	1996;	Barton,	
2009)	 but	 the	 negative	 effect	 observed	may	be	due	 to	 higher	 peak	 concentrations	 associated	with	
high	troughs	or	a	larger	AUC:MIC	ratio	rather	than	the	trough	per	se.	This	is	supported	by	a	number	of	
studies	 and	 reviews	 that	 have	 shown	 a	 lower	 incidence	 of	 nephrotoxicity	 with	 CIs	 compared	 to	
intermittent	infusions	(Schmelzer	et	al.,	2013;	Tafelski	et	al.,	2015;	Hao	et	al.,	2016).	
Finally,	 potential	 cost	 saving	 is	 a	 very	 real	 factor	 for	 healthcare	 budgets.	 Although	 cost	 saving	 in	
practice	have	been	shown	(Wysocki	et	al.,	2001)	 this	seems	unlikely	as	a	 large	cost	associated	with	
administration	by	either	method	is	TDM.	Checking	levels	starts	earlier	in	therapy	and	more	frequently	
with	suggested	CI	protocols	compared	with	intermittent	dosing.	The	questionnaire	responses	seem	to	
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agree	with	this,	with	only	two	respondents	suggesting	that	cost	savings	were	a	consideration	with	any	
antibiotic	and	CIs.	These	responses	may	have	related	to	articles	reporting	studies	using	smaller	doses	
of	β-lactams	in	the	CI	group	and	achieving	similar	efficacy.		
In	 summary,	 although	 in	 terms	 of	 RCTs	 the	 evidence	 is	 limited,	 the	 people	 have	 spoken	 and	 the	
perceived	benefits	associated	with	ease	of	dosing	and	reducing	toxicity	have	meant	that	vancomycin	
CIs	are	now	common	place	on	UK	CCUs.	
5.5	 The	use	of	extended	infusions	of	β-lactams	in	practice	
Many	other	β-lactam	antibiotics	have	been	investigated	in	RCTs	over	the	years	but	very	little	interest	
appears	 to	 be	 shown	 in	 using	 them	 as	 extended	 infusions	 on	 UK	 CCUs.	 From	 the	 results	 of	 the	
questionnaire	 it	 is	 apparent	 that	 the	 only	 CCUs	 using	 any	 other	 β-lactam	 antibiotics	 by	 extended	
infusions	are	large	Trusts	with	multiple	CCUs,	a	lot	of	level	3	beds	and	a	senior	pharmacist	integrated	
into	 the	 CCU	 team.	 There	 may	 be	 two	 reasons	 for	 this;	 the	 first	 is	 that	 meropenem	 and	
piperacillin/tazobactam	 are	 used	 empirically	 for	 a	 wide	 range	 of	 suspected	 micro-organisms	 and	
source	 sites.	 Most	 of	 the	 other	 β-lactams	 are	 used	 for	 very	 specific	 infections,	 for	 example	
flucloxacillin	 for	 a	 suspected	 staphylococcal	 spp.	 soft	 tissue	 infection.	 With	 this	 in	 mind	 even	 the	
smallest	CCU	will	 frequently	use	piperacillin/tazobactam	and	meropenem	but	may	rarely	 if	ever	use	
some	of	the	more	niche	β-lactams.	The	second	possible	reason	is	related	to	the	first;	the	largest	CCUs	
which	 are	 administering	 piperacillin/tazobactam	 and	meropenem	 by	 EII	 will	 also	 use	 a	 number	 of	
other	β-lactams	by	nature	of	their	size	and	specialist	areas,	e.g.	neurology,	cardiothoracics,	etc.	They	
therefore	may	approach	 the	 subject	 in	a	more	enthusiastic	manner	developing	guidelines	 for	 all	 of	
the	 β-lactams	 they	use	 commonly	 across	 the	 larger	 departments.	However,	 big	 doesn’t	 necessarily	
mean	 better;	 flucloxacillin	 is	 reportedly	 used	 in	 one	 Trust	 on	 its	 4	 CCUs	 despite	 there	 not	 being	 a	
single	RCT	investigating	its	efficacy	or	safety.	
5.6	 Professional	influence	on	the	adoption	of	extended	administration	methods		
The	 adoption	 of	 extended	 infusions	 of	 antibiotics	 correlates	 with	 whether	 or	 not	 the	 CCU	 has	 an	
experienced	 pharmacist(s)	 integrated	 into	 the	 team,	 attending	multi-professional	ward	 rounds	 and	
providing	seven-day	service.	This	could	be	an	unforeseen	advantage	of	having	a	senior,	experienced	
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pharmacist	 as	 part	 of	 the	 wider	 multi-professional	 team,	 driving	 novel,	 evidence-based	 medicines	
change	for	patient	benefit	that	otherwise	would	at	least	initially	go	largely	under	the	radar.	
5.7	 Drawbacks	affecting	adoption	of	extended	infusions	
Although	the	meta-analysis	showed	statistically	significant	differences	in	some	outcomes,	sub	analysis	
revealed	 that	 this	 was	 less	 convincing	 in	 more	 specific	 areas.	 Despite	 this,	 many	 CCUs	 are	 using	
extended	infusions,	so	one	is	led	to	ask	if	there	is	a	risk	of	this	resulting	in	patient	harm.	The	evidence	
from	 the	 RCTs	 suggests	 not,	 the	 overall	 outcomes	 suggested	 that	 at	 worst	 there	 is	 no	 difference	
between	 the	 effectiveness	 and	 safety	 of	 the	 different	methods.	 This	 fact	 combined	with	 the	 large	
amount	of	evidence	and	pk/pd	data	suggests	that	extended	infusions	are	at	least	as	good	as,	and	in	
some	instances	more	effective/safer	than	standard	licensed	methods	of	administration.	
5.8	 The	use	of	extended	infusions	in	specific	patient	groups	
Many	of	the	RCTs	focus	on	targeting	the	“worst-case”	scenario	such	as	 infection	with	pseudomonas	
aeruginosa	 or	 in	 the	 case	 of	 vancomycin	 methicillin	 resistant	 staphylococcus	 aereus,	 but	 many	
critically	 ill	 patients	 do	 not	 have	 these	 infection.	 Articles	 frequently	 reported	 exclusion	 of	 patients	
from	the	study	who	had	renal	failure,	but	these	patients	form	a	large	cohort	of	the	patients	that	are	
to	 be	 found	 every	 day	 on	 CCUs.	 Some	 of	 the	 responses	 to	 the	 questionnaire	 addressed	 this	 and	
although	extended	infusions	may	not	be	used	by	some	in	their	regular	practice,	patients	treated	with	
extended	 infusions	 may	 be	 considered	 to	 be	 at	 high	 risk	 of	 renal	 failure,	 especially	 those	 with	
pseudomonas	 aeruginosa	 or	 large	 burns.	 Conversely,	 those	 using	 extended	 infusions	 as	 their	 usual	
practice	would	convert	back	to	licensed	dosing	in	the	face	of	renal	impairment.		
5.9	 Combining	extended	infusions	with	TDM	in	practice	
The	survey	showed	that	every	CCU	using	vancomycin	relied	upon	TDM	to	monitor	serum	levels;	it	also	
showed	that	apart	from	aminoglycosides	there	was	no	other	TDM	taking	place.	Historically	TDM	has	
only	 ever	 been	 available	 for	 drugs	 with	 poor	 side	 effect	 profiles	 such	 as	 vancomycin	 and	 the	
aminoglycosides.	 Antibiotics	 that	 are	 deemed	 to	 be	 safe	 have	 therefore	 never	 had	 TDM	 systems	
developed.	However,	as	described	above	it	has	now	become	common	practice	to	use	TDM	to	confirm	
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that	vancomycin	serum	levels	are	therapeutic	throughout	the	dosing	interval	rather	than	to	monitor	
for	toxicity.	Ideally	all	commonly	used	antibiotics	would	have	a	means	of	TDM	available,	preferably	a	
point-of-care	 system	 that	 would	 facilitate	 rapid	 turnaround	 of	 results	 to	 guide	 therapy	 in	 a	
meaningful	 way.	 This	 could	 be	 used	 in	 combination	 with	 knowledge	 of	 the	 MIC	 of	 the	
antibiotic/micro-organism	combination	the	clinician	is	faced	with,	to	then	tailor	the	antibiotic	therapy	
for	the	patient	being	treated.	What	this	would	mean	is	that	for	the	most	part	patients	would	receive	
antibiotics	 by	 licensed	 administration	 methods	 or	 where	 extended	 infusions	 are	 usual	 practice	
therapy	can	be	rationalised.	
5.10	 Limitations	
The	 most	 important	 potential	 limitation	 in	 this	 study	 is	 the	 time	 between	 the	 two	 elements,	 the	
questionnaire	was	launched	towards	the	end	of	2013	and	the	meta-analysis	completed	in	April	2018.	
Just	by	looking	at	the	number	of	new	RCTs	published	in	the	last	5	years	it	is	evident	that	the	level	of	
interest	 is	 growing.	 In	 line	with	 this,	 anecdotally	 the	 number	 of	 posts	 on	 the	UKCPA	CCG	message	
board	 asking	 for	 both	 advice	 and/or	 guidelines	 is	 on	 the	 increase.	Although	 the	overall	 aim	of	 this	
piece	of	work	was	to	ascertain	if	UK	CCU	practice	is	in	line	with	the	evidence	base	this	required	two	
fundamental	unknowns	to	be	answered,	what	is	UK	CCU	practice	and	what	is	the	up	to	date	evidence.	
Both	of	these	elements	have	been	addressed	and	the	question	of	how	does	UK	practice	compare	to	
the	evidence	answered.	
5.11	 Future	research	
On	the	face	of	 it	no	more	studies	should	be	required.	The	systematic	review	identified	40	RCTs	and	
within	the	meta-analysis	many	of	the	major	outcomes	such	as	mortality	showed	no	publication	bias,	
statistical	 heterogeneity	 or	 statistical	 need	 for	 further	 research.	 However	 there	 is	 a	 big	 but	 and	 it	
surrounds	 the	 clinical	 heterogeneity	 in	 the	 articles.	 There	 is	 a	 lot	 of	 diversity	 in	 the	 antibiotics	
investigated,	the	underlying	condition	being	treated,	the	target	microorganisms	and	the	use	of	non-
study	 antibiotics	 to	 name	 just	 a	 few	 variables.	 To	 add	 to	 this	 many	 studies	 pre-date	 both	 the	
Cochrane	 collaboration	 advice	 on	 assessing	 for	 within	 study	 bias	 (Higgins	 et	 al.,	 2011)	 and	 the	
CONSORT	guidelines	advising	on	what	RCTs	should	ideally	report	(Schulz	et	al.,	2010).	All	these	factors	
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point	towards	more	data	being	required	for	individual	antibiotics	in	scenarios	clinically	relevant	to	the	
UK	patient	population.	
The	 β-lactam	 infusion	 study	 group	 (BLING)	 are	 just	 starting	 to	 enrol	 on	 their	 phase	 III	 randomised	
controlled	 trial	 of	 continuous	 β-lactam	 infusions	 compared	 with	 intermittent	 β-lactam	 dosing	 in	
critically	ill	patients	(BLING	III).	This	study	aims	to	enroll	7000	patients	across	100	CCUs	worldwide	and	
give	the	definitive	answer	to	the	question	do	CIs	of	β-lactam	antibiotics	improve	mortality.	The	study	
hopes	 to	complete	enrollment	at	 the	end	of	2021.	Even	 this	major	study	will	 leave	some	questions	
unanswered	 though.	 Firstly	 the	 group	 are	 investigating	 CIs	 so	 the	 question	 will	 remain	 over	 the	
efficacy	 and	 safety	 of	 EIIs,	 which	 are	 currently	 commonly	 used	 on	 UK	 CCUs.	 Again	 piperacillin	 (a	
penicillin)	 and	meropenem	 (a	 carbopenem)	 are	 lumped	 together	 as	 “β-lactams”	 and	 how	 this	 will	
affect	the	results	is	unknown,	as	the	meta-analysis	in	chapter	4	has	shown	there	may	be	an	argument	
for	 investigating	 antibiotics	 individually.	 This	 study	 will	 only	 answer	 the	 question	 about	 the	
effectiveness	of	the	antibiotics	it	 investigates	so	further	studies	will	be	required	to	investigate	other	
agents	 but	most	 notably	 vancomycin.	 Lastly	 BLING	 III	may	 struggle	 to	 recruit	 to	 schedule	 as	many	
large	 centres	 in	 the	UK	where	 the	majority	 of	 patients	may	 have	 been	 recruited	 are	 already	 using	
extended	infusion	and	may	not	be	willing	to	engage	with	the	study.	
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6 Conclusion		
Current	UK	critical	care	practice	of	 intravenous	antibiotic	administration	 is	 in	 line	with	the	evidence	
base.	 This	 meta-analysis	 shows	 that	 extended	 infusions	 are	 both	 safe	 and	 at	 least	 as	 effective	 as	
standard	 licensed	 administration	 methods.	 There	 is	 a	 significant	 benefit	 seen	 in	 clinical	 cure,	
microbiological	cure	and	reduction	in	mortality	associated	with	time-dependent	action	antibiotics.	By	
far	the	most	commonly	investigated	antibiotics	are	piperacillin/tazobactam	and	meropenem	and	it	is	
these	two	antibiotics	we	see	most	usually	prescribed	by	extended	infusions	on	UK	CCUs.	Experienced	
senior	 pharmacists	 are	 leading	 the	way	 by	 influencing	 the	 adoption	 of	 administration	 by	 extended	
infusions.	There	is	however	one	dichotomy	between	the	evidence	and	practice,	the	RCTs	have	almost	
exclusively	 investigating	piperacillin/tazobactam	and	meropenem	as	CI	but	100%	of	 the	CCUs	giving	
either	of	these	antibiotics	do	so	by	EII.		
Vancomycin	 is	 given	as	a	CI	on	approximately	50%	of	UK	CCUs	and	although	 there	are	only	2	RCTs	
investigating	its	administration	by	this	method	factors	other	than	just	efficacy	have	been	sited	for	its	
adoption.	 It	 is	 perceived	 to	 be	 easier	 to	manage	 and	 has	 been	 proven	 to	 have	 less	 nephrotoxicity	
when	administered	in	this	way.	
Future	 large	 studies	 and	 the	 availability	 of	 point-of-care	 TDM	 for	 more	 antibiotics	 will	 no	 doubt	
influence	the	long	term	uptake	of	extended	infusion	on	UK	CCUs.		
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Appendix	1:	Questionnaire	literature	search	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	 Medline	 (exp	"CRITICAL	CARE"/	AND	exp	"ANTI-
BACTERIAL	AGENTS"/)	AND	exp	"HEALTH	
CARE	SURVEYS"/	
10	
	
	
	
	
	 EMBASE	 (exp	"INTENSIVE	CARE"/	AND	exp	
"HEALTH	CARE	SURVEY"/)	AND	exp	
"ANTIBIOTIC	AGENT"/	
27	
	
	
	 CINAHL	 (exp	SURVEYS/	AND	exp	"CRITICAL	
CARE"/)	AND	exp	ANTIBIOTICS/	
8	
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Appendix	2:	Electronic	questionnaire	(screen	shots)	
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Appendix	3:	Participant	information	sheet	
	
					
	
	
Title	of	Project:	An	electronic	survey	of	hospital	pharmacists	to	ascertain	current	usual	antibiotic	
administration	practice	across	Critical	Care	Units	in	the	UK 
	
Name	of	Researcher:	Greg	Barton	BSc(hons)	MRPharmS,	Critical	Care/Burns	Specialist	Pharmacist,	
St	Helens	and	Knowsley	Teaching	Hospitals	NHS	Trust/PhD	student,	Liverpool	JMU	
	
Introduction	
You	are	being	 invited	to	take	part	 in	a	research	study.	Before	you	decide	 it	 is	 important	that	you	
understand	 why	 the	 research	 is	 being	 done	 and	 what	 it	 involves.	 Please	 take	 time	 to	 read	 the	
following	 information.	 Ask	 me	 if	 there	 is	 anything	 that	 is	 not	 clear	 or	 if	 you	 would	 like	 more	
information.	Take	time	to	decide	if	you	want	to	take	part	or	not.	
	
Why	is	the	study	being	done?	
There	 is	 growing	 interest	 in	 the	 use	 of	 novel	 methods	 of	 administration	 to	 improve	 existing	
antibiotics	 effectiveness	 in	 a	 time	 when	 very	 few	 new	 antibiotics	 are	 entering	 the	market.	 This	
study	is	being	undertaken	to	investigate	current	standard	antibiotic	administration	practices	across	
Critical	 Care	Units	 in	 the	UK.	 It	will	 investigate	 in	what	 areas,	 if	 any,	 non-standard	methods	 are	
being	used	and	why.	
	
Do	I	have	to	take	part?	
No.	It	is	up	to	you	to	decide	whether	or	not	to	take	part.	If	you	decide	not	to	take	part	in	the	study,	
your	 rights	will	 not	be	affected	 in	 any	way.	 Even	 if	 you	agree	 to	 take	part,	 you	 can	 change	your	
mind	at	any	 time	without	giving	any	reason.	The	 link	 to	 the	study	questionnaire	will	be	posted	3	
times	on	the	UKCPA	Critical	Care	Group	message	board.		
	
If	I	do	take	part,	what	will	I	have	to	do	and	what	will	be	done	to	me?	
Taking	part	 involves	completing	the	short	questionnaire	that	 follows	this	page;	this	questionnaire	
will	 take	approximately	10	minutes	 to	complete.	By	completing	and	 returning	 this	questionnaire,	
you	consent	to	participating	in	this	research	study	and	for	your	data	to	be	used	as	described	in	this	
information	sheet.	
	
What	are	the	risks	of	taking	part?	
There	are	no	identifiable	risks	to	taking	part	in	this	study.	
	
What	are	the	benefits	of	taking	part?	
The	benefits	are	not	personal	but	hopefully	this	study	will	provide	an	insight	into	current	practice	
and	 provide	 the	 critical	 care	 community	with	 a	 point	 of	 reference	 to	 base	 practice	 changes	 and	
future	studies	on.		
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Will	anyone	know	that	I’ve	taken	part?	
It	is	possible	that	you	could	be	identified	indirectly	through	some	of	the	information	provided	in	the	
questionnaire	but	this	information	will	only	be	accessed	by	the	principle	investigator,	Greg	Barton	
and	his	supervisory	team	at	Liverpool	John	Moores	University.	Data	from	individual	questionnaires	
will	be	published	in	a	way	that	the	respondent	cannot	be	identified.	
	
What	will	happen	to	the	results?	
The	results	of	this	study	will	feed	into	the	design	of	the	main	phase	of	my	PhD,	a	patient	outcome-
orientated	investigation	comparing	current	usual	practice	of	antibiotic	administration	in	the	UK	and	
extended	intermittent	infusions.	Available	results	will	be	presented	at	the	UKCPA	conference	or	the	
Critical	 Care	 Groups	 Advanced	 Practice	Masterclass	 and	 the	 final	 results	 published	 in	 a	 relevant	
critical	care/anaesthesia	journal.	All	data	published	will	be	anonymised.	The	data	collected	will	be	
held	indefinitely	at	least	until	the	publication	of	the	study.	
		
Who	should	I	contact	if	I	want	to	know	more	about	the	study?	
Email	 the	 Principle	 Investigator,	 Greg	 Barton,	 at	 g.barton@ljmu.ac.uk	 if	 you	 have	 any	 questions,	
concerns	or	comments.	
	
Who	should	I	contact	if	I	have	a	concern	about	the	study?	
If	 you	 are	 unhappy	 with	 the	 way	 in	 which	 this	 project	 has	 been	 conducted,	 or	 wish	 to	 raise	 a	
concern,	you	should	contact	my	director	of	studies	by	emailing	N.C.Henney@ljmu.ac.uk	or	writing	
to:	Neil	Henney,	School	of	Pharmacy	and	Biomolecular	Sciences,	Liverpool	John	Moores	University,	
James	Parsons	Building,	Byrom	Street,	Liverpool,	L3	3AF	
	
Version	
This	participant	information	sheet	was	last	updated:	24/9/13	
	
This	project	has	been	looked	at	and	approved	by	the	University	Research	Ethics	Committee	and	has	been	
assigned	the	reference	number	Insert	your	reference	number	(from	your	screening	email)	here	
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Appendix	4:	UKCPA	message	board	posts	(initial,	week	2	and	week	6)	
Initial:	
Dear	Colleague,				
I	would	be	most	grateful	if	you	would	complete	this	survey	on	antibiotic	administration	practice	in	the	
Critical	Care	setting.				
The	link	is:-			
www.BOS				
(you	may	have	to	copy	and	paste	it	if	it	does	not	work	automatically)				
On	the	opening	page	you	will	be	asked	some	simple	demographic	details	about	yourself	and	your	
Critical	Care	Unit	(ICU/HDU).	Information	about	the	grade	of	pharmacist	and	the	name	of	the	
hospital/unit	are	included	to	manage	duplication	of	responses	from	the	same	unit,	duplicate	
responses	will	be	removed	and	if	there	are	discrepancies	between	forms	from	the	same	unit	then	as	a	
default	the	most	senior	pharmacists	response	will	be	taken.	This	information	will	not	be	included	in	
any	publications.	All	other	information,	such	as	specialty	of	the	unit,	will	be	used	to	analyse	trends	in	
the	final	data.	If	you	don’t	know	the	answer	please	don’t	let	this	hinder	you	completing	the	rest	of	the	
survey,	choose	‘don’t	know’.				
If	you	do	not	wish	to	be	contacted	as	part	of	the	follow	up	of	none	responders,	please	contact	me	on	
the	following	email	address,	g.barton@ljmu.ac.uk				
If	you	work	in	a	Trust	with	more	than	one	ICU/HDU	that	have	different	standard	practices,	I	would	be	
most	grateful	if	you	would	complete	one	survey	per	unit.				
There	are	also	some	basic	workforce	questions	on	pharmacy	practice	which	or	may	or	may	not	
influence	prescribing	practice	in	the	intensive	care.				
The	survey	should	take	less	than	10	minutes	to	complete.				
Thank	you	all	so	much,	for	helping	me	undertake	this	research.	I	intend	to	present	the	results	at	a	
UKCPA	meeting	and	publish	in	a	peer	reviewed	journal.				
Should	you	require	information	or	feedback	then	please	do	not	hesitate	to	contact	me.				
Best	wishes,	
Greg	Barton,	
Critical	Care/Burns	specialist	pharmacist,	
St	Helens	and	Knowsley	Teaching	hospitals	NHS	Trust	
Liverpool	John	Moores	University 
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2	week	follow	up:	
Dear	All,				
Thank	you	so	much	to	all	of	you	who	have	completed	this	survey	on	antibiotic	administration	practice	
in	the	Critical	Care	setting.		
To	date	we	have	had	x	complete	replies	which	is	excellent.			For	the	results	to	be	valid,	we	really	need	
a	response	rate	of	above	70	%.	There	are	(approximately)	240	intensive	care	units	in	the	UK.			We	are	
therefore	looking	for	around	170	responses.	Ideally	more.				
Please	consider	completing	this	survey.	
The	link	is:-			
www.BOS				
(you	may	have	to	copy	and	paste	it	if	it	does	not	work	automatically)				
On	the	opening	page	you	will	be	asked	some	simple	demographic	details	about	yourself	and	your	
Critical	Care	Unit	(ICU/HDU).	Information	about	the	grade	of	pharmacist	and	the	name	of	the	
hospital/unit	are	included	to	manage	duplication	of	responses	from	the	same	unit,	duplicate	
responses	will	be	removed	and	if	there	are	discrepancies	between	forms	from	the	same	unit	then	as	a	
default	the	most	senior	pharmacists	response	will	be	taken.	This	information	will	not	be	included	in	
any	publications.	All	other	information,	such	as	specialty	of	the	unit,	will	be	used	to	analyse	trends	in	
the	final	data.	If	you	don’t	know	the	answer	please	don’t	let	this	hinder	you	completing	the	rest	of	the	
survey,	choose	‘don’t	know’.				
If	you	do	not	wish	to	be	contacted	as	part	of	the	follow	up	of	none	responders,	please	contact	me	on	
the	following	email	address,	g.barton@ljmu.ac.uk	
If	you	work	in	a	Trust	with	more	than	one	ICU/HDU	that	have	different	standard	practices,	I	would	be	
most	grateful	if	you	would	complete	one	survey	per	unit.				
There	are	also	some	basic	workforce	questions	on	pharmacy	practice	which	or	may	or	may	not	
influence	prescribing	practice	in	the	intensive	care.				
The	survey	should	take	less	than	10	minutes	to	complete.				
Thank	you	all	so	much,	for	helping	me	undertake	this	research.	I	intend	to	present	the	results	at	a	
UKCPA	meeting	and	publish	in	a	peer	reviewed	journal.				
	
Should	you	require	information	or	feedback	then	please	do	not	hesitate	to	contact	me.				
Best	wishes,	
Greg	Barton,	
Critical	Care/Burns	specialist	pharmacist,	
St	Helens	and	Knowsley	Teaching	hospitals	NHS	Trust	
Liverpool	John	Moores	University	
	
	
	 160	
6	week	follow	up:	
Dear	All,				
Thank	you	so	much	to	all	of	you	who	have	completed	this	survey	on	antibiotic	administration	practice	
in	the	Critical	Care	setting.		
For	the	record,	we	have	had	y	completed	surveys	to	date,	which	is	excellent.	For	those	of	you	who	
have	not	had	time	to	complete	yet.	There	is	still	time	left.	We	intend	to	keep	the	survey	open	for	at	
least	4	more	weeks.		
Please	complete,	the	results	to	date	are	very	interesting.	For	those	of	you	who	work	with	colleagues	
who	do	not	have	access	to	this	site,	we	would	be	most	grateful	if	you	could	pass	on.				
Please	consider	completing	this	survey.	
The	link	is:-		
www.BOS				
(you	may	have	to	copy	and	paste	it	if	it	does	not	work	automatically)				
On	the	opening	page	you	will	be	asked	some	simple	demographic	details	about	yourself	and	your	
Critical	Care	Unit	(ICU/HDU).	Information	about	the	grade	of	pharmacist	and	the	name	of	the	
hospital/unit	are	included	to	manage	duplication	of	responses	from	the	same	unit,	duplicate	
responses	will	be	removed	and	if	there	are	discrepancies	between	forms	from	the	same	unit	then	as	a	
default	the	most	senior	pharmacists	response	will	be	taken.	This	information	will	not	be	included	in	
any	publications.	All	other	information,	such	as	specialty	of	the	unit,	will	be	used	to	analyse	trends	in	
the	final	data.	If	you	don’t	know	the	answer	please	don’t	let	this	hinder	you	completing	the	rest	of	the	
survey,	choose	‘don’t	know’.				
If	you	do	not	wish	to	be	contacted	as	part	of	the	follow	up	of	none	responders,	please	contact	me	on	
the	following	email	address,	g.barton@ljmu.ac.uk	
If	you	work	in	a	Trust	with	more	than	one	ICU/HDU	that	have	different	standard	practices,	I	would	be	
most	grateful	if	you	would	complete	one	survey	per	unit.				
There	are	also	some	basic	workforce	questions	on	pharmacy	practice	which	or	may	or	may	not	
influence	prescribing	practice	in	the	intensive	care.				
The	survey	should	take	less	than	10	minutes	to	complete.				
Thank	you	all	so	much,	for	helping	me	undertake	this	research.	I	intend	to	present	the	results	at	a	
UKCPA	meeting	and	publish	in	a	peer-reviewed	journal.				
Should	you	require	information	or	feedback	then	please	do	not	hesitate	to	contact	me.				
Best	wishes,	
Greg	Barton,	
Critical	Care/Burns	specialist	pharmacist,	
St	Helens	and	Knowsley	Teaching	hospitals	NHS	Trust	
Liverpool	John	Moores	University		
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Appendix	5:	Initial	PROSPERO	entry	
	
	 	
PROSPERO International prospective register of systematic reviews 
Review title and timescale 
1 Review title 
Give the working title of the review. This must be in English. Ideally it should state succinctly the interventions or exposures 
being reviewed and the associated health or social problem being addressed in the review. 
Extended versus intermittent infusions of antibiotics for the treatment of patients with sepsis: A systematic review and meta-
analysis  
2 Original language title 
For reviews in languages other than English, this field should be used to enter the title in the language of the review. This will 
be displayed together with the English language title.  
English 
3 Anticipated or actual start date 
Give the date when the systematic review commenced, or is expected to commence. 
16/06/2016 
4 Anticipated completion date 
Give the date by which the review is expected to be completed. 
01/08/2017 
5 Stage of review at time of this submission 
Indicate the stage of progress of the review by ticking the relevant boxes. Reviews that have progressed beyond the point of 
completing data extraction at the time of initial registration are not eligible for inclusion in PROSPERO. This field should be 
updated when any amendments are made to a published record. 
  The review has not yet started  ×     
      
Review stage Started Completed  
Preliminary searches No Yes 
Piloting of the study selection process No Yes 
Formal screening of search results against eligibility criteria Yes Yes 
Data extraction Yes Yes 
Risk of bias (quality) assessment No Yes 
Data analysis No No 
 
  Provide any other relevant information about the stage of the review here. 
Review team details 
6 Named contact 
The named contact acts as the guarantor for the accuracy of the information presented in the register record. 
Greg Barton 
7 Named contact email 
Enter the electronic mail address of the named contact. 
g.barton@ljmu.ac.uk 
8 Named contact address 
Enter the full postal address for the named contact.  
pharmacy department, Whiston hospital, Warrington road, Prescot, L35 5DR 
9 Named contact phone number 
Enter the telephone number for the named contact, including international dialing code. 
00441514261600 
10 Organisational affiliation of the review 
Full title of the organisational affiliations for this review, and website address if available. This field may be completed as 
'None' if the review is not affiliated to any organisation. 
None 
Website address: 
11 Review team members and their organisational affiliations 
Give the title, first name and last name of all members of the team working directly on the review. Give the organisational 
affiliations of each member of the review team. 
  Title First name Last name Affiliation 
Mr Greg Barton Pharmacy department, St Helens and Knowsley 
Teaching Hospitals NHS Trust; School of Pharmacy 
and Biomolecular Sciences, Liverpool John Moores 
University 
Mr Michael Lloyd Pharmacy department, St Helens and Knowsley 
Teaching Hospitals NHS Trust 
 
12 Funding sources/sponsors 
Give details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, 
sponsoring and/or financing the review. Any unique identification numbers assigned to the review by the individuals or 
bodies listed should be included. 
None 
13 Conflicts of interest 
List any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic 
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14 Collaborators 
Give the name, affiliation and role of any individuals or organisations who are working on the review but who are not listed as 
review team members. 
  Title First name Last name Organisation details 
Professor Charles Morecroft School of Pharmacy and Biomolecular Sciences, 
Liverpool John Moores University 
Dr Neil Henney School of Pharmacy and Biomolecular Sciences, 
Liverpool John Moores University 
 
Review methods 
15 Review question(s) 
State the question(s) to be addressed / review objectives. Please complete a separate box for each question. 
To compare the clinical efficacy and safety of extended intravenous administration of antibiotics with standard intravenous 
administration practice in patients with a severe acute bacterial (presumed or proven) infection. 
16 Searches 
Give details of the sources to be searched, and any restrictions (e.g. language or publication period). The full search strategy 
is not required, but may be supplied as a link or attachment. 
The search will use the following terms in each data base as a starting point, (antibiotic OR antibacterial OR anti-infective 
OR beta lactam OR penicillin OR cephalosporin OR carbopenem OR glycopeptides OR vancomycin OR I could go on a bit 
here….) AND (intensive care OR critical care OR sepsis OR septic shock OR critical illness) AND (pharmacokinetic OR 
pharmacodynamics OR drug schedule OR intermittent OR interval OR continuous OR discontinuous) These terms will be 
searched in each database as they are and also matched to the thesaurus. Where appropriate the term will be exploded 
and/or astrixed to find all possibilities with the same root (e.g. antibiotic*) and/or hyphenated (e.g. anti-bacterial). Searches 
will not be restricted by limits applied to age, date or language. The search will utilise the following databases, Cochrane 
Central Register of Controlled Trials (The Cochrane Library), Medline, Embase. References from relevant papers will also be 
reviewed, as will the investigators own library. Expert opinion will be sort to identify other papers including those in press.  
17 URL to search strategy 
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to PROSPERO and we will store 
and link to it. 
 
I give permission for this file to be made publicly available 
No 
18 Condition or domain being studied 
Give a short description of the disease, condition or healthcare domain being studied. This could include health and 
wellbeing outcomes. 
Antibiotic management of sepsis  
19 Participants/population 
Give summary criteria for the participants or populations being studied by the review. The preferred format includes details of 
both inclusion and exclusion criteria. 
Inclusion: Male or non-pregnant females aged 18 years or over with a presumed or proven bacterial infection requiring 
intravenous antibiotics. Exclusion: Under 18 years of age and/or pregnancy  
20 Intervention(s), exposure(s) 
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed 
Treatment with antibiotics using an extended or continuous infusion as the method of administration.  
21 Comparator(s)/control 
Where relevant, give details of the alternatives against which the main subject/topic of the review will be compared (e.g. 
another intervention or a non-exposed control group). 
Compared to licensed intermittent infusions or bolus methods of antibiotic administration of the same antibiotic as the 
intervention arm. 
22 Types of study to be included 
Give details of the study designs to be included in the review. If there are no restrictions on the types of study design eligible 
for inclusion, this should be stated. 
Inclusion criteria: This systematic review and meta-analysis will include open label or blinded parallel group randomised 
controlled trials (RCTs). Exclusion criteria: Studies will be excluded from the systematic review based on the following 
conditions: all studies in humans under the age of 18, RCTs involving cross-over of participants, all non-RCTs (e.g. 
retrospective studies, commentaries, meeting abstracts, editorials, review articles and book chapters).  
23 Context 
Give summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria. 
24 Primary outcome(s) 
Give the most important outcomes. 
1) Clinical cure (any pre-defined criteria specific to the infection being studied that addresses signs and symptoms if 
infection) 2) Number of participants who experienced at least one serious adverse event (AE) (result in death, is life 
threatening, involved or prolonged hospitalisation, involved persistent or significant disability or incapacity, is another 
condition that investigators judge to represent significant harm/hazard) 
Give information on timing and effect measures, as appropriate. 
25 Secondary outcomes 
List any additional outcomes that will be addressed. If there are no secondary outcomes enter None. 
1) All cause mortality 2) Infection recurrence with 14 days of resolution of primary infection 3) Time to clinical cure (defined 
as the time from initiation of antibiotics to attainment of clinical cure) 4) Microbiological cure (any pre-defined criteria that 
assessed microbiological outcomes) 5) Secondary/super infection (a new infection with different organisms from those 
observed in the primary infection) 6) Number of participants withdrawing as a result of an AE 7) Number of participant with at 
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26 Data extraction (selection and coding) 
Give the procedure for selecting studies for the review and extracting data, including the number of researchers involved and 
how discrepancies will be resolved. List the data to be extracted. 
Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources (such as references 
and the investigators' personal library) with be screened by the primary investigator. A second investigator will review a 
randomly generated sample of 10% of titles and/or abstracts. The random list will be generated by listing all retrieved titles 
alphabetically and selecting every tenth paper for secondary review.The full texts of the potentially eligible studies will be 
retrieved and independently assessed for eligibility by both investigators. Any disagreement will be resolved through 
discussion (involving a third member of the team if necessary). A standardised form will be used to extract data from the 
included studies for assessment of study quality/risk of bias and evidence synthesis. Two investigators will extract the data 
independently and any discrepancies identified will be resolved through discussion (with a third member of the team if 
necessary). Missing data will NOT be requested from the study authors (only peer-reviewed published data will be included 
in the study). 
27 Risk of bias (quality) assessment 
State whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, and whether and 
how this will influence the planned synthesis. 
Two investigators will independently assess the risk of bias in included studies by using the Cochrane Collaboration's tool for 
assessing risk of bias in randomised trials (as described below): 1) Selection Bias i) Randomisation sequence generation: 
was the allocation sequence adequately generated? ii) Treatment allocation concealment: was the allocated treatment 
adequately concealed from study participants and clinicians and other healthcare or research staff at the enrolment stage? 
2) Performance Bias Blinding of participants and personnel: were the participants and researchers sufficiently blinded from 
knowledge of which intervention a participant received? 3) Detection Bias Blinding of outcome assessment: Where the 
researchers assessing outcomes and analysing data sufficiently blinded to the intervention allocation throughout the trial? 4) 
Attrition bias Incomplete outcome data: were participant exclusions, attrition and incomplete outcome data adequately 
addressed in the published report? 5) Reporting bias Selective outcome reporting: is there evidence of selective outcome 
reporting and might this have affected the study results? 6) Other sources of bias: was the trial apparently free of any other 
problems that could produce a high risk of bias? Disagreements between the investigators over the risk of bias in particular 
studies will be resolved by discussion, with involvement of a third member of the team where necessary. 
28 Strategy for data synthesis 
Give the planned general approach to be used, for example whether the data to be used will be aggregate or at the level of 
individual participants, and whether a quantitative or narrative (descriptive) synthesis is planned. Where appropriate a brief 
outline of analytic approach should be given. 
The Meta-analysis will be performed using Comprehensive Meta-Analysis (enter details here). Publication bias will be 
assessed by visual inspection of the funnel plot. Risk ratio with an associated 95% confidence interval using a random 
effects model will be used to measure treatment effect. Heterogeneity of included studies will be assess using  
29 Analysis of subgroups or subsets 
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid response if no subgroup 
analyses are planned. 
Any antibiotic for which there are 5 or more published RCTs 
Review general information 
30 Type and method of review 
Select the type of review and the review method from the drop down list. 
Meta-analysis, Systematic review 
Infections and infestations 
31 Language 
Select the language(s) in which the review is being written and will be made available, from the drop down list. Use the 
control key to select more than one language. 
English 
Will a summary/abstract be made available in English? 
Yes 
32 Country 
Select the country in which the review is being carried out from the drop down list. For multi-national collaborations select all 
the countries involved. Use the control key to select more than one country. 
England 
33 Other registration details 
Give the name of any organisation where the systematic review title or protocol is registered together with any unique 
identification number assigned. If extracted data will be stored and made available through a repository such as the 
Systematic Review Data Repository (SRDR), details and a link should be included here.  
34 Reference and/or URL for published protocol 
Give the citation for the published protocol, if there is one. 
Give the link to the published protocol, if there is one. This may be to an external site or to a protocol deposited with CRD in 
pdf format. 
 
I give permission for this file to be made publicly available 
Yes 
35 Dissemination plans 
Give brief details of plans for communicating essential messages from the review to the appropriate audiences. 
intend to publish in a peer-reviewed journal widely read within critical care.  
Do you intend to publish the review on completion? 
Yes 
36 Keywords 
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37 Details of any existing review of the same topic by the same authors 
Give details of earlier versions of the systematic review if an update of an existing review is being 
registered, including full bibliographic reference if possible. 
38 Current review status 
Review status should be updated when the review is completed and when it is published. 
Ongoing 
39 Any additional information 
Provide any further information the review team consider relevant to the registration of the review. 
40 Details of final report/publication(s) 
This field should be left empty until details of the completed review are available.  
Give the full citation for the final report or publication of the systematic review. 
Give the URL where available. 
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Appendix	6:	Systematic	review	search	strategies	and	results	
Evidence Services | library.nhs.uk 
Medline:	
 
1. Medline; exp ANTI-INFECTIVE AGENTS/; 1651437 results. 
2. Medline; exp ANTI-BACTERIAL AGENTS/; 609040 results. 
3. Medline; (anti-infect* OR antiinfect* OR anti-bact* OR antibact* OR anti-biot OR antibiot OR 
anti-microbi* OR antimicrobi*).ti,ab; 157538 results. 
4. Medline; exp BETA-LACTAMS/; 116390 results. 
5. Medline; (beta-lactam* OR betalactam* OR (ß lactam*) OR B-lactam OR (B lactam*) OR ß-
lactam* OR (beta lactam)).ti,ab; 29353 results. 
6. Medline; exp GLYCOPEPTIDES/; 54743 results. 
7. Medline; exp AMINOGLYCOSIDES/; 138154 results. 
8. Medline; 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7; 23 results. 
9. Medline; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7; 1802624 results. 
10. Medline; exp ADMINISTRATION, INTRAVENOUS/; 130657 results. 
11. Medline; (infusion* OR injection* OR intravenous* OR drip*).ti,ab; 862210 results. 
12. Medline; 10 OR 11; 903387 results. 
13. Medline; 9 AND 12; 134917 results. 
14. Medline; exp BACTERIAL INFECTIONS/ OR exp SEPSIS/; 858167 results. 
15. Medline; exp CARDIOVASCULAR INFECTIONS/ OR exp CATHETER-RELATED 
INFECTIONS/ OR exp INTRAABDOMINAL INFECTIONS/ OR exp RESPIRATORY TRACT 
INFECTIONS/ OR exp SOFT TISSUE INFECTIONS/ OR exp URINARY TRACT 
INFECTIONS/ OR exp WOUND INFECTION/; 483375 results. 
16. Medline; infect*.ti,ab; 1358989 results. 
17. Medline; CRITICAL ILLNESS/; 19880 results. 
18. Medline; (critical AND illness).ti,ab; 10190 results. 
19. Medline; 14 OR 15 OR 16 OR 17 OR 18; 2146996 results. 
21. Medline; PHARMACOKINETICS/; 259435 results. 
22. Medline; exp DRUG ADMINISTRATION SCHEDULE/; 90822 results. 
23. Medline; (continuous* OR intermittent* OR discontinuous* OR bolus* OR interval*).ti,ab; 
1007265 results. 
24. Medline; 21 OR 22 OR 23; 1308849 results. 
25. Medline; 20 AND 24; 8028 results. 
26. Medline; randomised AND controlled AND trial.pt; 416907 results. 
27. Medline; controlled AND clinical AND trial.pt.; 402788 results. 
28. Medline; randomized.ab.; 410610 results. 
29. Medline; placebo.ab.; 168451 results. 
30. Medline; drug AND therapy.fs.; 1967548 results. 
31. Medline; randomly.ab; 247239 results. 
32. Medline; trial.ab.; 344942 results. 
33. Medline; groups.ab.; 1536018 results. 
34. Medline; 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33; 3817721 results. 
35. Medline; exp ANIMALS/ NOT humans.sh.; 4221082 results. 
36. Medline; 34 NOT 35; 3288156 results. 
37. Medline; 25 AND 36; 5138 results. 
38. Medline; 37 [Limit to: (Age group Young Adult or Adult or Middle aged or Aged or Aged, 
80 and over)]; 3084 results. 
 
Embase:	
	
137. EMBASE; exp ANTIINFECTIVE AGENT/ OR exp ANTIBIOTIC AGENT/; 0 results. 
138. EMBASE; exp ANTIINFECTIVE AGENT/; 0 results. 
139. EMBASE; (anti-infect* OR antiinfect* OR anti-bact* OR antibact* OR anti-biot OR antibiot 
OR anti-microbi* OR antimicrobi*).ti,ab; 207524 results. 
140. EMBASE; (beta-lactam* OR betalactam* OR (ß lactam*) OR B-lactam OR (B lactam*) 
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OR ß-lactam* OR (beta lactam)).ti,ab; 44207 results. 
141. EMBASE; (glycopeptide OR vancomycin).ti,ab; 32901 results. 
142. EMBASE; aminoglycoside*.ti,ab; 18770 results. 
143. EMBASE; (glycopeptide* OR vancomycin).ti,ab; 36565 results. 
144. EMBASE; 138 OR 139 OR 140 OR 142 OR 143; 2520517 results. 
145. EMBASE; exp INTRAVENOUS DRUG ADMINISTRATION/; 313831 results. 
145. EMBASE; exp INTRAVENOUS DRUG ADMINISTRATION/; 313831 results. 
146. EMBASE; (infusion* OR injection* OR intravenous* OR drip*).ti,ab; 1050739 results. 
147. EMBASE; 145 OR 146; 1238934 results. 
148. EMBASE; exp INFECTION/; 2810888 results. 
149. EMBASE; exp SEPSIS/; 195449 results. 
150. EMBASE; CRITICAL ILLNESS/; 24067 results. 
151. EMBASE; infect*.ti,ab; 1644492 results. 
152. EMBASE; ((critical illness)).ti,ab; 15685 results. 
153. EMBASE; 148 OR 149 OR 150 OR 151 OR 152; 3302485 results. 
154. EMBASE; 147 AND 153; 182558 results. 
155. EMBASE; PHARMACOKINETICS/; 114592 results. 
156. EMBASE; PHARMACODYNAMICS/; 22406 results. 
157. EMBASE; exp DRUG INFUSION/; 13797 results. 
158. EMBASE; (continuous* OR intermittent* OR discontinuous* OR bolus* OR 
interval*).ti,ab; 1232809 results. 159. EMBASE; 155 OR 156 OR 157 OR 158; 1362270 
results. 
160. EMBASE; 154 AND 159; 25883 results. 
161. EMBASE; (random* OR factorial* OR crossover* OR cross AND over* OR cross-over* 
OR placebo* OR doubl* ADJ blind* OR singl* ADJ blind* OR assign* OR allocate* OR 
volunteer*).ti,ab; 553198 results. 
162. EMBASE; exp RANDOMIZED CONTROLLED TRIAL/; 405905 results. 
163. EMBASE; 161 OR 162; 854501 results. 
164. EMBASE; 160 AND 163; 3261 results. 
165. EMBASE; 164 [Limit to: Human]; 2975 results. 
166. EMBASE; 165 [Limit to: Human and (Human Age Groups Adult 18 to 64 years or Aged 
65+ years)]; 2069 results. 
	
	
	
	
	
	
	
	
	
	
	
	
Appendix	7:	Definitions	of	low,	high	and	unclear	risk	of	bias	for	each	category	Sequence	generation	(selection	bias)	 Was	sequence	generation	adequate?	 Low	risk	 Random	sequence	generation	is	described	(for	example	by	computer	generation	or	random	number	tables)	High	risk	 Sequence	generation	is	in	part	or	completely	non-randomised	(for	example	patients	allocated	by	clinician	or	order	of	admission	into	the	study)	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Allocation	concealment	(selection	bias)	
Was	allocation	concealment	adequate?	 Low	risk	 Neither	patients	nor	enrolling	investigators	could	predict	assignment	(e.g.	opaque	sealed	envelopes,	off-site	randomisation)	High	risk	 Either	patients	and	or	enrolling	investigators	could	predict	assignment	(e.g.	unsealed	envelopes,	alternation,	allocation	by	patient	identifier	e.g.	hospital/NHS	number)	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Blinding	of	participants	and	personnel	(performance	bias)	
Was	blinding	of	participants	and	personnel	adequate?	 Low	risk	 Blinding	of	patients	and	key	study	personnel	stated	and	appears	to	be	robust	High	risk	 No	or	incomplete	blinding,	or	blinding	attempted	but	likely	to	have	been	broken	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias		 	 	 	
	 168	
Blinding	of	outcome	assessment	(detection	bias)	
Was	blinding	of	outcome	assessors	adequate?	 Low	risk	 Blinding	of	outcome	assessors	stated	and	appears	to	be	robust	High	risk	 No	or	incomplete	blinding,	or	blinding	attempted	but	likely	to	have	been	broken	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Incomplete	outcome	data	(attrition	bias)	
Was	incomplete	outcome	data	adequately	addressed?	
Low	risk	 Any	of	the	following,	
• No	missing	outcome	data		
• Reasons	for	missing	outcome	data	unlikely	to	be	related	to	true	outcome		
• Missing	outcome	data	balanced	in	numbers	across	intervention	groups,	with	similar	reasons	for	missing	data	across	groups.	
• For	dichotomous	outcomes	data,	the	proportion	of	missing	outcomes	compared	with	observed	event	risk	not	enough	to	have	a	clinically	relevant	impact	on	the	intervention	effect	estimate	
• Appropriate	method	used	for	imputing	missing	data	High	risk	 Any	of	the	following,	
• Reason	for	missing	outcome	data	likely	to	be	related	to	true	outcome,	with	imbalance	in	numbers	of	or	reasons	for	missing	data	across	intervention	groups	
• For	dichotomous	outcome	data,	the	proportion	of	missing	outcomes	compared	with	observed	event	risk	enough	to	induce	clinically	relevant	bias	in	intervention	effect	estimate	
• ’As-treated’	analysis	done	with	substantial	departure	of	the	intervention	received	from	that	assigned	at	randomisation	
• Potentially	inappropriate	application	of	simple	imputation.	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	
	 169	
Selective	reporting	(reporting	bias)	 Are	reports	free	of	selective	outcome	reporting?	 Low	risk	 All	outcomes	stated	a	priori	that	are	of	interest	in	the	review	have	been	reported	in	the	pre-specified	way	High	risk	 Any	of	the	following:		
• Not	all	outcomes	of	the	study	stated	a	priori	have	been	reported	
• One	or	more	of	the	outcomes	are	reported	using	measurements,	analysis	methods,	or	subsets	of	the	data	that	were	not	pre-specified	
• One	or	more	reported	outcome	was	not	stated	a	priori	without	clear	justification	for	their	reporting	is	provided,	such	as	an	unexpected	adverse	effect	
• One	or	more	outcomes	of	interest	in	the	review	are	reported	incompletely,	incorrectly	or	ambiguously	as	so	cannot	be	entered	in	the	meta-analysis	
• Study	report	fails	to	include	results	for	a	key	outcome	that	would	be	expected	to	have	been	reported	for	such	a	study	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Other	bias	 Was	study	free	from	other	potential	sources	of	bias	not		covered	elsewhere	
Low	risk	 Study	appears	to	be	free	from	other	sources	of	bias	including	funding	sources,	conflicts	of	interest,	use	of	open	label	antibiotics,	noticeable	differences	in	baseline	demographics	between	study	groups	such	as	age,	severity	of	illness	High	risk	 One	or	more	important	factor	providing	a	risk	of	bias	such	as	industry	funding,	notable	conflicts	of	interest,	lack	of	clarity	around	open	label	antibiotic	use,		noticeable	differences	in	baseline	demographics	between	study	groups	such	as	age,	severity	of	illness	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	
Appendix	8:	Individual	bias	assessments	of	each	of	the	included	articles	
	
	
	
Abdul-Aziz	2016	 Beta-Lactam	Infusion	in	Severe	Sepsis	(BLISS):	a	prospective,	two-centre,	open-labelled	
randomised	controlled	trial	of	continuous	versus	intermittent	beta-lactam	infusion	in	
critically	ill	patients	with	severe	sepsis	
	
Method	 Prospective,	two-centre,	open-labelled	randomised	controlled	trial	
Participants	 140	ICU	patients	(males	66%	intervention	group,	71%	control,	age	range	41-68;	average	54	years	old	
intervention	group,	56	control)	were	eligible	for	inclusion	after	meeting	the	following	criteria:	(1)	
adult	(C18	years);	(2)	developed	severe	sepsis	(defined	as	presumed	or	confirmed	infection	with	new	
organ	dysfunction)	[24]	in	the	previous	48	h;	(3)	indication	for	cefepime,	meropenem	or	
piperacillin/tazobactam	with	\24	h	therapy	at	time	of	assessment;	and	(4)	expected	ICU	stay	greater	
than	48	h.	Patients	were	excluded	if	they	(1)	were	receiving	renal	replacement	therapy	(RRT);	(2)	had	
impaired	hepatic	function	(defined	as	total	bilirubin[100	mmol/mL);	(3)	were	receiving	palliative	
treatment;	(4)	had	inadequate	central	venous	catheter	access;	or	(5)	death	was	deemed	imminent.	
Interventions	 Participants	currently	receiving,	or	about	to	receive,	cefepime,	meropenem	or	
piperacillin/tazobactam	were	randomly	allocated	to	either	a	CI	(intervention	arm)	or	IB	(control	arm)	
treatment	arm.	Each	antibiotic	dose	was	prepared	by	an	on-duty,	unblinded	ICU	pharmacist	in	
accordance	with	standard	pharmacy	practice.	The	dosing	regimen	was	determined	by	the	treating	
intensivist,	with	guidance	from	a	local	dosing	protocol.	To	ensure	early	achievement	of	therapeutic	
beta-lactam	exposures	in	the	intervention	arm,	a	single	loading	dose	infused	over	30	min	was	given	at	
initiation	of	antibiotic	therapy	meaning	that	the	continuous	infusion	group	received	a	larger	antibiotic	
dose	on	day	1	post-randomisation	compared	to	those	in	the	control	arm.	The	study	antibiotic	was	
administered	until	(1)	the	treating	intensivist	decided	to	cease	the	drug;	(2)	the	participant	withdrew	
from	the	study;	(3)	ICU	discharge;	or	(4)	ICU	death.	All	subsequent	patient	management	including	
addition	of	other	antibiotics	and	non-study	drugs	was	at	the	treating	intensivist’s	discretion.	
Outcomes	 The	primary	endpoint	investigated	in	this	study	was	clinical	cure	at	14	days	after	antibiotic	cessation.	
Clinical	outcome	was	rated	as	either	(1)	resolution:	complete	disappearance	of	all	signs	and	
symptoms	related	to	infection;	(2)	improvement:	a	marked	or	moderate	reduction	in	disease	severity	
and/or	number	of	signs	and	symptoms	related	to	infection;	or	(3)	failure:	insufficient	lessening	of	the	
signs	and	symptoms	of	infection	to	qualify	as	improvement,	death	or	indeterminate	for	any	reason.	
Clinical	cure	was	scored	as	a	‘‘Yes’’	for	resolution	and	a	‘‘No’’	for	all	other	findings	(i.e.	sum	of	2	and	3	
above).	Secondary	endpoints	investigated	in	this	study	include	(1)	PK/PD	target	attainment;	(2)	ICU-
free	days	at	day	28;	(3)	ventilator-free	days	at	day	28;	(4)	survival	at	day	14;	(5)	survival	at	day	30;	(6)	
time	to	white	cell	count	(WCC)	normalisation	
Notes	 sample	size	calculation	suggested	120,	enrolled	140	to	allow	for	drop	out	and	ended	with	126	getting	
>3days	of	drug.	Both	groups	very	similar	in	terms	of	sex,	age,	sickness	severity,	etc.	main	reason	for	
drop	out	was	need	for	RRT	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	 Low	risk	
"Randomisation	was	performed	using	a	computer	program	
(http://www.randomization.com)	based	on	blocks	of	four	with	an	
allocation	ratio	of	1:1	stratified	by	participating	sites"	
Allocation	concealment	(selection	
bias)	 Low	risk	
"Opening	sequentially	numbered	opaque,	sealed	and	stapled	
envelopes"	"tamper	evident	envelopes"	
Blinding	of	participants	and	
researchers	(performance	bias)	 High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	 High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	
No	patients	were	lost	to	follow	up.	Analysis	was	performed	primarily	
on	an	ITT	basis	and	then	a	mITT	including	all	patients	that	received	at	
least	one	dose	of	antibiotics.	Per-protocol	analysis	was	performed	on	
all	patients	receiving	>3day	antibiotics.	Sample	size	calculation	
required	120	participants	and	140	were	randomised	to	allow	for	drop	
out.	126	received	>3days	antibiotics	therefore	sample	size	was	
adequate		
Selective	reporting	(reporting	bias)	
Low	risk	 All	pre-specified	primary	and	secondary	outcomes	were	reported	
Other	bias	
Low	risk	 No	conflicts	of	interest	or	funding	issues	of	note.	Open	label	antibiotic	use	clear	documented		
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Adembri	2008	 Linezolid	pharmacokinetic/pharmacodynamic	profile	in	critically	ill	septic	patients:	
intermittent	versus	continuous	infusion	
	
Method	 Prospective,	open-label,	randomised	controlled	trial	
Participants	 18	Septic	ICU	patients	with	a	microbiologically	documented	infection	caused	by	either	glycopeptide-
resistant	or	glycopeptide-sensitive	Gram-positive	strains	but	with	no	clinical	improvement	after	5	
days	of	glycopeptide	therapy	were	considered	eligible	for	enrolment	in	the	study.Exclusion	criteria	
were	the	following:	age	<18	years;pregnancy;	previous	knownallergic	reaction	to	linezolid;	creatinine	
clearance	<40	mL/min;	platelet	count	<80	000;	and	the	simultaneous	administration	of	other	drugs	
(such	as	erythromycin)	capable	of	interfering	with	the	linezolid	assay	
Interventions	 Group	I	(n=9)	received	linezolid	as	a	30-min	intermittent	intravenous	(i.v.)	administration	(600mg	
q12h);	and	Group	C(n=9)	received	linezolid	as	300mg	i.v.	loading	dose	(given	in	30	min)+900mg	
continuous	infusion	on	Day	1,	followed	by	continuous	infusion	of	1200	mg/daily.	Mean	duraction	of	
therapy	10	dyas	(7-15	days)	
Outcomes	 Global	response	(clinical	success/failure),	Microbiological	efficacy	(eradication	vs	failure	where	culture	
were	available)	
Notes	 69%	male,	mean	age	range	57-64	years	old,	no	significant	physiological	differences	between	groups.	
One	patient	died	before	completing	serum	sample	collection	and	one	was	excluded	because	he	
developed	renal	failure	with	ClCR	<40	mL/min	during	the	sampling	period.	Clinical	success	included	
resolution	AND	IMPROVEMENT,	failure	was	persistance	or	new	infection		
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 "By	closed	envolope	method"	but	opacity	of	envolope	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 18	patients	enrolled.	None	lost	to	follow	up	but	2	excluded	-	one	died	
before	completing	sample	collection	and	one	developed	renal	failure	
(CrCl	<40mL/min)	during	sample	collection.		
Selective	reporting	(reporting	bias)	 Low	risk	 All	prespecified	outcomes	were	reported	
Other	bias	 Unclear	risk	 Open	label	antibiotics	with	similar	antibacterial	cover	permitted	but	
numbers	not	reported		
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Angus	2000	 Pharmacokinetic-pharmacodynamic	evaluation	of	ceftazidime	continuous	infusion	vs	
intermittent	bolus	injection	in	septicaemic	melioidosis	
	
Method	 Prospective,	single	centred,	randomised	controlled	trial	
Participants	 34	patients	with	clinically	suspected	septicaemic	melioidosis	(age	range	18	to	73,	47%	male,	average	
body	weight	49kg	(35-75kg)).	"Pregnant	women,	patients	who	had	already	received	effective	
antimicrobial	therapy	and	those	with	known	hypersensitivity	to	beta-lactam	antibiotics	were	
excluded"			
Interventions	 Patients	were	randomised	to	receive	ceftazidime	120mg/kg/day	in	0.9%	NaCl	by	either	continuous	
infusion	or	bolus	injection	for	10	days	
Outcomes	 Not	clearly	stated	but	"…	study	of	the	pharmacokinetics	and	in	vivo	bacterial	killing	rates….."	
Notes	 A	typical	50kg	patient	received	6g/day	in	the	continuous	infusion	group	vs	5.4g	on	day	one	then	
4.8g/day	in	the	bolus	group.	Average	APACHE	II	score	21	in	bolus	group	but	15	in	infusion	group	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	 Patients	were	randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 34	patients	enrolled,	data	from	21	suitable	for	pharmacokinetic	
analysis	(8	patients	from	the	infusion	and	5	from	the	bolus	groups	
excluded).	Of	these	21,	15	had	septic	melioidosis,	5	had	non-septic	
melioidosis	and	7	didn't	have	melioidosis	(numbers	not	consistant).	
Stated	mortality	not	consistant	between	text	and	table	1.	11	of	the	13	
excluded	patients	died	but	it	is	not	stated	which	group	(infusion	vs	
bolus)	these	patients	where	in.		
Selective	reporting	(reporting	bias)	 High	risk	 Outcomes	not	clearly	stated	in	the	paper.	In	the	discussion	the	authors	
state	that	"the	objective	of	this	study	was	to	devise	the	optimum	cost-
effectiveness	intraveneous	regimen	for	ceftazidime	administration…..".	
Authors	also	state	"the	original	objective	of	the	study	to	compare	
bacterial	clearance	rates	between	the	two	regemins	could	not	be	
fulfilled....."	
Other	bias	 High	risk	 groups	not	well	matched,	bolus	group	appeared	to	be	more	unwell	at	
enrollment	(APACHE	score	21	vs	15,	CrCl	(mL/min)	23	vs	38).	Patients	
received	considerably	different	doses	between	the	groups		
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Bodey	1979	 A	randomized	study	of	carbenicillin	plus	cefamandole	or	tobramycin	in	the	treatment	of	
febrile	episodes	in	cancer	patients	
	
Method	 Prospective,	single	centre,	randomised	controlled	trial	
Participants	 Patients	with	malignancy	who	were	neutropenic	and	had	a	fever	associated	with	a	proven	or	
suspected	bacterial	infection	was	eligible	for	inclusion.	490	febrile	episodes	(number	of	patients	not	
stated)	were	entered	into	the	study.	Final	analysis	was	carried	out	on	235	documented	infections	in	
204	patients	(56%	male,	42%	>	50years	old).	Some	afebrile	but	proven	infection	episodes	were	
included	as	were	some	non-neutropenic	episodes	(were	patients	were	expected	to	develop	
neutropenia).	Patients	with	penicillin	allergy	or	whose	fever	was	considered	to	be	from	a	non-
infective	cause	(e.g.	recent	blood	transfusion)	were	considered	ineligible.		
Interventions	 Patients	received	carbenicillin	(5g	over	2	hours	every	4	hours)	plus	one	of	the	following	three	
regimens.	Either	cefamandole	as	an	intermittent	infusion	(3g	over	30	minutes	every	6	hours),	a	
continuous	infusion	(12g	over	24	hours),	or	tobramycin	(loading	dose	of	90mg/m2	over	30	minutes	
followed	immediately	a	continuous	infusion	of	360mg/m2/24hours)	
Outcomes	 Predefined	outcomes	were	"cure",	"relapse"	and	"super-infection"	
Notes	 Outcomes	expressed	by	episode	not	patient	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 Sequence	generated	from	random	number	tables	
Allocation	concealment	(selection	
bias)	
Unclear	 Sealed	envolope	but	opacity	of	envolope	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 Of	the	490	febrile	episodes	only	450/460	(contradiction	in	the	paper	so	
unclear)	could	be	evaluated.	234	febrile	episodes	couldn't	be	
demonstrated	as	being	caused	by	infection	and	so	were	excluded	from	
further	analysis.	216	febrile	episodes	(235	infections,	19	patients	had	2	
simultaneous	infections)	were	assessed.	10	patients	had	2	epidoes	and	
1	had	3.	Participants	receiving	less	than	12	hours	of	antibiotics	were	
excluded	from	evaluation	
Selective	reporting	(reporting	bias)	 High	risk	 Reported	on	all	predefined	outcomes	and	some	extra	(e.g.	respose	by	
organism)	but	on	approximately	half	of	the	enrolled	episodes	(235	
infections	out	of	460	episodes	receiving	antibiotics)	
Other	bias	 Unclear	risk	 Funding	and	declarations	of	interest	not	stated.	Cefamandole	supplied	
by	Eli	Lilly	&Co		
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Buck	2005	 Pharmacokinetics	of	piperacillin-tazobactam:	Intermittent	dosing	versus	continuous	
infusion	
	
Method	 Prospective,	single	centre,	open-labelled	randomised	clinical	observational	trial	
Participants	 24	patients	(17	male,	age	32-76)	with	community	or	hospital-aquired	infections	were	enrolled	
(specifically	(late	onset)	hospital-	acquired	pneumonia,	severe	community-acquired	pneumonia,	
severe	urinary	tract	infection,	cholangitis	in	patients	with	risk	factors,	complicated	peritonitis,	
patients	at	risk	with	fever	of	unknown	origin).	Exclusion	criteria	were	lack	of	informed	consent,	
pregnancy	or	lactation	in	women,	known	hypersensitivity	or	intolerance	to	piperacillin–tazobactam,	
and	epilepsy	
Interventions	 Fixed	combination	of	4	g	piperacillin	and	0.5	g	tazobactam	every	8	h	by	intravenous	intermittent	
bolus	injection	versus	fixed	combination	of	2	g	piperacillin	and	0.5	g	tazobactam	loading	dose	by	
bolus	injection	over	1	h	followed	by	8	g	piperacillin	and	1	g	tazobactam	by	constant	rate	infusion	over	
23	h	(day	1)	and	24	h	from	day	2.	Dose	was	adjusted	in	patients	with	impaired	renal	function	
Outcomes	 pharmacokinetic	(serum	concentration	time	profiles).	Clinical	or	bacteriological	success	(based	on	
clinical	evaluation)	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	 Unclear	
patients	randomised	to	therapy	arms	but	method	of	randomisation	not	
stated	
Allocation	concealment	(selection	
bias)	 Unclear	 Randomised	by	envelope	but	opacity	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	 High	risk	 Open	label,	not	blinded	
Blinding	of	outcome	assessment	
(detection	bias)	 High	risk	 Open	label,	not	blinded	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 All	patients	enrolled	in	the	study	included	in	the	results	
Selective	reporting	(reporting	bias)	
Unclear	risk	
Clinical	and	bacteriological	success	was	not	a	primary	objective	and	not	
statistically	assessed	in	the	results	"groups	were	comparable".	
Reported	all	pre-stated	outcomes	
Other	bias	
Unclear	risk	 Study	sponsored	by	grants	from	Wyeth	Lederle.	Other	antibiotics	and	renal	replacement	therapy	were	alllowed.		
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Chytra	2012	 Clinical	and	microbiological	efficacy	of	continuous	versus	intermittent	application	of	
meropenem	in	critically	ill	patients:	a	randomized	open-label	controlled	trial	
	
Method	 Prospective,	single	centre,	open	label,	randomised	trial	
Participants	 240	patients	(males	65%	in	the	CI	group	and	69.2%	in	the	control	group,	average	age	44.9	in	the	CI	
group	and	47.2	in	the	control	group)	"who	suffered,	at	admission	or	during	the	ICU	stay,	from	severe	
infection	and	received	meropenem	with	predicted	duration	of	treatment	for	at	least	four	days	were	
considered	for	inclusion",	all	enrolled	patients	fulfilled	the	criteria	of	sepsis.	Exclusion	criteria	
included	<18	years	old,	pregnancy,	acute	or	chronic	renal	failure	and	hypesensitivity/allergy	to	
meropenem		
Interventions	 Infusion	group	received	a	loading	dose	of	2	g	of	meropenem	over	30	minutes	followed	immediately	
by	continuous	infusion	of	4	g	of	meropenem	over	24	hours.	Bolus	group	received	2	g	of	meropenem	
over	30	minutes	every	8	hours.	
Outcomes	 Primary	outcome	measures	-	clinical	and	microbiological	efficacy.	Secondary	outcomes	-	meropenem-
related	length	of	mechanical	ventilation,	meropenem-related	length	of	ICU	and	hospital	stay,	ICU	and	
in-hospital	mortality,	duration	of	meropenem	treatment,	the	total	dose	of	meropenem	and	the	safety	
of	both	dosing	regimens.	
Notes	 Funded	by	Czech	Ministry	of	Education	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 no	mention	of	sequence	generation,	see	below	
Allocation	concealment	(selection	
bias)	
Low	risk	 "randomized	using	sealed	opaque	envelopes	in	one-to-one	proportion	
without	stratification"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Of	the	240	patients	enrolled	only	198	made	final	analysis.	None	where	
lost	to	follow	up	and	reasons	were	stated	for	other	exclusions	-	3	
patients	died	within	4	days,	antibiotic	therapy	was	de-
escalated/terminated	in	21	and	2	patients	were	transferred	to	other	
hospitals		
Selective	reporting	(reporting	bias)	 Low	risk	 All	pre-specified	outcomes	were	reported	
Other	bias	 Low	risk	 approximately	50%	of	patients	in	each	group	received	concomitant	
antibiotic	therapy	but	use	clearly	documented	and	the	groups	were	
evenly	matched.	No	conflicts	of	interest	or	industry	funding		
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Cotrina-Luque	2015	
Continuous	versus	intermittent	piperacillin/tazobactam	infusion	in	infection	due	to	or	
suspected	pseudomonas	aeruginosa	
	
Method	 Prospective,	multi	centre,	double	blinded,	randomised	trial	
Participants	 78	patients	(out	of	400	patients	"initially	contemplated	theoretically	for	enrolment",	average	age	64	
years	old,	male	59%)	with	"complicated"	or	nosocomial	infection	due	to	suspected	or	proven	P.	
aeruginosa	infection.	Aged	18	or	over,	40kg	or	over	and	consent.	The	exclusion	criteria	were:	more	
than	one	prior	piperacillin–tazobactam	dose	administered	before	being	enrolled;	potential	death	
within	72	h	after	enrollment;	a	declaration	that	the	patient	could	not	be	resuscitated;	central	nervous	
system	disease;	pneumonia	requiring	mechanical	ventilation;	neutrophil	count	<500	cel/	mL;	
suspected	infection	by	Acinetobacter	baumannii	or	extended-spectrum	beta	lactamase	(ESBL)-
producing	Enterobacteriaceae;	cystic	fibrosis;	a	need	for	haemodialysis,	peritoneal	dialysis,	
hemoperfusion,	or	plasmapheresis;	state	of	shock	(systolic	arterial	pressure	<90	mmHg	for	>2	h);	
evidence	of	hypoperfusion	despite	adequate	fluid	support;	high-dose	sympathomimetic	treatment	
(e.g.,	noradrenaline	>1	mcg/Kg/h);	or	creatinine	clearance	<20	mL/	min	
Interventions	 CI	group	were	given	an	initial	loading	dose	of	piperacillin–tazobactam	2/0.25	g	over	30	min.,	
immediately	followed	by	continuous	infusion	of	piperacillin–tazobactam	8/1	g	over	24	h	plus	100	mL	
of	placebo	(saline	solution)	given	for	30	min	every	8	h.	The	II	group	received	an	initial	loading	dose	of	
piperacillin–tazobactam	4/0.5	g	by	continuous	infusion	of	placebo	(saline	solution)	plus	piperacillin–
tazobactam	4/0.5	g	in	100	mL	of	saline	for	30	min	every	8	h.	The	maximum	duration	of	treatment	in	
both	groups	was	14	days,	which	could	be	shortened	depending	on	the	patient’s	condition	
Outcomes	 The	primary	efficacy	endpoint	was	the	percentage	of	patients	having	a	satisfactory	clinical	response	
at	completion	of	treatment,	defined	as	clinical	cure	(complete	resolution	of	the	clinical	signs	and	
symptoms	of	infection)	or	clinical	improvement	(resolution	or	reduction	of	most	clinical	signs	and	
symptoms).	The	secondary	efficacy	endpoints	were	microbiological	response	at	completion	of	
treatment;	microbiological	response	at	3	days	after	starting	treatment;	time	to	microbiological	cure;	
clinical	response	at	3	days	after	starting	treatment;	time	to	defervescence;	percentage	of	patients	
who	were	switched	to	sequential	oral	therapy;	antibiotic-free	period	
Notes	 Of	the	11	participating	hospitals	5	enrolled	at	least	1	patient	but	83	of	the	final	sample	came	from	1	
centre.	Funded	by	the	Ministry	of	Health	and	Social	Policy	of	Spain	with	no	commercial	interest.	
Patients	were	followed	up	until	death	or	60	days	after	start	of	treatment.	400	patient	(200	in	each	
arm)	were	required	to	show	a	difference	in	14	day	survival	but	only	78	patients	were	randomised.	
Lower	total	daily	dose	in	the	CI	group		(9g	vs	13.5g).	Data	in	Table	3	doesn't	add	up.	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	
Allocated	to	one	of	the	two	study	groups	by	the	Pharmacy	Department	
of	each	participating	hospital,	using	the	list	of	random	numbers	
provided	by	the	coordinator	center	at	the	start	of	the	study.	The	
randomization	code	for	each	patient	consisted	of	three	letters	
(corresponding	to	the	hospital)	and	three	numbers	(corresponding	to	
the	randomization	sequence).	Randomization	was	carried	out	
according	to	whether	the	indication	for	antibiotic	treatment	was	
empirical	or	targeted	(with	a	positive	culture	of	P.	Aeruginosa);	hence,	
there	were	two	randomization	lists	for	this	purpose	
Allocation	concealment	(selection	
bias)	
Unclear	risk	
doesn't	stat	whether	unblinded	pharmacy	staff	were	involved	in	any	
way	in	patient	care.	Pharmacy	staff	would	be	potentially	aware	which	
therapy	was	next	"Patients	were	randomly	assigned	in	a	1:1	ratio	to	
receive	
piperacillin–tazobactam	as	either	continuous	infusion	or	standard	
intermittent	infusion"	
Blinding	of	participants	and	
researchers	(performance	bias)	 Unclear	risk	
double	blinded	but	doesn't	state	if	pharmacy	staff	involved	in	
production	were	also	involved	in	patient	care	
Blinding	of	outcome	assessment	
(detection	bias)	 Unclear	risk	
double	blinded	but	doesn't	state	if	pharmacy	staff	involved	in	
production	were	also	involved	in	patient	care	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	
400	patients	initially	contemplated	theoretically	for	enrolment	(200	for	
each	group),	152	were	assessed	for	eligibility	and	78	were	ultimately	
included	(19.5	%).	No	further	mention	of	the	248	theoretical	patients	
that	weren't	enrolled.	Clear	reasons	were	documented	for	the	
exclusion	of	the	74	that	were	assessed	but	uneligible.	
Selective	reporting	(reporting	bias)	
Unclear	risk	 Reported	on	all	prespecified	outcomes	but	unable	to	assess	as	outcomes	changed	in	view	of	power	calculation	and	low	enrollment	
Other	bias	
Unclear	risk	 No	comercial	funding,	no	conflicts	of	interest.	Use	of	Concomitant	antibiotics	not	discussed	
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De	Jongh	2007	 Continuous	versus	intermittent	infusion	of	temocillin,	a	directed	spectrum	penicillin	for	
intensive	care	patients	with	nosocomial	pneumonia:	stability,	compatibility,	population	
pharmacokinetic	studies	and	breakpoint	selection	
	
Method	 Prospective,	unblinded,	randomised	trial	
Participants	 17	patients	(mean	age	57,	males	75%	(9	out	of	12))	with	a	high	probability	of	infection	from	
nosocomial	origin	and	no	suspicion	of	an	infection	by	Pseudomonas	spp.	or	another	temocillin-
resistant	bacteria.	Exclusion	criteria	were	(i)	age	<18	or	>75	years;	(ii)	patient’s	weight	<50	or	>100	kg;	
(iii)	renal	insufficiency	(estimated	clearance	,45	mL/	min);	(iv)	haemodialysis;	(v)	estimated	survival	<5	
days;	(vi)	documentation	of	temocillin-resistant	organism;	(vii)	meningitis	or	other	proven	infections	
of	the	CNS;	(viii)	IgE-mediated	allergy	to	penicillins;	(ix)	severe	granulocytopenia	(<500	poly-
morphonuclear	leucocytes/mm3);	(x)	pregnancy;	(xi)	patients	having	participated	in	another	study	
<30	days	before;	and	(xii)	retrospectively,	marked	deterioration	of	the	renal	function	during	the	study	
period	
Interventions	 Continuous	infusion	group	received	a	loading	dose	(2	g)	administered	over	30	min	followed	by	
infusion	of	4	g	over	24	hours;	twice	daily	regemin	was	2	g	temocillin	every	12	h	injected	over	a	30	min	
period.	All	patients	also	received	flucloxacillin	(six	times	1	g/day).	
Outcomes	 Stability	and	compatibility;	probability	of	target	attainment	probabilities;	
pharmacokinetic/pharmacodynamic	(PK/PD)	breakpoints.	
Notes	 Clinical	outcome	and	survival	at	28	days	were	not	predetermined	but	mentioned	in	the	results	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Patients	randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Unblinded	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 4	out	of	10	patients	enrolled	in	the	twice	daily	arm	were	excluded	as	
there	clinical	records	were	not	"evaluable",	no	further	information	is	
provided	on	their	clinical	outcome.	
Selective	reporting	(reporting	bias)	 Unclear	risk	 The	only	relevant	outcome	(clinical	outcome)	was	not	a	prespesified	
outcome	but	reported	upon	
Other	bias	 Unclear	risk	 Authors	had	various	industry	affiliactions	"S.	C.	is	working	under	
contract	with	Eumedica	s.a.,	Brussels,	Belgium,	and	R.	D.	J.	and	P.	M.	T.	
are	unpaid	advisors	to	Eumedica	s.a.,	Brussels,	Belgium".	"S.	C.	is	
supported	by	a	First-Entreprise	grant	awarded	by	the	Direction	
Generale	de	la	Recherche	et	des	Technologies	of	the	Region	Wallonne.	
This	work	was	supported	by	the	Belgian	Fonds	de	la	Recherche	
Scientifique	Medicale	(grant	numbers	3.4549.00	and	3.4542.02)	and	by	
a	grant-in-aid	from	Eumedica	s.a.,	Brussels,	Belgium	to	R.	D.	J.".	unclear	
if	open	label	antibiotic	use	allowed.		
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Dulhunty	2013	 Continuous	infusion	of	beta-lactam	antibiotics	in	severe	sepsis:	a	multicenter	double-
blind,	randomized	controlled	trial.	
	
Method	 Prospective,	multi	centre,	double	blinded,	randomised	controlled	trial	
Participants	 60	patients	(males	76.7%	in	the	intervention	group	and	63.3%	in	the	control,	average	age	54	in	the	
intervention	group	and	60	in	the	control)	with	(1)	severe	sepsis	in	the	previous	48	hours	(2)	planned	
commencement	or	commencement	within	the	previous	24	hours	of	ticarcillin-clavulanate,	
piperacillin-tazobactam	or	meropenem;	and	(3)	an	expected	or	actual	ICU	stay	greater	than	48	hours.	
Patients	were	excluded	if	they	were	<18	years	of	age,	had	an	allergy	to	one	or	more	of	the	study	
medications,	were	receiving	palliative	or	supportive	treatment	only,	were	receiving	continuous	renal	
replacement	therapy,	did	not	have	central	venous	catheter	access	with	at	least	3	lumens	(a	dedicated	
lumen	was	required	for	study	drug	administration),	or	had	received	the	study	drug	for	>24	hours.	
Interventions	 either	(1)	active	infusion	and	placebo	bolus	(intervention	arm)	or	(2)	placebo	infusion	and	active	bolus	
(control	arm).	The	24	hour	dose	was	chosen	by	the	clinician	and	unaffected	by	which	arm	the	patient	
was	randomised	to.	
Outcomes	 Primary	endpoint	was	plasma	antibiotic	concentration	above	MIC.	Secondary	endpoints	included	
clinical	response.	Time	to	clinical	resolution.	Vital	status	at	ICU	discharge.	Vital	status	at	hospital	
discharge.	ICU-	free	days.	Adverse	events.	
Notes	 sample	size	calculation	and	therefore	target	number	of	patients	enrolled	relate	to	the	primary	
endpoint	only	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 Randomisation	was	stratified	by	institution	with	1:1	allocation	to	
treatment	arm	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 "Following	study	enrollment,	an	unblinded	research	nurse	or	
pharmacist	responsible	for	preparation	of	the	blinded	medications	
determined	allocation	status	by	opening	a	sequentially	numbered	
sealed	envelope"	opacity	of	envelopes	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Low	risk	 Double-blind,	nurses	and	medical	staff	survey	with	regards	to	which	
therapy	option	they	thought	the	patient	was	receiving	
Blinding	of	outcome	assessment	
(detection	bias)	
Low	risk	 Double-blind,	nurses	and	medical	staff	survey	with	regards	to	which	
therapy	option	they	thought	the	patient	was	receiving	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Data	for	all	60	patients	enrolled	was	analysed.	No	patients	were	lost	to	
follow	up.	Only	22	patients	in	each	arm	(out	of	30)	had	4	or	more	days	
of	randomised	treatment	and	had	samples	taken	for	plasma	antibiotic	
levels.	Reasons	for	this	clearly	stated	in	CONSORT	diagram.	
Selective	reporting	(reporting	bias)	 Low	risk	 Al	predetermined	outcomes	reported	on	(clinical	response	a	secondary	
outcome	but	actually	report	clinical	cure	–	both	defined	in	the	paper)	
Other	bias	 Unclear	risk	 No	industry	financial	support	for	the	study	but	many	potential	conflicts	
of	interest	stated	e.g.	"J.	A.	R.	has	served	as	a	consultant	for	
AstraZeneca,	Pfizer,	Gilead	and	Janssen-Cilag.	S.	A.	R.	W.	has	attended	
Advisory	Boards	and	acted	as	a	consultant	to	Janssen-Cilag	and	
AstraZeneca.	C.	G.	has	served	as	a	consultant	for	Janssen-Cilag	and	
Pfizer"		
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Dulhunty	2015	 A	Multicenter	Randomized	Trial	of	Continuous	versus	Intermittent	β-Lactam	Infusion	in	
Severe	Sepsis	
	
Method	 Prospective,	multicenter,	double-blind,	double-dummy,	randomized	controlled	trial	
Participants	 422	patients	(males	61.3	in	CI	group	and	61.4	in	II,	average	age	64	in	CI	and	65	in	II)	meeting	the	
criteria	for	severe	sepsis	and	commenced	on	piperacillin-tazobactam,	ticarcillin-clavulanate	or	
meropenem	by	the	treating	doctor	were	included	patinets	were	excluded	if	the	had	received	the	
prescribed	β-lactam	antibiotic	for	more	than	24	hours	prior	to	randomization,	were	less	than	18	years	
of	age,	were	pregnant	or	had	an	allergy	or	potential	allergy	to	study	medications	
Interventions	 Participants	were	randomized	to	receive	the		β-lactam	antibiotic	by	either	continuous	infusion	or	
intermittent	infusion	over	30	minutes,	in	addition	to	an	infusion	of	0.9%	sodium	chloride	
administered	as	a	double-dummy	placebo	
Outcomes	 Primary	outcome	measures	-	alive	ICU-free	days	determined	at	Day	28	after	randomization.	
Secondary	outcome	measures	-	Day-90	mortality,	clinical	cure	assessed	at	Day	14	post	antibiotic	
cessation,	alive	organ	failure–free	days	at	Day	14	and	duration	of	bacteremia	postrandomization.	
Adverse	events	recorded	and	assesssed	for	causality.	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 Quote	"Permuted	block	randomization	stratified	by	site	allocated	
participants	into	treatment	groups	in	a	1:1	ratio"	
Allocation	concealment	(selection	
bias)	
Low	risk	 Quote	"An	unblinded	staff	member	at	each	site	used	a	consecutively	
labeled	sealed	opaque	envelope	to	determine	treatment	allocation	
before	study	drug	preparation".	Not	immediately	clear	how	the	
unblinded	member	of	staff	was	otherwise	involved	in	the	study/clinical	
care	of	the	patients	but	elsewhere	states	"Participants,	treating	
clinicians,	and	study	investigators	undertaking	study	assessments	or	
data	collection	were	masked	to	treatment	allocation"	
Blinding	of	participants	and	
researchers	(performance	bias)	
Low	risk	 Quote	"Concealment	was	achieved	by	opaque	labeling	and	double-
dummy	administration	with	adequacy	of	blinding	reported	previously.	
Participants,	treating	clinicians,	and	study	investigators	undertaking	
study	assessments	or	data	collection	were	masked	to	treatment	
allocation"	
Blinding	of	outcome	assessment	
(detection	bias)	
Low	risk	 Quote	"Concealment	was	achieved	by	opaque	labeling	and	double-
dummy	administration	with	adequacy	of	blinding	reported	previously.	
Participants,	treating	clinicians,	and	study	investigators	undertaking	
study	assessments	or	data	collection	were	masked	to	treatment	
allocation"	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 443	patients	were	randomised	11	then	excluded,	reasons	stated	in	
CONSORT	diagram.	432	patients	included	in	intention	to	treat	analysis,	
422	included	in	modified	intention	to	treat	analysis	(excluded	aptients	
accounted	for).	Per	protocol	analysis	however	only	included	286	
patient,	not	stated	what	happened	to	remaining	patients	
Selective	reporting	(reporting	bias)	 Low	risk	 All	prespecified	outcomes	were	reported	upon	
Other	bias	 Unclear	risk	 Funding	support	in	part	from	Baxter	Healthcare	Pty	Ltd	
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Feld	1977	 A	comparative	trial	of	sisomicin	therapy	by	intermittent	versus	continuous	infusion	
	
Method	 Prospective,	randomised	controlled	trial	
Participants	 120	patients	(aged	15	to	76;	52%	male)	with	fever	and	a	proven	or	presumed	infection	secondary	to	
gram	negative	bacilli	were	first	treated	with	a	combination	of	carbenicillin	and	a	cephalosporin	
antibiotic.	If	after	48	to	72	they	didn't	show	signs	of	improvement	then	they	received	study	drug.	
exclusion	criteria	not	stated		
Interventions	 Sisomicin	loading	dose	of	30mg/m	followed	immediately	via	a	continuous	infusion	of	
120mg/m/24hours	vs	30mg/m	over	30	minutes	6	hourly	
Outcomes	 complete	response,	superinfection	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 18	of	139	possible	episodes	deemed	"inevaluable"	for	response.	11	
where	due	to	infections	assumed	not	to	respnd	to	aminogycosides.	
The	other	7	patients	were	excluded	for	receiving	other	antibiotics	but	
indication	not	clear.	All	episodes	evaluated	for	toxicity	(not	a	pre-
specified	outcome)	
Selective	reporting	(reporting	bias)	 Low	risk	 All	prestated	outcomes	reported	on	
Other	bias	 Unclear	risk	 Sisomicin	supplied	by	Schering		
	
	
	
	
	 	
	
	
	 181	
	
	
	
	
	
	
	
	
	
	
	
Feld	1984	 Empiric	therapy	for	infections	in	patients	with	granulocytopenia.	Continuous	v	
interrupted	infusion	of	tobramycin	plus	cefamandole	
	
Method	 Prospective,	randomised	controlled	trial	
Participants	 78	febrile	episodes	in	70	patient	(mean	age	54	(range	19	to	83);	60%	males	in	the	"evaluable"	
episodes)	with	neutropenia	and	malignant	neoplasms	with	presumed	or	proven	infections	due	to	
gram-negative	bacilli.	Patients	were	ineligble	if	they	had	"poor	veins",	allergy	to	one	or	both	study	
drugs,	pregnant	or	lactating	women,	creatinine	>2mg/dL	
Interventions	
Tobramycin	60	mg/m2	(approx.	1.5mg/kg)	loading	dose	over	30	minutes,	followed	by	300	mg/m2	
(approx.	7.5mg/kg)	daily	as	a	continuous	infusion	(adjusted	to	maintain	a	serum	concentration	of	
approximately	4	to	5	mg/L)	vs	tobramycin	75	mg/m2	over	30	minutes	every	6	hours	(adjusted	to	a	
peak	serum	concentration	of	approximately	6	to	7	mg/L);	minimum	treatment	duration	of	seven	days	
or	five	days	after	the	patient	became	afebrile	
Outcomes	 Clinical	cure/failure/partial	response,	mortality,	superinfection,	nephrotoxicity	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Method	of	administration	determined	by	a	series	of	random	
allocations	(stratified	by	hospital)	but	how	random	allocations	
generated	not	stated		
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Sealed	envelopes	but	opacity	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 7	episodes	were	considered	inevaluable	for	response,	5	had	none	
suceptable	organisms	e.g.	candida	spp.	1	patient	received	aditional	
antibiotics	for	a	proven	staphylococcal	infection.	1	died	within	"a	few	
hours"	of	enrolment	having	received	only	one	dose	of	study	drug.	all	
patients	were	considered	evaluable	for	toxicity	
Selective	reporting	(reporting	bias)	 Unclear	risk	 There	were	3	superinfections	but	not	stated	in	which	study	arm	these	
occurred	
Other	bias	 Unclear	risk	 outcomes	stated	as	episodes	rather	than	as	participants	with	one	or	
more	episodes,	other	open	label	antibiotics	allowed		
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Georges	2005	 Cefepime	in	critically	ill	patients:	Continuous	infusion	vs.	an	intermittent	dosing	regimen	
	
Method	 Prospective,	open-label,	randomised	trial	with	2	"balanced"	parallel	groups	
Participants	 50	participants	receiving	artificial	ventilation	(mean	age	48,	82%	males)	with	either	probable/certain	
nosocomial	pneumonopathy	or	bacteremia	thought	to	be	senaitive	to	cefepime.	Exclusions:	younger	
than	18	years	old	or	older	than	75.	Life	expectancy	of	less	than	7	days.	Allergy	to	Beta	lactams.	
Resistance	to	cefepime	and/or	amikacin.	CrCl	less	than	30mL/min.	administration	of	antibiotics	in	the	
3	preceding	days	except	in	cases	of	clinical	failure	or	isolation	of	a	resistant	bacterium,	septic	shock.	
pregnancy.	cystic	fibrosis	
Interventions	 2	g	cefepime	diluted	in	50	ml	of	0.9%	NaCl		continuously	over	12	hours,	twice	daily	versus	2	g	
cefepime	diluted	in	100	ml	of	0.9%	NaCl	over	30	minutes,	twice	daily.	No	loading	dose	was	given.	
Amikacin	was	given	simultaneously	with	cefepime.	In	both	groups,	a	single	daily	dose	of	15	
mg/kg/day	was	infused	after	a	loading	dose	of	20	mg/kg/day	and	then	adjusted	according	to	serum	
levels	
Outcomes	 Bacterial	MIC.	Pk/Pd	parameters	(AUCss,	AUCss/MIC,	AUICss,	t>MIC,	t>five-fold	MIC,	t>french	
breakpoint).	Clinical,	laboratory	and	bacteriological	efficacy,	tolerance	and	mortality.	
Notes	 Prospective,	open-label,	randomised	trial	with	2	"balanced"	parallel	groups	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	with	"two	balanced	groups".	Method	of	randomisation	
not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Method	of	allocation	concealment	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 open	label	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 3	participants	excluded	from	analysis	for	allergy,	shock	and	death	
Selective	reporting	(reporting	bias)	 High	risk	 Unclear	when	outcomes	were	decided	(before	or	after	study	
completion)	"at	the	end	of	treatment,	Clinical,	laboratory	and	
bacteriological	efficacy,	tolerance	and	mortality	were	analysed".	
Unclear	how	many	patients	data	analysed.	3	patients	were	withdrawn	
from	the	study	for	"allergy,	shock,	and	death	independent	of	the	
infection"		
Other	bias	 Unclear	risk	 Simultaneous	amikacin	in	both	groups	and	other	"authorised	
antimicrobial	treatment"	(2	patients	received	glycopeptide,	1	
antifungal).	"Helpful"	discussions	with	Bristol-Myers	Squibb		
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Hanes	2000	 Intermittent	and	continuous	ceftazidime	infusion	for	critically	ill	trauma	patients	
	
Method	 Randomised	controlled	trial	
Participants	 32	critically	ill	trauma	patients	(aged	16-65,	mean	age	34,	males	81%)	with	gram-negative	nosocomial	
pneumonia.	Exclusion:	known	sensetivity	to	cephalosporins,	CrCl	less	than	30mL/min,	resistant	
causative	pathogen.	
Interventions	 ceftazidime	2	g	intravenouslyover	3o	mins	every	8	hours	or	ceftazidime	2g	as	an	intravenous	bolus	
followed	by	60	mg/kg	per	day	as	a	continuous	intravenous	infusion	
Outcomes	 Pk	parameters,	clinical	response	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomly	assigned	but	randomisation	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 Quote	"Fifteen	and	17	patients	were	randomly	assigned	to	receive	
intermittent	and	continuous	ceftazidime	therapy,	respec-	tively.	One	
patient	(continuous	group)	was	excluded	from	outcome	analysis	
secondary	to	an	Acinetobacter	calcoaceticus	pneumonia	
intermediately	sensitive	to	ceftazidime	and	another	patient	
(intermittent	group)	was	excluded	from	all	analyses	secondary	to	
concomitant	Enterococcus	urinary	tract	infection	from	initial	cultures"	
Selective	reporting	(reporting	bias)	 High	risk	 Outcomes	reported	not	specified	a	priori.	Reporting	of	results	unclear	-	
unclear	if	reporting	affect	vs	mean	or	actual	MICs,	outcomes	discussed	
as	percentages	of	each	treatment	not	absolute	numbers	relatable	to	
MICs/organisms		
Other	bias	 Unclear	risk	 "supported	by	GlaxoWellcome"	
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Lagast	1983	 Treatment	of	Gram-Negative	Bacillaty	Septicemia	with	Cefoperazone	
	
Method	 Randomised	controlled	trial	
Participants	 40	non-neutropenic	and	5	neutropenic	patients	(age	not	stated,	44%	(20/45)	male)	with	proven	
aerobic	gram-negative	bacillary	septicaemia.	Exclusions:	high	likelyhood	of	death	from	non-infectios	
causes,	history	of	allergy	to	penicillins	or	cephalosporins,	hepatic	impairment	(bilirubin	>2mg%)	or	
renal	impairment	(creatinine	>2mg%)		
Interventions	 Both	groups	received	4g/day.	Intermittent	group	received	2g	over	15mins	bd.	Continuous	group	
received	a	loading	dose	of	1g	over	15mins	followed	by	3g	over	the	remainder	of	the	24	hours	on	day	
1	and	the	4g/24hours	thereafter	
Outcomes	 Cure	(defined	as	disappearance	of	clinical	and	laboratory	evidence	of	infection),	Failure	(death	or	
clinical	deterioration	requiring	antibiotic	change),	super-infection,	Bacterial	colonisation,	
Bacteriological	cure	at	48	to	72	hours		
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Outcomes	reported	for	all	45	patients	
Selective	reporting	(reporting	bias)	 High	risk	 Focus	on	clinical	failure	-	cure	not	reported.	Adverse	events	reported	
but	not	stated	a	priori	as	an	outcome.	Failure	not	reported	by	
intervention	group	
Other	bias	 Unclear	risk	 Patients	age	and	severity	of	illness	not	stated.	Funded	by	pfizer	
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Laterre	2015	 Temocillin	(6g	daily)	in	critically	ill	patients:	continuous	infusion	versus	three	times	a	
daily	administration	
	
Method	 Prospective,	two-centre,	randomised,	controlled	trial	
Participants	 32	patients	(53%	male,	age	range	54	to79)	residing	in	adult	ICU	with	clinical	signs	of	abdominal	or	
pulmonary	infection	likely	to	be	sensitive	to	temocillin.	Exclusions:	potentially	infected	with	a	
pathogen	resistant	to	temocillin,	allergy	to	any	penicillin,	pragnancy/lactation	or	participation	in	
another	investigational	drug	study	in	the	preceeding	4	weeks		
Interventions	 Patients	received	either	continuous	infusion	(2g	load	over	30	mins	followed	by	6g	over	24	hours)	or	
intermittent	infusion	(2g	over	30	mins	every	8	hours).	Dose	was	modified	according	to	renal	function	
using	predetermined	Creatinine	clearance/dose	banding.	For	patinets	receiving	CRRT	(4	patients)		
temocillin	was	administered	at	a	fixed	dose	by	continuous	infusion.	
Outcomes	 Pk	data,	clinical	cure,	superinfection,	overall	ICU	mortality,	adverse	events	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	not	stated.	Quote	"divided	into	three	groups"	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 Not	all	patients	followed	up	for	pk	data.	"Thirty-two	patients	were	
included	and	analysed	for	clinical	efficacy,	and	pharmacokinetics	were	
measured	in	29	of	them"	
Selective	reporting	(reporting	bias)	 High	risk	 Unclear	when	outcomes	were	decided	(before	or	after	study	
completion)	
Other	bias	 Unclear	risk	 Quote	"Temocillin	and	ticarcillin	were	obtained	as	Negaban	(Eumedica	
s.a.,	Brussels,	Belgium)	and	Timentin	(GlaxoSmithKline	Belgium,	
Rixensart,	Belgium),	respectively".	"This	work	was	supported	in	part	by	
Eumedica	s.a.	Other	support	was	obtained	from	the	Belgian	Fonds	de	
la	Recherche	Scientifique	Medicale	and	the	Belgian	Region	Wallonne".		
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Lau	2006	 Randomized,	Open-Label,	Comparative	Study	of	Piperacillin-Tazobactam	Administered	
by	Continuous	Infusion	versus	Intermittent	Infusion	for	Treatment	of	Hospitalized	
Patients	with	Complicated	Intra-Abdominal	Infection	
	
Method	 Multicenter,	prospective,	randomised,	open-label	comparative	study	
Participants	 262	Hospitalized	male	and	nonpregnant,	nonlac-	
tating	female	patients	≥18	years	old	(males	60%,	age	range	18	-	95)	with	peritonitis,	an	intra-
abdominal	or	a	periappendiceal	abscess,	and/or	complicated	perforated	diverticulitis	(but	not	
uncomplicated	appendicitis)	were	eligible	for	enrollment.	Exclusions:	underlying	immunodeficiency	or	
were	receiving	immunosuppressant	medications,	including	>5	mg	prednisone	or	equivalent	per	day;	
other	infections	requiring	systemic	antibiotic	or	antifungal	treatment;	infections	caused	by	organisms	
resistant	to	piperacillin-tazobactam;	active	or	treated	leukemia	or	a	systemic	malignancy	that	
required	chemotherapy,	immunotherapy,	radiation	therapy,	or	antineoplastic	therapy	within	the	past	
year;	known	hypersensitivity	to	β-lactams;	infected	pancreatic	or	peripancreatic	necrosis	in	
association	with	necrotizing	pancreatitis;	severe	renal	dysfunction	(concurrent	hemodialysis,	
peritoneal	dialysis,	or	creatinine	clearance	<20	ml/	min	after	adequate	hydration);	neutropenia	(white	
blood	cell	count,	<1,000/mm3);	thrombocytopenia	(platelet	count,	<35,000/mm3);	high	levels	of	liver	
enzymes	(aspartate	aminotransferase,	alanine	aminotransferase,	total	bili-	rubin,	or	alkaline	
phosphatase	levels	more	than	five	times	the	upper	limit	of	normal);	an	international	normalized	ratio	
two	or	more	times	the	upper	limit	of	normal;	multiorgan	system	failure;	irreversible	shock;	or	an	
anticipated	discharge	from	the	hospital	in	less	than	4	days.	
Interventions	 Piperacillin-tazobactam	was	administered	as	either	a	one-time	i.v.	bolus	of	2	g/0.250	g	infused	over	
30	min,	followed	by	12	g/1.5	g	infused	continuously	over	24	h,	or	an	intermittent	i.v.	infusion	of	3	
g/0.375	g	infused	over	30	min	every	6	h.	Duration	4	-	14	days	
Outcomes	 Clinical	response	at	the	test	of	cure,	bacteriological	response	at	the	test	of	cure,	time	to	
defervescence,	time	to	WBC	normalisation,	Safety	
Notes	 on	day	1	continuous	infusion	patients	received	a	bigger	dose	(14g	vs	12g	Piperacillin)	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomly	assigned	but	randomisation	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 262	patients	were	randomised	and	treated	and	then	4	excluded	to	
make	a	"modified	all-treated"	of	258.	Of	this	remaining	group	only	167	
patients	were	"clinically	evaluable"	and	only	114	"bacteriologically	
evaluable".	Of	those	excluded	after	the	modified	all-treated	step,	16	
were	excluded	for	undefined	reasons.	
Selective	reporting	(reporting	bias)	 High	risk	 Did	not	report	outcomes	for	all	treated	patients	
Other	bias	 High	risk	 Did	not	reach	pre	spesified	sample	size	of	180	patients	to	assess	
clinical	response	(167	pts	evaluated).	Continuous	infusion	group	
potentially	sicker	(APACHE	score	>20	in	7	vs	0	patients	although	mean	
score	8.3	vs	7.6).	Study	supported	by	and	authors	affiliated	
to/employed	by	Wyeth	Pharmaceuticals.		
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Lipman	1999	 Continuous	infusion	ceftazidime	in	intensive	care:	a	randomized	controlled	trial	
	
Method	 Single	site,	randomised	controlled	trial	
Participants	 18	adult	patients	(male/female	split	and	age	not	stated)	with	normal	renal	function	requiring	
ceftazidime	according	to	usual	clinical	practice.	Exclusions	not	independently	stated.	
Interventions	 Continuous	infusion	group	received	12	mg/kg	over	2	min	followed	immediately	by	2	g	over	478	min.	
They	then	received	2	g	given	as	an	infusion	every	8	h.	The	bolus	group	received	12	mg/kg	of	
ceftazidime	over	2	min	followed	immediately	by	2	g	infused	over	28	min.	Subsequently	they	received	
2	g	infused	over	30	min	every	8	h.	treatment	duration	not	stated.	
Outcomes	 Plasma	ceftazidime	concentrations	for	first	8	hours,	adverse	drug	events	
Notes	 Number	of	patients	in	each	arm	not	stated.	Only	relevant	outcome	was	adverse	events	but	no	
absolute	numbers	stated	therefore	unable	to	include	in	meta	analysis	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 Randomly	assigned	using	"computer	generated	random	numbers"	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 Not	stated	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Not	stated	
Other	bias	 High	risk	 Groups	not	evenly	matched	in	age	and	severity	of	illness	"the	infusion	
group	were	older	(64	vs	53	years;	P	<0.05)	and	had	higher	APACHE	II	
scores	(20.5	vs	15.5;	P	<0.05)".	Funding	not	stated.		
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Lu	2013	 Treatment	study	of	hospital	acquired	pneumonia	by	optimizing	dosing	regimen	of	
piperacillin/tazobactam:	prolonged	vs.	regular	infusion	(abstract	only)	
	
Method	 Randomised	controlled	trial	
Participants	 50	ICU	patients	(58%	males,	average	age	67	and	69	years	old)	with	hospital-aquired	pneumonia.	
Other	inclusion	criteria	and	exclusion	criteria	unknown	
Interventions	 Control	group:	Piperacillin/Tazobactam	4.5g	30	minute	infusion	every	6	hours.	Treatment	group:	
Piperacillin/Tazobactam	4.5g	by	prolonged	infusion	over	3	hours	every	6	hours.	
Outcomes	 Treatment	success	rate,	remedial	treatment	rate,	cost	
Notes	 Unable	to	determine	how	this	study's	outcomes	align	with	stated	meta-analysis	outcomes	therefore	
results	not	included	in	data	analysis	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomly	divided	but	method	not	stated	in	abstract	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	in	abstract	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Not	stated	in	abstract	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Not	stated	in	abstract	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 All	enrolled	patients	made	it	to	final	analysis	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Unable	to	determine	if	outcomes	stated	a	priori	
Other	bias	 Unclear	risk	 Unable	to	determine	if	there	are	any	other	sources	of	bias	
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Lubasch	2003	 Optimizing	ceftazidime	pharmacodynamics	in	patients	with	acute	exacerbation	of	severe	
chronic	bronchitis	
	
Method	 Multi-centred,	open	label,	randomised	controlled	trial	
Participants	 81	patients	(56	males	(69%),	mean	age	65.3	years	old)	with	purulent	exacerbations	of	severe	chronic	
bronchitis	(FEV1<50%	predicted	in	stable	phase).	Inclusion	criteria:	age	>	40	years;	in	females	
patients,	a	negative	pregnancy	test,	or	post-menopause;	written	informed	consent;	known	chronic	
bronchitis	with	an	FEV1	<	50%	of	predicted	value;	signs	of	acute	exacerbation	[at	least	two	of	the	
following	symptoms:	(i)	dyspnoea	or	increased	dyspnoea;	(ii)	increased	sputum	volume;	(iii)	increased	
cough;	(iv)	increased	sputum	purulence;	(v)	increased	bronchial	retention	of	secretion;	and	(vi)	fever	
≥37.8°C	and/or	chills].	Exclusion	criteria	were:	pregnancy	or	lactation	period;	allergy	or	intolerance	to	
β-lactams	and/or	aminoglycosides;	radiological	suspicion	of	pneumonia,	asthma,	cystic	fibrosis,	
empyema,	lung	abscess,	active	tuberculosis	or	bronchial	carcinoma;	peak	flow	<150	L/min	in	males	
and	<100	L/min	in	females;	neuromuscular	diseases;	other	infection	requiring	systemic	antibiotic	
therapy;	AIDS	or	HIV-positivity;	systemic	prednisolone	long-term	therapy	(prednisolone	>30	mg	
equivalent);	antibiotic	pre-treatment	within	last	72	h;	progressive	lethal	disease,	or	life	expectancy	<1	
month;	alcohol	or	drug	abuse;	creatinine	>2.5	mg/L	or	creatinine	clearance	<40	mL/min/1.73	m2;	
shock;	mechanical	ventilation;	neutropenic	patients	(<2000	granulocytes/mm3);	uncooperative	
patient;	or	participation	in	a	clinical	trial	within	the	last	4	weeks.		
Interventions	 For	the	extended	infusion	group	ceftazidime	2	g	iv	as	a	loading	dose,	followed	by	ceftazidime	2	g	iv	
over	7	h	every	12	h,	short	infusion	group	ceftazidime	2	g	intravenously	over	30mins	every	8	h	
Outcomes	 Clinical	assessment,	lung	function,	and	laboratory,	sputum	
and	bacteriological	examinations	were	performed	before	treatment,	between	days	3	and	5,	between	
days	8	and	9,	and	within	72	h	of	the	end	of	treatment.	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Patients	randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Clinical	outcomes	reported	for	all	patients.	Bacteriological	outcomes	
reported	for	all	patients	with	pre-treatment	pathogens	
Selective	reporting	(reporting	bias)	 Low	risk	 Reported	on	all	pre-specified	outcomes	of	interest	
Other	bias	 Unclear	risk	 Study	sponsored	by	GlaxoSmithKline	
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McNabb	2001	 Cost-effectiveness	of	Ceftazidime	by	continuous	infusion	versus	intermittent	infusion	for	
nosocomial	pneumonia	
	
Method	 Prospective,	open-labelled,	randomised	controlled	trial	
Participants	 41	adult	patients	(mean	age	56	in	II	group	and	46	in	CI	group;	56%	males)	in	intensive	care	with	
nosocomial	pneumonia	clinically	suspected	to	be	bacterial	in	origin.	Exclusions:	AIDS,	neutropenia,	or	
had	a	documented	allergy	to	Beta-lactam	antibiotics,	signs	or	symptoms	of	pneumonia	at	the	time	of	
admission,	initial	APACHE	II	>25,	pregnancy,	significant	renal	dysfunction	(serum	creatinine	
>2.5mg/dL	or	creatinine	clearance	<20mL/min,	documented	active	tuberculosis,	cystic	fybrosis,	viral	
pneumonia,	infection	with	a	microorganism	known	to	be	resistant	to	study	medication,	antimicrobial	
therapy	with	activity	against	suspected	pathogens	for	more	than	48	hours	prior	to	enrolment	without	
a	persistently	positive	culture.	
Interventions	 If	creatinine	clearance	(CrCl)	was	>50mL/min	then	ceftazidime	was	administered	either	as	an	
intermittent	infusion	(II)	of	2g	iv	every	8	hours	or	as	a	continuous	infusion	(CI)	of	3g	over	24hours.	The	
continuous	infusion	group	received	an	initial	dose	of	1g	at	the	start	of	therapy.	For	CrCl	31-50mL/min	
the	dose	was	2.5g	CI	over	24	hours	vs	2g	II	every	12	hours,	and	CrCl	20-30mL/min	2g	CI	over	24	hours	
vs	2g	II	every	24	hours.	All	patients	received	once	daily	tobramycin	at	a	dose	of	7mg/kg	according	to	a	
reference	published	protocol	
Outcomes	 Cost	analysis,	adverse	events,	clinical	outcome	
Notes	 Clinical	and	microbiological	outcomes	reported	in	Nicolau	2001	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 forty	one	patients	were	randomised	but	six	were	subsequently	
declared	non-evaluable	due	to	their	short	duration	of	therapy	(<5	
days)	(5	from	CI	and	1	from	II)	
Selective	reporting	(reporting	bias)	 Low	risk	 Reported	on	all	pre-spesified	outcomes	of	interest	
Other	bias	 Unclear	risk	 Financial	support	was	provided	by	Glaxo	Wellcome	
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Nicolau	1999a	 Pharmacokinetics	of	continuous	and	intermittent	ceftazidime	in	intensive	care	unit	
patients	with	nosocomial	pneumonia	
	
Method	 Prospective,	randomised	controlled	trial	
Participants	 24	ICU	patients	(62	%	males,	age	range	23	to	64	years	old)	who	had	been	hospitalised	for	≥72hours	
and	then	developed	a	suspected	bacterial	pneumonia.	Exclusion	criteria	were	not	stated.	
Interventions	 if	creatinine	clearance	(CrCl)	was	>50mL/min	then	ceftazidime	was	administered	either	as	an	
intermitent	infusion	(II)	of	2g	iv	every	8	hours	or	as	a	continuous	infusion	(CI)	of	3g	over	24hours.	The	
continuous	infusion	group	received	an	initial	dose	of	1g	at	the	start	of	therapy.	For	CrCl	31-50mL/min	
the	dose	was	2.5g	CI	over	24	hours	vs	2g	II	every	12	hours,	and	CrCl	20-30mL/min	2g	CI	over	24	hours	
vs	2g	II	every	24	hours.	All	paients	received	once	daily	tobramycin	at	a	dose	of	7mg/kg	according	to	a	
reference	published	protocol	
Outcomes	 Pharmacokinetic	parameters.	Adverse	events.	No	clinical	outcomes	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Patients	randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Only	patients	with	normal	renal	function	included	in	pk	studies	but	all	
patients	assessed	for	adverse	events	
Selective	reporting	(reporting	bias)	 High	risk	 Absolute	number	of	adverse	events	not	reported	just	that	"No	adverse	
events	were	attributed	to	the	dosing	regimen	of	ceftazidime"	
Other	bias	 Unclear	risk	 Sponsored	by	a	grant	from	Glaxo	pharmaceuticals.	Age	mismatch	
between	the	groups	(average	age	of	45	vs	36.5	in	the	intermittent	and	
continuous	groups	respectively)		
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Nicolau	1999b	 Pharmacokinetic	and	pharmacodynamics	of	continuous	and	intermittent	ceftazidime	
during	the	treatment	of	nosocomial	pneumonia	
	
Method	 Prospective,	single-centre,	single	blind,	randomised	controlled	trial	
Participants	 34	ICU	patients	with	nosocomial	pneumonia	(61%	males,	age	range	28	-	72).	Patients	aged	18	or	over	
who	had	been	hospitalised	for	at	least	72	hours	were	considered	eligible	for	the	study	
whensuspected	to	have	a	bacterial	pneumonia	based	on	clinical	evidence.	No	specific	exclusion	
criteria	stated.	
Interventions	 if	creatinine	clearance	(CrCl)	was	>50mL/min	then	ceftazidime	was	administered	either	as	an	
intermitent	infusion	(II)	of	2g	iv	every	8	hours	over	30mins	or	as	a	continuous	infusion	(CI)	of	3g	over	
24hours.	The	continuous	infusion	group	received	an	initial	dose	of	1g	over	30	mins	at	the	start	of	
therapy.	For	CrCl	31-50mL/min	the	dose	was	2.5g	CI	over	24	hours	vs	2g	II	every	12	hours,	and	CrCl	
20-30mL/min	2g	CI	over	24	hours	vs	2g	II	every	24	hours.	Patients	whose	actual	body	weight	was	
>100kg	were	given	1.5x	the	renally	adjusted	dose.	All	paients	received	once	daily	tobramycin	at	a	
dose	of	7mg/kg	according	to	a	previously	described	protocol	
Outcomes	 Pharmacokinetic	outcomes,	adverse	events,	no	clinical	outcomes	
Notes	 very	similar	to	Nicolau	1999b	but	appears	to	be	a	different	group	of	patients	(based	on	age	range)	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomly	assigned	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Single	blinded	but	which	group	blinded	not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Single	blinded	but	which	group	blinded	not	stated	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 41	patients	participated	but	data	only	analysed	for	34.	Reasons	for	
exclusion	not	stated	
Selective	reporting	(reporting	bias)	 High	risk	 Outcomes	not	stated	a	priori.	Adverse	events	not	stated	for	
intermittent	group	"all	patients	tolerated	the	continuous	infusions	with	
no	infusion-related	adverse	events….."	
Other	bias	 Unclear	risk	 Sponsored	by	a	grant	from	Glaxo	Pharaceuticals.		
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Nicolau	2001	 Continuous	versus	intermittent	administration	of	ceftazidime	in	intensive	care	unit	
patients	with	nosocomial	pneumonia	
	
Method	 Prospective,	open-labelled,	randomised,	controlled	pilot	study	
Participants	 41	adult	patients	(mean	age	56	in	II	group	and	46	in	CI	group;	56%	males)	in	intensive	care	with	
nosocomial	pneumonia	clinically	suspected	to	be	bacterial	in	origin.Exclusions:	AIDS,	neutropenia,	or	
had	a	documented	allergy	to	Beta-lactam	antibiotics,	signs	or	symptoms	of	pneumonia	at	the	time	of	
admission,	initial	APACHE	II	>25,	pregnancy,	significant	renal	dysfunction	(serum	creatinine	
>2.5mg/dL	or	creatinine	clearance	<20mL/min,	documented	active	tuberculosis,	cystic	fybrosis,	viral	
pneumonia,	infection	with	a	microorganism	known	to	be	resistant	to	study	medication,	antimicrobial	
therapy	with	activity	against	suspected	pathogens	for	more	than	48	hours	prior	to	enrollment	without	
a	persistently	positive	culture.	
Interventions	 If	creatinine	clearance	(CrCl)	was	>50mL/min	then	ceftazidime	was	administered	either	as	an	
intermitent	infusion	(II)	of	2g	iv	every	8	hours	or	as	a	continuous	infusion	(CI)	of	3g	over	24hours.	The	
continuous	infusion	group	received	an	initial	dose	of	1g	at	the	start	of	therapy.	For	CrCl	31-50mL/min	
the	dose	was	2.5g	CI	over	24	hours	vs	2g	II	every	12	hours,	and	CrCl	20-30mL/min	2g	CI	over	24	hours	
vs	2g	II	every	24	hours.	All	paients	received	once	daily	tobramycin	at	a	dose	of	7mg/kg	according	to	a	
reference	published	protocol	
Outcomes	 clinical	and	microbiological	outcome	at	14	and	21	days	post-therapy	or	at	the	time	of	institutional	
discharge.	Patients	who	received	5	or	more	days	of	therapy	were	considered	for	inclusion.	Clinical	
outcomes	defined	as	cure,	improvement	or	failure,	microbiological	outcomes	defined	as	eradication,	
presumed	eradication	or	persistance	
Notes	
	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Forty	one	patients	were	randomised	but	six	were	subsequently	
declared	non-evaluable	due	to	their	short	duration	of	therapy	(<5	
days)	(5	from	CI	and	1	from	II).	Reasons	not	stated	in	this	paper	but	
documented	in	full	in	McNabb	2001	
Selective	reporting	(reporting	bias)	 Low	risk	 Reported	on	all	pre-specified	outcomes	of	interest	
Other	bias	 Unclear	risk	 Financial	support	was	provided	by	Glaxo	Wellcome	
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Okimoto	2009	 Clinical	effects	of	continuous	infusion	and	intermittent	infusion	of	meropenem	on	
bacterial	pneumonia	in	the	elderly	(abstract	only)	
	
Method	 Randomised	controlled	trial	
Participants	 50	patients	over	65	years	old	(60%	males,	age	range	65	to	102)	with	moderate	community-acquired	
pneumonia.	Other	inclusion	and	exclusion	criteria	unknown.	
Interventions	 Control:	500mg	meropenem	intravenous	twice	daily,	continuous:	1g	intravenous	over	24hours	
infused	continuously	
Outcomes	 Clinical	efficacy	on	both	the	third	day	of	treatment	and	the	final	day	of	treatment	
Notes	 Unable	to	determine	how	this	study's	outcomes	align	with	stated	meta-analysis	outcomes	therefore	
results	not	included	in	data	analysis	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomly	divided	but	method	not	stated	in	abstract	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	in	abstract	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 All	enrolled	patients	made	it	to	final	analysis	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Unable	to	determine	if	outcomes	stated	a	priori	
Other	bias	 Unclear	risk	 Unable	to	determine	if	there	are	any	other	sources	of	bias	
	
	 195	
	
	
	
	
	
	
	
	
	
	
	
	
	
Rafati	2006	 Clinical	efficacy	of	continuous	infusion	of	piperacillin	compared	with	intermittent	dosing	
in	septic	critically	ill	patients	
	
Method	 Prospective,	single	site,	randomised	controlled	trial		
Participants	 40	ICU	patients	(67.5%	male,	mean	age	range	48	to	50)	with	sepsis	with	systemic	inflammatory	
response	syndrome	due	to	a	suspected	or	proven	infection.	Exclusion:	under	18	years	old,	
hypersensitivity	or	allergy	to	Beta	lactam	antibiotics,	renal	dysfunction	(dialysis	or	creatinine	
clearance	<40mL/min)	
Interventions	 Piperacillin	2	g	intravenously	(i.v.)	over	30	minutes	as	a	loading	dose	followed	by	8	g	i.v	daily	over	24	h	
(continuous	infusion	(CI)	group;	n=20)	or	piperacillin	3	g	i.v.	every	6	h	over	30	minutes	(intermittent	
infusion	(II)	group;	n=20).	All	patients	received	15mg/kg	amikacin	daily.	
Outcomes	 Clinical	efficacy,	pk/pd	
Notes	 Groups	received	different	total	daily	doses	(10g	day	1	then	8g	(CI	group)	vs	12g/day	(II	group))	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 All	patients	enrolled	included	in	analysis	
Selective	reporting	(reporting	bias)	 Low	risk	 Mortality	not	stated	a	priori	just	"clinical	efficacy"	
Other	bias	 Unclear	risk	 Sponsored	by	grants	from	Tehran	University	of	Medical	Sciences	
research	board.	Conflicts	of	interest	not	stated.	Unclear	if	open	label	
antibiotic	use	permitted.			
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Roberts	2007	 Is	continuous	infusion	ceftriaxone	better	than	once-a-day	dosing	in	intensive	care?	A	
randomized	controlled	pilot	study	
	
Method	 Prospective,	single	site,	open	label,	randomised	controlled	trial	
Participants	 57	ICU	patients	(58%	male,	mean	age	range	43	-	52	years	old)	aged	18-80	years	old,	infected	site	(as	
defined	by	clinical	suspicion)	and	a	clinical	indication	for	ceftriaxone	(with	or	without	positive	
cultures),	with	normal	renal	function	and	SIRS,	informed	consent	and	treatment	for	4	or	more	days	
with	ceftriaxone.	Exclusions:	history	of	organ	transplant	or	recent	treatment	with	cytotoxic	drugs	
Interventions	 2g	ceftriaxone	intravenous	(iv)	bolus	daily	vs	2g	iv	over	24	hours.	Day	one	bolus	group	received	2.5g	
bolus	and	continuous	group	a	500mg	bolus	then	2g/24hours.	Mean	duration	of	treatment	6.1	days	
(bolus)	and	5.5	days	(continuous)	
Outcomes	 Clinical	response	and	cure,	bacteriological	response/cure	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 "Patients	were	randomized	into	two	groups….(sequence	generated	
from	a	table	of	random	numbers)"	
Allocation	concealment	(selection	
bias)	
Low	risk	 "using	sequential	opaque	sealed	envelopes"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label	at	point	of	administration	of	ceftriaxone	
Blinding	of	outcome	assessment	
(detection	bias)	
Low	risk	 "Clinical	and	bacteriological	outcomes	were	assessed	at	the	cessation	
of	ceftriaxone	treatment	by	a	critical	care	physician	blinded	to	the	
groupings	and	with	no	role	in	the	management	of	the	subjects"	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 "Analysis	of	data	was	primarily	performed	on	an	intention-to-treat	
(ITT)	basis.	However,	as	this	was	a	pilot	study,	a	priori,	we	also	elected	
to	analyse	patients	that	received	at	least	4	days	of	antibiotic	therapy."	
"Seven	of	the	recruited	patients	did	not	receive	at	least	4	days	of	
ceftriaxone	therapy	and	were	not	included	in	the	subgroup	analysis."	
Selective	reporting	(reporting	bias)	 Low	risk	 Reported	all	pre-specified	outcomes	of	interest	
Other	bias	 High	risk	 "Forty-three	(of	57	enrolled)	patients	received	concomitant	antibiotics	
during	ceftriaxone	therapy	of	whom	19	patients	received	more	than	
one	additional	antibiotic".	Authors	state	there	was	no	statistical	
difference	in	the	number	of	antibiotics	used	between	the	infusion	and	
bolus	groups	(P	=	0.66)	but	no	further	details	are	given	with	regards	to	
type	of	antibiotics		
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Roberts	2009a	 Meropenem	dosing	in	critically	ill	patients	with	sepsis	and	without	renal	dysfunction:	
intermittent	bolus	versus	continuous	administration?	Monte	Carlo	dosing	simulations	
and	subcutaneous	tissue	distribution	
	
Method	 Single	site,	randomised	controlled	study	
Participants	 10	ICU	patients	(70%	male,	mean	age	range	55	to	57	years)	with	known	or	suspected	sepsis	and	
normal	renal	function	
Interventions	 Continuous	group	received	a	500mg	bolus	followed	immediately	by	a	continuous	infusion	of	3000mg	
over	24	hours.	Bolus	group	received	1500mg	bolus	for	the	first	dose	then	1g	8	hourly	thereafter.	
Outcomes	 Stated	objectives	were	comparison	of	observed	plasma	and	tissue	concentration-time	profiles,	
pharmacokinetic	variability	(population	pk	model),	pk/pd	profile	of	dosing	regimens	and	expected	
probability	of	target	attainment	
Notes	 Clinical	outcome	not	stated	as	an	outcome	but	mortality	stated	in	results	table	1	(survivors	vs	non-
survivors).	Timing	of	this	assessment	not	stated.	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Patients	were	randomised	using	random	numbers	concealed	in	opaque	
sealed	envelopes,	method	of	random	number	generation	not	clear	
Allocation	concealment	(selection	
bias)	
Low	risk	 …."opaque	sealed	envelopes"	
Blinding	of	participants	and	
researchers	(performance	bias)	
Unclear	risk	 Not	stated	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Outcome	of	interest	reported	for	in	all	10	patients	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Mortality	not	stated	as	an	outcome	but	reported	
Other	bias	 Unclear	risk	 use	of	other	open	label	antibiotics	not	stated	
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Roberts	2009b	 Piperacillin	penetration	into	the	tissue	of	critically	ill	patients	with	sepsis	-	Bolus	versus	
continuous	administration?	
	
Method	 Prospective,	single	site,	randomised	controlled	trial	
Participants	 13	critically	ill	patients	(77%	male,	mean	age	42	years	old	in	bolus	group	and	24.5	in	continuous	
group)	with	known	or	suspected	sepsis	in	whom	piperacillin/tazobactam	was	deemed	appropriate	
treatment.	Exclusions:	known/suspected	allergy	to	penicillin	or	piperacillin/tazobactam.	Renal	
impairment		
Interventions	 Continuous	group:	day	1	4.5g	intravenously	(i.v.)	over	20	minutes	then	9g	over	24	hours,	day	2	
onwards	13.5g	over	24	hours.	Bolus	group	4.5g	6-8	hourly	at	prescribers	discretion.	Course	length	not	
stated.	
Outcomes	 Clinical	outcome,	determination	of	unbound	piperacillin	fraction	in	plasma,	drug	assay	
Notes	 Outcome	data	not	included	in	meta-analysis	and	as	this	patient	group	and	an	additional	3	patients	are	
reported	again	in	Roberts	2010	(included)	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Not	stated	
Allocation	concealment	(selection	
bias)	
Low	risk	 "opaque	sealed	envolopes"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label,	physicians	allowed	to	select	the	dose	used	in	bolus	group	
(either	6	or	8	hourly)	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 "Cure"	reported	for	all	13	patients	(although	cure	is	not	defined,	
definitions	provided	for	"resolution",	"improvement"	and	"failure"	
Selective	reporting	(reporting	bias)	 Low	risk	 All	relevant	prestated	outcomes	reported	for	all	patients	
Other	bias	 High	risk	 Continuous	group	younger.	Young	patient	group	with	very	good	
(augmented?)	renal	function	and	very	little	use	of	vassopressors	-	not	
typical	sepsis/septic	shock	patients.	Other	antibiotic	use	not	stated.		
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Roberts	2010	 First-dose	and	steady-state	population	pharmacokinetics	and	pharmacodynamics	of	
piperacillin	by	continuous	or	intermittent	dosing	in	critically	ill	patients	with	sepsis	
	
Method	 Prospective,	single	site,	randomised	controlled	trial	
Participants	 16	critically	ill	patients	(69%	male,	mean	age	41	years	old	in	bolus	group	and	30	in	continuous	group)	
with	known	or	suspected	sepsis	in	whom	piperacillin/tazobactam	was	deemed	appropriate	
treatment.	Exclusions:	known/suspected	allergy	to	penicillin	or	piperacillin/tazobactam.	Renal	
impairment		
Interventions	 In	section	2.1	it	is	stated	that	patients	received	16g/day	in	the	bolus	group	versus	12g/day	in	the	
continuous	group	but	then	goes	on	to	say	in	section	2.2	that	the	Continuous	group:	day	1	4.5g	
intravenously	(i.v.)	over	20	minutes	then	9g	over	24	hours,	day	2	onwards	13.5g	over	24	hours.	Bolus	
group	4.5g	6-8	hourly	at	prescribers	discretion.	Course	length	not	stated.	
Outcomes	 (i)	Comparison	of	the	observed	plasma	concentration–time	profiles	for	piperacillin	administered	by	
intermittent	or	continuous	dosing	to	critically	ill	patients	with	sepsis	at	first	dose	and	at	steady	state;	
(ii)	to	describe	the	pharmacokinetic	variability	of	piperacillin	in	these	patients	with	a	population	
pharmacokinetic	model;	and	(iii)	to	assess	the	pharmacokinetic/pharmacodynamic	profile	of	various	
piperacillin	dosing	regimens	and	to	assess	the	expected	probability	of	target	attainment	(PTA)	by	MIC	
against	bacterial	pathogens	commonly	encountered	in	critical	care	units.	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Random	numbers	selected	from	an	opaque	sealed	envelope.	Method	
of	number	generation	not	stated	
Allocation	concealment	(selection	
bias)	
Low	risk	 "….Opaque	sealed	envelope"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Open	label,	prescriber	selected	dose	(6	vs.	8	hourly)	in	the	bolus	group	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Open	label	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Clinical	outcome	reported	for	all	16	patients	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Mortality	not	stated	a	priori	
Other	bias	 High	risk	 Open	label	use	of	other	antibiotics	not	stated.	Both	groups	untypical	of	
the	normal	ICU	septic	patient	-	young	and	stable	(good	renal	function	
and	minimal	vasopressor	use)		
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Sakka	2007	 Population	pharmacokinetics	and	pharmacodynamics	of	continuous	versus	short-term	
infusion	of	imipenem-cilastatin	in	critically	ill	patients	in	a	randomised,	controlled	trial	
	
Method	 Prospective,	single	site,	randomised	controlled	trial	
Participants	 20	surgical	ICU	patients	(55%	male,	mean	ages	59	(intermittent)	to	62	(continuous)	years	old)	with	
ICU-aquired	pneumonia	and	normal	renal	function.	Exclusions:	renal	replacement	therapy	
Interventions	 1g/1g	imipenem/cilastatin	i.v.	over	40min	then	at	4	hours	2g/2g	per	24	hours	for	3	days	versus	1g/1g	
i.v.	over	40	mins	3	times	daily	for	3	days.	
Outcomes	 Pharmacokinetic	and	pharmacodynamic	analysis,	which	coveriates	best	predict	patient	survival	and	
imipenem	clearance	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 "….randomation	code	was	provided	to	the	clinical	investigator	in	
sealed	envelopes"	but	opacity	not	stated.	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 No	mention	of	blinding	highly	likely	to	be	un-blinded		
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 No	mention	of	blinding	highly	likely	to	be	un-blinded		
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Patients	lost	to	follow	up	not	explicitly	stated	but	outcomes	of	interest	
reported	for	all	20	patients	
Selective	reporting	(reporting	bias)	 Unclear	risk	 Reported	on	adverse	events	(not	stated	as	an	outcome	a	priori)	
Other	bias	 Unclear	risk	 "Antibiotic	pre-treatment	was	given	to	eight	patients	in	the	short-
term-infusion	group	(four	patients	pre-treated	with	ceftriaxone,	one	
with	cefuroxime,	two	with	piperacillin-tazobactam,	and	one	with	
moxifloxacin).	For	comparison,	nine	patients	in	the	continuous	group	
received	antibiotic	therapy	before	administration	of	imipenem-
cilastatin	(four	patients	pre-treated	with	ceftriaxone,	two	with	
cefuroxime,	two	with	piperacillin-	tazobactam,	and	one	with	
cefepime)."	Study	financially	supported	by	MSD		
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Schmelzer	2013	 Vancomycin	intermittent	dosing	versus	continuous	infusion	for	treatment	of	ventilator-
associated	pneumonia	in	trauma	patients	
	
Method	 Prospective,	randomised	controlled	trial	
Participants	 73	adult	(>18	years	old)	ICU	patients	(89%	males,	average	age	41.3	years	old	(intermittent	group)	and	
40.3	years	old	(continuous	group))	stated	on	empiric	vancomycin	after	bronchoalveolar	lavage	for	
suspected	VAP.	Exclusions:	abnormal	renal	function	(CrCl	<	60mL/min),	pregnancy,	ascites	or	known	
allergy	to	vancomycin	
Interventions	 Intermittent	group	started	on	15mg/kg	every	12	hours	with	a	pre	dose	level	checked	before	the	fifth	
dose.	Dose	adjusted	as	per	protocol	and	once	level	in	range	15-20mg/L	level	checked	every	7	days	
until	end	of	therapy.	Continuous	group	loaded	with	20	mg/kg	then	dosed	at	0.9-2.4	mg/kg/hour	
dependent	on	renal	function,	level	checked	after	48	hours	and	dose	adjusted	as	per	protocol	until	
level	in	range	15-25mg/L.	once	in	range	level	checked	every	7	days	until	end	of	therapy.	doses	
rounded	to	the	nearest	200mg	
Outcomes	 Attainment	of	a	level	in	the	appropriate	range	for	each	group	at	48	hours.	Number	of	levels	draw	
after	48	hours.	Number	of	dose	changes	required	until	discontinuation.	Total	cost.	Incidence	of	
nephrotoxicity.	Clinical	outcomes.	
Notes	 Study	not	powered	for	clinical	outcomes	so	although	collected	results	not	compared	between	groups.	
12	patients	enrolled	in	the	study	more	than	once.	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 "Patients	were	randomized	to	either	the	intermittent	or	the	
continuous	dosing	groups	using	computer-generated	random	number	
tables"	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Not	stated	but	highly	likely	to	be	unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Not	stated	but	highly	likely	to	be	unblinded	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 18	patients	were	withdrawn	from	the	study	as	a	result	of	
discontinuation	of	the	drug	before	48	hours	or	failure	to	draw	levels	at	
the	correct	time.	This	attrition	was	however	allowed	for	in	the	original	
sample	size	calculation	and	the	sample	size	in	each	group	was	still	met	
Selective	reporting	(reporting	bias)	 Unclear	risk	 All	outcomes	reported	on	except	clinical	outcome	for	which	the	data	
was	collected	but	as	the	study	was	powered	strictly	as	a	
pharmacokinetic	study	it	wasn't	compared	between	groups	or	
reported	in	the	paper	
Other	bias	 High	risk	 Funding	and	affiliations	not	stated.	Other	open	label	antibiotic	use	not	
discussed		
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van	Zanten	2007	 Continuous	vs.	intermittent	cefotaxime	administration	in	patients	with	chronic	
obstructive	pulmonary	disease	and	respiratory	tract	infections:	pharmacokinetics/	
pharmacodynamics,	bacterial	susceptibility	and	clinical	efficacy	
	
Method	 Prospective,	open-label,	randomised	controlled	study	
Participants	 93	hospitalised	patients	(69%	males,	mean	age	65.3	years	(continuous)	and	68.6	years	(intermittent))	
requiring	antibiotic	therapy	for	moderate	to	severe	acute	exacerbations	of	COPD	(GOLD	classes	2-4).	
Exclusions:	included	suspected	or	proven	resistance	to	cefotaxime,	administration	of	antibiotics	in	the	
preceding	48	hours,	allergy	to	B-lactam	antibiotics,	bilirubin	>20micromol/L,	serum	creatinine	
concentration	>120micromol/L	or	WCC	<3.0x109/L	
Interventions	 "Continuous	infusion	of	cefotaxime	(2	g	over	24	h)	after	an	initial	loading	dose	of	1	g	given	over	30	
min	(group	1),	or	cefotaxime	1	g	intravenously	in	three	dosages	per	day	at	intervals	of	8	h	infused	
over	a	period	of	30	min	(group	2)".	
Outcomes	 Clinical	assessment	(success,	failure,	non-evaluable).	Pharmacokinetic/pharmacodynamic	parameters.	
Evaluation	of	antibiotic	resistance	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 open	label	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 open	label	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 10	patients	excluded	including	5	deaths	"Of	the	93	patients	initially	
enrolled,	10	were	excluded	for	the	following	reasons:	death	due	to	
cardiac	failure	(n	=	5);	antibiotic	treatment	in	the	48-h	period	before	
initiation	of	cefotaxime	therapy	(n	=	2);	final	diagnosis	of	squamous	cell	
carcinoma	instead	of	infection	(n	=	1);	and	protocol	violations	(n	=	2).	
These	consisted	of	an	unintended	conversion	from	intermittent	to	
continuous	therapy	(n	=	1)	and	a	switch	to	oral	therapy	after	losing	
venous	access	(n	=	1).	Of	the	five	patients	who	died	after	inclusion	in	
the	study,	three	died	within	24	h	of	admission.	The	other	two	patients,	
one	in	group	1	and	one	in	group	2,	died	on	day	3	after	admission.	All	
patients	died	from	cardiac	causes	[congestive	heart	failure	(n	=	4)	or	
decompensated	cor	pulmonale	(n	=	1)].	None	of	these	cases	was	
thought	to	be	related	to	a	failure	of	antibiotic	treatment."	
Selective	reporting	(reporting	bias)	 Unclear	risk	 All	a	priori	outcomes	included	but	drug	related	adverse	events	also	
included	in	results	
Other	bias	 Unclear	risk	 "The	manufacturer	of	cefotaxime,	Hoechst	Marion	Roussel,	provided	a	
restricted	research	grant	for	analysing	serum	cefotaxime	
concentrations	and	for	assessing	MIC	values."		
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Wright	1979	 Gentamicin	and	penicillin	in	the	treatment	of	severe	respiratory	infections	
	
Method	 Prospective,	randomised	controlled	trial	
Participants	 36	patients	(male/female	split	not	documented,	age	range	11	-	73	years	old)	mechanically	ventilated	
on	a	respiratory	ICU	with	either	1)	severe	pneumonia,	2)	COPD	with	super	infection	or	3)	"shock	lung"	
or	"adult	respiratory	distress	syndrome".	Exclusions	not	explicitly	stated		
Interventions	 "Group	A	received	penicillin	5000000	units	in	5%	dextrose	water	by	rapid	intravenous	bolus	injection	
every	6	hours	and	gentamicin	60	mg/m'	in	5%	dextrose	water	every	8	hours	by	intravenous	bolus	
administration	over	half	an	hour.	Group	B	received	the	same	penicillin	regimen	but	the	gentamicin	
was	infused	over	8	hours	by	a	constant	infusion	pump	after	an	initial	loading	dose	calculated	by	the	
same	formula"	dose	adjusted	for	renal	dysfunction	
Outcomes	 None	stated	
Notes	 	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Not	stated	but	assume	not	blinded	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 Not	stated	but	assume	not	blinded	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 36	patients	involved	in	trial	and	all	followed	up	but	levels	only	included	
in	the	results	for	30	patients	
Selective	reporting	(reporting	bias)	 Unclear	risk	 No	outcomes	stated	a	priori	
Other	bias	 Unclear	risk	 use	of	other	open	label	antibiotics	not	clear.	Funding	and	conflicts	of	
interest	not	stated.	Groups	markedly	different	sizes	(bolus	13	patients,	
constant	infusion	23	patients).	ARDS/shock	lung	not	necessarily	caused	
by	infection.		
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Wysocki	2001	 Continuous	versus	Intermittent	Infusion	of	Vancomycin	in	Severe	Staphylococcal	
Infections:	Prospective	Multicenter	Randomized	Study	
	
Method	 Multicentre	prospective	randomised	controlled	study	
Participants	 160	patients	from	10	medico-surgical	ICUs	(Male	65%,	mean	age	63	years	old)	given	vancomycin	for	
MRSA	infections	(suspected	or	well	established)	acquired	72	h	after	admission.	Exclusion:	received	
vancomycin	72	h	before	current	infection,	beta-lactam	allergy,	previously	included	in	the	same	
protocol,	or	currently	in	another	protocol	
Interventions	 Vancomycin	15	mg/kg	i.v.	Infused	over	60	minutes,	followed	by	30	mg/kg	continuous	infusion	vs	
vancomycin	15	mg/kg	i.v.	Infused	over	60	minutes	q12h;	mean	treatment	duration	range	13	to	14	
days	
Outcomes	 Efficacy;	safety;	pharmacokinetics,	treatment	adjustments	and	monitoring;	cost	
Notes	 Multicentre	prospective	randomised	controlled	study	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 “Randomisation	was	stratified	by	centre	using	a	random-number	table	
and	a	block	randomisation	method	with	a	block	size	of	8”	
Allocation	concealment	(selection	
bias)	
Low	risk	 “The	infusion	mode	was	contained	in	sealed	opaque	envelopes	
labelled	consecutively	with	the	randomisation	numbers”		
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 “Clinical	failure	was	first	evaluated	by	local	investigators,	and	since	the	
treatment	was	not	administered	in	a	blinded	fashion,	a	committee	
blinded	to	the	infusion	mode	reviewed	the	charts	from	patients	with	
clinical	failure,	aswell	as	those	of	all	of	the	study	patients	who	died	in	
the	ICU”	Patients	and	clinicians	were	not	blinded	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 “Clinical	failure	was	first	evaluated	by	local	investigators,	and	since	the	
treatment	was	not	administered	in	a	blinded	fashion,	a	committee	
blinded	to	the	infusion	mode	reviewed	the	charts	from	patients	with	
clinical	failure,	aswell	as	those	of	all	of	the	study	patients	who	died	in	
the	ICU”	Patients	and	clinicians	were	not	blinded	
Incomplete	outcome	data	
(attrition	bias)	
High	risk	 160	patients	randomly	assigned	but	only	119	analysed	
Selective	reporting	(reporting	bias)	 High	risk	 “After	reviewing	clinical,	laboratory,	radiological,	and	pathological	
findings,	the	committee	decided	by	consensus	if	death	could	
reasonably	be	attributed	to	the	staphylococcal	infection”	stated	
analysis	carried	out	on	an	intention	to	treat	bases	but	this	is	not	the	
case	
Other	bias	 High	risk	 Administration	of	non-glycopeptide	antibiotics	in	combination	with	
vancomycin	was	permitted	(and	was	only	reported	if	>	5	d	use).	Author	
conflict	of	interest	not	stated.		
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Bao	2017	 Clinical	outcomes	of	extended	versus	intermittent	administration	of	
piperacillin/tazobactam	for	the	treatment	of	hospital-acquired	pneumonia:	a	
randomized	controlled	trial	
	
Method	 Single	centre,	prospective,	single	blinded,	randomised	controlled	trial	
Participants	 50	adult	ICU	patients	(58%	male,	median	age	71	(range	56	-	82))	with	hospital-acquired	pneumonia.	
Exclusions	"severe	pyemia	with	hypotension	or/and	evidences	of	failure	of	organ	function	(shock:	
systolic	pressure	<90	mmHg	or	diastolic	pressure	<60	mmHg,	requiring	more	than	4	h	of	
administration	of	vasopressor	agents;	renal	impairment:	urine	volume	<20	mL/h	or	<80	mL/4	h	after	
excluding	any	other	potentials;	acute	renal	failure	requiring	dialysis;	creatinine	clearance	(CLcr)	<40	
mL/min).	Other	exclusion	criteria	were:	documented	infection	caused	by	pathogens	beyond	the	
antibacterial	spectrum	of	piperacillin/tazobactam;	previously	diagnosed	repeated	lung	infection	(e.g.,	
bronchial	obstruction,	ob-	structive	pneumonia,	pulmonary	abscess,	empyema,	and	active	
tuberculosis);	history	of	allergy	to	penicillins;	pregnancy	or	breast-feeding	women."	
Interventions	 "Patients	were	randomized	to	receive	piperacillin/tazobactam	4/0.5	g	administered	either	over	30	
min	every	6	h	as	the	II	group	or	3	h	every	6	h	as	the	EI	group	using	a	syringe	pump	via	a	central	
venous	catheter"	for	a	duration	of	7	to	14	days.	Use	of	placebo	not	mentioned.	Requirement	for	
additional	open	label	antibiotics	classed	as	clinical	failure	
Outcomes	 Clinical	outcome	(success	or	failure),	pk/pd	parameters,	adverse	events,	cost	
Notes	 Inclusion	criteria	state	age	range	18-70	years	but	median	age	in	both	groups	71	with	a	range	of	56	to	
80	in	the	II	group	and	82	in	the	EI	group	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomized	by	the	institution	with	1:1	allocation	to	each	arm	but	
method	of	randomisation	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 Allocation	status	determined	by	opening	sequentially	numbered	sealed	
envelopes	but	opacity	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Unblinded	research	nurse	or	pharmacist	was	responsible	the	
preparation	of	the	blinded	drug	but	unclear	if	that	person	then	had	any	
further	involvement	in	the	care	of	the	patient.	Patients	administered	
either	a	30	min	or	3	hour	infusion	without	a	placebo	therefore	at	the	
very	least	the	nursing	staff	would	be	unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 As	above	
Incomplete	outcome	data	
(attrition	bias)	
Unclear	risk	 52	patients	originally	enrolled	but	2	were	withdrawn,	one	withdrew	
informed	consent,	one	creatinine	clearance	diminished	severely	after	
enrolment.	Remaining	50	patients	reported	in	final	findings	
Selective	reporting	(reporting	bias)	 Low	risk	 All	pre-stated	outcomes	reported	
Other	bias	 Low	risk	 No	conflicts	of	interest.	Nationally	funded.	Concomitant	antibiotic	use	
documented	and	deemed	as	clinical	failure			
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Fan	2017	 Clinical	outcomes	of	extended	versus	intermittent	infusion	of	piperacillin/tazobactam	in	
critically	ill	patients:	a	prospective	clinical	trial	
	
Method	 single-centre,	open-label,	prospective,	randomised	clinical	trial	
Participants	 367	adults	patients	(67%	males,	mean	age	69	in	EI	group	and	70	in	non-EI	group)	on	a	mixed	
medical/surgical	ICU	with	bacterial	infection	or	neutropenic	fever.	Excisions:	"pregnancy;	received	
more	than	48	hours	of	treatment	with	effective	antibiotics	(defined	by	specimen	culture	and	
sensitivity	results)	within	5	days	before	the	initiation	of	EI	or	Non-EI	infusion	piperacillin/tazobactam;	
or	concomitant	use	of	β-lactam	antibiotics."	
Interventions	 EI	group,	piperacillin/tazobactam	was	dosed	according	to	renal	function,	at	4.5	g	every	8–12	hours	
and	infused	over	4	hours.	Non-EI	group,	dosed	according	to	renal	function,	at	4.5	g	every	6–8	hours	
for	normal	renal	function,	and	infused	over	30	minutes	
Outcomes	 Primary	clinical	outcome	was	14	day	mortality.	Secondary	clinical	outcomes	included	in-hospital	
mortality	rate,	time	to	defervescence	(defined	as	the	first	day	when	oral,	tympanic,	or	axillary	
temperature	was	<	38.0°C	or	when	rectal	or	core	temperature	was	<	38.5°C	for	the	entire	24	hours	in	
patients	who	had	baseline	temperatures	above	this	range	and	who	were	considered	a	clinical	success	
at	the	test	of	cure),	duration	of	mechanical	ventilatory	support,	length	of	ICU	stay,	and	duration	of	
hospital	stay	
Notes	 Single-centre,	open-label,	prospective,	randomised	clinical	trial	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 A	computer-generated	unique	hospital	number	was	assigned	to	each	
patient	on	admission	to	the	hospital.	Patients	whose	hospital	number	
ended	with	an	even	number	(excluding	the	last	checking	digit)	were	
assigned	to	the	EI	group,	whereas	those	whose	hospital	number	ended	
with	an	odd	number	were	assigned	to	the	non-EI	group	
Allocation	concealment	(selection	
bias)	
High	risk	 intensivists	and	investigators	could	predict	assignment	as	this	was	
fixed	and	defined	in	the	protocol	i.e.	even	hospital	numbers	received	EI	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 both	intensitist	and	investigator	unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
High	risk	 both	intensitist	and	investigator	unblinded	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 466	patients	assessed	for	eligibility	and	those	excluded	clearly	
accounted	for.	375	assigned	to	a	group	but	8	patients	received	the	
incorrect	method	of	administration	leaving	the	367	patients	for	
analysis	therefore	all	patients	accounted	for.	
Selective	reporting	(reporting	bias)	 Unclear	risk	 all	outcomes	stated	a	priori	reported	plus	adverse	events	
Other	bias	 Unclear	risk	 Concomitant	antibiotic	use	only	discussed	between	survivor	and	
nonsurvivors	so	split	between	treatment	groups	not	described.	No	
specific	mention	of	funding.		
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Ram	2018	 Extended	versus	bolus	infusion	of	broad	spectrum	β-lactams	for	febrile	neutropenia:	an	
un-blinded	randomized	trial	
	
Method	 Single-centre,	open-label,	un-blinded,	prospective	randomised	controlled	trial	
Participants	 105	adults	(72%	(bolus)	and	77%	(EI)	males,	median	age	60.1	(bolus)	and	60.4	(EI))	undergoing	
hematopoietic	cell	transplantation	or	receiving	induction	or	consolidation	chemotherapy	for	acute	
leukaemia	with	febrile	neutropenia.	Exclusion:	"....scheduled	for	outpatient	follow-up	during	
neutropenia,	receiving	maintenance	chemotherapy	for	acute	lymphoblastic	leukemia,	and	if	their	
calculated	creatinine	clearance	was	less	than	40	ml/min.	Patients	infected	or	colonized	with	bacteria	
resistant	to	study	antibiotics	within	30	days	prior	to	enrolment	were	also	excluded	from	this	study"	
Interventions	 Piperacillin-tazobactam	(4.5	g	intravenously	every	8	hours),	or	ceftazidime	(2	g	intravenously	every	8	
hours)	in	case	of	a	documented	history	of	penicillin	allergy.	Intermittent	bolus	infusion	=	30-minute	
infusion,	or	extended	infusion	=		administered	over	4	hours.	Patients	in	the	extended	infusion	arm	
received	a	single	loading	dose	of	study	medication	over	30	minutes,	followed	6	hours	later	by	the	first	
extended	infusion	of	study	medication.	Vancomycin,	amikacin	and	fluroquinolones	were	allow	for	
specified	indications	as	per	local	guidance.		
Outcomes	 The	primary	study	end-point	was	overall	response	on	day	4	post	symptom	onset,	defined	as	a	
composite	of	4	criteria:	1.	Resolution	of	fever	for	at	least	24	hours;	2.	Microbiological	eradication	(for	
microbiologically	documented	infection):	sterile	cultures	on	days	3	and	4;	3.	Clinical	response	(for	
clinically	documented	infection):	resolution	of	signs	and	symptoms	of	infection;	and	4.	No	need	for	a	
change	in	the	antibiotic	regimen	(addition	of	an	aminoglycoside	or	a	fluoroquinolone	within	48	hours	
of	initiating	treatment	was	not	considered	treatment	failure).	Treatment	was	considered	successful	if	
all	criteria	were	met.	
Secondary	end	points	were:	1.	Breakthrough	bloodstream	infection	≥5	days	after	initiation	of	
treatment;	2.	Recurrent	fever	≥5	days	after	initiation	of	treatment;	3.	Infection	with	Clostridium	
difficile.	4.	Death	within	30	days	of	enrolment	into	study;	5.	Duration	of	hospitalization;	6.	Acute	
kidney	injury	(doubling	of	serum	creatinine	level)	within	4	days;	and	7.	Use	of	noradrenaline	due	to	
persistent	hypotension.	
Notes	 Adequately	powered	according	to	own	calculation	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Low	risk	 "Enrolment	and	randomization	were	done	prior	to	hospital	admission	
for	HCT	patients	and	before	starting	chemotherapy	for	patients	with	
acute	leukemia.	Patients	were	randomly	assigned	in	advance	at	a	1:1	
ratio	using	computerized	random	number	generation	to	receive	either	
bolus	infusion	or	extended	infusion	of	β-lactam	in	case	of	a	febrile	
neutropenia."	
Allocation	concealment	(selection	
bias)	
Low	risk	 "Allocation	was	concealed	in	sequentially	numbered	sealed	opaque	
envelopes	which	were	opened	by	a	study	coordinator	who	marked	the	
patient's	file	with	the	allocation	arm"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
Low	risk	 "Study	endpoints	were	assessed	by	study	investigators	who	were	
blinded	to	each	participant’s	random	assignment"	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 123	patients	enrolled,	105	patients	had	febrile	episodes	so	were	
included	in	ITT	analysis,	91	patients	were	included	in	per-protocol	
analysis.	All	patient	accounted	for,	no-one	lost	to	follow	up	
Selective	reporting	(reporting	bias)	 Low	risk	 All	primary	outcomes	reported	in	both	ITT	and	per-protocol	groups	
Other	bias	 Unclear	risk	 Study	funding	not	stated,	"RB	received	consulting	fees	from	Merck	Ltd.	
and	Pfizer	pharmaceuticals."		
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Yang	2017	
Clinical	effect	and	efficacy	factors	of	modified	piperacillin-tazobactam	dosing	regimens	
in	abdominal	tumor	patients	with	post-operative	pneumonia	
	
Method	 Prospective	randomised	controlled	trial	
Participants	 100	adults	(58%	males,	average	age	68.34	years)	with	pneumonia	after	abdominal	tumor	surgery	who	
exhibited	no	pre-operative	heart	or	lung	disease	or	respiratory	dysfunction	during	the	operation	or	
anaesthesia	and	they	had	no	lung	metastesis.	The	patients	underwent	radical	excision	of	their	tumor	
and	had	no	post	operative	bleeding,	fistula	formation	or	cardiac	dysfunction.	Drug	susceptibility	
testing	showed	an	MIC	of	4,	8,	or	16	mcg/mL	for	TZP.	Exclusions:	infection	or	antibiotics	for	more	than	
48	before	admission,	kidney	injury,	infection	with	TZP-insensitive	organism,	recurrent	pulmonary	
infection	due	to	previously	existing	factors,	penicillin	allergy,	pregnant/lactating	females,	"those	with	
any	factor	likely	to	increase	patients'	risk	or	interfere	with	the	clinical	trial."	
Interventions	 Patients	were	split	into	4	groups	of	25:	simple	pneumonia,	pneumonia	with	pleural	effusion,	
pneumonia	and	atelectasis,	and	severe	pneumonia.	These	groups	were	then	divided	randomly	into	a	
control	group	(n=12)	and	a	treatment	group	(n-13).	Control	group	TZP	4.5g	6h	by	regular	infusion	over	
30	minutes	or	treatment	group	same	dose	over	3	hours	
Outcomes	 Cure/healing	time	
Notes	 Unable	to	extract	relevant	outcomes	from	the	published	data	therefore	not	included	in	meta-analysis	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 randomised	but	method	not	stated	
Allocation	concealment	(selection	
bias)	
Unclear	risk	 randomised	but	method	not	stated	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 unblinded	
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 not	stated	if		assessor	were	blinded	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 all	patients	reported	on	in	the	final	results	
Selective	reporting	(reporting	bias)	 Low	risk	 all	outcomes	stated	a	priori	reported	
Other	bias	 Low	risk	 No	apparent	conflicts	of	interest	or	problems	with	funding		
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Zhao	2017	 Pharmacokinetic	and	Pharmacodynamic	Efficacies	of	Continuous	versus	Intermittent	
Administration	of	meropenem	in	Patients	with	Severe	Sepsis	and	Septic	Shock:	A	
Prospective	Randomized	Pilot	Study	
	
Method	 Single-centre,	prospective,	randomised,	comparative	study	
Participants	 50	adults	(42%	males,	average	age	68	in	continuous	group	and	67	in	intermittent	group)	diagnosed	
with	severe	sepsis	or	septic	shock	and	admitted	to	the	ICU,	received	meropenem	therapy,	and	
provided	informed	consent	were	included	in	the	study,	concomitant	antimicrobial	therapy	was	
permitted.	Exclusion:	age	<18	years,	pregnancy,	acute	or	chronic	renal	failure	with	a	glomerular	
filtration	rate	(GFR;	calculated	with	the	Cockcroft	formula)	<50	ml/min,	immunodeficiency	or	taking	
immunosuppressant	medication,	allergy	to	meropenem,	and	previous	application	of	meropenem	in	
the	past	2	weeks.	
Interventions	 The	patients	in	the	continuous	group	received	a	loading	dose	of	0.5	g	of	meropenem	in	100	ml	of	
normal	saline	i.v.	infused	over	30	min	followed	immediately	by	continuous	infusion	of	3	g	of	
meropenem	over	24	h.	The	patients	in	the	intermittent	group	received	the	first	dose	of	1.5	g	of	
meropenem	in	100	ml	of	normal	saline	infused	over	30	min,	and	then	1	g	in	100	ml	of	normal	saline	
infused	over	30	min	for	every	8	h.	The	dose	for	both	groups	on	day	1	was	3.5	g	and	3	g/day	
thereafter.	
Outcomes	 Primary:	clinical	Success	(complete	or	partial	resolution)/failure,	microbiological	outcomes	inc.	
eradication	and	superinfection.	Secondary:ICU	mortality,	length	of	ICU	stay,	duration	of	meropenem	
therapy	
Notes	 Single-centre,	prospective,	randomised,	comparative	study	
Risk	of	bias	
Bias	 Judgement	 Support	
Random	sequence	generation	
(selection	bias)	
Unclear	risk	 Randomised	but	method	not	stated	-	"randomized	into	equally	
numbered	groups	using	sealed	opaque	envelopes	without	
stratification."	
Allocation	concealment	(selection	
bias)	
Low	risk	 "randomized	into	equally	numbered	groups	using	sealed	opaque	
envelopes"	
Blinding	of	participants	and	
researchers	(performance	bias)	
High	risk	 Not	stated	and	researchers	"not	involved	in	clinical	stratergy"	but	
patient	and	staff	would	be	aware	of	which	group	they	had	been	
allocated	to		
Blinding	of	outcome	assessment	
(detection	bias)	
Unclear	risk	 Not	stated,	reasearchers	not	involved	in	clinical	stratergy	
Incomplete	outcome	data	
(attrition	bias)	
Low	risk	 Outcomes	of	interest	stated	for	all	participants	
Selective	reporting	(reporting	bias)	 Low	risk	 All	prestated	outcomes	of	interest	reported	
Other	bias	 Unclear	risk	 No	conflicts	of	interest	stated,	funded	by	Chinese	Medical	Association,	
concomitant	use	of	antibiotics	not	commented	on		
Appendix	9:	Summary	of	the	outcomes	for	each	article	
Study	
Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Abdul-Aziz	
2016	
P/T,	M,	
Cefepime	
T	 CI	 Clincal	Cure	at	14/7	(1)	 all	ITT	
(mITT/PP	
in	supp	
tables)	
actual	
numbers	
39	 70	 24	 70	 	 	 	 	
	 	 	 	 Pip/taz	 	 	 22	 38	 15	 47	 	 	 	 	
	 	 	 	 Mero	 	 	 14	 21	 8	 21	 	 	 	 	
	 	 	 	 Cefepime	 	 	 3	 11	 1	 2	 	 	 	 	
	 	 	 	 ICU-free	days	(2)	 	 Median		 	 	 	 	 20	 	 17	 	
	 	 	 	 ventilator	free	days	(2)	 	 Median		 	 	 	 	 22	 	 14	 	
	 	 	 	 Survival	at	14/7	(2)	 	 actual	
numbers	
56	 70	 50	 70	 	 	 	 	
	 	 	 	 Survival	at	30/7	(2)	 	 actual	
numbers	
52	 70	 44	 70	 	 	 	 	
	 	 	 	 AE	(-)	 	 actual	
numbers	
0	 70	 0	 70	 	 	 	 	
Adembri	
2008	
Linezolid	 T	 CI	 Clinical	Cure	(1?)	 PP	 actual	
numbers	
6	 8	 6	 8	 	 	 	 	
	 	 	 	 Microbiological	Cure	(1?)	 PP	 actual	
numbers	
8	 9	 7	 11	 	 	 	 	
Angus	
2000	
Ceftazidime	 T	 CI	 All	cause	mortality	(-)	 *	 actual	
numbers	
3	 10	 9	 11	 	 	 	 	
Bodey	
1979	
C/C	 T	 CI	 Cure	 data	from	episodes	not	
patients	therefore	excluded	
from	MA	
	 	 	 	 	 	 	
	 	 	 	 Relapse	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 Superinfection	 	 	 	 	 	 	 	 	 	 	
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Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Buck	2005	 P/T	 T	 CI	 Responsea	 ITT	 actual	
numbers	
8	 12	 8	 12	 	 	 	 	
Chytra	
2012	
M	 T	 CI	 Clinical	Cure	
(cured/improved)(1)	
ITT	 actual	
numbers	
88	 120	 81	 120	 	 	 	 	
	 	 	 	 Clinical	Cure	
(cured/improved)(1)	
CE	 actual	
numbers	
88	 106	 81	 108	 	 	 	 	
	 	 	 	 Clinical	Cure	 ITT	 actual	
numbers	
30	 120	 24	 120	 	 	 	 	
	 	 	 	 Clinical	Cure	 CE	 actual	
numbers	
30	 106	 24	 108	 	 	 	 	
	 	 	 	 post	hoc	sub	groups	(1)	 all	PP	 actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 1a)	cultures	based	 	 	 86	 100	 75	 101	 	 	 	 	
	 	 	 	 1b)	Empirical	 	 	 4	 6	 6	 7	 	 	 	 	
	 	 	 	 2)without	conc.	Abx	tx	
against	G-	
	 	 80	 95	 76	 102	 	 	 	 	
	 	 	 	 3)	APACHE	II	>20	 	 	 37	 49	 42	 53	 	 	 	 	
	 	 	 	 4)	MIC	>	or	=1.5mg/L	 	 	 10	 14	 12	 21	 	 	 	 	
	 	 	 	 Microbiological	Cure	(1)	 PP	 actual	
numbers	
87	 96	 80	 102	 	 	 	 	
	 	 	 	 i)	verified	 	 	 67	 96	 62	 102	 	 	 	 	
	 	 	 	 ii)	presumed	 	 	 20	 96	 18	 102	 	 	 	 	
	 	 	 	 post	hoc	sub	groups	(1)	 all	PP	 actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 1a)	cultures	based	 	 	 82	 90	 74	 95	 	 	 	 	
	 	 	 	 1b)	Empirical	 	 	 5	 6	 5	 7	 	 	 	 	
	 	 	 	 2)without	conc.	Abx	tx	
against	G-	
	 	 77	 85	 75	 96b	 	 	 	 	
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Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Chytra	
2012	
M	 T	 CI	 3)	APACHE	II	>20	 	 	 41	 47	 36	 49	 	 	 	 	
	 	 	 	 4)	MIC	>	or	=1.5mg/L	 	 	 11	 14	 13	 21	 	 	 	 	
	 	 	 	 meropenem	related	
length	of		
all	ITTand	
PP	
	 	 	 	 	 	 	 	 	
	 	 	 	 1)	mechanical	vent.	(2)	 ITT	 Median		 	 	 	 	 9	 	 11	 	
	 	 	 	 	 PP	 	 	 	 	 	 9	 	 12	 	
	 	 	 	 2)	ICU	stay,	LOS	(2)	 ITT	 Median		 	 	 	 	 10	 	 12	 	
	 	 	 	 	 PP	 	 	 	 	 	 10	 	 13	 	
	 	 	 	 3)	Hospital	stay,	LOS	(2)	 ITT	 Median		 	 	 	 	 26	 	 22	 	
	 	 	 	 	 PP	 	 	 	 	 	 28	 	 25	 	
	 	 	 	 ICU	mortality	(2)	 ITT	 actual	
numbers	
18	 120	 25	 120	 	 	 	 	
	 	 	 	 	 PP	 	 14	 106	 17	 108	 	 	 	 	
	 	 	 	 in	hospital	mortality	(2)	 ITT	 actual	
numbers	
21	 120	 28	 120	 	 	 	 	
	 	 	 	 	 PP	 	 17	 106	 19	 108	 	 	 	 	
	 	 	 	 duration	of	M	tx	(2)	 ITT	 Median	
(days)	
	 	 	 	 7	 	 8	 	
	 	 	 	 	 PP	 	 	 	 	 	 7	 	 8	 	
	 	 	 	 total	M	dose	(2)	 ITT	 Median	
(dose	in	
g)	
	 	 	 	 24	 	 48	 	
	 	 	 	 	 PP	 	 	 	 	 	 24	 	 48	 	
	 	 	 	 safety	(2)	 ITT	
(episodes)	
actual	
numbers	
10	 120	 12	 120	 	 	 	 	
	 	 	 	 withdrawal	due	to	
adverse	events	(-)	
ITT	 actual	
numbers	
0	 120	 0	 120	 	 	 	 	
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Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Chytra	
2012	
M	 T	 CI	 Superinfection	(-)	 PP	 actual	
numbers	
7	 96	 8	 102	 	 	 	 	
Cotrina-
Luque	
2016	
P/T	 T	 CI	 Clinical	responsec;	end	of	
Tx(1)	
ITT	 actual	
numbers	
26	 40	 32	 38	 	 	 	 	
	 	 	 	 Clinical	Cure	at	end	of	
Txw	
ITT	 actual	
numbers	
7	 40	 12	 38	 	 	 	 	
	 	 	 	 Microbiological	
response;	end	of	Tx	(2)	
ITT	 actual	
numbers	
2	 32	 2	 25	 	 	 	 	
	 	 	 	 Microbiological	
response;	day	3	(2)	
ITT	 actual	
numbers	
2	 32	 2	 25	 	 	 	 	
	 	 	 	 Time	to	microbiological	
cure	(2)	
ITT	 Median	
(days)	
	 	 	 	 3	 	 3	 	
	 	 	 	 Clincal	responsec;	day	3	
(2)	
ITT	 actual	
numbers	
18	 33	 17	 29	 	 	 	 	
	 	 	 	 Time	to	defervescence	
(2)	
ITT	 Median	
(days)	
	 	 	 	 2	 	 3	 	
	 	 	 	 %	patients	switched	to	
oral	(2)	
ITT	 actual	
numbers	
8	 40	 11	 38	 	 	 	 	
	 	 	 	 Antibiotic-free	periodd	(2)	 ITT	 	 	 	 	 	 	 	 	 	
De	Jongh	
2008	
Temocillin	 T	 CI	 Clinical	outcome	
successful	(-)	
**	 actual	
numbers	
6	 6	 6	 6	 	 	 	 	
	 	 	 	 survival	at	28	days	(-)	 **	 actual	
numbers	
6	 6	 6	 6	 	 	 	 	
Dulhunty	
2013	
P/T,	M,	T/C	 T	 CI	 Clinical	response;		7-14/7	
post	abx	stopped	(2)	
ITT	 actual	
numbers	
23	 30	 15	 30	 	 	 	 	
	 	 	 	 ICU	mortality	(2)e	 ITT	 actual	
numbers	
2	 30	 4	 30	 	 	 	 	
Study	
Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Dulhunty	
2013	
P/T,	M,	T/C	 T	 CI	 in	hospital	mortality	(2)e	 ITT	 actual	
numbers	
3	 30	 6	 30	 	 	 	 	
	 	 	 	 ICU-free	days	(2)	 ITT	 Median	
(days)	
	 	 	 	 19.5	 	 17	 	
	 	 	 	 Adverse	events	(2)	 ITT	 actual	
numbers	
0	 30	 0	 30	 	 	 	 	
Dulhunty	
2015	
P/T,	M,	T/C	 T	 CI	 Alive	ICU-free	days	(1)	 all	ITT	
(mITT/PP	
in	supp	
tables)	
Median	
(days)	
	 	 	 	 18	 	 20	 	
	 	 	 	 Alive	ICU-free	days;	ICU	
survivors	(-)	
	 Median	
(days)	
	 	 	 	 21	 	 22	 	
	 	 	 	 Day	90	mortality	(2)	 	 actual	
numbers	
156	 212	 158	 220	 	 	 	 	
	 	 	 	 ICU	survival	(-)	 	 actual	
numbers	
180	 212	 182	 220	 	 	 	 	
	 	 	 	 Hospital	survival	(-)	 	 actual	
numbers	
168	 212	 164	 220	 	 	 	 	
	 	 	 	 Clinical	cure;	14/7	post	
abx	cessation	(2)	
	 actual	
numbers	
111	 212	 109	 220	 	 	 	 	
	 	 	 	 Alive	organ	failure	free	
days	(2)	
	 Median	
(days)	
	 	 	 	 6	 	 6	 	
	 	 	 	 Duration	of	bacteremia	
post	randomisation	(2)	
	 Median	
(days)	
	 	 	 	 0	 	 0	 	
	 	 	 	 ICU	length	of	stay	(-)	 	 Median	
(days)	
	 	 	 	 7	 	 6	 	
	 	 	 	 Hospital	length	of	stay	(-)	 	 Median	
(days)	
	 	 	 	 16	 	 14	 	
	 	 	 	 Adverse	events	(-)	 	 actual	
numbers	
20	 212	 28	 220	 	 	 	 	
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Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
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Form?	 EI	
Event	
EI	
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Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Dulhunty	
2015	
P/T,	M,	T/C	 T	 CI	 Serious	adverse	events	(-
)	
	 actual	
numbers	
19	 212	 25	 220	 	 	 	 	
Feld	1977	 Sisomicin	 C	 CI	 Clincal	Cure	(1?)	 episodes	
(exclude)	
actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 Mortality	(-)	 ITT	 actual	
numbers	
8	 63	 6	 57	 	 	 	 	
	 	 	 	 Superinfection	(1?)	 can't	find	 actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 Nephrotoxicity	(-)	 episodes	
(exclude)	
actual	
numbers	
	 	 	 	 	 	 	 	
Feld	1984	 Tobramycin	 C	 CI	 Response	(-)	 episodes	
(exclude)	
actual	
numbers	
10	 12	 17	 22	 	 	 	 	
	 	 	 	 Mortality	(-)	 pts	with	
proven	
infection	
actual	
numbers	
2	 10	 5	 16	 	 	 	 	
	 	 	 	 Nephrotoxicity	(-)	 evaluable	
patients	
actual	
numbers	
2	 28	 6	 40	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT?	 actual	
numbers	
2	 30	 1	 40	 	 	 	 	
Georges	
2005	
Cefepime	 T	 CI	 Clinical	cure	(2?)	 PP	 actual	
numbers	
22	 26	 16	 24	 	 	 	 	
	 	 	 	 days	of	ventilation	(2?)	 PP	 Mean	
(days)	
	 	 	 	 24	 	 25	 	
	 	 	 	 days	on	ICU	(2?)	 PP	 Mean	
(days)	
	 	 	 	 34	 	 40	 	
	 	 	 	 Clinical	failure	(2?)	 PP	 actual	
numbers	
4	 26	 7	 24	 	 	 	 	
	 	 	 	 Bacteriological	cure	(2?)	 PP	 actual	
numbers	
18	 26	 13	 24	 	 	 	 	
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Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
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Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Georges	
2005	
Cefepime	 T	 CI	 No	eradication	(2?)f	 PP	 actual	
numbers	
2	 26	 3	 24	 	 	 	 	
	 	 	 	 Failure	(2?)	 PP	 actual	
numbers	
1	 26	 2	 24	 	 	 	 	
	 	 	 	 Overinfection	(2?)	 PP	 actual	
numbers	
3	 26	 4	 24	 	 	 	 	
	 	 	 	 Mortality	(2?)	 PP	 actual	
numbers	
3	 26	 3	 24	 	 	 	 	
Hanes	
2000	
Ceftazidime	 T	 CI	 Clinical	response	(1?)g	 PP	 actual	
numbers	
9	 16	 10	 14	 	 	 	 	
	 	 	 	 superinfection	(-)	 PP	 actual	
numbers	
7	 16	 3	 14	 	 	 	 	
	 	 	 	 days	of	ventilation	(-)	 	PP	 Mean	
(days)	
	 	 	 	 13.3	 	 22.9	 	
	 	 	 	 days	on	ICU	(-)	 PP	 Mean	
(days)	
	 	 	 	 15.5	 	 26.8	 	
	 	 	 	 hospital	stay	(-)	 PP	 Mean	
(days)	
	 	 	 	 28.7	 	 41.7	 	
Lagast	
1983	
Cefoperazone	 T	 CI	 Clinical	cure	(1?)	 ITT	 actual	
numbers	
14	 20	 20	 25	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1?)h	 ITT	 actual	
numbers	
n/a	 n/a	 n/a	 n/a	 	 	 	 	
	 	 	 	 Superinfection	(1?)	 ITT	 actual	
numbers	
2	 20	 1	 25	 	 	 	 	
	 	 	 	 Death	(1?)	 ITT	 actual	
numbers	
5	 20	 4	 25	 	 	 	 	
	 	 	 	 withdrawal	due	to	
adverse	events	(-)	
ITT	 actual	
numbers	
0	 20	 0	 25	 	 	 	 	
Study	
Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
total	
Standard	
Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Laterre	
2015i	
Temocillin	 T	 CI	 Clinical	cure	(-)	 ITT	 actual	
numbers	
13	 14	 11	 14	 	 	 	 	
	 	 	 	 Overall	ICU	mortality	(-)	 ITT	 actual	
numbers	
2	 14	 5	 14	 	 	 	 	
	 	 	 	 Adverse	reaction	(-)	 ITT	 actual	
numbers	
1	 14	 0	 14	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT	 actual	
numbers	
1	 14	 0	 14	 	 	 	 	
Lau	2006	 P/T	 T	 CI	 Clincal	success	(1)j	 mITT	 actual	
numbers	
96	 128	 104	 130	 	 	 	 	
	 	 	 	 	 CE	 actual	
numbers	
70	 81	 76	 86	 	 	 	 	
	 	 	 	 	 BE	 actual	
numbers	
46	 56	 49	 58	 	 	 	 	
	 	 	 	 Bacteriological	response	
(2)k	
BE	 actual	
numbers	
47	 56	 51	 58	 	 	 	 	
	 	 	 	 Time	to	defervescence	
(2)	
	 median	
(days)	
	 	 	 	 3	 2	to	
8	
3	 2	to	
6	
	 	 	 	 Time	to	WBC	
normalisation	(2)	
	 Median	
(days)	
	 	 	 	 3	 2	to	
11	
3	 2	to	
11	
	 	 	 	 safety	(2)	(adverse	
events)l	
mITT	 actual	
numbers	
22	 130	 18	 132	 	 	 	 	
	 	 	 	 as	above	but	all	 mITT	 actual	
numbers	
116	 130	 115	 132	 	 	 	 	
	 	 	 	 safety	(2)	(withdrawal	
due	to	adverse	events)l	
mITT	 actual	
numbers	
2	 130	 1	 132	 	 	 	 	
	 	 	 	 as	above	but	all	 mITT	 actual	
numbers	
6	 130	 3	 132	 	 	 	 	
Study	
Name	
Antibiotic	 T	vs	C	vs	
MIC:AUC	
EII	
or	
CI	
Outcome	 Sample	
Tested		
Form?	 EI	
Event	
EI	
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Event	
Standard	
Total	
EI	 conf.	
int.	
Standard	 conf.	
int.	
Lipman	
1999	
	 T	 CI	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Lu	2013	 P/T	 T	 EII	 treatment	success		 ITT	 actual	
numbers	
22	 25	 20	 25	 	 	 	 	
	 	 	 	 Relapse	 ITT	 actual	
numbers	
1	 25	 2	 25	 	 	 	 	
Lubasch	
2003	
Ceftazidime	 T	 EII	 Clinical	outcome	(1)m	 ITT	 actual	
numbers	
37	 41	 36	 40	 	 	 	 	
	 	 	 	 bacteriological	efficacy	
(1)	
BE	 actual	
numbers	
37	 41	 35	 40	 	 	 	 	
	 	 	 	 safety	(-)	 patients	
not	
separated	
out	
	 	 	 	 	 	 	 	 	
McNabb	
2001u	
Ceftazidime	 T	 CI	 adverse	events	(-)	 ITT	 actual	
numbers	
11	 17	 13	 18	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT	 actual	
numbers	
3	 17	 3	 18	 	 	 	 	
Nicolau	
1999b	
Ceftazidime	 T	 CI	 adverse	events	(-)	 ITT	 actual	
numbers	
0	 11	 0	 13	 	 	 	 	
Nicolau	
2001	
Ceftazidime	 T	 CI	 clinical	cure	at	day	14-21	
(1)	
CE	 actual	
numbers	
7	 17	 6	 18	 	 	 	 	
	 	 	 	 clinical	cure	and	
improvement	at	14-21/7	
(1)	
CE	 actual	
numbers	
16	 17	 15	 18	 	 	 	 	
	 	 	 	 microbiological	erad	at	
day	14-21	(1)n	
BE	 actual	
numbers	
	 20	 	 31	 	 	 	 	
	 	 	 	 microbiological	erad	and	
presumed	erad	14-21/7n	
BE	 actual	
numbers	
	 20	 	 31	 	 	 	 	
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Nicolau	
2001	
Ceftazidime	 T	 CI	 microbiological	response	 BE	 actual	
numbers	
10	 13	 12	 15	 	 	 	 	
	 	 	 	 bacterial	eradication	(-)	 BE	 Average	
(days)	
	 	 	 	 6	 2	to	
10	
3.9	 0.1	
to	
7.7	
	 	 	 	 safety	(-)	 ITT	 actual	
numbers	
patients	not	separated	out	(but	reported	in	
McNabb	2001)	
	 	 	
	 	 	 	 Superinfection	 ITT	 actual	
numbers	
patients	not	separated	out	(but	reported	in	
McNabb	2001)	
	 	 	
	 	 	 	 ICU	length	of	stay	(-)	 CE	 Average	
(days)	
	 	 	 	 8.5	 5.2	
to	
11.9	
9.3	 5.3	
to	
13.3	
Okimoto	
2009	
M	 T	 CI	 Efficacy	rate	(-)	 ?	 actual	
numbers	
20	 25	 19	 25	 	 	 	 	
	 	 	 	 bacterial	eradication	(-)	 ?o	 actual	
numbers	
11	 12	 15	 17	 	 	 	 	
Pedeboscq	
2001	
P/T	 T	 CI	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Rafati	
2006	
Piperacillin	 T	 CI	 WCC	normalisation	(-)	 pts	with	
abnormal	
WCC	
actual	
numbers	
12	 16	 10	 12	 	 	 	 	
	 	 	 	 Mortality	(-)	 mITT	 actual	
numbers	
5	 20	 6	 20	 	 	 	 	
Roberts	
2007	
Ceftriaxone	 T	 CI	 Clinical	response	(1)p	 ITT	 actual	
numbers	
25	 29	 23	 28	 	 	 	 	
	 	 	 	 Clinical	cure	(1)	 ITT	 actual	
numbers	
13	 29	 5	 28	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1)q	 ITT	 actual	
numbers	
18	 29	 14	 28	 	 	 	 	
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Roberts	
2007	
Ceftriaxone	 T	 CI	 Superinfection	(1)	 ITT	 actual	
numbers	
1	 29	 2	 28	 	 	 	 	
	 	 	 	 Secondary	infection	(1)	 ITT	 actual	
numbers	
1	 29	 0	 28	 	 	 	 	
	 	 	 	 Clinical	response	(1)p	 PP	 actual	
numbers	
24	 25	 22	 25	 	 	 	 	
	 	 	 	 Clinical	cure	(1)	 PP	 actual	
numbers	
13	 25	 5	 25	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1)q	 PP	 actual	
numbers	
18	 25	 14	 25	 	 	 	 	
	 	 	 	 Superinfection	(1)	 PP	 actual	
numbers	
1	 25	 2	 25	 	 	 	 	
	 	 	 	 Secondary	infection	(1)	 PP	 actual	
numbers	
1	 25	 0	 25	 	 	 	 	
	 	 	 	 mortality	(-)	 ITT	 actual	
numbers	
3	 29	 0	 28	 	 	 	 	
	 	 	 	 adverse	events	 	 	 "neither	was	associated	with	an	increased	
incidence	of	AE"	
	 	 	
Roberts	
2009a	
M	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
2	 5	 0	 5	 	 	 	 	
Roberts	
2009b	
P/T	 T	 CI	 Clinical	outcomer	 ITT	 actual	
numbers	
6	 6	 7	 7	 	 	 	 	
Roberts	
2010	
P/T	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
0	 8	 0	 8	 	 	 	 	
Sakka	
2007	
I/C	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
1	 10	 2	 10	 	 	 	 	
	 	 	 	 ICU	LOS	(-)	 ITT	 Average	
(days)	
	 	 	 	 14	 6	to	
22	
12	 5	to	
19	
Study	
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int.	
Standard	 conf.	
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Sakka	
2007	
I/C	 T	 CI	 Adverse	events	(-)	 ITT	 actual	
numbers	
0	 10	 0	 11	 	 	 	 	
Schmelzer	
2013	
Vancomycin	 MIC:AUC	 CI	 Nephrotoxicity	(2)	
(defined	AE	in	MA(1))	
PP	 actual	
numbers	
1	 28	 3	 27	 	 	 	 	
van	
Zanten	
2006	
Cefotaxime	 T	 CI	 Clinical	outcome	(1)s	 NE	 actual	
numbers	
37	 40	 40	 43	 	 	 	 	
	 	 	 	 Microbiological	analysis	
(1)	
NE	 actual	
numbers	
not	relevant	to	this	
study	
	 	 	 	 	
	 	 	 	 AE	(-)	 NE	 actual	
numbers	
0	 40	 0	 43	 	 	 	 	
	 	 	 	 Mortality	(-)	 ITT	 actual	
numbers	
4	 47	 1	 46	 	 	 	 	
Wright	
1979	
Gentamicin	 C	 CI	 Mortality	(-)	 ITT	 actual	
numbers	
5	 23	 3	 13	 	 	 	 	
Wysocki	
2001	
Vancomycin	 MIC:AUC	 CI	 Efficacy	(1)t	 PP	 actual	
numbers	
48	 61	 47	 58	 	 	 	 	
	 	 	 	 Safety	(1)	 PP	 actual	
numbers	
12	 n/a	 12	 n/a	 	 	 	 	
	 	 	 	 Nephrotoxicity	(defined	
AE	in	MA(1))	
PP	 actual	
numbers	
10	 61	 11	 58	 	 	 	 	
	 	 	 	 mortality	(-)v	 PP	 actual	
numbers	
21	 61	 19	 58	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Bao	2017	 P/T	 T	 EII	 Clinical	outcome	(1)x	 PP	 actual	
numbers	
22	 25	 20	 25	 	 	 	 	
	 	 	 	 AE	(1)	 PP	 actual	
numbers	
23	 25	 19	 25	 	 	 	 	
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Bao	2017	 P/T	 T	 EII	 SAE	(-)	 PP	 actual	
numbers	
5	 25	 4	 25	 	 	 	 	
	 	 	 	 WAE	(-)	 PP	 actual	
numbers	
2	 25	 3	 25	 	 	 	 	
Fan	2017	 P/T	 T	 EII	 Mortality	14/7	(1)	 PP	 actual	
numbers	
21	 182	 29	 185	 	 	 	 	
	 	 	 	 Mortality	in	hospital	(2)	 PP	 actual	
numbers	
52	 182	 59	 185	 	 	 	 	
	 	 	 	 Time	to	defervescence	
(2)	
PP	 mean	
(days)	
	 	 	 	 4	 	 6	 	
	 	 	 	 Duration	of	mechanical	
support	(2)	
PP	 mean	
(days)	
	 	 	 	 5	 	 5	 	
	 	 	 	 ICU	length	of	stay	(2)	 PP	 median	
(days)	
	 	 	 	 3	 	 4	 	
	 	 	 	 Hosptial	length	of	stay	
(2)	
PP	 median	
(days)	
	 	 	 	 20	 	 21	 	
	 	 	 	 AE	(-)	 PP	 actual	
numbers	
0	 182	 0	 185	 	 	 	 	
Ram	2018	 P/T,	
ceftazidime	
T	 EII	 Overall	response	(1)y	 ITT	 actual	
numbers	
35	 47	 32	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
35	 43	 30	 48	 	 	 	 	
	 	 	 	 Clincal	failure	(1)z	 ITT	 actual	
numbers	
3	 47	 11	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
1	 43	 5	 48	 	 	 	 	
	 	 	 	 Fever	(2)	 ITT	 median	
(days)	
	 	 	 	 2	 	 2	 	
Study	
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Ram	2018	 P/T,	
ceftazidime	
T	 EII	 	 PP	 median	
(days)	
	 	 	 	 2	 	 2	 	
	 	 	 	 Noradrenaline	(2)	 ITT	 actual	
numbers	
4	 47	 10	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
2	 43	 4	 48	 	 	 	 	
	 	 	 	 AKI	(2)	 ITT	 actual	
numbers	
3	 47	 6	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
3	 43	 4	 48	 	 	 	 	
	 	 	 	 C.	diff	(2)	 ITT	 actual	
numbers	
0	 47	 2	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
0	 43	 2	 48	 	 	 	 	
	 	 	 	 breakthrough	BSI	(2)	 ITT	 actual	
numbers	
2	 47	 7	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
2	 43	 7	 48	 	 	 	 	
	 	 	 	 Breakthrough	fever	after	
day	4	(2)	
ITT	 actual	
numbers	
6	 47	 10	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
5	 43	 9	 48	 	 	 	 	
	 	 	 	 LoS	 ITT	 median	
(days)	
	 	 	 	 23	 	 24	 	
	 	 	 	 	 PP	 median	
(days)	
	 	 	 	 22	 	 23	 	
	 	 	 	 Death,	30	days	 ITT	 actual	
numbers	
1	 47	 2	 58	 	 	 	 	
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Ram	2018	 P/T,	
ceftazidime	
T	 EII	 	 PP	 actual	
numbers	
1	 43	 2	 48	 	 	 	 	
Yang	2017	 P/T	 T	 EII	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Zhao	2017	 M	 T	 CI	 Clinical	success	(1)aa	 ITT	 actual	
numbers	
16	 25	 14	 25	 	 	 	 	
	 	 	 	 Superinfection	(1)	 ITT	 actual	
numbers	
1	 25	 4	 25	 	 	 	 	
	 	 	 	 ICU	length	of	stay	(2)	 ITT	 average	
(days)	
	 	 	 	 10	 	 10	 	
	 	 	 	 ICU	mortality	(2)	 ITT	 actual	
numbers	
7	 25	 8	 25	 	 	 	 	
	 	 	 	 Duration	of	meropenem	
treatment	(2)	
ITT	 average	
(days)	
	 	 	 	 7.6	 	 9.4	 	
	
	
	
	
	
	
	
	
Key	
		
ITT	 Intention	To	Treat	
mITT	 modified	Intention	To	Treat	
PP	 per-protocol	
CE	 Clinically	evaluable	
BE	 Bacteriologically	evaluable	
NE	 Number	of	evaluable	patients	
*	 those	included	in	PK/PD	analysis	
**	
limited	to	pts	with	evaluable	
samples	
	 	1	 stated	primary	outcome	
2	 stated	secondary	outcome	
-	 outcome	not	stated	a	priori	
?	
stated	a	priori	but	not	clear	if	1	or	
2	
	 	
	 	P/T	 Piperacillin/tazobactam	
M	 Meropenem	
	 	
	 	
	 	C/C	 Carbenicillin/cefamandole	
T/C	 Ticarcillin/clavulanate	
I/C	 Imipenem/cilistatin	
	 	
	 	
	 	EI	 Extended	infusion	
EII	 Extended	intermittent	infusion	
CI	 Continuous	infusion	
	 	T	 Time	dependent	kill	
C	 Concentration	dependent	kill	
MIC:AUC	 Ratio	dependent	kill	
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Notes	
	
	 	a	 resolution	or	improvement	of	clinical	and	laboratory	signs	of	infection	
b	 deduced	from	percentage	stated	
c	 clinical	cure	and	clinical	improvement	
d	 time	between	the	end	of	the	1st	treatment	and	the	beginning	of	a	2nd	for	the	same	
focus	of	infection	
e	 expressed	in	the	paper	as	survival	
f	 no	eradication:	clinical	recovery	but	pathogen	persistent	
g	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
h	 stated	in	method	but	then	not	reported	on	as	CI	vs	II	
i	 I've	not	included	the	pts	on	CVVH	as	they	all	received	CI	
j	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
k	 success	=	eradication/presumed	eradication,	failure	=	persistence/presumed	
persistence	
l	 limited	to	treatment-related	rather	than	all	
m	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
n	 primary	outcomes	not	reported	in	the	body	of	the	paper	
o	 sample	those	patient	that	grew	a	microorganism	
p	 "resolution"	and	"improvement"		regard	as	clinical	response	for	the	purpose	of	this	
MA	
q	 success	=	eradication/presumed	eradication,	failure	=	everything	else	
r	 clinical	outcome	cure	in	the	table	and	resolution/improvement/failure	in	definition	
s	 "cure",	"improvement"	or	no	requirement	for	antibiotic	treatment	within	48hrs	of	
discontinuation	classified	as	successful	clinical	response	
t	 efficacy	defined	as	clinical	failure	(death	or	clinically	unchanged/worsening)		
u	 reported	in	both	McNabb	2001	and	Nicolau	2001	
v	 in	ICU	mortality	
w	 numbers	in	table	don't	add	up	
x	 "cure"	and	"improvement"	classified	as	successful	clinical	response	and	no	additional	
antibiotic	therapy	required	
y	 composite	of	4	elements	inc.	clinical	failure	
z	 clinical	failure	reversed	to	give	clinical	response	
aa	 clinical	success	defined	as	complete	or	partial	resolution	
	
